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Abstract 
Background: Peripheral arterial occlusive disease is a manifestation of the inflammatory 
disease atherosclerosis, characterised by reduced blood flow to the limbs by narrowing and 
blocking of arteries. This disease affects more than 200 million adults worldwide and is a 
powerful indicator of widespread arterial disease. It is associated with increased risk of death, 
heart attack and stroke. Models to predict which patients with peripheral arterial occlusive 
disease will suffer these outcomes are lacking. Traditional null hypothesis testing methods to 
develop outcome models for this population are limited by the complexity of variable 
interaction and some variables exhibiting small although clinically important effects. The 
Information-Theoretical approach and particularly multi-model analysis and inference has 
been applied in other scientific fields but has not been applied to the population of patients with 
peripheral arterial occlusive disease. 
 
Objective: The specific aims of this study were (1) to determine the association of the 
circulating cells of inflammation with clinical disease severity and traditional risk factors for 
the composite end-point of major adverse event consisting of death, heart attack or stroke and 
death alone using traditional null hypothesis testing statistics (Kaplan-Meir survival analysis 
and Cox proportional hazards analysis) compared to the novel approach of multi-model 
analysis; (2) to generate a predictive model for these cardiovascular outcomes in patients with 
peripheral arterial occlusive disease.  
 
Design: Longitudinal cohort design with 632 patients considered and 398 patients included.  
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Methods: Patients were prospectively recruited from 2002 to 2014 from The Townsville 
Hospital and Townsville Mater Hospital and followed up until death, discharge from clinic or 
the conclusion of data collection on 1/12/2014. The blood sample for this study was obtained 
at recruitment if the patient was well, or otherwise at greater than one month post interventional 
procedure, major adverse event or resolution of infection. Kaplan-Meir analysis was performed 
for each endpoint and Cox proportional hazards analysis was used to test the association of 
each of the circulating cell types (total white cell count and its subsets neutrophils, 
lymphocytes, monocytes, the calculated neutrophil lymphocyte ratio and haemoglobin) with 
the endpoint of major adverse event and death a priori and with adjustment for risk factors. 
Further analysis was undertaken using a novel approach of multi-model analysis to generate 
an average best fit model for major adverse event and death. 
 
Results: Disease severity was significantly associated with major adverse event using Kaplan-
Meier and log rank analysis. Cox proportional hazards analysis for each cell type with major 
adverse event demonstrated high total white cell count, high neutrophil count and high 
monocyte count to be significantly associated in all analyses with both mid and high 
lymphocyte counts significantly associated. For the outcome of death high total white cell 
count, high neutrophil count, and high neutrophil/lymphocyte ratio were significantly 
associated in all analyses with high lymphocyte count protective. The importance of adjusting 
for traditional risk factors, disease severity and medication use in Cox proportional hazards 
analysis was demonstrated. Both the average best fit models from multi-model averaging for 
major adverse event and death feature clinical disease severity and circulating cell counts as 
stronger predictors than the risk factors traditionally associated with the establishment of the 
disease. High monocyte category was the cell type with the strongest positive influence in the 
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model for major adverse event, with high lymphocyte count having the strongest negative (i.e. 
protective) influence. The model for the outcome of death showed the disease severity 
categories of tissue loss and rest pain as having the strongest influence with high neutrophil 
count the strongest influencing cell type, and again high lymphocyte count having the strongest 
protective influence. Methods to enable the clinician to apply the model at the bedside or clinic 
are discussed using information from clinical history, disease severity and full blood count 
alone.   
 
Conclusion: The Information-Theoretic approach of multi-model averaging is more 
appropriate and meaningful than traditional null hypothesis testing approaches for patients with 
peripheral arterial occlusive disease. Disease severity and circulating cell counts better 
discriminate patients at high risk of major adverse events and death than traditional risk factors. 
Circulating cell counts may be modelled with disease severity and traditional risk factors to 
guide treatment selection, aid patient compliance with lifestyle change and medical therapy, 
drive future pathophysiological research and generate potential treatments for patients with 
peripheral arterial occlusive disease. 
 
Key words: 
Peripheral arterial occlusive disease, peripheral arterial  disease, leucocytes, total white cell 
count, death, mortality, major adverse event, multi-model averaging. 
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1. Introduction to circulating cell counts in peripheral 
arterial occlusive disease. 
Inflammation of the arteries causes peripheral arterial occlusive disease which has limb and 
life threatening implications. Models to better predict patients at high risk of major adverse 
cardiovascular events are required to add to known information from traditional risk factors 
and disease severity to enable patient tailored treatment and increase patient compliance with 
lifestyle changes and medical management. 
 
1.1. Background 
1.1.1. Definition and prevalence of peripheral arterial occlusive disease 
Peripheral arterial occlusive disease is one manifestation of the inflammatory disease 
atherosclerosis, characterised by reduced blood flow to the limbs caused by arterial stenosis 
and occlusions. Peripheral arterial occlusive disease affects between 10 and 29% of people 
over the age of 55 years with prevalence increasing with age,1-9 and has been reported as high 
as 33% in populations with diabetes mellitus.10 Peripheral arterial occlusive disease affects an 
estimated 27 million adults in Europe and North America alone,11,12 and an estimated 202 
million adults worldwide.13 Atherosclerosis is associated with the main causes of mortality on 
a worldwide scale with the absolute number of deaths from these causes continuing to 
increase.14 
 
Symptomatic peripheral arterial occlusive disease ranges in severity from intermittent 
claudication (reproducible pain in the lower limbs on exercise that resolves with rest) to critical 
limb ischaemia (rest pain and/or ulceration or tissue loss – gangrene).12 Patients with peripheral 
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arterial occlusive disease often report a reduced quality of life from the reduction in walking 
distance and speed which limits mobility and independence.15-18  A large proportion of the 
patients with peripheral arterial occlusive disease are asymptomatic1 (for every one 
symptomatic there are three to four asymptomatic patients with peripheral arterial occlusive 
disease)5,8 although these patients are exposed to similar elevated cardiovascular risk.19 
 
Peripheral arterial occlusive disease is a manifestation of the systemic inflammatory disease of 
atherosclerosis, a multi-factorial disease that affects all of the arterial systems of the body, 
principally involving the medium and large elastic and muscular arteries and can cause 
ischaemia to the end organs of the body including heart, brain, intra-abdominal organs and the 
tissues of the lower limbs. The presence of peripheral arterial occlusive disease is an indicator 
of diffuse and significant arterial disease and has been associated with an increased risk of 
cardiovascular and cerebrovascular events including death, myocardial infarction, stroke, and 
peripheral vascular intervention including major amputation.11,12,20,21 Traditional risk factors 
for ischaemic vascular diseases do not explain all epidemiological features of these diseases.22 
 
1.1.2. Natural history of peripheral arterial occlusive disease 
Peripheral arterial occlusive disease is pathologically progressive however the presentation and 
symptoms of peripheral arterial occlusive disease patients do not necessarily follow a linear 
trajectory. Traditionally the severity of peripheral arterial occlusive disease has been classified 
with the Rutherford and Fontaine classification systems (Appendix I). Of the patients with 
symptomatic peripheral arterial occlusive disease who present with intermittent claudication 
(reproducible leg pain on exercise that improves with rest) only one quarter will clinically 
deteriorate with worsening claudication or the development of critical limb ischaemia.23,24 
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Despite this relatively small proportion of patients with intermittent claudication progressing 
clinically, this same patient group has 5 year mortality of 10-15%, with the majority (75%) 
dying from cardiovascular causes.25 Within the same time a further 20% of this population will 
sustain a non-fatal heart attack or stroke.25 Of the 1-3% of patients who present with critical 
limb ischaemia, 20-25% are dead within 12 months26,27 while a further 30% undergo major 
amputation.28 The 10 year mortality in the critical limb ischaemia population is 75%.26 A flow 
diagram representing the clinical progression of peripheral arterial occlusive disease and 
cardiovascular outcomes adapted from Norgren et al.28 is presented in Figure 1.1. 
 
Figure 1.1: Flow Diagram of clinical progression of peripheral arterial occlusive disease 
Adapted from Norgren et al. 28 
PAOD = Peripheral Arterial Occlusive disease 
CV = Cardiovascular 
 
Coronary artery disease, cerebrovascular disease, and peripheral arterial occlusive disease are 
all manifestations of atherosclerosis and therefore commonly occur together. Peripheral arterial 
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occlusive disease is a powerful indicator of diffuse and significant atherothrombotic 
disease.21,29,30 In the REACH (Reduction of Atherothrombosis for Continued Health) registry 
containing 67 888 patients more than one half of the patients with peripheral arterial occlusive 
disease had demonstrated atherosclerotic disease in another arterial territory (coronary or 
cerebral)31 with the peripheral arterial occlusive disease subpopulation demonstrating the 
highest one year atherothrombotic event (cardiovascular death, heart attack, stroke, or 
hospitalisation for a cardiovascular event) rate of 21.1% which was greater than patients with 
coronary artery disease (15.2%) or cerebrovascular disease (14.5%).32 In the first year of this 
registry 10% of peripheral arterial occlusive disease patients required lower limb intervention 
and 1.6% required major amputation.32 The higher risk of adverse cardiovascular events in 
patients with peripheral arterial occlusive disease is clinical importance and the ability of 
clinicians to be able to accurately assess this risk and predict major adverse events should affect 
both conservative and interventional management of this patient population. The primary 
endpoint of this study will be major adverse event: a composite outcome of death, heart attack 
or stroke. 
 
1.1.3. Peripheral arterial occlusive disease mortality implications 
Patients with peripheral arterial occlusive disease have an increased risk of subsequent heart 
attack and stroke and are 6 times more likely to die from cardiovascular disease within 10 years 
than patients without peripheral arterial occlusive disease.29 Patients with symptomatic 
peripheral arterial occlusive disease have a 15yr accrued survival rate of approximately 22% 
compared to a survival rate of 78% in patients without peripheral arterial occlusive disease.28 
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Peripheral arterial occlusive disease patients frequently suffer from concomitant coronary 
artery disease and cerebrovascular atherosclerosis and therefore are at a particularly high risk 
for cardiovascular complications.3,28,33 In the REACH study the risk of major adverse events 
for patients with peripheral arterial occlusive disease was twice as high in the patients that had 
involvement of more than one vascular bed.31 While commonality exists in risk factors for the 
development of atherosclerotic disease in all arterial beds, smoking, hypertension and diabetes 
appear most important risk factors for the development of peripheral arterial occlusive 
disease13, compared to hypertension and lipid profile being a more important factor in the 
development of coronary artery disease. Despite these differences atherosclerosis may affect 
multiple arterial beds in patients with peripheral arterial occlusive disease, in one population 
study, patients with peripheral arterial occlusive disease had ischaemic heart disease as a 
comorbidity in 58% and cerebrovascular disease in 34%.33 The method of detection of coronary 
artery disease in the peripheral arterial occlusive disease population greatly affects the reported 
prevalence with variation from 19% to 90% of patients with peripheral arterial occlusive 
disease diagnosed as also having coronary artery disease with >90% being diagnosed as having 
coronary artery disease if angiography or autopsy is used.34-36  
 
The presence of peripheral arterial occlusive disease has been associated with an increased risk 
of cardiovascular and cerebrovascular events including death, myocardial infarction, stroke, 
and peripheral vascular intervention including major amputation.12,20,21,23,29,30,33,37,38 In the 
Framingham study almost 70% of the deaths in the patients with intermittent claudication were 
due to a cardiovascular cause.39 Patients with peripheral arterial occlusive disease have been 
reported to have a higher incidence of major adverse event than patients with isolated coronary 
artery disease or cerebrovascular disease.32 The relative risk of fatal and non-fatal 
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cardiovascular events in patients with peripheral arterial occlusive disease is 3.1  of death and 
5.9 of death from cardiovascular disease times that of control patients after adjustment for age 
and cardiovascular risk factors.29,30 Similar results have been demonstrated in other 
populations.40,41 The clinical severity of peripheral arterial occlusive disease has been 
associated with higher mortality with severe symptomatic patients experiencing 15 fold 
increase in mortality rate in the San Diego population study equating to 75% 10 year 
mortality.29 
 
Patients with peripheral arterial occlusive disease are medically managed to reduce this risk of 
cardiovascular morbidity and mortality at significantly lower rates than patients with ischaemic 
heart disease despite comparable mortality.42,43 The increased mortality risk of patients with 
peripheral arterial occlusive disease once established is less clearly related to traditional risk 
factors, Brevetti et al. (2010)44 proposed that the subsequent cardiovascular risk is related to 
the severity and extent of the underlying atherosclerotic disease and possibly other factors 
including inflammation. 
 
1.1.4. Inflammation 
Inflammation has long been suspected of playing a central role in the development and 
progression of systemic atherosclerosis.45-48 Atherosclerosis is increasingly understood to be 
an active, inflammatory process in which the circulating inflammatory cells have integral 
roles.46,47,49,50 No longer a lipid storage disease, inflammatory cells are involved not only in the 
initiation and evolution of atheroma with dysfunctional endothelium but in the acute 
thrombotic complications of atheroma arising from exacerbated inflammation and plaque 
rupture.46,51,52 
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The longitudinal relationship between inflammation and peripheral arterial occlusive disease 
has been established.53-57 Inflammation is associated with the presence,53 progression54 and 
severity of peripheral arterial occlusive disease.58,59 The risk of major adverse cardiovascular 
event in patients with peripheral arterial occlusive disease is less clearly related to traditional 
risk factors than in patients with ischaemic heart disease or cerebrovascular disease29,38,60,61 and 
may be more related to the systemic inflammation.21,62-68 Increasing evidence indicates that 
inflammatory parameters are associated with the risk of future ischaemic events.69 While 
systemic inflammation plays a role in peripheral atherosclerosis over and above the traditional 
risk factors, markers of inflammation have not been inconsistent as a predictive tool.44,59,63,70,71 
Combining inflammatory markers with peripheral arterial occlusive disease severity and 
traditional risk factors improves risk stratification59,65 
 
Few studies have investigated the prognostic implications of circulating cells and adverse 
events in peripheral arterial occlusive disease.24,72-74 The need to assess the relationship 
between systemic inflammation and cardiovascular risk was identified by Brevetti et al.44 who 
recommended following a sufficiently large population longitudinally with measures of 
systemic inflammation, traditional risk factors and measures of peripheral arterial occlusive 
disease severity. Low grade systemic inflammatory response leads to an increased number of 
circulating neutrophils and decreased lymphocyte count.75-77 Assessment of circulating cell 
counts as a marker of systemic inflammation is inexpensive and already routinely obtained pre-
operatively, although it’s correlation with cardiovascular outcomes in patients who present 
with peripheral artery disease has not been firmly established. 
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1.2. Risk factors for outcome in peripheral arterial occlusive disease 
The presented study will assess the association and predictive value of circulating total and 
differential cell counts with cardiovascular outcomes in peripheral arterial occlusive disease 
patients and will compare these to the traditional risk factors for peripheral arterial occlusive 
disease in the development of models to predict cardiovascular outcomes. The precedent for 
the inclusion of each risk factor will be discussed separately. 
 
1.2.1. Age 
Age is a standard factor included in predictive models and is important in the peripheral arterial 
occlusive disease population as an increase in both incidence and prevalence of peripheral 
arterial occlusive disease has been shown with increasing age. 1,28 Mortality is a known function 
of increasing age.78 
 
1.2.2. Sex 
Cardiovascular mortality in both asymptomatic and symptomatic peripheral arterial occlusive 
disease is significantly higher in men.79 Prevalence of both symptomatic and asymptomatic 
peripheral arterial occlusive disease is higher in men than in women with the ratio increasing 
in more severe stages of the disease,1,2,80 Although, a higher incidence of women with critical 
limb ischaemia has been repoted.9 Cardiovascular mortality in both asymptomatic and 
symptomatic peripheral arterial occlusive disease is significantly higher in men.79 
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1.2.3. Smoking status 
Smoking is a strong risk factor for the development of peripheral arterial occlusive disease.81,82 
Smoking promotes the progression of peripheral arterial occlusive disease, increases rates of 
heart attack and stroke, increases risk of both graft occlusion and major amputation and 
worsens survival.8,83-85 The strong association between smoking and elevated total white cell 
count has been documented in many studies,22,86-91 and even exposure to second hand smoke 
in the “ATTICA study” (from the province of Attica in Greece which included Athens) was 
associated with elevated total white cell count.92 Smoking increases the risk and reduces the 
success of peripheral vascular intervention.80 The mechanisms by which smoking increases 
risk in peripheral arterial occlusive disease patients may be through increasing circulating white 
blood cell aggregation and reducing the deformability of cells, predisposing to 
microvasculature plugging and subsequent damage from the release of proteolytic enzymes 
and free radicals damaging the vessel endothelium, promoting further thrombosis and vessel 
occlusion.93 
 
1.2.4. Diabetes mellitus 
The Framingham study94 showed a 3.5 fold risk among men and 8.6 fold risk among women 
with diabetes of developing peripheral arterial occlusive disease. The diabetic population has 
poorer outcomes from peripheral revascularisation95 and requires major amputation at a rate 
five to fifteen times higher than non-diabetics.28,96,97  Large population studies have shown than 
diabetic patients with peripheral arterial occlusive disease have 3-4 times the mortality risk of 
their healthy controls.95,98 Diabetes is associated with elevated total white cell count.87,89,90,99 
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1.2.5. Hypertension 
Hypertension is associated with all forms of cardiovascular disease,28 and hypertension is an 
independent predictor of mortality.100-103 Hypertension increases the risk of peripheral arterial 
occlusive disease28 and peripheral arterial occlusive disease increases the risk of mortality,24,104 
but whether hypertension is an independent risk factor for mortality within the population with 
established peripheral arterial occlusive disease remains unclear. 
 
1.2.6. Ischaemic heart disease 
In the PARTNERS (Peripheral Arterial Disease Awareness, Risk and Treatment: New 
Resources for Survival) study over 50% of outpatients with peripheral arterial occlusive disease 
had a history of coronary artery disease.5 In the REACH registry the one year cardiovascular 
event (cardiovascular death, heart attack, stroke or cardiovascular related hospitalisation) rate 
of patients with both ischaemic heart disease and peripheral arterial occlusive disease was 
23.1% compared to 17.4% in those patients with peripheral arterial occlusive disease alone. 
Ischaemic heart disease is a predictor of short and long term mortality in vascular patients 
undergoing revascularisation or aneurysm repair.105 
 
1.2.7. Stroke  
A combination of stroke or transient ischaemic attack (TIA) was one of the identified risk 
factors that predicted mortality at 5 and 10 years in a review of mortality in 2642 consecutive 
peripheral arterial occlusive disease patients.106 Touze et al.107 quantified the risk of heart attack 
and non-stroke vascular mortality to ~2% per year following stroke or TIA. 
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1.2.8. Disease severity 
The clinical stage of peripheral arterial occlusive disease as described by Rutherford and 
Fontaine (Appendix I) is important to include in outcome modelling because rate of major 
adverse event in patients with critical limb ischaemia approaches 20% at one year and 40-70% 
at 5 years28,108 and their all cause and cardiovascular mortality has been reported as three times 
that of patients who present with intermittent claudication.64 In the San Diego population 
study29 severe symptomatic patients experienced 15 fold increase in mortality rate equating to 
75% 10 year mortality, similar to the 80% 10 year mortality of Dormandy et al.34 with rest 
pain. 
 
When ankle-brachial index is used as an objective measure of the severity of peripheral arterial 
occlusive disease an ankle-brachial index <0.9 has been shown to predict all-cause mortality 
with a relative risk ratio of 3.8109 5 year all-cause mortality (Hazard Ratio 1.4)110 and stroke 
with hazard ratio 2.5 for fatal stroke111 Peripheral arterial occlusive disease patients with an 
ankle-brachial index <0.5 demonstrate twice the rate of mortality of claudicants with an ankle-
brachial index >0.5.24 Mehler104 showed a 10% increase in relative risk of major adverse event 
for each 0.1 decrease in ankle-brachial index. Similar results were generated by Resnick20 who 
also showed ankle-brachial index >1.4 to have a similar increase in mortality rate. The German 
Epidemiological Trial on Ankle Brachial Index (getABI) which included 6880 unselected 
patients from the primary care setting demonstrated that patients with an ABI <0.5 had a 31.4% 
5 year all-cause mortality while in the patients with an ABI >1.1 mortality in the same time 
frame was 8.6%.110,111 
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While ankle-brachial index has been proposed to be included in models of outcome for patients 
with peripheral arterial occlusive disease,19,81,112,113 the relationship with mortality and in-
particular the cut points that should be used remain unclear. McDermott114 did not demonstrate 
a significant difference in the survival of patients with an ankle-brachial index 0.31-0.49 when 
compared to ankle-brachial index 0.50-0.92 after adjustment for traditional risk factors but did 
demonstrate a lower cumulative survival in patients with an ankle-brachial index <0.30. Other 
studies have failed to demonstrate an association between ankle-brachial index and non-fatal 
cardiovascular events.19,115,116 In this study the clinical severity of disease (Appendix I) was 
used and not ankle-brachial index. 
 
1.2.9. Aspirin and HMG-Co-A reductase inhibitor (Statin) use 
The Antithrombotic Trialists Collaboration have demonstrated that patients with 
cardiovascular disease experience a 25% odds reduction in subsequent major adverse events 
by the use of aspirin.117 Aspirin use has been associated with significantly lower total white 
cell count in four separate non-randomised studies of cardiovascular risk86,88,87,118 involving a 
total of  >160 000 patients although these trials were not specifically designed to investigate 
this relationship and confounding variables may have influenced this apparent association.99  
 
The JUPITER trial (Justification for the Use of statins in Prevention: an Intervention Trial 
Evaluating Rosuvastatin use) in a non-peripheral arterial occlusive disease population 
demonstrated a 44% reduction in all-cause and cardiovascular morality.119 The Heart 
Protection Study reported that 40 mg Simvastatin daily in patients with peripheral arterial 
occlusive disease (even if not diagnosed with ischaemic heart disease) experienced 24% 
proportional reduction in major adverse events.120,121 It is not surprising then that Statin use is 
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more common in survivors of the high risk peripheral arterial occlusive disease population with 
critical limb ischaemia at 12 months.122 Short term statin use has been shown to reduce major 
adverse events within six months of vascular surgery.123,124 Shillinger et al.125 demonstrating 
that peripheral arterial occlusive disease patients receiving Statin therapy for a minimum of 4 
weeks prior to endovascular peripheral intervention had significantly improved survival and 
event free survival rates, with the patients with the higher markers of inflammation benefiting 
the most from statin therapy.125  
 
Statin use also favourably influences leg function,126 and have been associated with infra-
inguinal graft patency and limb salvage after infra-inguinal bypass surgery.127 It remains 
unclear in the peripheral arterial occlusive disease population whether the reduced risk of major 
adverse events from statin use are due to the lipid lowering or anti-inflammatory effects.125, 128 
 
1.2.10. Traditional Risk Factors for peripheral arterial occlusive disease in this study 
In this study the risk factors of age, sex, smoking status, diabetes mellitus, hypertension, 
ischaemic heart disease, aspirin and statin use were recorded for all included participants. The 
contribution of these risk factors to mortality and major adverse event as potential confounding 
factors for the analysis of circulating cell counts is considered and addressed. These risk factors 
were also included in model formation for the outcomes of major adverse event and death. 
 
1.3. Predictive models for outcome in patients with peripheral arterial 
occlusive disease    
Current cardiovascular risk prediction in patients with peripheral arterial occlusive disease is 
limited to using equations attained through large observational studies such as Atherosclerosis 
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Risk in Communities (ARIC),90,129 Framingham,80,94 Honolulu130 and Strong Heart131 studies. 
These models have been generated using the traditional approach of null-hypothesis testing 
and stepwise regression analysis which has multiple limitations.132 Further risk stratification 
has been proposed to include co-morbid disease, clinical stage of peripheral arterial occlusive 
disease, and haemodynamic severity of disease supplemented with biologic markers of 
inflammation.133,134 The Information-Theoretical statistical paradigm132 and particularly the 
multi-model averaging approach has not been previously applied to generate outcome models 
for patients with peripheral arterial occlusive disease. 
 
In the population of patients with peripheral arterial occlusive disease who are at an established 
high risk of major adverse cardiovascular events a central goal of treatment is to reduce 
morbidity and mortality.3 A risk stratification tool for patients with peripheral arterial occlusive 
disease would not only provide prognostic cardiovascular risk information but provide 
individual data that may assist clinicians to convey the importance of lifestyle modification 
and adherence to medical therapies.133 This is clinically important as risk factor modification 
and adherence to medical therapies can reduce burden of disease.135,136 Targeted smoking 
cessation has been shown to reduce mortality risk in peripheral arterial occlusive disease.83,85 
 
Individualising outcome prediction rather than at population level will allow the identification 
of the patients within this population at highest risk and may allow for targeted interventions. 
Interventions including exercise training, claudication medications and selective 
revascularisation can improve or remove lower extremity ischaemic symptoms and may avoid 
lower limb amputation. Outcome modelling may assist clinicians in making decisions between 
open revascularisation, endovascular revascularisation, conservative management or primary 
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amputation.137 Outcome predictive models have been developed for patients with coronary 
heart disease but are not currently available for patients with peripheral arterial occlusive 
disease.133  
 
Outcome models have been developed for patients undergoing open abdominal aortic 
aneurysm (AAA) repair. The Glasgow Aneurysm Score (GAS)138 was developed using logistic 
regression to identify significant factors determining post-operative outcome for open AAA 
repair. The GAS was prospectively validated among patients undergoing elective AAA 
repair139 and has subsequently been retrospectively validated using large national database 
samples.140-142 The GAS has been previously criticised that its low positive predictive value 
does not reliably identify high-risk patients and is inaccurate in predicting morbidity.143,144 The 
Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity 
(POSSUM) score145 contains both physiological and operative components but can only be 
used to predict mortality pre-operatively if the physiological component is used alone.146,147 
Variations on the POSSUM model, the P-POSSUM148,149 and V-POSSUM, have shown 
variable results when undergoing validation as a pre-operative predictive score.143 Vascular 
Biochemical and Haematological Outcome Model (VBOHM) also used logistic regression 
using a minimal bloodwork panel dataset and although initially designed for audit150 has been 
subsequently applied to elective and emergency AAA repair with good predictive value 
although there were problems with the calibration of the initial model.143,151 VBOHM 
modelling has also been applied to describe outcomes following major amputation in critical 
limb ischaemia patients.152 Other outcome models for AAA repair such as the Leiden score153 
which adjusts for centre specific mortality and the Lee Customised Probability Index for 
vascular surgical patients154 which included the protective effect of statin use were both 
53 
Chapter 1: Introduction to circulating cell counts in peripheral arterial occlusive disease 
problematic when applied to other populations (including endovascular repair of abdominal 
aortic aneurysms). The Acute Physiological and Chronic Health Evaluation scoring system 
(APACHE-AAA) has also been applied to this population with similar effect.155 
 
To the authors knowledge no predictive outcome models have been applied to the peripheral 
arterial occlusive disease population with respect to outcomes of major adverse event and total 
mortality. The proposed model for investigation in the current study will combine traditional 
risk factors, disease severity, aspirin and statin use and circulating cell counts. Circulating cell 
counts are routinely obtained on full blood count analysis with an established WHO standard 
for measurement and excellent inter-assay precision. The aim is then to produce an accurate 
and reliable model using objective standardised measures which the clinician can easily and 
inexpensively apply at the bedside or in the outpatient clinic. 
 
1.4. Circulating cell counts 
The presented study will assess the association and predictive value of circulating total and 
differential cell counts with cardiovascular outcomes in peripheral arterial occlusive disease 
patients. The precedent for the inclusion of each cell type will be discussed separately. 
 
1.4.1. Total white cell count 
Atherosclerosis has been demonstrated to be a systemic inflammatory process and total white 
cell count provides an objective measure of inflammatory status.50,156 The role that white blood 
cells play in this inflammatory processes as mediators of host defence and inflammation can 
be either acute or chronic and may be either reparative or maladaptive.49 White blood cells may 
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contribute to the progression of vascular disease and the risk of subsequent major adverse event 
through physically plugging microvasculature, chemically mediating the inflammatory 
response through free radical production, or promoting thrombosis, all of which cause resultant 
endothelial cell dysfunction.157,158 The white blood cell may be an underutilized predictive 
index in patients, suggesting which patients may be at an increased risk of cardiovascular 
complications related to a heightened systemic inflammatory response. 
 
In population studies of apparently healthy participants total white cell count has been 
associated with the development of cardiovascular disease,22,159 cardiovascular death,160-166 and 
all cause mortality160,161,165,167-169 even after adjusting for traditional cardiovascular risk 
factors.147 
 
Meta-analysis by Danesh et al.170 examined prospective cohort studies and demonstrated a 
combined risk ratio of 1.4 (1.3-1.5) of elevated total white cell count for the development of 
coronary heart disease in the largest seven studies investigating this relationship involving 5337 
patients.  
 
The relationship between total white cell count and heart attack in large population 
epidemiologic studies has been well published.161,162,170-175 and persists even after adjustment 
for smoking and other traditional risk factors.22,163,176  
 
Primary stroke177-179 and death after stroke180,181 have both been shown to have association with 
elevated total white cell count. Patients with high total white cell count have also been reported 
to have larger central nervous system lesions at presentation and more severe presenting 
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symptoms.182 Smoking has long been associated with an elevated total white cell count 183-
188but the predictive value of total white cell count is not fully explained by this 
relationship.171,189 
 
Rheologically active leucocytes play a pathophysiological role in atherogenesis through 
endothelial injury and adhesion with plugging of the microvascular circulation and induction 
of tissue ischaemia, propagated by increase in leucocyte number, further leucocyte attachment 
to the endothelium, and reduction in perfusion pressure causing ongoing positive 
feedback.190,191 Whether the observed leucocytosis is causative or reactive to the underlying 
atherosclerotic process remains debated.99,190,192 
 
Despite the advantages of being inexpensive, part of the routine laboratory assessment, being 
reliable with established World Health Organisation (WHO) standards193 and excellent inter-
assay precision, the impact of leukocyte count on cardiovascular risk is largely under 
investigated. This under-investigation is probably because of a tendency of both investigators 
and industry to focus on new assays and molecular mechanisms. 74,191 Total white cell count 
exhibits most of the characteristics desirable in a cardiovascular disease risk predictor 
described by Pearson et al.194 in that it is standardised with the coefficient of variance of 
measurement <3% with established population norms; association with cardiovascular clinical 
end points has been established in observational studies and clinical trials; improves overall 
prediction of risk beyond that of traditional risk factors alone; is generalizable to various 
population groups; and is of acceptable cost. Total white cell count does not however meet the 
criteria of independence from other traditional risk factors and the interdependence on smoking 
needs careful consideration when assessing the role of total white cell count as a risk predictor 
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for major adverse events.191 Coller99 reported that inappropriate multivariate adjustments in 
previous investigations may have resulted in underestimating the true association of increased 
total white cell count with the increased risk of cardiovascular disease. 
 
 Total white cell count in ischaemic heart disease 
The bulk of the published evidence on the association of total white cell count with death, heart 
attack and stroke in patients with atherosclerotic disease is from patients with known ischaemic 
heart disease. In patients with ischaemic heart disease total white cell count has been associated 
with higher mortality following heart attack86,87,89,118,189,195-201 recurrent heart attack189,202,203 
and angiographic severity of coronary artery disease.204 In the Evaluation of c7E3 for 
Prevention of Ischemic Complications (EPIC) study, the total WBC count correlated best with 
three year mortality.205 The effect of total white cell count on mortality following acute heart 
attack may not be linear with evidence of a J-shaped relationship between mortality and total 
white cell count reported in large registry sudies89,201,206 although this phenomena does not 
appear consistent in clinical trial data possibly due to the exclusion of patients with other 
medical conditions resulting in very low total white cell count.205 In following up patients with 
unstable angina the incidence of major adverse event of patients with high total white cell count 
has been reported as much as eight times that of their counterparts with low total white cell 
count.207 The excess risk of elevated total white cell count after heart attack may be at least in 
part attenuated by in-hospital revascularisation.200,208 However, total white cell count has also 
been associated with mortality post coronary artery bypass grafting (CABG)209-211 and 
percutaneous coronary intervention (PCI)205,212-216 and stroke after CABG.217 total white cell 
count has also been associated with new onset congestive cardiac failure.87,89,218  
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In the REACH registry a similar number of patients were reported as having both ischaemic 
heart disease and peripheral arterial occlusive disease to those who were identified as having 
peripheral arterial occlusive disease alone.219 The true proportion of patients with peripheral 
arterial occlusive disease that also have coronary artery disease may be even higher, with >90% 
of patients with peripheral arterial occlusive disease having coronary artery disease if 
angiogram or autopsy is used for diagnosis.34-36 The high prevalence coronary artery disease in 
the population of patients with peripheral arterial occlusive disease make the findings of total 
white cell count association with major adverse events in the coronary artery disease population 
very pertinent to the population of patients with peripheral arterial occlusive disease. 
 
 Total white cell count in peripheral arterial occlusive disease 
Total white cell count has been associated with the presence of peripheral arterial occlusive 
disease in population studies. In the NHANES (National Health and Nutrition Examination 
Survey 1999-2002) total white cell count was associated with the presence of peripheral arterial 
occlusive disease as diagnosed by ankle-brachial index <0.9, with odds ratio of 1.67 for the top 
quartile (>7.3 x109 cells/L) compared to the bottom quartile (≤ 4.9 x109/L).53 Total white cell 
count has also been shown to be related to the presence of carotid and femoral 
atherosclerosis.220 Total white cell count along with elevated fasting plasma glucose level has 
been associated with asymptomatic peripheral arterial occlusive disease in a population of 125 
patients with type 2 diabetes.221 
 
Total white cell count has been proposed as the ideal marker of cardiovascular risk in peripheral 
arterial occlusive disease patients.74 Total white cell count has been associated with an 
increased risk of cardiovascular event in patients with intermittent claudication,24 patients 
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undergoing treatment for symptomatic peripheral arterial occlusive disease74 and all-cause 
mortality in peripheral arterial occlusive disease patients.24,222 Few studies have assessed the 
association of total white cell count with cardiovascular outcome in patients with peripheral 
arterial occlusive disease and these are addressed in detail in Chapter 3.223 
 
Total white cell count has also been associated with adverse operative outcomes in patients 
with peripheral arterial occlusive disease, with higher total white cell counts in failed versus 
successful amputations in diabetic paitents,224 incisional complications after infra-inguinal 
bypass surgery225 and higher total white cell count has been used to predict femoral-popliteal 
bypass failure.226 
 
 
1.4.2. Neutrophil Count 
Neutrophils can adhere to the endothelium and facilitate plaque disruption by releasing 
superoxide radicals, proteolytic enzymes and arachidonic acid metabolites.190,227,228 In addition 
neutrophils can aggregate with platelets and contribute to the microvascular and macrovascular 
plugging promoting infarction.72,228,229 Neutrophils have also been implicated in adverse end-
organ effects following ischaemic insult230,231 possibly by the activation and reduced 
deformability of neutrophils induced by ischaemia232 including the short term ischaemia of 
intermittent claudication.233 
 
Neutrophil count was the major cell subtype that contributed to risk of heart attack in the 
Caerphilly study,176 and elevated neutrophil count was significantly associated with the risk 
of recurrent ischaemic events in the Clopidogrel versus aspirin in patients at risk of adverse 
ischaemic events trial (CAPRIE) study69 and Studies of Left Ventricular Dysfunction 
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(SOLVD) trials.208 A large study by Horne et al.229 which investigated 3277 patients with or 
at high risk for ischaemic heart disease showed that the high neutrophil quartile was a better 
predictor of death or heart attack than total white cell count. Neutrophil count has been 
associated with mortality following heart attack205,234,235 and cardiovascular mortality.236 
Neutrophil count has also been shown to be significantly associated with the incidence of 
stroke in a Japanese cohort.178 Constitutional neutropenia of Yemenite Jews appears to convey 
protection against atherosclerotic disease in an observational study.237 
 
In patients with peripheral arterial occlusive disease, neutrophil count >5.8 x109cells/L 
increased risk for adverse events and added prognostic information to traditional 
atherothrombotic risk factors.72 Neutrophil count >4.6 x 109cells/L associated with an 
increased risk of heart attack and stroke independent of confounding factors and 
cardiovascular treatment in 259 consecutive peripheral arterial occlusive disease patients.74 
Pre-procedural neutrophil count has been demonstrated to predict outcome in patients with 
peripheral arterial occlusive disease undergoing endovascular intervention.238 
 
1.4.3. Lymphocyte Count  
Lymphopenia has been described as being indicative of a generalized state of 
immunodepression with survival adversely influenced by the depressed immune function.49 
Described mechanisms of lymphopenia include margination and redistribution of lymphocytes 
within the lymphatic system and accelerated apoptosis.99 Lymphopenia after major surgery has 
been associated with cortisol (a glucocorticoid hormone) production as a response to 
neuroendocrine stress and predisposes to post-operative complications.239,240  
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The protective effect of relative lymphocytosis has been observed in large studies69,205,208 but 
the underlying mechanisms require further investigation. A large study by Horne et al.229 
which investigated 3277 patients with or at high risk for ischaemic heart disease, showed that 
the low lymphocyte quartile was a better predictor of death or heart attack than total white 
cell count. In the Clopidogrel versus aspirin in patients at risk of adverse ischaemic events 
(CAPRIE) study elevated lymphocyte count was inversely related with the risk of recurrent 
ischaemic events69 with similar results in large studies of patients with ischaemic heart disease 
following coronary percutaneous intervention,205 and Studies of Left Ventricular 
Dysfunction.208 
 
In patients with peripheral arterial occlusive disease lymphocyte counts were reported as 
significantly higher in patients with critical limb ischaemia who had successful limb salvage 
after bone marrow implantation.241 
 
1.4.4. Calculated: Neutrophil / Lymphocyte Ratio (NLR) 
Neutrophil/lymphocyte ratio has been described as a reflection of the balance of the 
neutrophilia of inflammation and the relative lymphopenia of cortisol-induced stress 
response.49 The study by Horne et al.229 showed that the best predictor of death or heart attack 
was the calculated neutrophil/lymphocyte ratio. Neutrophil/lymphocyte ratio has a strong 
relationship within patients with coronary artery disease to adverse outcomes229,242-246 
following heart attack227,243,247,248 in patients undergoing percutaneous intervention212,249 and 
coronary bypass surgery.250,251 Neutrophil/lymphocyte ratio has also been found to be a useful 
predictor of death, adverse outcomes and recurrence in Oncology patients.75,252-259 
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Pre-operative neutrophil/lymphocyte ratio identified patients at increased risk of death 
following major vascular surgery,49 in patients with chronic critical limb ischaemia,260 and 
predicted late mortality following thoracic endovascular aneurysm repair.261 Elevated NLR 
has been proposed as a tool to identify patients with peripheral arterial occlusive disease at 
high risk of developing critical limb ischaemia.262 Elevated NLR >3.0 has also been shown to 
be associated with a higher cardiovascular mortality in a cohort of 503 patients with 
symptomatic peripheral arterial occlusive disease.263 
1.4.5. Monocyte Count 
Ross described monocyte derived macrophages as mediating all the stages of atherosclerotic 
plaque formation and rupture.47 Monocyte count in patients with ischaemic heart disease is 
associated with adverse cardiovascular events although to a lesser extent than neutrophil 
count.99 Monocyte count associated with the presence of peripheral arterial occlusive disease 
in population studies.264 Patients with peripheral arterial occlusive disease have monocytes that 
are more active than control groups when expression of CD40 and CD11b was compared.265 
Elevated monocyte count in patients with peripheral arterial occlusive disease has been 
associated with vein graft stenosis following lower limb bypass surgery but not mortality.266 
One study of 24 patients with critical limb ischaemia reported that elevated monocyte counts 
preoperatively diminish after successful revascularisation with bypass surgery.267 Clear 
association of baseline monocyte counts in patients with peripheral arterial occlusive disease 
with cardiovascular endpoints remains to be established. 
 
1.4.6. Eosinophil Count 
Eosinophil count was associated with heart attack in the Caerphilly study176 and eosinophilia 
predicted cardiovascular mortality in a population study with 30 year follow up in the 
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Netherlands.268 In patients with coronary artery disease a more complex relationship between 
eosinophil count and mortality following PCI has been described, with an elevated eosinophil 
count associated with an improved outcome in the first 6 months after PCI but after this time 
being associated with increased mortality.269 Clear associations of eosinophil counts with 
adverse cardiovascular events are yet to be established in patients with peripheral arterial 
occlusive disease therefore eosinophil counts were recorded but not analysed in the current 
study. 
1.4.7. Basophil Count 
No significant association between basophils and cardiovascular mortality has been reported 
despite inclusion in differential white cell count analysis in large studies. Therefore, basophil 
count was recorded but not analysed in the current study. 
 
1.4.8. Haemoglobin 
Low haemoglobin concentration may be an independent risk factor of cardiovascular risk in 
the general population270 with the Framingham study demonstrating a U-shaped relationship 
between haematocrit and mortality.271,272 Inflammation has been shown to cause immune 
driven depression of haematopoiesis in a manner roughly proportional to the duration and 
severity of disease.273,274 
 
In coronary artery disease patients a low haemoglobin concentration has been shown to be a 
predictor of mortality after heart attack,275 cardiac surgery,276-280 PCI,215,272,281,282 and in 
patients with heart failure.270,283,284 The relationship does not appear to be linear with as many 
as 48% of the mortalities occurring in the lowest quintile of haemoglobin concentration.281 
Transfusion with red blood cells has been shown to reduce the mortality associated with low 
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haemoglobin concentration after heart attack.272 Low haemoglobin concentration has also been 
associated with non-cardiac surgery mortality285,286 and postoperative outcomes in elderly 
patients undergoing non-cardiac surgery.287 
 
In patients with peripheral arterial occlusive disease, low haemoglobin concentration has been 
associated with <30 day mortality,288 two year49 and five year mortality following major 
vascular surgery independent of chronic renal disease and heart failure.288 Low pre-operative 
haemoglobin has been shown to be a predictor of amputation site healing,224 incisional 
complications,225 and early loss of bypass patency.289 Low haemoglobin has been associated 
with mortality in patients with asymptomatic carotid artery stenosis.290 The relationship 
between haemoglobin and the composite endpoint of major adverse event remains unclear in 
patients with peripheral arterial occlusive disease. 
 
1.5. Significance of this study 
The clinical risk factors for the development of peripheral arterial occlusive disease have been 
well established,1,25,28,31,37,73,80,82,94,129,134,219,291-295 and there is evidence that the severity of 
peripheral arterial occlusive disease is associated with the outcomes of death and major adverse 
event.8,21,24,29,34,40,114,185,296,297 There is also evidence that circulating markers of inflammation 
in patients with peripheral arterial occlusive disease are associated with the outcomes of major 
adverse event and death.24,69,72,74,160,161,165,167-169,223,263 However, which circulating markers of 
inflammation best contribute to models of outcome for patients with peripheral arterial 
occlusive disease remains unclear.  
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Models of outcome for patients with peripheral arterial occlusive disease have been proposed 
to include clinical risk factors, severity of disease and circulating markers of 
inflammation.133,134 Models for outcome that combine these variables are not currently 
available for patients with peripheral arterial occlusive disease133 despite their development for 
other manifestations of atherosclerosis such as coronary artery disease298,299 and subsequent 
heart failure.300  
 
Null hypothesis testing paradigm of statistical analysis has traditionally been used to infer 
associations for model creation and a selection of these methods were utilised in this study 
including Kaplan-Meir survival analysis with log-rank testing and Cox proportional hazards 
analysis. Null hypothesis testing techniques were used to establish the important variables 
associated with the outcomes of death and major adverse event and compare this study 
population to previously described populations. The limitations of the traditional null 
hypothesis testing approach are discussed, in particular the inadequacies of using techniques 
such as stepwise regression for model development. Stepwise regression and similar techniques 
are inherently compromised in populations with multiple interacting variables, especially if 
there are small but clinically important effects301 such as in the population with peripheral 
arterial occlusive disease.  Stepwise regression often results in the over or under estimation of 
variable strength,302 missing true predictors303 or the selection of less important predictors303 
depending on which variables are included in the model.304,305 Null hypothesis testing 
techniques are not only unable to quantify the process that leads to final model selection but 
are unable to objectively compare competing models.306 
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The relatively modern statistical paradigm of Information-Theoretical analysis132 is described 
with exploration of why this approach is more appropriate in the development of outcome 
models for patients with peripheral arterial occlusive disease. In this thesis the novel approach 
of Information-Theoretical based multi-model inference is applied to data from patients with 
peripheral arterial occlusive disease. Outcome models were subsequently developed for this 
population for the outcomes of major adverse event and death. Results of the multi-model 
analysis are presented including the development of an averaged best fit model for each 
outcome. To the authors knowledge this study is the first to comparatively assess traditional 
risk factors, clinical disease severity and circulating cell counts for the outcomes of death and 
major adverse event through the application of multi-model averaging from the Information-
Theoretical statistical paradigm132 which is widely used to in other scientific disciplines such 
as ecology and the behavioural sciences. This approach has enabled the generation of accurate 
and reliable models for the outcomes of major adverse event and death using clinical risk 
factors, clinical stage of disease and the circulating cell counts as markers of inflammation. 
The clinician can easily and inexpensively apply the developed models at the bedside or in the 
outpatient clinic with information routinely collected for these patients. The results of this 
model may be used to improve patient compliance with lifestyle change and medical therapy, 
risk stratify patients to aid in clinical decision making and guide future pathophysiological and 
therapeutic research.
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2. Aim, Objectives and Hypothesis 
The overall aim of this study was to develop an improved model to predict outcome in patients 
with peripheral arterial occlusive disease. The hypothesis that total and differential white cell 
count, haemoglobin and neutrophil lymphocyte ratio are associated with the incidence of major 
adverse event (composite outcome of death, heart attack or stroke) and death was tested by a 
cohort design study of prospectively recruited patients with symptomatic peripheral arterial 
occlusive disease. A schematic overview of the thesis is presented in Figure 2.1 and will be 
referred to throughout the thesis. 
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2.1. Objective 1 
Systematic review of the published literature on the association of total white cell count with 
cardiovascular outcomes in patients with peripheral arterial occlusive disease. This objective 
is addressed and presented in Chapter 3.223 
 
2.2. Objective 2 
Describe the cohort characteristics and compare to previously described cohorts with 
peripheral arterial occlusive disease. This objective is addressed in Chapter 5. 
 
2.3. Objective 3 
Describe the cardiovascular events sustained by the cohort and compare to previously 
described cohorts with peripheral arterial occlusive disease. The cardiovascular events of 
interest were major adverse event (composite endpoint of death, heart attack or stroke), death, 
heart attack, stroke, major amputation and peripheral revascularisation. This objective is 
addressed in Chapter 6.  
 
2.4. Objective 4 
Test the association of disease severity at presentation with the outcome of major adverse event 
(composite outcome of death, heart attack or stroke) in this population of patients with 
peripheral arterial occlusive disease. 
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2.4.1. Hypothesis 1 
Disease severity is associated with the outcome of major adverse event (composite outcome of 
death, heart attack or stroke) in a population of patients with peripheral arterial occlusive 
disease. This hypothesis is addressed in Chapter 7. 
 
2.5. Objective 5 
Test the association of total and differential circulating cell counts with the endpoint of major 
adverse event (composite outcome of death, heart attack or stroke) in this population of patients 
with peripheral arterial occlusive disease. 
 
2.5.1. Hypothesis 2 
Baseline total and differential circulating cell counts are associated with major adverse events 
(composite outcome of death, heart attack or stroke) in patients with peripheral arterial 
occlusive disease.  
 
The circulating cell counts investigated were total white cell count, neutrophil count, 
lymphocyte count, monocyte count, haemoglobin concentration and calculated neutrophil-
lymphocyte ratio. This hypothesis is addressed in Chapter 8 Section 4. This hypothesis was 
tested using null hypothesis testing methods of Kaplan-Meir survival analysis, log rank testing 
and Cox proportional hazards. The novel Information-Theoretical approach of multi-model 
averaging was then used to compare the circulating cell counts with traditional risk factors for 
the outcome of major adverse event. A resultant averaged model was created to predict the 
outcome of major adverse event in the studied population of patients with peripheral arterial 
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occlusive disease using circulating cell counts, clinical disease severity, traditional risk factors, 
aspirin and statin use. 
 
2.6. Objective 6 
Test the association of total and differential circulating cell counts with the endpoint of death 
in patients with peripheral arterial occlusive disease. 
 
2.6.1. Hypothesis 3 
Baseline total and differential circulating cell counts are associated with death in patients with 
peripheral arterial occlusive disease.  
 
The circulating cell counts investigated were the same as previously detailed in Hypothesis 2 
however the outcome is the singular cardiovascular endpoint of death. This hypothesis is 
addressed in Chapter 8 Section 5. This hypothesis was testing using null hypothesis testing 
methods of Kaplan-Meir survival analysis, log rank testing and Cox proportional hazards. The 
novel Information-Theoretical approach of multi-model averaging was then used to compare 
the circulating cell counts with traditional risk factors for the outcome of death A resultant 
averaged model was created to predict the outcome of death in the studied population of 
patients with peripheral arterial occlusive disease using circulating cell counts, clinical disease 
severity, traditional risk factors, aspirin and statin use. 
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Each chapter in the thesis will be preceded by representation of the schematic overview of the 
thesis with red outline highlighting the position within the overall thesis. For example the 
following Chapter 3223 is preceded by Figure 3.1 with red highlight box around the position 
within the overall document. 
 
2.7. Scope of the thesis 
This thesis includes a systematic review examining the available literature on the association 
of circulating cells and the outcomes of major adverse event and death in patients with 
peripheral arterial occlusive disease. A prospectively recruited cohort of 632 patients is then 
considered for inclusion into the study and the characteristics of the included cohort and 
incidence of cardiovascular events over the duration of the study are described. The total and 
differential cell counts are then tested for association with the composite outcome of major 
adverse event and the singular cardiovascular outcome of death using traditional null 
hypothesis testing methods and the Information-Theoretical approach of multi-model analysis. 
An averaged model is then developed for each outcome of major adverse event and death and 
methods of applying this model by the bedside or in the outpatient clinic are described. The 
aim of this thesis is to provide prognostic information for individual patients that may aid 
patient compliance with medical therapy and guide clinical decision making. Suggested 
directions for using the outcomes of this thesis to guide further research are also discussed. 
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3. Association of total white cell count with mortality 
and major adverse events in patients with peripheral 
arterial occlusive disease: a systematic review223 
 
3.1. Abstract 
Objectives: Peripheral arterial occlusive disease (PAOD) is principally caused by 
atherosclerosis an established inflammatory disease. Total white cell count (TWCC) is a 
marker of inflammation and has been associated with outcomes for patients with inflammatory 
diseases. The aim of this systematic review was to assess the association of TWCC with 
mortality and major adverse events (MAE) in PAOD patients. 
 
Methods: Studies investigating the association of TWCC with outcome in patients with PAOD 
were identified by a literature search using Medline and Cochrane databases. To be eligible for 
inclusion studies needed to investigate the association of TWCC with mortality or a composite 
endpoint that included mortality in patients with PAOD. Studies were excluded when the 
primary focus was carotid artery disease, aortic aneurysmal disease, intracranial vascular 
disease, rheumatoid arthritis and treatment with chemotherapy or transplantation of stem cells. 
Secondary searching of reference lists and relevant reviews was performed. 
 
Results: Ten studies including 8490 patients with PAOD met the inclusion criteria. All studies 
investigated more than 100 patients with four studies assessing more than 1000 patients. Study 
quality varied with well-established risk factors of outcome such as age, smoking, diabetes and 
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ankle brachial index being adjusted for inconsistently. The study populations were also 
disparate. Few studies reported relative risk and 95% confidence intervals for the association 
of TWCC with mortality or MAE. TWCC was positively and significantly associated with 
death alone in four of five studies investigating 3387 patients. TWCC was positively and 
significantly associated with MAE in five of six studies investigating a total of 6848 patients.  
 
Conclusion: Current evidence suggests a positive association of TWCC with mortality and 
MAE in patients with PAOD. Further well designed prospective studies are required with high 
quality analysis and more complete reporting of outcomes.  
 
Additional note: Publications revealed through replication of literature searching prior to thesis 
submission are included in the introduction section of this thesis. 
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3.2. Introduction 
Peripheral arterial occlusive disease (PAOD) is one manifestation of the inflammatory disease 
atherosclerosis, characterized by arterial stenosis and occlusions of peripheral arteries.12 PAOD 
prevalence is approximately 29% in people aged 70 years or older or those aged over 55 years 
with risk factors of smoking or diabetes.5 Inflammation plays a key role in the development, 
progression and complications of atherosclerosis. Inflammatory processes interacting with 
endothelial dysfunction initiate a progressive process within the arterial wall resulting in 
reduction or obstruction of blood supply to end organs of the body including brain, heart, intra-
abdominal organs and the tissues of the lower limbs causing morbidity and mortality.44,46,52 
Patients with PAOD have up to six times the ten year mortality of age matched controls.19,29 
The presence of either symptomatic or asymptomatic PAOD is an indicator of diffuse and 
significant disease in all arterial beds,11 including coronary and cerebral arteries, and associated 
with a high cardiovascular event rate.38 Predicting the risk of cardiovascular events in 
individuals with PAOD enables management to be tailored appropriately, for example by 
intensifying medical management or offering lower risk operative or endovascular 
management. Established predictors of outcome for patients with PAOD include age,112 
gender,79 smoking,28 diabetes,95 ankle brachial index20 and medications including antiplatelet 
therapy117 and HMG-CoA reductase inhibitors (statins).125 Markers of inflammation are well 
established risk predictors in patients with coronary heart disease29,44,64 but have been relatively 
less well investigated in patients with PAOD.  
 
PAOD patients have increased circulating markers of inflammation compared to the population 
without this disease.53,307 Total white cell count (TWCC) assessed within a peripheral venous 
sample is recognized as a marker of inflammation and altered concentrations of monocytes and 
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neutrophils have been implicated in atherosclerosis.46 Leucocytosis has been associated with 
reduced survival in patients with coronary heart disease.99 TWCC has been shown to be a 
reliable predictor of outcome in patients with stable coronary heart disease170 or acute coronary 
syndrome,227,242 and after coronary artery bypass grafting (CABG)210,211,217,250,251 or 
percutaneous coronary intervention (PCI).212,215,308 TWCC also predicts mortality in other 
surgical252-255,258 and cancer309-312 patients. 
 
It has been suggested that risk stratification models of PAOD patients should combine clinical 
risk factors, clinical stage of disease, a measure of PAOD severity (ABI), and a measure of 
systemic inflammation.133 TWCC is routinely measured in patients with PAOD and could be 
added to models used to predict outcome for these patients. The independent association of 
TWCC with outcome in PAOD patients has however not previously been systematically 
examined. The aim of this systematic review was to examine the association of TWCC with 
mortality and the composite endpoint of major adverse events (MAE) in patients with PAOD. 
 
3.3. Methods 
Protocol: The preferred reporting items for systematic reviews and meta-analysis (PRISMA) 
guidelines313 and meta-analysis of observational studies in epidemiology (MOOSE) 
proposal314 were followed using a standardized written protocol. Searching and study selection 
was conducted independently by two investigators.  
 
Search criteria: A literature search was performed of articles published between 1st January 
1946 and 1st November 2013. Databases searched included Medline (via PubMed and Ovid 
SP 1946 - present including in-process and non-indexed citations), and Cochrane Database of 
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Systematic Reviews. The search was conducted using the following terms: (“Arteriosclerosis” 
OR “Peripheral Arterial Disease” OR “Peripheral Vascular Disease” OR “Arterial Occlusive 
Disease”) AND (“Leucocyte Count” OR “Leukocyte Count”) with prior checking in the MeSH 
database to include synonyms. All subheadings were included in the searches. Publications 
selected for inclusion had their keywords searched manually to ensure no alternative expression 
or relevant keywords were unintentionally excluded. Reference lists from included 
publications and relevant literature reviews were also examined to increase the yield of possible 
studies. Studies identified in the latter way are shown in Figure 3.2 as additional records. 
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Figure 3.2: PRISMA flowchart 
WCC = white cell count 
n = number of participants 
 
Eligibility criteria: For inclusion in this review studies needed to assess the association of 
TWCC with mortality or a composite of endpoints including death in patients with PAOD. 
Only publications in English were included. Studies were excluded when the primary focus 
was carotid artery disease, aortic aneurysmal disease, intracranial vascular disease, rheumatoid 
arthritis or treatment with chemotherapy or transplantation of stem cells.  
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Data extraction: Data was extracted from included studies by two independent investigators. 
Information collected included: study design; participant profile including age, gender, 
cardiovascular risk factors, medications and method of measuring severity of occlusive PAOD; 
study inclusion and exclusion criteria; and duration of follow up. The end-point definitions 
with type and incidence of events were recorded. The method of statistical analysis and 
subsequent results were also recorded. Data was standardized to include both event numbers 
and percentages of the relevant study population where possible. Potential sources of bias or 
conflict of interest were recorded. 
 
Data analysis: Data was transcribed into a Microsoft Excel worksheet. Any discrepancies 
between investigators were reviewed by the author panel until a consensus was reached. No 
published quality assessment tool was found to assess study quality in PAOD. Therefore, a 
novel quality assessment tool was developed to assess the risk of bias.315 The tool was designed 
to assess the inclusion of specific confounding variables relevant to PAOD within individual 
studies to enable comparison between studies. Risk of bias in methodology or reporting was 
estimated by assessing sample size, whether established risk factors for outcome in PAOD 
were adjusted for in analyses and follow up time (Table 3.1). 
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Table 3.1: Risk of bias assessment tool 
 
Risk of 
Bias 
 
Sample 
Size 
Confounding Variables Adjusted (Univariate / multivariate) Follow 
up 
Gender Age Smoking Diabetes 
Mellitus 
Medications Ankle 
Brachial 
Index 
High <100 Not 
Reported 
Not 
Reported 
Not 
Reported 
Not 
Reported 
Not 
Reported 
Not 
Reported 
<1 year 
Not 
statistically 
adjusted 
Not 
statistically 
adjusted 
Not 
statistically 
adjusted 
Not 
statistically 
adjusted 
Not 
statistically 
adjusted 
Not 
statistically 
adjusted 
Medium >100 
<1000 
Recorded 
not reported 
Recorded 
not reported 
Recorded 
not reported 
Recorded 
not reported 
Antiplatelet 
and statin 
reported 
N/A 1-2 
years 
Statistical 
adjustment 
unclear 
Statistical 
adjustment 
unclear 
Statistical 
adjustment 
unclear 
Statistical 
adjustment 
unclear 
Statistical 
adjustment 
unclear 
Statistical 
adjustment 
unclear 
Low >1000 Reported Reported Reported Reported Reported Reported >2 years 
Statistically 
adjusted 
Statistically 
adjusted 
Statistically 
adjusted 
Statistically 
adjusted 
Statistically 
adjusted 
Statistically 
adjusted 
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3.4. Results 
Study selection: Searching identified a total of 688 articles in Medline and 927 in PubMed 
(Figure 3.2). No relevant reviews were found in the Cochrane database of systematic reviews. 
After combining with 1170 additional articles the 969 duplicates were removed. 1782 articles 
screened did not meet inclusion criteria. Thirty four full text articles were reviewed. Three 
studies investigating the association of TWCC with the presence of PAOD without any 
assessment of the incidence of morbidity or mortality of patients with PAOD were excluded 
(labelled epidemiology in Figure 3.2). Twelve articles were excluded for the following reasons: 
measurement of neutrophil-lymphocyte ratio without TWCC;260 inclusion of TWCC but no 
test for the association with mortality or a composite endpoint including mortality;152 
investigation of thoracic endovascular aneurysm repair patients which are a separate subset of 
the PAOD population;261 outcome measures did not include mortality or a composite endpoint 
including mortality238,316-319 exclusion of patients with endpoints of clinical importance such as 
graft occlusion, myocardial infarction, stroke or patients requiring arteriography.266 Ultimately 
ten studies were included in this systematic review.24,49,72-74,122,222,320-322 
 
Study quality: The assessment of bias data for all the selected studies are shown in Table 3.2. 
All selected studies involved more than one hundred patients, with four studies including 
greater than 1000 patients.24,49,73,320 All studies adjusted for gender in statistical analysis 
although adjustment for other variables was less consistent, with neither Belch et al. 12 or Violi 
et al. 73 reporting adjusting for age. Smoking has a well-established association with TWCC 
and mortality but was not adjusted for in two studies122,320while Arain et al. 222 reported 
adjusting for smoking status but did not publish details. Diabetes was not adjusted for in two 
included studies320,321 despite evidence that PAOD patients with diabetes have higher rates of 
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mortality than PAOD patients without diabetes.95,323 The trend for included papers to not report 
or adjust for medications and ABI raises the possibility of bias in the included studies. 
Medication adjustment was reported in only four of the ten studies,72,74,122,222 with the 
remaining papers not adjusting for antiplatelet or statin use, both of which have been reported 
to be associated with reduced cardiovascular events in PAOD patients.125,324 ABI, an objective 
measure of disease severity with previously demonstrated association with cardiovascular 
events,20,8,104,325 was not adjusted for in five49,122,320-322 of the ten studies.24,49,72-74,122,222,320-322 
Pedrinelli et al.322 reported adjusting for all significant variables in a step-wise regression 
analysis although details were not included in report. Amaranto et al.320 adjusted for the least 
confounding variables (i.e. gender and age alone), while two studies, namely those reported by 
Arain et al.222 and Giugliano et al.74, adjusted for all included confounding variables. Only one 
study had a follow up of less than one year with follow up being only 6 months.12 Three studies 
had follow up of more than 2 years.49,74,222 
Table 3.2: Assessment of risk of bias 
 
Risk of Bias 
 
Sample 
Size 
Confounding Variable Adjustment in Statistical Analysis Follow up 
Gender Age Smoking DM Medications ABI 
Amaranto et al.54 Low Low Low High Low High High Medium 
Low Low High High High High 
Arain et al.55 Medium Low Low High Low Low Low Low 
Low Low Low Low Low Low 
Barani et al.56 Medium Low Low Low Low Low Low Medium 
Low Low High Low Low High 
Belch et al.58 Medium Low High Low High High High High 
Low High Low High High High 
Bhutta et al.57 Low Low Low Medium Low High High Low 
Low Low Low Low High High 
Dormandy et al.59 Low Low Low Low Low High Low Medium 
Low Low Low Low High Low 
Giugliano et al.60 Medium Low Low Low Low Low Low Low 
Low Low Low Low Low Low 
Haumer et al.61 Medium Low Low Low Low Medium* Low Medium 
Low Low Low Low Medium* Low 
Pedrinelli et al.62 Medium Low Low Low Low High High Medium 
Medium Medium Medium Medium High High 
Violi et al.63 Low Low Low Low Low High Low Medium 
Low High Low Medium High Low 
* = statin alone 
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Characteristics of included studies: All investigations were cohort design and eight of the ten 
were prospective,12,24,72-74,122,222,322 with the remaining two studies involving retrospective 
examination of prospectively maintained databases.49,320 Six studies49,72,122,222,320,322 
investigated the endpoint of all-cause mortality although Dormandy and Murray24 did not 
provide information on the association of TWCC and all-cause mortality so was unable to be 
included in this section of the analysis. Six studies used composite outcomes with varying 
definitions shown in Table 3.3.24,72-74,320,321 MAE was the most common composite outcome 
consisting of myocardial infarction (MI), stroke and death or vascular death in four studies.72-
74,320 An amputation score used by Belch et al. 321 gave a weighted score to amputation and 
death. Violi et al. 73 used a composite endpoint that in addition to MAE included major 
amputation and excision of ischaemic viscera.  
 
Characteristics of included participants: The ten included studies had a total of 8490 patients 
with PAOD. There was marked heterogeneity between studies with respect to the included 
participant groups (Table 3.3). Patients recruited included those undergoing major open 
vascular surgery49,320 or major endovascular surgery,320 with critical limb ischaemia,122,321,322 
with intermittent claudication,24,73,74 and referred for lower limb investigations.72,222 The 
variation in the study populations of PAOD patients was further demonstrated in the wide range 
of participant characteristics (Table 3.4). The inclusion of male participants varied from 50-
93%.49,122 The average age of included patients was also widely ranging varying from 63-80 
years.73,122 The prevalence of smokers ranged from 25-77%74,122 although the definition varied 
across studies with Belch et al. 321 putting both current and previous smokers in the same group 
but Pedrinelli et al. 322 recording both current and former smokers separately. The prevalence 
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of hypertension varied from 35-84%,73,320 hypercholesteremia from 47-82%72,222 and diabetes 
from 25-57%.122,222 A history of previous MI was present in only 2% of the patients in the 
study reported by Amaranto et al. 320 whereas 54% of the patients in the investigation of Arain 
et al. 222 had a history of coronary artery disease or cerebrovascular disease. The severity of 
PAOD as assessed by ABI was reported in six studies.24,72-74,122,222 In the study of Dormandy 
et al.24 16% of patients had ABI <0.05 despite clinically being graded as Rutherford stage 1-3. 
In the study of Barani et al.122 mean ABI was 0.31 and 28% of the non-survival group presented 
with gangrene, in contrast to the study of Arain et al.222 where 53% had ABI >0.9. Renal 
impairment was reported in only two studies.122,320 
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Table 3.3: Study Characteristics 
Author Sample 
Size 
Cohort 
Design 
Inclusion Criteria Exclusion Criteria Primary Endpoint Secondary Endpoint Follow 
up (mo) 
Amaranto 
et al.320 
1773 Ra Major Vascular Surgery: 
Endovascular: CAS, T/EVAR, LES (804) 
Open: CEA, T/AAA, LEB (969) 
'Major' elective endovascular or open intervention 
within 30 days of vascular index procedure, No pre-op 
TWCC, TWCC outside normal range 
Death, MAE, TIA, 
Infection, Bleeding, Re-
operation & amputation 
Death 
MAE = death, stroke 
and MI 
14c 
Arain et 
al.222 
226 P Referral for lower-extremity vascular 
evaluation 
ABI >1.3, not consented, lost to follow up All-Cause Mortality - 71 c 
Barani et 
al.122 
259 P Admission with Critical Limb Ischaemia  No written consent All-Cause Mortality Vascular death 12 
Belch et 
al.321 
366 P Critical Limb Ischaemia Infection Amputation score 1-7 d - 6 
Bhutta et 
al.49 
1021 Ra Major Vascular Surgery (CEA, EVAR, 
Open AAA, LEB) 
Fistula formation, vascular trauma, mesenteric 
revascularisation, thoracic aneurysm 
Death within 2 years - 24 
Dormand
y et al.24 
1969 P Claudication, ABI <0.85 in both arteries 
of at least one leg or re-vascularised  
Platelet active drugs, β blockers, rest pain or gangrene All-cause mortality MAE = MI, stroke and 
vascular death 
12 
Giugliano 
et al.74 
259 P ABI<0.9 selected from patients referred 
to Vascular Lab (365) 
ABI > 0.9; critical limb ischaemia; revascularisation 
<6/12; unstable angina, MI or stroke in last 3/12; 
decompensated heart failure; cancer; hepatic, renal or 
inflammatory disease. TWCC > reference range 
MI, Stroke (including 
fatal) 
 30 c 
Haumer 
et al.72 
398 P >50% stenosis on angiogram of 
symptomatic limb 
(Consecutive admissions to ward) 
Acute infection unrelated to PAOD, missing data or 
TWCC, no follow up. 
Death, MI, PCI,CABG, 
stroke, carotid operation,  
Death alone. 
MAE = death, stroke 
and MI 
20 c 
Pedrinelli 
et al.322 
108 P Critical Limb Ischaemia undergoing 
angiogram 
Patients on oral anticoagulants or fibrates at baseline All-cause mortality - 19.2 c 
Violi et 
al.73 
2111 P Claudication, ABI <0.8 in one foot, 
previous amputation or revascularisation 
surgery 
Antiplatelet, anticoagulant or NSAIDs, rest pain or 
ulcer, MI, stroke or surgical intervention <3/12, angina 
requiring CABG or PCI, liver insufficiency, renal 
disorders or life expectancy <2 yrs., patient withdrew, 
adverse events, concomitant disease, therapy refusal, 
antibiotics, >80 yr. 
Major: Death, MI, stroke, 
excision of ischaemic 
viscera, major amputation 
Minor: angina, MI, 
TIA, minor stroke, 
renal failure, HTN, 
vascular surgery, PTA 
/thrombolysis 
18 
CAS = Carotid artery stent 
T/EVAR = Thoracic or abdominal endovascular aneurysm  
LES = Lower extremity stent 
CEA = Carotid endarterectomy 
T/AAA = open thoracic or abdominal aortic aneurysm repair 
LEB = Lower extremity bypass 
TWCC = Total white cell count 
MI = Myocardial infarction 
TIA = Transient ischaemic attack 
MAE = Major adverse event 
PCI = Percutaneous coronary intervention 
CABG = Coronary artery bypass grafting 
ABI = Ankle brachial index 
PAOD = Peripheral arterial occlusive disease 
HTN = hypertension 
PTA = Percutaneous transluminal angioplasty 
R = Retrospective 
P = Prospective 
(mo) = Months 
a = from prospectively maintained database 
b = Non-Matched 
c = median 
d = Amputation score =1 no amputation to  
7 hip exarticulation or death 
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Table 3.4: Participant characteristics 
Author Group Cases Male Age Smoking HTN Cholesterol DM Previous MI ABI Severity of PAOD Renal 
Impairment 
Amaranto 
et al.320 
 
Endo 804 580(71%) 71.2±10.4 NR 677(83.3
%) 
485(60%) 203(25.1%) 20(2.5%) NR NR 99(12.3%) 
Open 969 617(63%) 69.6±10.5 NR 822(84.3
%) 
618 (63.4%) 251(25.7%) 19(1.9%) NR NR 106(10.9%) 
Arain et al. 
222 
Cohort 226 121 (54%) 68.4±11 137 (61%) 150(66%) 105(47%) 56(25%) 122(54%)a <0.9 114 (50%) NR Measured 
NR 
Barani et al. 
122 
Survivor 198 99(50%) 74±10 69(35%) 141(71%) HDL/LDL 
reported 
100(51%) NR 0.31±0.21 Gangrene 16(8%) 1(0.5%) 
Non 
Survivors 
61 39 (64%) 80±10 15(25%) 40(66%) HDL/LDL 
reported 
35(57%) NR 0.32±0.26 Gangrene 17(28%) 4(7%) 
Belch et al. 
321 
Cohort 366 221(60%) NRb 244(66%)c NR NR NR NR NR NR NR 
Bhutta et al. 
49 
Cohort 1021 944 (93%) 71±8.45 191d(19%) d NR d d e NR NR NR 
Dormandy 
et al.24 
Cohort 1969 1572(80%) 63.2±9.1 1396(71%) 1113 
(57%) 
Mean 6.5 
mmol/L 
±1.5 
277(14%) 203 (10%) <0.05=316 
(16%), >0.85=1
89 (10%) 
F = II NR 
Giugliano 
et al.74 
Cohort 259 196(76%) 66.9±9.1  199(77%) c 212(82%) 200(77%) 125(48%) 115(44%) 0.69±0.18 F = II NR 
Haumer et 
al.72 
NC≥ 5.8g/L 136 86(63%) 65(57-75)* 77(57%) 101(74%) 100(74%) 62(46%) 35(26%) 0.56 (0.41-
0.71)* 
CLI 36 (27%) NR 
NC≤ 5.8g/L 262 147(56%) 71(60-76)* 94(36%) 196(75%) 215(82%) 95(36%) 63(24%) 0.59(0.45-
0.75)* 
CLI 53(20%) NR 
Pedrinelli et 
al.322 
Cohort 108 78(72%) 72±10 73 (68%) c 88(82 %) 51(47%) 41(38%) 33(31%)g 0.3 (0-0.6) n=55 F = III 27 (25%) 
F = IV 81 (75%) 
NR 
Violi et al.73 
 
Cohort 2111 
 
1764(84%) 
 
63±0.16** 718(34%) 745(35%) NR 397(19%) NR <0.8 
=1021(48%) 
F = II NR 
Endo = Endovascular 
NR = Not Reported 
F= Fontaine classification system 
HTN = Hypertension 
DM = Diabetes Mellitus 
MI = Myocardial Infarction 
ABI = Ankle Brachial Index 
PAOD = Peripheral Arterial Occlusive Disease 
NC = Neutrophil Count 
HDL = High Density Lipid 
LDL = Low Density Lipid 
CLI = Critical Limb Ischaemia 
a = Coronary Artery disease OR Cerebrovascular disease 
b = Age not reported but adjusted for in linear regression 
c =Smokers includes current smokers and previous smokers 
d = Recorded, Univariate regression reported 
e = Ischaemic Heart Disease OR Cardiac Failure 
f = Defined by statin use 
g = Self-reported MI, angina or use of nitro-glycerine, definite MI 
on resting ECG, self-reported history of coronary PCI or CABG 
* = Inter-Quartile Range 
** = SE
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Association of TWCC with death: The association of TWCC with death alone was reported in five studies 
including 3387 patients (Table 3.5).49,122,222,320,322 Four studies, including 2140 patients, reported a 
positive association of TWCC with death after adjusting for other risk factors.122,222,320,322 One study did 
not report an adjusted analysis because TWCC was not associated with death on univariate analysis.49 
In the two studies that examined major open vascular surgical procedures49,320 neither demonstrated a 
significant linear association between TWCC and death but when a quadratic term was used for TWCC 
in the study reported by Amaranto et al.320 a significant association was demonstrated. Odds or hazard 
ratios were reported in only four studies,49,122,222,320 confidence intervals were only published in three 
studies49,122,222 consequently meta-analysis was not possible. One study that did demonstrate an 
association322 between TWCC and death did not publish their method of multivariate statistical analysis. 
Only one study222 adjusted for all confounding variables and this study reported the most positive 
association of TWCC with death (risk ratio of 3.72).  
 
Table 3.5: Association between white cell count and mortality in peripheral arterial occlusive disease patients. 
Author Population Cases Analysis RR/OR/HR 95% CI P Value Adjusted 
Amaranto 
et al.320 
Major 
Endovascular 
Surgery 
804 * OR=1.82 
 
NR 0.015 
 
Age, gender, diabetes, CHF, MI, renal 
impairment, HTN, lipids, emergent 
procedure 
Major Open 
Vascular Surgery 
969 * OR=1.168 NR 0.005*** Age, gender, diabetes, CHF, MI, renal 
impairment, HTN, lipids, emergent 
procedure 
Arain et 
al.222 
Lower Extremity 
Evaluation 
226 ** HR=3.37 1.56-7.27 
 
NR Age, gender, smoking, hypertension, 
CAD/CVD, serum creatinine, ABI & 
CRP 
Subset ABI <0.9 114 ** HR=3.72 1.38-
10.01 
NR Age, gender, smoking, hypertension, 
CAD/CVD, serum creatinine, ABI & 
CRP 
Barani et 
al.122 
CLI 259 * OR=1.202 1.054-
1.370 
0.006 NR 
Bhutta et 
al.49 
Major Vascular 
Surgery 
1021 NR OR=1.02 0.95-1.09 0.54 Univariate regression only 
Pedrinelli 
et al.322 
CLI 108 
 
NR NR NR <0.04 NR 
RR = Relative Risk 
OR = Odds ratio 
HR = Hazard ratio 
NR = Not reported 
NS = Not significant 
CLI = Critical limb ischaemia 
CHF = Congestive heart failure 
MI = Myocardial infarction 
HTN = Hypertension 
CAD = Coronary artery disease 
CVD = Cerebrovascular disease 
ABI = Ankle Brachial Index 
*Per 1000/μL increase 
**Top tertile compared to bottom 
tertile 
*** Quadratic term for WCC 
****Deceased vs alive median
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Association of TWCC with MAE: The association of TWCC with MAE was assessed in six studies 
including 6848 patients (Table 3.6).24,72-74,320,321 The composite outcome of MAE defined as death, MI 
or stroke was positively associated with TWCC in five 24,73,74,320,321 of the six included studies although 
definitions for inclusion in this group varied between studies. Three studies published an odds or hazard 
ratio73,74,320,321 and one study relative risk321 but only three published confidence intervals.73,74,321 The 
only study reporting no association between TWCC and MAE72 did not publish any results other than 
reporting no significant association. As a result of the abovementioned inconsistencies meta-analysis 
was not possible. Three studies reporting a positive association73,320,321 had a high risk of bias in three or 
more sections of the assessment tool (Table 3.2). The remaining two positively associated studies had 
less marked risk of bias noted. Dormandy et al.24 did not report adjustment for medication alone. The 
study reported by Giugliano et al.74 had the lowest risk of bias of all included studies. The investigation 
that reported no association between TWCC and MAE adjusted for all confounding risk factors except 
aspirin.72 The study reported by Haumer et al.72 had the broadest outcome inclusion criteria, including 
PCI, CABG and carotid operations together with other MAE making direct comparison problematic. 
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Table 3.6: Association between white cell count and major adverse events in peripheral arterial occlusive disease patients 
Author Population Cases Endpoint Analysis RR/OR/HR 95% CI P Value Adjusted 
Amaranto et al. 
320 
Major 
Endovascular 
Surgery 
804 MAE * OR 1.672 NR 0.001 NR 
Major Open 
Vascular 
Surgery 
969 MAE * OR 0.58 NR 0.580 NR 
MAE*** * OR 1.07 NR 0.119 NR 
Belch et al. 12 CLI 366 Amputation scorea ≥ 9x109/L RR 1.6 1.2-2.0 0.001 Gender, smoking, prostacycline Rx 
Dormandy et al. 
24 
Claudication 1969 MAE NR NR NR 0.05 NR 
Giugliano et al. 
74 
Claudication 259 MAE * HR 1.35 1.10-1.65 <0.01 Age, gender, ABI, smoking, diabetes 
mellitus, hypercholesteremia, 
hypertension, previous MI and previous 
stroke 
HR 1.29 1.06-1.57 <0.02 Medications 
MAE ROC and Bootstrap 
groups >7.7 x109 
compared to≤ 7.7 x109 
HR 3.03 1.38-6.61 0.005 
Log rank 
Age, gender, ABI, smoking, diabetes 
mellitus, hypercholesteremia, 
hypertension, previous MI and previous 
stroke 
HR 2.58 1.21 – 5.49 Medications 
MAE ABI ≤ 0.63 and 
TWCC >7.7 x109 
compared to ABI ≥ 0.63 
and TWCC <7.7 x109 
HR 5.77 2.04-16.34 0.010 NR 
Haumer et al. 
6172 
Inpatient 
Angiograms 
398 MAE ** NR NR 0.22 
 
NR 
Violi et al. 73 Claudication, 
previous 
amputation or 
bypass 
2111 MAE + excision of 
ischaemic viscera, 
amputation above the ankle 
Population standardised 
odds ratio 
OR1.15 1.023 (90%) – 
1.301 (09%) 
0.0507  
**Top compared to bottom tertile 
*** Quadratic term for WCC 
RR = Relative Risk 
OR = Odds ratio 
HR = Hazard ratio 
NR = Not reported 
CLI = Critical limb ischaemia 
MI = Myocardial infarction 
ABI = Ankle Brachial Index 
NR = Not reported 
NS = Not significant 
aAmputation Score graded 1-7 (1 no amputation to 7 hip 
disarticulation or death) 
*Per 1000/μL increase 
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3.5. Discussion 
There is a current deficiency in predictive markers of outcome for PAOD patients. TWCC is a 
recognized marker of systemic inflammation in many diseases. In the current systematic review 
we assessed the association of TWCC with death and MAE in PAOD patients. Overall the 
current studies suggest a positive but inconsistent association of TWCC with death and MAE. 
 
Predicting the PAOD patients who will die is clinically important and prognostic indicators of 
risk have been proposed to include clinical risk factors, stage of disease and circulating 
biomarkers for these models to be accurate predictors of outcome.133 Before these models are 
adopted in the clinical setting they need to be rigorously tested in studies using consistent 
definition of terms and thoroughness in adjusting for other known confounders. 
 
A major finding of this review was the heterogeneity of reported studies, with great variation 
in the included patients and their characteristics making compilation of results challenging. 
This emphasizes the importance of adjusting for established confounding variables and fully 
reporting the results of adjusted analyses. Without this information a meta-analysis of collated 
studies was not possible. Whilst adjustment for some confounders was consistent between 
studies with all studies adjusting for gender, and all studies except those reported by Belch et 
al.321 and Violi et al.73 adjusting for age, the known confounders of medication and ABI were 
poorly adjusted for in the selected studies. Pedrinelli et al.322 reported the confounders of 
gender, age, smoking and diabetes although it was unclear whether these variables were 
adjusted for in their statistical analysis. The only selected study to adjust for all confounders in 
the assessment tool was Arain et al.222 who reported the strongest association of TWCC with 
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death. Giugliano et al.74 was the highest quality study with the lowest assessed risk of bias, and 
reported the strongest positive association of TWCC with MAE.  
 
Variation in the definition of MAE was another key finding. The endpoint of death, stroke and 
MI (MAE) (+/- CABG, +/- PCI) was used in three studies but in one study death from causes 
other than MI and stroke was not included in MAE74. Some investigators included re-
intervention such as revascularization with bypass or endovascular surgery or major 
amputation with MAE. An agreed international definition for MAE in PAOD patients would 
assist literature review and comparison of reported series. 
 
There is evidence that TWCC may better predict outcome in endovascular interventions and 
lower limb operations than when combining all major vascular operations including aortic and 
carotid surgery. Two studies investigating patients undergoing angiogram or major 
endovascular interventions were able to demonstrate an association between TWCC and 
outcome on both univariate and multivariate analyses.320,322 A similar result was seen in a study 
that focused on lower limb bypass316 although the sample size was small and the outcome was 
MI in isolation rather than a composite outcome thus not meeting inclusion criteria for this 
review. TWCC was not linearly associated with mortality of patients undergoing major open 
vascular surgery in two large groups,49,320 though when a quadratic term was used for TWCC320 
a significant association with death was found, raising the possibility of a more complex 
relationship in these patients which will need to be considered in statistical analyses in the 
future. There are many potential confounders in open operations for aortic and carotid disease 
and in this patient group it may be more appropriate to examine these interventions separately 
in the future. 
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The timing of blood sampling in relation to surgical intervention was variable in the included 
studies. In one study the most recent TWCC prior to the procedure320 was used, whilst in some 
investigations timing was not specified. Both Violi, et al.73 and Dormandy, et al.24 included 
patients that previously had arterial reconstructive surgery without reporting the timing of this 
surgery relative to study entry. Ulceration, tissue loss and gangrene of the lower limb are all 
potential confounders of TWCC in patients with PAOD. None of the studies focusing on 
critical limb ischaemia reported differentiating rest pain from gangrene.72,122,321 None of the 
included studies adjusted for antibiotic use and only in the investigation reported by Violi et 
al.73 were patients on antibiotics excluded. 
 
The limitations of this review include the small number of studies identified and the 
heterogeneous nature of populations studied and endpoint definitions. TWCC is the most 
commonly measured inflammatory marker that has been associated with the clinical outcomes 
of atherosclerotic disease, although its use for risk stratification remains unproven in the PAOD 
population. It has been suggested that risk factor modification and targeted medical therapy in 
the high risk population would be of benefit;12,135,326 and that prognostic modelling that 
identifies high risk patients may increase patient compliance to lifestyle change and 
pharmacological therapy. The relationship between TWCC and specific outcomes within 
defined subgroups of the PAOD population based on stage of disease requires further study 
before it is able to be used in modelling to predict outcome. Further analysis of differential 
WCC should be undertaken in the same manner, to assess its value in determining high risk 
patients for targeted interventions. Future studies should also standardise reporting including 
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timing of blood sampling, infection or tissue loss in the limb, antibiotic usage at the time of 
sampling and the timing and method of revascularisation in relation to sampling.  
 
In conclusion this systematic review demonstrated a positive but inconsistent association of 
TWCC with death and MAE in patients with PAOD. If TWCC is associated with death and 
MAE in higher quality large studies as a readily obtainable marker of inflammation it may be 
easily integrated into predictive models of outcome for PAOD patients. 
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4. Study design and methodology 
This chapter will describe selection of the study participants with inclusion and exclusion 
criteria. Data collection and retrospective data validation that was undertaken to ensure 
completeness of recorded cardiovascular events and potential confounding factors will be 
explained. Definitions and methods of recording cardiovascular endpoints and confounders 
will then be addressed in detail. The procedures section of this chapter will model the individual 
patient trajectory through the study, in particular selection of the most appropriate “study 
baseline bloods”. Statistical analysis that was employed to test the hypotheses will conclude 
the chapter, including the a priori power calculation that was performed to ensure an adequate 
sample size was recruited. 
 
4.1. Participants  
This study was part of a larger prospective cohort study of patients which included patients 
with known peripheral arterial occlusive disease, aortic aneurysm and/or carotid artery disease. 
Ethical approval for this study was granted by James Cook University Human Ethics 
Committee ethics approval number H2196 (Appendix A), the Townsville Health Services 
District ethics committee Protocol 61/05 (Appendix B) and the Mater Hospital Townsville 
ethics committee (Appendix C). Prospective recruitment has occurred since 2002 from The 
Townsville Hospital and Townsville Mater Hospital during vascular surgical outpatient clinics 
or upon admission to hospital to undergo a vascular interventional procedure. All patients 
included in this study signed an informed consent form (Appendix D or Appendix F) after 
being given an information sheet (Appendix E or Appendix G). Patients were followed until 
death, discharge from clinic or the conclusion of data collection for this study (1/12/2014). 
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Enrolment in the study was voluntary and did not affect the clinical management of the patients 
in any way. 
 
Of the 1439 patients enrolled in the larger cohort study who were recruited from the above sites 
before November 1 2014, 632 patients were initially selected as meeting the inclusion criteria 
(3.1.1 page 95) and not the exclusion criteria (Section 3.1.2 page 96) and underwent chart 
review and data collection. Power calculations are shown in Section 3.3.3 (page 127) which 
demonstrated this to be an adequate sample size. 
 
4.1.1. Inclusion criteria 
Inclusion criteria were chosen to broadly select all recruited patients with symptomatic 
peripheral arterial occlusive disease. 
• Consecutive patients recruited into the “The role of differences in circulating factors 
in the pathogenesis of vascular disease” study who provided written consent. 
• Patients recruited from The Townsville Hospital, Townsville Mater Hospital Pimlico 
and Townsville Mater Hospital Hyde Park. 
• Symptomatic peripheral arterial occlusive disease – defined as having features 
consistent with the disease on clinical history or examination by a vascular surgical 
consultant. 
• Pre-operative or “study baseline bloods” available for analysis. “Study baseline 
bloods” were defined as blood sampling: either at recruitment when well with no 
signs of infection or current antibiotic treatment; or greater than one month post 
interventional procedure or major adverse event and the absence of active infection, 
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antibiotic treatment or other exclusion criteria (see also “Inclusion with caution” 
Section 3.2.3 page 98). 
• Minimum follow up of one month after admission to the study or interventional 
procedure. Patients were included if death occurred in this period. 
• Ankle Brachial Index (ABI) is a measure of severity of peripheral arterial occlusive 
disease and is calculated by the Doppler systolic blood pressure at the ankle divided 
by the brachial systolic blood pressure. Elevated Ankle Brachial Index >1.4 results 
from incompressible arteries of the lower limb and has been an exclusion criteria in 
previous studies investigating TWCC and outcome of peripheral arterial occlusive 
disease.74,222 However, these patients have a documented risk of critical limb 
ischaemia and raised all-cause mortality20,116,325,327 and form an important subset of 
peripheral arterial occlusive disease patients therefore these patients were included in 
this study. 
 
4.1.2. Exclusion criteria 
• Aneurysmal disease requiring intervention – either open surgical or endovascular 
management.  
o Although occlusive and aneurysmal arterial disease share some common risk 
factors, similar pathophysiology and indeed common circulating markers of 
inflammation, there are some obvious discrepancies among risk factors, genetic 
determinants and histological disease progression.328 The confounding effect of 
two similar inflammatory processes running in parallel would have been difficult 
to control for with the chosen statistical analysis. Therefore patients with 
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aneurysmal disease that was significant enough to require intervention during the 
course of the study were excluded. 
o Patients with small asymptomatic abdominal aortic aneurysms <5cm maximal 
aortic diameter and small peripheral aneurysms that did not require intervention 
over the course of the study were included.  
• No pre-operative or “study baseline” bloods available. 
• Total white cell count (TWCC) >15 x109 cells/L (reference range 3.5-11.0 x109 
cells/L) 
o TWCC<15 x109 cells/L includes >99% of the non-oncology adult patients at our 
testing centres and values outside this range raise the possibility of confounding 
variables elevating the white cell count; for example subclinical infection. 
o Low TWCC <3.5 x109 cells/L were included as U or J shaped relationships 
between TWCC and cardiovascular endpoints have been previously 
reported.89,201 
• Malignancy 
• Haematological disorders 
• Known cause for leucocytosis 
• Renal failure requiring dialysis 
o Inflammatory markers are a predictor of outcome in chronic renal failure, 
however the causes of this inflammation appear different to the peripheral 
arterial occlusive disease population with separate risk factors, inflammatory 
signals associated with dialysis, decreased renal function, volume overload and 
inter-current clinical events all playing a contributing role.329  
• Chart not available for review and validation of collected data. 
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o This excluded patients recruited from other hospitals and they were not included 
in this study. 
• Immune modifying medication including steroids, clozapine, immune-suppressants 
(including but not limited to: Sirolimus, Tacrolimus, Cyclosporine, Mycophenolate 
Mofetil) 
• Upper limb amputation 
• Lower limb amputation during the course of study for trauma or tumour. 
o Trauma causes activation of systemic inflammatory immune response which is 
further augmented by the “second hit” of an amputation operation and can lead 
to systemic inflammatory response syndrome, the interactions and consequences 
of which are detailed elsewhere.330 Interpretation of inflammatory markers in 
this setting and their correlation with mortality is outside the scope of this study.  
o Inflammation has a role in tumour establishment and progression331 and this 
process will confound inflammatory marker levels. These patients were also 
excluded under ‘malignancy’. 
 
4.1.3. Inclusion with caution 
• Active infection at time of recruitment  
o Active infection including infection of ischaemic ulcers is an important 
confounder because elevation of white cell count associated with infection 
would be indistinguishable from elevation due to inflammatory or ischaemic 
processes alone.  
o Infection was defined as wound culture positive for pathogens, documentation of 
clinician suspected infection or antibiotic prescription. 
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o These patients were eligible for inclusion if later blood tests were available after 
the clinical resolution of infection and cessation of antibiotic therapy, a 
minimum of four weeks post-operatively and prior to any cardiovascular 
endpoint  
 
4.1.4. Data Collection and Validation 
Patients were prospectively recruited from the outpatient departments or when admitted to 
hospital to undergo a vascular surgical procedure. A Microsoft Access (2010/2013) front end 
was used to access a SQL (structured query language) database server (R2, 2008) that was 
established to collect clinical information over time, enabling retrospective analysis of the 
progression of the disease process. The collected data for this study included: clinical history 
of presenting condition and risk factors for vascular disease; medications including total daily 
dose; previous cardiovascular events; results from blood analysis including biochemistry and 
full blood counts. Other variables and endpoints were also recorded as part of the research 
process although this data was not intended for use in this study but other studies underway 
within the larger “The role of differences in circulating factors in the pathogenesis of vascular 
disease” study being conducted from the same database. The data collected but not intended 
for use in this study included additional medical history, additional blood results including 
electrolytes, liver function tests, coagulation profile, lipid profile, HbA1C (measure of glycated 
haemoglobin – specifically the beta-N-1-deoxy fructosyl component of haemoglobin), CRP 
and homocysteine where available. Details of all vascular and cardiac admissions and 
interventions as well as all medications and dosage were recorded although were not used in 
this study. 
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The principal investigator reviewed all of the medical records of the recruited patients. All 
chart reviews were conducted by the author with consistent method, over the briefest time 
period possible. Thus inter-rater error was eliminated through the use of a single investigator 
and intra-rater error was reduced through consistency of method. Paper and electronic patient 
records were reviewed for details of every inpatient hospitalisation, outpatient visit, laboratory 
and pathology results, relevant correspondence and notification of death. AUSLAB 
(Queensland Health Clinical and Scientific Information System), Sullivan and Nicolaides 
Pathology and Queensland Medical Laboratories data systems were reviewed in the collection 
of blood analysis results. All laboratories adhered to the WHO quality assurances in 
haematology guidelines.193 Validity of chart reviews can be enhanced by decreasing the 
number of reviewers, using consistency of method and reporting inter-rater reliability 
(eliminated in this study by single investigator data collection).332 Patients were continually 
recruited prospectively and patients were followed in outpatient clinics to collect outcome data 
when being reviewed as part of their ongoing clinical care by vascular surgical consultants. 
Treatment of patients was not altered in any way by inclusion or exclusion from this study. 
 
Archived data in the database is owned, controlled, and is continually edited by other 
investigators with separate research questions. Therefore all data was extracted from the 
database on completion of data collection at a single point in time. The extracted data 
spreadsheet was then rechecked against the database and errors from extraction were corrected 
for each patient in the study. Where there was concern relating to extracted data, patient 
medical records and electronic records were used to confirm correct results. 
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All information extracted from medical charts can have its validity questioned, dependent on 
the patient reporting and the doctor recording, chart reviews can have variable results, largely 
depending on the history of interest with concordance less likely in asymptomatic 
conditions.333,334 This is important to acknowledge as the risk factors of peripheral arterial 
occlusive disease that were required to be adjusted for in statistical analysis are often 
asymptomatic. Subsequently the collection of this data did not come from the record of the 
patients self-report alone, instead efforts were taken with data collection to collect 
corroborating evidence from other sources both in the patient chart and electronically to 
minimise the effects of patient recall or single doctor recording.  
 
Whilst every effort was made to minimise missing data, due to the nature of retrospective data 
validation there were some incomplete data sets which were excluded. The most common 
missing information was no “study baseline bloods” in 27 patients and <1 month follow up in 
18 patients. Only patients that had complete data sets were included in the current study.  
 
4.2. Outcome measures and variables 
All patient information was entered through a Microsoft Access front end and stored in a SQL 
(structured query language) database developed for this purpose on a secure James Cook 
University server. All values, outcome measures and variables were validated retrospectively 
from multiple sources by the principal investigator to eliminate inaccuracy. The outcome 
measures and confounding variable definitions and reasons for inclusion in the study are 
presented followed by description of the method used for data collection. 
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4.2.1. Outcome Measures 
 Primary Outcome – composite of cardiovascular events 
Major Adverse Event (MAE): was defined as the first event in the composite outcome of death, 
heart attack or stroke. Each of these are defined individually below. 
 Secondary Outcomes – individual cardiovascular events 
Death by cause: cessation of life with cause recorded when available. Death certificates are not 
readily available for research purposes in the state of Queensland. The recorded arrival of the 
patients’ body at a Queensland Health mortuary was the most common method of confirming 
death and autopsy to confirm cause of death when performed. In other cases collateral was 
sought from the patients general practitioner or treating physician to confirm date and cause if 
known. 
Heart attack: heart muscle cell death diagnosed with evidence of myocardial necrosis consistent 
with ischaemia according to the universal definition of myocardial infarction (heart attack):335 
o Cardiac biomarker (Troponin I or T, creatinine kinase –myoglobin fraction) rise 
above the 99th percentile. 
o And at least one of the following: 
 Symptoms of cardiac ischaemia – chest pain or angina equivalent (arm, 
neck, jaw, back or epigastric pain) lasting for more than 20 minutes. 
 ECG (electrocardiogram) changes indicative of new ischaemia: 
o New ST segment change or new left bundle branch block. 
o Development of pathological Q waves on ECG. 
 Imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormality.  
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o Does not include all percutaneous coronary intervention unless accompanied by 
peri-procedural myocardial necrosis meeting above criteria with the level of 
biomarker sensitivity raised to 3 x 99th percentile by convention.335 
o Does not include all coronary artery bypass graft operations unless peri-procedural 
evidence of myocardial ischaemia with the conventional range 5 x 99th 
percentile.335 
o If leading to death, death was the secondary outcome rather than heart attack. 
Stroke: damage to function of brain cells due to either ischaemia or haemorrhage. 
o Defined by sudden onset focal or global demonstrable neurological defect lasting 
longer than 24 hours. 
o If leading to death, death was the secondary outcome rather than stroke. 
Major amputation: below knee, above knee and hindquarter amputations were defined as major 
amputations. Digital amputation and trans-tarsal amputation were considered minor 
amputations. Major amputation was included as it is a clinically relevant non-fatal outcome for 
patients with peripheral arterial occlusive disease with considerable morbidity. 
 
All other cardiovascular and vascular events including admissions to hospital were recorded in 
the database for the patients recruited to this study. Further outcomes were not intended for 
analysis within this study and were therefore not included as secondary outcomes.  
 
 Method of recording cardiovascular outcomes 
In consultation with the director of the Department of Vascular and Endovascular Surgery unit 
at The Townsville Hospital, senior research nurse and database manager, the hierarchical 
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recording of all cardiovascular events was reviewed and upgraded prior to the commencement 
of data collection. The purpose of this upgrade was to improve the accuracy of the database 
records and enable subgroup analysis by specific cardiovascular event. The hierarchical 
redesign was done to clearly record differentiated cardiovascular events and did allow for 
collection of more cardiovascular event detail than was analysed by this study but will be 
referenced with greater ease during future research on this patient group.  
 
4.2.2. Variables 
Full blood counts which include total and differential white cell count and haemoglobin 
concentration were measured by standardised means by Pathology Queensland Clinical and 
State-wide Service (the pathology service for Queensland Health), Queensland Medical 
Laboratories (QML) Pathology and Sullivan and Nicolaides Pathology Laboratories only. 
Total white cell count (TWCC) has been demonstrated to have diurnal336 and seasonal 
variation337 so date and time of blood collection was recorded and analysed to minimise 
unrecognised systematic error from data collection. Preliminary analysis of the time of blood 
sampling in this study (with linear regression and best fit residual calculations) showed no 
correlation to cell count values or cardiovascular events and is therefore not controlled for as a 
variable or presented in the results. An overview of the precedence for inclusion of each of the 
individual circulating cell parameters for their association with cardiovascular events is 
presented in Chapter 1. 
 
Activation of white blood cells by smoking and hypertension338 or ischaemia increases their 
adhesion to endothelium158 and makes them much less deformable (~2000 times) than red 
blood cells321,339 possibly contributing to the small vessel plugging340 and the cascade that 
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follows to produce ischaemic events.177  Activated white blood cells may be released from 
ischaemic tissue and cause adverse effects in remote organs.230,231,341 Whilst measurement of 
activation of white blood cells was outside the scope of the current study, mobilisation of white 
blood cells from the marginalised pool is an important potential contributor to an elevated 
circulating white cell count in this population. 
 
4.2.3. Confounding Variables 
Data was collected on variables other than circulating cell counts that may either predispose or 
protect patients from cardiovascular events. These variables have been grouped into risk factors 
and medications. Disease severity at presentation is also a confounding variable and definitions 
and rationale for inclusion will be presented following risk factors and medications. 
 
 Patient Risk Factors 
Although commonly referred to as risk factors for peripheral arterial occlusive disease in the 
clinical setting, many of the confounding variables below have only been demonstrated to have 
an association with peripheral arterial occlusive disease. Smoking and hypercholesterolemia 
are the only two true risk factors; having been shown in prospective controlled studies that 
altering the factor affects the course of the disease.28 The other confounding variables presented 
in Table 4.1 have been shown to be associated with mortality and cardiovascular events and 
therefore were adjusted for in statistical analysis. 
 
 
Table 4.1: Risk factors and precedent for association with cardiovascular events 
Confounding 
variables - risk 
factors 
Definition for 
data collection 
Precedent of association with cardiovascular events 
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Age Years, Days 
(calculated from 
date of birth) 
Increase in both incidence and prevalence of PAOD with increasing 
age.28 Mortality is also a function of increasing age.78 
Sex Male/Female Prevalence of both symptomatic and asymptomatic PAOD is higher in 
men than in women with the ratio increasing in more severe stages of 
the disease.1,2,80 Some studies report a higher incidence of women with 
critical limb ischaemia.9 Cardiovascular mortality in both asymptomatic 
and symptomatic PAOD is significantly higher in men.79 
Diabetes 
Mellitus 
Diagnosis of 
diabetes or on 
treatment for 
diabetes 
Mortality is higher in PAOD patients with diabetes mellitus.95 Patients 
with critical limb ischaemia have higher rates of major amputation and 
mortality if diabetic.97 HbA1C and diabetic medications including dose 
were recorded in the database where available but this data was not 
available for all patients and was not intended for analysis in this study. 
Smoking Never, Current or 
Ex-smoker 
(>30days) 
Cigarettes 
smoked per day 
Years smoked  
The number of cigarettes smoked is associated with presence of PAOD, 
disease severity, risk of amputation, graft occlusion and mortality.28 
Patient report of their smoking was used for this study as this has been 
previously established to be a valid measure.342 Objective measure of 
smoking habit such as serum cotinine, thiocyanate or CO exhale are 
more accurate in confirming smoking habit in certain populations343 
although was not available to be applied across this entire cohort. 
Ischaemic 
Heart Disease 
Diagnosis of 
ischaemic heart 
disease or on 
treatment for 
ischaemic heart 
disease  
Ischaemic heart disease is a predictor of short and long term mortality in 
vascular patients undergoing revascularisation or aneurysm repair.105 
Stroke Medical diagnosis 
of stroke 
A combination of stroke or transient ischaemic attack (TIA) was one of 
the identified risk factors that predicted mortality at 5 and 10 years in a 
review of mortality in 2642 consecutive PAOD patients.106 Touze et 
al.107 quantified the risk of heart attack and non-stroke vascular mortality 
to ~2% per year following stroke or TIA. 
Hypertension Diagnosis of 
hypertension or 
on treatment for 
hypertension  
Hypertension increases the risk of PAOD28 and PAOD increases the risk 
of mortality,24,104 but whether hypertension is an independent risk factor 
within the PAOD population for mortality remains unclear. 
PAOD = Peripheral arterial occlusive disease; CLI = Critical limb ischaemia; TIA = Transient ischaemic attack 
 
 Medications 
All participants in this study had their medications recorded at entry into the study and reviewed 
at subsequent outpatient appointments or admission to hospital. All medications were recorded 
with total daily dosage. Vascular patients are commonly on multiple medications and an 
overview by description of the total medication usage of the cohort will be presented in Chapter 
5, but as all medications were not considered significant confounders they will not be presented 
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here. The two medications that were adjusted for as potential confounding variables are 
described in Table 4.2 with justification for inclusion as confounding variables.  
 
Table 4.2: Medications and precedent for association with cardiovascular events 
Confounding 
Variables 
Medications 
Precedent for medication association with cardiovascular events 
Aspirin The Antithrombotic Trialists Collaboration analysed 287 randomised trials 
including more than 135000 patients and reported that the odds of a vascular event 
(vascular death, non-fatal heart attack or nonfatal stroke) were reduced by 22% in 
high risk patients receiving antiplatelet therapy.117 Consistent in the subset of 
patients with diagnosed PAOD.117 
Statins The JUPITER trial (Justification for the use of statins in Prevention: an intervention 
trial evaluating Rosuvastatin use) in a non-PAOD population demonstrated a 44% 
reduction in all-cause and cardiovascular morality and a concomitant reduction in 
CRP levels.119. The Heart Protection Study demonstrated a 22% risk reduction for 
first major vascular event in PAOD patients allocated to Simvastatin.120 Short term 
statin use has been shown to reduce major adverse events within six months of 
vascular surgery.123,124 Shillinger et al.125 demonstrating that PAOD patients 
receiving Statin therapy for a minimum of 4 weeks prior to peripheral endovascular 
intervention had significantly improved survival and event free survival rates. 
Further analysis showed that the patients with the higher markers of inflammation 
benefited the most from statin therapy.125  Statin use has also been associated with 
improved graft patency and limb survival127 and has been shown to have anti-
inflammatory effects.128 
PAOD = Peripheral arterial occlusive disease; CRP = C reactive protein; JUPITER = Justification for the use of 
statins in prevention: an intervention trial evaluating Rosuvastatin. 
 
 Disease severity at presentation 
The severity of an individual patient’s disease was assessed by a vascular surgical consultant 
on recruitment to the study with both clinical history and physical examination. The disease 
severity was classified as either asymptomatic (excluded from this study), intermittent 
claudication, rest pain, tissue loss or acute lower limb ischaemia, a combination of both the 
Rutherford344 and Fontaine345 classification systems for peripheral arterial occlusive disease as 
seen in Appendix I.  
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Patients with intermittent claudication are expected to have an annual major adverse event rate 
of 5%-7% approximately 2.5 times higher than age matched controls independent of risk 
factors.28  Patients with rest pain or tissue loss have a ~20% mortality in the first year after 
presentation.28 The division of critical limb ischaemia into rest pain and tissue loss groups has 
been suggested previously as these two groups have appreciably different natural histories.26 
The short term mortality of patients presenting with acute lower limb ischaemia is 15-20%, 
with long term mortality risk after resolution of the acute event reverting to that of the 
claudication group or rest pain and tissue loss group depending on the outcome of the acute 
event.28 For this reason, the patients with acute limb ischaemia at recruitment to the study are 
presented and analysed separately throughout the results chapters. 
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4.3. Procedures 
Study participants had all risk factors, medications and any history of cardiovascular event 
recorded at point of entry into the study. At each outpatient appointment any subsequent 
cardiovascular events or significant vascular events were recorded along with review and 
recording of the patient risk factors and medication use. Measures of circulating differential 
cell count were recorded at study entry but not at subsequent cardiovascular event or significant 
vascular event unless this was the entry point to the study. Four hypothetical patients are now 
presented as examples of individual participant progress through the study, the data collection 
points and the appropriate selection of “study baseline bloods”.  
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4.3.1. Example 1: “Hypothetical Patient A” 
(OPD, outpatient department) 
 
A pictorial representation of the course of the individual participant “Hypothetical Patient A” 
through this study is shown in Figure 4.1. Hypothetical Patient A was recruited into the study 
after meeting the inclusion criteria with demonstrable symptomatic peripheral arterial 
occlusive disease (represented in blue Figure 4.1). Hypothetical Patient A has “study baseline 
bloods” (represented in red Figure 4.1) soon after recruitment to the study. This patient is 
managed non-operatively through out-patient department (OPD) appointments (represented in 
green Figure 4.1). The patient’s risk factors and medications were reviewed and recorded at 
each outpatient visit. Medications may have been introduced to reduce the risk of future 
cardiovascular events and these were recorded at each visit. Hypothetical Patient A did not 
sustain any cardiovascular events and was discharged from follow up (from the study) at the 
conclusion of data collection for the study.  
Figure 4.1: Progress of Hypothetical Patient A through the study. 
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4.3.2. Example 2: “Hypothetical Patient B” 
OPD = Outpatient Department appointment, MAE = Major adverse event (death, heart attack or stroke) 
 
Figure 4.2 shows ‘Hypothetical Patient B’ who was recruited (represented in blue in Figure 
4.2) from the outpatient department (OPD) with symptomatic peripheral arterial occlusive 
disease and has study baseline bloods (represented in red in Figure 4.2) at the time of 
recruitment. While being followed up as an outpatient having all risk factors and medications 
reviewed at each visit, Hypothetical Patient B experiences a non-fatal major adverse event 
(MAE) (represented in black in Figure 4.2). The type of major adverse event (death, heart 
attack, stroke or major amputation) and time from study entry were both retrospectively entered 
into the database. The bloods taken immediately prior to or at the time of the major adverse 
event (“Other bloods” represented in orange, Figure 4.2) were not used in this study. At the 
time of any cardiovascular event (including major adverse event) risk factors and medication 
use were again reviewed. Hypothetical Patient B did not die as a result of the sustained major 
adverse event and was subsequently reviewed in the outpatient department and was discharged 
from follow up (from the study) at the conclusion of the study having sustained an MAE but 
not death.   
Figure 4.2: Progress of Hypothetical Patient B through the study. 
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4.3.3. Example 3: “Hypothetical Patient C” 
MAE = Major adverse event (death, heart attack or stroke) 
 
Hypothetical Patient C is shown in Figure 4.3, pictorially representing the progressive nature 
of peripheral arterial occlusive disease. “Patient C” requires peripheral revascularisation 
(represented as green in Figure 4.3), this event was recorded in the database and risk factors 
and medication use were reviewed. Patient C later requires major amputation (both significant 
vascular events represented as green in Figure 4.3) with the event recorded in the database and 
risk factors and medication use again reviewed. The time from recruitment to major amputation 
was retrospectively calculated. For this study, only the bloods taken at, or shortly after, study 
entry and not associated with a vascular intervention or major adverse event will serve as the 
“study baseline bloods” (represented as red in Figure 4.3). Bloods taken at the time of 
peripheral revascularisation, major amputation and prior to the fatal event (“Other bloods” 
represented in orange, Figure 4.3) were not recorded. Time from study entry to major adverse 
event and time from study entry to death would be the same for this patient as the first major 
adverse event was death. 
  
Figure 4.3: Progress of Hypothetical Patient C through the study 
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4.3.4. Example 4: “Hypothetical Patient D”  
(OPD = Outpatient Department appointment, MAE = Major adverse event (death, heart attack or stroke) 
 
Hypothetical "Patient D” is recruited to the study as the result of a non-fatal significant vascular 
event (vascular admission to hospital or vascular intervention). Pre-operative bloods for this 
patient (“Potential study baseline bloods”, represented in red, Figure 4.4) were used for “study 
baseline bloods” unless active infection was present or the patient was on antibiotic therapy. 
For example if the significant vascular event was revascularisation for tissue loss or gangrene 
with concomitant infection, or minor or major amputation with infection of tissue recorded, 
then the “study baseline bloods” were a minimum of 4 weeks post-operatively if infection had 
resolved and the patient was no longer on antibiotic therapy (“Potential study baseline bloods 
2”, also represented in red, Figure 4.4). Bloods taken in the post-operative period (“Other 
bloods 3”, represented in orange, Figure 4.4) were not recorded or analysed due to the inability 
to control for post-operative change in inflammatory markers. “Other Bloods 4” (represented 
in orange, Figure 4.4) were not recorded or analysed due to the close association with 
subsequent major adverse event.  
Figure 4.4: Progress of Hypothetical Patient D through the study 
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4.4. Data Analysis 
4.4.1. Kaplan-Meier log rank survival analysis 
Kaplan-Meier analysis is used throughout all results chapters to present and compare the 
freedom from endpoint (survival) using TIBCO Spotfire S+ 8.2 for Windows 2010 (TIBCO 
Software Inc. Boston, USA). The Kaplan-Meier survival analysis allows comparison of 
populations within the study, taking account of the patients discharged from follow up without 
event. 
 
The survival rate is expressed as the Kaplan-Meier survivor function (S) is seen in Equation 1: 
 
  
 𝑆𝑆(𝑡𝑡) = 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑖𝑖𝑛𝑛𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑛𝑛𝑖𝑖𝑖𝑖𝑖𝑖 𝑖𝑖𝑛𝑛𝑛𝑛𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑛𝑛𝑠𝑠 𝑖𝑖𝑜𝑜𝑛𝑛𝑠𝑠𝑛𝑛𝑛𝑛 𝑡𝑡ℎ𝑖𝑖𝑛𝑛 𝑡𝑡
𝑡𝑡𝑜𝑜𝑡𝑡𝑖𝑖𝑖𝑖 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑖𝑖𝑛𝑛𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑛𝑛𝑖𝑖𝑖𝑖𝑖𝑖 𝑖𝑖𝑡𝑡𝑛𝑛𝑖𝑖𝑖𝑖𝑛𝑛𝑖𝑖  
Equation 1: Survivor rate for Kaplan-Meier 
analysis. 
Where S = Kaplan-Meier survival function, 
 t = time. 
 
The product limit method of Kaplan-Meier346 is used to estimate S (Equation 2): 
 
 
𝑺𝑺�(𝒕𝒕) =  ��𝟏𝟏−  𝒅𝒅𝒊𝒊
𝒏𝒏𝒊𝒊
�
𝒕𝒕𝒊𝒊≤𝒓𝒓
 
 
Equation 2: Product limit method of Kaplan-
Meier. 
Where ?̂?𝑆 = an estimate of the survival function, 
ti = duration of study at point i,  
di = number of events up to point i,  
ni = number of individuals at risk just prior to ti 
 
S is based upon the probability that an individual survives at the end of a time interval. If a 
subject is last followed up at time ti and then leaves the study for any reason (e.g. is discharged 
from follow up) ti is counted as their censorship time. Censoring indicates that the period of 
observation was terminated prior to the patient experiencing the outcome of interest and occurs 
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for two reasons in this study, the patient was discharged from follow up or the study data 
collection period ended (and the patient was discharged from study follow up). 
 
Survival is not the absence of death but the absence of the endpoint in question and the 
statistical term of survival used in Kaplan-Meier analysis has the potential to become confusing 
when discussing some terminal and some non-terminal outcomes in relation to cardiovascular 
events. For this reason the survival function in this study will refer to the freedom from death, 
freedom from heart attack, freedom from stroke, freedom from peripheral revascularisation and 
freedom from the composite outcome of major adverse events as specified. For example, the 
survival rate for the endpoint heart attack is referred to as freedom from heart attack at time 
point ti. 
 
Samples of survival times are frequently highly skewed, therefore although both the median 
and the mean are presented throughout the results chapters, the median is generally considered 
a better measure of central location than the mean. The median survival time is calculated as 
the smallest survival time for which the survivor function is less than or equal to 0.5. In some 
of the following data sets the survivor function is always greater than 0.5, therefore the median 
survival time was not able to be calculated and is expressed as n/a. A confidence interval for 
the median survival time is constructed using a robust nonparametric method.347 This 
confidence interval is not applicable if the median survival time is not calculable and is 
expressed as n/a. With skewed survival data, calculation of the upper confidence interval using 
the Bookmeyer-Crowley347 method may result in an answer of infinity due to a need to divide 
by 0 in the calculation. Where this occurs in the results chapters the upper confidence interval 
is described as not calculable and presented as n/a.  
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Mean survival time is estimated by the area under the survival curve and is based upon the 
entire range of data. It is possible to calculate the mean even if the survivor function remains 
greater than 0.5. The standard error of the mean was calculated using calculated using 
Greenwood’s formula (Equation 3)348 is also presented. 
 
𝒗𝒗𝒗𝒗𝒓𝒓 �𝑺𝑺�(𝒕𝒕)� = �𝑺𝑺�(𝒕𝒕)�𝟐𝟐 ∑ 𝒅𝒅𝒋𝒋(𝒓𝒓𝒋𝒋−𝒅𝒅𝒋𝒋)𝒓𝒓𝒋𝒋𝒋𝒋:𝝉𝝉𝒋𝒋<𝒕𝒕   
Equation 3: Greenwoods formula for standard error 
of the mean (Kaplan-Meier analysis). 
Where ?̂?𝑆 = an estimate of the survival function 
t = duration of study 
𝜏𝜏𝑗𝑗 = duration of study at point j when an event is 
sustained 
dj = number of events up to point j,  
𝑟𝑟𝑗𝑗 = number of individuals at risk just prior to tj 
 
Average yearly freedom from event time was generated (Equation 4) to allow comparison to 
previously published literature and was done acknowledging this average does not always 
accurately reflect the actual freedom from event which was observed in the study. 
 
�
# 𝒐𝒐𝒐𝒐 𝒊𝒊𝒏𝒏𝒅𝒅𝒊𝒊𝒗𝒗𝒊𝒊𝒅𝒅𝒊𝒊𝒗𝒗𝒊𝒊𝒊𝒊 𝒘𝒘𝒊𝒊𝒕𝒕𝒘𝒘 𝒗𝒗𝒏𝒏 𝒆𝒆𝒗𝒗𝒆𝒆𝒏𝒏𝒕𝒕 𝒊𝒊𝒏𝒏 𝒗𝒗 𝒈𝒈𝒓𝒓𝒐𝒐𝒊𝒊𝒑𝒑
𝒕𝒕𝒐𝒐𝒕𝒕𝒗𝒗𝒊𝒊 𝒏𝒏𝒊𝒊𝒏𝒏𝒏𝒏𝒆𝒆𝒓𝒓 𝒐𝒐𝒐𝒐 𝒑𝒑𝒗𝒗𝒓𝒓𝒕𝒕𝒊𝒊𝒑𝒑𝒊𝒊𝒑𝒑𝒗𝒗𝒏𝒏𝒕𝒕𝒊𝒊 𝒊𝒊𝒏𝒏 𝒕𝒕𝒘𝒘𝒗𝒗𝒕𝒕 𝒈𝒈𝒓𝒓𝒐𝒐𝒊𝒊𝒑𝒑�
𝒏𝒏𝒆𝒆𝒗𝒗𝒏𝒏 𝑲𝑲𝒗𝒗𝒑𝒑𝒊𝒊𝒗𝒗𝒏𝒏 − 𝑴𝑴𝒆𝒆𝒊𝒊𝒆𝒆𝒓𝒓 𝒐𝒐𝒓𝒓𝒆𝒆𝒆𝒆𝒅𝒅𝒐𝒐𝒏𝒏 𝒐𝒐𝒓𝒓𝒐𝒐𝒏𝒏 𝒆𝒆𝒗𝒗𝒆𝒆𝒏𝒏𝒕𝒕 (𝒚𝒚𝒆𝒆𝒗𝒗𝒓𝒓𝒊𝒊) 
Equation 4: Average annual event rate. 
 
The continuous variables of cell count were statistically divided into tertiles to minimise the 
effect of non-normal distribution on Kaplan-Meir and Cox proportional hazards analysis. The 
categories of each cell type were derived with the following formula in S+: 
> with(FinalAnalysis, quantile(celltype, 0:3/3, na.rm=T)) 
(where celltype = heading for each cell type continuous data column in the FinalAnalysis 
worksheet) 
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Kaplan-Meier log rank survival analysis was used to examine for statistical difference between 
disease severity at presentation groups for major adverse event Chapter 7. The Log rank test 
was used to assess whether the difference in disease severity groups were due to chance alone. 
The Log rank test is unable to adjust for other confounding factors but was performed prior to 
considering adjustment for disease severity in later Cox proportional hazards modelling of cell 
types and individual cardiovascular outcomes.  
 
The association between cell types and major adverse events and death were tested in a 
stepwise manner testing each cell type with each outcome in turn. These results are presented 
separately in Chapter 8 Section 4 and 5. Each association was first assessed with Kaplan-Meier 
survival analysis. Comparison between two survival Kaplan-Meier curves should be based on 
formal non-parametric testing such as the log rank test, however the log rank test is unable to 
explore and adjust for the effects of confounding variables e.g.: age, risk factors for peripheral 
arterial occlusive disease, disease severity at presentation and medication usage and therefore 
was not used to assess the circulating cell types in this study. Adjustment for the confounding 
factors which are known to affect survival was considered preferable to simple analysis 
therefore Cox proportional hazards regression analysis was conducted instead of log rank 
testing. 
 
4.4.2. Cox proportional hazards regression 
Cox proportional hazards regression is the chosen method used to investigate the effect of 
several variables upon the time it takes for a specified event to take place. All Cox proportional 
hazard regression models were conducted using TIBCO Spotfire S+ 8.2 for Windows 2010 
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(TIBCO Software Inc. Boston, USA). A simplified version of the Cox proportional hazards 
model is presented in Equation 5. 
 
𝝀𝝀(𝒕𝒕,𝔁𝔁) = 𝝀𝝀𝟎𝟎(𝒕𝒕) 𝐞𝐞𝐞𝐞𝐞𝐞(𝜷𝜷𝔁𝔁)  Equation 5: Cox semi-parametric model. 
 Where λ(t,x) =hazard function that depends on time-
point t,  
λ0(t) =baseline hazard function that depends on time 
only,  
exp (βx) =covariate related component 
 
The Cox proportional hazards model also provides an estimate of the effect of each variable 
and allows an estimate of the hazard (or risk) of an event given a set value for prognostic 
variables which is not dependent on time (Equation 6). When there is a positive regression 
coefficient the hazard is higher and when there is a negative coefficient a better prognosis is 
implied with higher values for that variable. The hazard ratio (Equation 6) was obtained by 
comparing two groups at the same time (t), for example the Low TWCC Category and the Mid 
TWCC Category, or the Low TWCC Category and the High TWCC Category. 
 
𝑯𝑯𝑯𝑯 =  𝝀𝝀(𝒕𝒕,𝔁𝔁𝟏𝟏)
𝝀𝝀(𝒕𝒕,𝔁𝔁𝟐𝟐) =  𝝀𝝀𝟎𝟎(𝒕𝒕) 𝐞𝐞𝐞𝐞𝐞𝐞(𝜷𝜷𝔁𝔁𝟏𝟏)𝝀𝝀𝟎𝟎(𝒕𝒕) 𝐞𝐞𝐞𝐞𝐞𝐞(𝜷𝜷𝔁𝔁𝟐𝟐)=  𝐞𝐞𝐞𝐞𝐞𝐞(𝜷𝜷𝔁𝔁𝟏𝟏)
𝐞𝐞𝐞𝐞𝐞𝐞(𝜷𝜷𝔁𝔁𝟐𝟐) 
Equation 6: Hazard ratio.  
λ(t,x) =hazard function that depends on time-point t,  
λ0(t) =baseline hazard function that depends on time 
only,  
exp (β 𝓍𝓍) =covariate related component 
𝓍𝓍1 and 𝓍𝓍2= are the covariate explanatory variables 
 
 
Initial Cox analysis was a priori (without adjustment for confounding factors), followed by 
adjustment for well-established traditional clinical risk factors of age, sex, smoking, 
hypertension, diabetes mellitus and history of ischaemic heart disease or stroke (labelled 
traditional risk factors). This was done to enable comparison to previously published literature. 
The Cox proportional hazard always compared to the low circulating cell count group. Further 
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adjustment was made to include severity of disease status at presentation and medications 
aspirin and statins (labelled comprehensive risk factors). The evidence to include disease 
severity as a confounding variable presented in Chapter 7. As there is precedent for medication 
use to have significant effect on cardiovascular outcomes in patients with peripheral arterial 
occlusive disease, the comprehensive risk factor adjustment included the medications of aspirin 
and statin use as well as disease severity, age, sex, smoking, hypertension, diabetes mellitus, 
and history of ischaemic heart disease or stroke. When categorical co-variables were 
significantly associated with the outcome of Cox proportional hazards modelling the model 
was stratified for these variables and is presented in the results chapters as strata (variables/s). 
Stratification (Equation 7) allows the baseline hazard function to differ between subsamples 
and automatically excludes the stratification variables from explanatory data sets.349 
 
𝝀𝝀𝒊𝒊(𝒕𝒕,𝔁𝔁) =  𝝀𝝀𝑺𝑺𝟎𝟎(𝒕𝒕) 𝐞𝐞𝐞𝐞𝐞𝐞(𝜷𝜷𝔁𝔁) Equation 7: Stratified Cox proportional hazards model. 
where s = 1, 2.., S – number of stratum 
𝜆𝜆𝑖𝑖(𝑡𝑡,𝓍𝓍) =hazard function that depends on time-point t for 
stratum s,  
λS0(t) =baseline hazard function that depends on time only 
for strum s,  
exp (β 𝓍𝓍) =covariate related component 
 
The assumptions of the Cox model were tested to ensure that the model could be appropriately 
applied to the data. Non-informative censoring bias was minimised during data collection. Care 
was taken in the recording of clinical data to ensure that discharge from follow up was not 
related to the probability of an event occurring. This was done via several means: thorough 
review of the patient’s medical records (not only those related to vascular surgery), searching 
for admission to other Queensland Health hospitals for admission related to vascular condition 
or major adverse event and searching for record of the patient’s death. The Cox proportional 
hazard assumption that the hazard function remains proportional over time was tested 
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statistically using the Cox.zph function. This function tests proportionality plots of the 
Schoenfeld350 residuals versus log(time) and gives a Cox.zph value of significance that tests 
the proportional nature of the predictors tested. If the Cox.zph is significant then the time 
dependent covariates are not proportional with the potential implication that the assumption of 
the Cox model that relative hazard remains proportional over time may be breached. The global 
zph had the same function but instead of being applied to each variable is applied to the model 
as a whole. This violation should be taken into account and if possible the appropriate 
modification of the model should be used to enable precise interpretation.351 
 
This study does use multiple planned comparisons between individual cell types and each 
outcome respectively. These planned comparisons are complementary in nature and as such no 
correction for multiple comparisons was indicated or applied.352,353 
 
4.4.3.  Multi-model averaging 
Further statistical analysis uses the Information-Theoretical approach132 to compare multiple 
models for each outcome. Multi-model averaging is considered the most useful technique for 
exploring a range of variables that may be associated with a particular outcome132 and was 
conducted using statistical package R version 3.2.0.354 The multi-model averaging package 
used was MuMIn: Multi-Model Inference. R package version 1.13.4.355  
 
Traditional null hypothesis testing using stepwise regression has been commonly used for 
biological modelling using threshold based removal and introduction algorithms to obtain the 
best fit model when no terms can be added or removed. Stepwise regression results in a final 
model that does not contain any weak interaction terms and contains variables that are either 
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strong predictors or involved with strong interaction.356 Although stepwise regression has been 
used commonly, it has many limitations including multiple testing357 and the trade-off between 
model complexity and accuracy of parameter estimates.356 In stepwise regression, variables 
can appear as significant or non-significant depending on which other variables are present in 
the model.304,305 This is especially true when many interacting terms are used, particularly if 
these terms have small effects.301 Stepwise regression also is unable to compare models and 
does not have model likelihoods and estimates of precision.306 Stepwise regression is also 
unable to account for uncertainty linked to the process of selecting the final model, providing 
less than ideal coverage and narrow confidence intervals.306 The limitations of stepwise 
regression have raised questions over its applicability for complex modelling in other scientific 
disciplines including ecology and the behavioural sciences.358-362 Stepwise regression is not an 
appropriate analysis for this dataset due to multiple inter-related variables with small effects 
potentially creating severe bias and over or under estimation of the effect of variables.302 
Stepwise regression in similar datasets regardless of protocol has the potential to miss true 
predictors and identify significance for unimportant predictors.303 
 
The Information-Theoretical approach, is well described by Burnham and Anderson132 who 
explain that this approach which arises from likelihood theory compares multiple competing 
models at once by asking “how certain are we that any given model is the best approximating 
model?”363 The process of which quantifies model selection uncertainty to give the model, 
from within the model set, that loses the least information - and gives the best approximation 
of the truth.  
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The Information-Theoretical approach to multi-model averaging was selected for this study 
because it is a complex model with proven interactions between variables and there are small 
effects of some or all of the variables.302 To the author’s knowledge, this is the first time the 
Information-Theoretical approach has been applied to risk factor modelling for patients with 
peripheral arterial occlusive disease. 
 
 The process of multi-model averaging 
Akaike information criterion (AIC, Equation 8364) is used to compare multiple competing 
models all at once by asking “how certain are we that the given model is the best approximating 
model for the true process underlying the outcome being investigated?”363 In doing so model 
uncertainty is quantified and accounted for through the assessment of the Kullback-Leibler 
information.365 Kullback-Leibler information is the absolute distance of models from the 
biological truth,132 allowing multiple competing models to be compared and ranked according 
to their relative distance from the truth. Ranking competing models by AIC allows them to be 
sorted in terms of information loss in approximating the unknowable truth.306  
 
𝑨𝑨𝑨𝑨𝑨𝑨 =  −𝟐𝟐𝟐𝟐𝟐𝟐𝟐𝟐 �𝓛𝓛�𝜽𝜽��𝒅𝒅𝒗𝒗𝒕𝒕𝒗𝒗��  + 𝟐𝟐𝟐𝟐 Equation 8: Akaike information Criterion 
Where AIC = Akaike information Criterion, 
log(ℒ�𝜃𝜃��𝑑𝑑𝑑𝑑𝑡𝑡𝑑𝑑� = maximised log-likelihood  
   over the unknown parameters (θ) (The coefficient -2 applied for historical reasons)364 
K = number of parameters estimated in that  
   model 
 
AICc is used to approximate AIC (Equation 9364) when n/k is less than 40 (where n is the 
number of models and k is the number of fitted parameters in the most complex model).366  
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𝑨𝑨𝑨𝑨𝑨𝑨𝒑𝒑  =  𝐀𝐀𝐀𝐀𝐀𝐀 + 𝟐𝟐𝟐𝟐(𝟐𝟐 + 𝟏𝟏)𝐧𝐧 − 𝟐𝟐 − 𝟏𝟏  Equation 9: Akaike information Criterion corrected for sample size. 
Where AICc = corrected Akaike 
information  
   Criterion, 
AIC = Akaike information Criterion, 
K = number of parameters estimated in that  
   model  
n = the number of models 
  
AICc is thus expanded for calculation with Equation 10132: 
 
𝑨𝑨𝑨𝑨𝑨𝑨𝒑𝒑 = −𝟐𝟐𝒊𝒊𝒐𝒐𝒈𝒈�𝓛𝓛�𝜽𝜽��𝒅𝒅𝒗𝒗𝒕𝒕𝒗𝒗�� + 𝟐𝟐𝑲𝑲+ 𝟐𝟐𝑲𝑲(𝑲𝑲 + 𝟏𝟏)(𝒏𝒏 − 𝑲𝑲 − 𝟏𝟏) 
Equation 10: Akaike information 
criterion corrected for sample size 
calculation. 
AICc = corrected Akaike information  
   Criterion,  
log(ℒ�𝜃𝜃��𝑑𝑑𝑑𝑑𝑡𝑡𝑑𝑑�) = maximised log-likelihood  
   over the unknown parameters (θ) (The coefficient -2 applied for historical reasons)364 
K= total number of estimate parameters of  
   the model,  
n = the number of models,  
 
 
The individual AIC values (or in this case AICc values) are not interpretable as they contain 
arbitrary constants and greatly affected by sample sizes.132 AICc takes into account how well a 
model fits the data but models with a larger number of fitted parameters (k) will have larger 
AICc values. Each AICc is useless on its own, deriving it’s meaning from comparison with the 
AICc values of other models, with the model having the lowest AIC representing the “best 
approximating model”. The AICc values are rescaled such that the model with the minimum 
AICc has a value of 0 and are represented as Δi. 367  
 
 
𝜟𝜟𝒊𝒊 = 𝑨𝑨𝑨𝑨𝑨𝑨𝒊𝒊 − 𝑨𝑨𝑨𝑨𝑨𝑨𝒏𝒏𝒊𝒊𝒏𝒏 Equation 11: Δi or relative AIC 
Δi  = Relative AICc for model i 
AICi = corrected Akaike information  
   Criterion for model i 
AICmin = minimum corrected Akaike 
information Criterion,  
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The Δi values are easy to interpret and allow strength of evidence comparison and ranking of 
candidate models. The larger Δi is for any given model i, the less plausible the fitted model can 
be the best approximating model within the candidate set.360 
 
The likelihood of an individual model gi is expressed in Equation 12 and in the results chapters 
the log of this value is displayed log(𝓛𝓛). 
 
𝓛𝓛(𝒈𝒈𝒊𝒊|𝒅𝒅𝒗𝒗𝒕𝒕𝒗𝒗) = 𝒆𝒆𝒆𝒆𝒑𝒑(−𝜟𝜟𝒊𝒊/𝟐𝟐) Equation 12: Likelihood of model gi 
Where gi = model I   (for i = 1,2… R,) 
Δi  = Relative AICc for model i (Equation 
11) 
exp (-½Δi) = transformation of Δi to provide 
the likelihood of the model, given the data 
 
 
The Akaike weight wi is to be interpreted as the probability of the model i being the best 
approximating the data set. Akaike weights measure the weight of evidence that model i is the 
actual Kullback-Leibler best model in the set and it is convention these values sum to 1 so wi 
can be used as a probability.367 The scaled model weights can then be used to rank the models, 
quantifying the evidence favouring one model over another.  
 
𝒘𝒘𝒊𝒊 =  𝒆𝒆𝒆𝒆𝒑𝒑(−𝜟𝜟𝒊𝒊/𝟐𝟐)∑ 𝒆𝒆𝒆𝒆𝒑𝒑(−𝜟𝜟𝒓𝒓/𝟐𝟐)𝑯𝑯𝒓𝒓=𝟏𝟏  Equation 13: Akaike weight Where wi = Akaike weight for model i   (for i = 1,2… R,) 
R = number of models 
Δi  = Relative AICc for model i (Equation 
11) 
exp (-½Δi) = transformation of Δi to provide 
the likelihood of the model, given the data 
 
Multi-model inference is using a set of models rather than any single model on which to base 
inference of parameter estimates which has both practical and philosophical advantages.132,360 
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Multi-model inference is done by calculating the cumulative evidence for the models 
containing a particular parameter combined with an estimate of the explained variation.132 A 
model averaged estimator obtained from multi-model inference gives that estimator better 
precision and reduced bias over the estimator of that parameter from the selected best model 
alone.360 
 
The models in this study that were not significantly different to the “best” model were selected 
using the Δi <2 function by convention.132 Subsequently multi-model prediction is performed 
by averaging all the models with Δi <2, which estimates the relative influence of the potential 
predictors (labelled standardised coefficients) thus estimates the multi-model effects of 
determinants with respective standard error. The goal of this process is to generate an 
approximating model that accurately predicts the information in the entire data set after 
separation from the noise.360 The standardised coefficients were then divided by their own 
standard error to generate a z score and subsequent p values. The interpretation of these p 
values is somewhat different to null hypothesis testing science such as Cox proportional 
hazards and stepwise regression. The use of these p value is are not traditionally part of the 
information theoretic approach368; they are examined with reference to each data set in 
respective results chapters. 
 
 
The common terms used when describing and discussing the information-theoretic approach 
described above are summarised for ease of reference in Table 4.3.  
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Table 4.3: Common terms and definitions in multi-model analysis 
Term Description Equation Summary explanation 
AIC Akaike Information 
Criterion  
Equation 8: 
−2log �ℒ�𝜃𝜃��𝑑𝑑𝑑𝑑𝑡𝑡𝑑𝑑��  + 2K Quantifies information lost in approximating the biological 
truth (adjusted for fit and model 
complexity). Used to compare 
and rank different models. 
AICc Akaike Information 
Criterion corrected 
for sample size 
Equation 9: AIC + 2K(K + 1)n − K − 1  
Used to approximate AIC for 
small sample size. 
Used in place of AIC for this 
thesis. 
Equation 10: 
−2𝑙𝑙𝑙𝑙𝑙𝑙�ℒ�𝜃𝜃��𝑑𝑑𝑑𝑑𝑡𝑡𝑑𝑑�� + 2𝐾𝐾 + 2𝐾𝐾(𝐾𝐾 + 1)(𝑛𝑛 − 𝐾𝐾 − 1) 
Δi 𝛥𝛥𝑖𝑖 or relative AIC Equation 11: 
𝐴𝐴𝐴𝐴𝐴𝐴𝑖𝑖 − 𝐴𝐴𝐴𝐴𝐴𝐴𝑛𝑛𝑖𝑖𝑛𝑛 
The difference between model 
score and the “best” model. 
Facilitates comparison and 
ranking of models. 
Best model 𝛥𝛥𝑖𝑖 =0 
𝓛𝓛 Likelihood of model 
gi 
Equation 12: 
𝑒𝑒𝑒𝑒𝑒𝑒(−𝛥𝛥𝑖𝑖/2) Transformation of 𝛥𝛥𝑖𝑖 to give the likelihood of a model. 
log(𝓛𝓛) Log likelihood of 
model gi 
log( 𝑒𝑒𝑒𝑒𝑒𝑒(−𝛥𝛥𝑖𝑖/2)) Measures lack of fit of model to 
the observed data. 
wi Akaike weight Equation 13: 
𝑒𝑒𝑒𝑒𝑒𝑒(−𝛥𝛥𝑖𝑖/2)
∑ 𝑒𝑒𝑒𝑒𝑒𝑒(−𝛥𝛥𝑛𝑛/2)𝑅𝑅𝑛𝑛=1  
Probability that model is the 
best in the data set. 
Total of all wi =1 
Quantifies evidence comparing 
models. 
df Degrees of freedom 
of model 
Also referred to in the above 
equations as K 
The number of independent 
values that can be assigned 
within a given model. 
z 
score 
Standardised 
coefficients divided 
by standard error 
𝑆𝑆𝑡𝑡𝑑𝑑𝑛𝑛𝑑𝑑𝑑𝑑𝑟𝑟𝑑𝑑𝑆𝑆𝑠𝑠𝑒𝑒𝑑𝑑 𝑐𝑐𝑙𝑙𝑒𝑒𝑐𝑐𝑐𝑐𝑆𝑆𝑐𝑐𝑆𝑆𝑒𝑒𝑛𝑛𝑡𝑡
𝑆𝑆𝑡𝑡𝑑𝑑𝑛𝑛𝑑𝑑𝑑𝑑𝑟𝑟𝑑𝑑 𝑒𝑒𝑟𝑟𝑟𝑟𝑙𝑙𝑟𝑟 𝑙𝑙𝑐𝑐 𝑐𝑐𝑙𝑙𝑒𝑒𝑐𝑐𝑐𝑐𝑆𝑆𝑐𝑐𝑆𝑆𝑒𝑒𝑛𝑛𝑡𝑡 Used to describe strength and robustness of coefficients. 
p 
value 
Quantifies strength of 
coefficient effect 
R version 3.2.0.354 used Quantifies strength of 
coefficient effect. 
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4.4.4. Power Analysis 
Preliminary analysis of previously collected data indicated a major adverse event rate of 
approximately 30% which in this group of 632 selected patients would be conservatively 
expected to yield 180 major adverse events. The sample size estimate was based on the work 
of Peduzzi (Equation 14).369,370 
 
N = 10 k / p Equation 14: Required sample size for Cox proportional hazards.  
where N = minimum number of cases to include, 
p = the proportions of negative events (major adverse event) in the 
population, 
k = the number of predictor variables 
 
This study will used age, sex, smoking, hypertension, history of ischaemic heart disease, 
history of stroke, diabetes mellitus, disease severity at presentation, aspirin and statin as 
predictor variables (i.e. k=10) and the proportion of major adverse event in the population (p) 
is 0.30 (30%) from previous experience with the study population. 371 The minimum number 
of cases predicted to be required was therefore 333 (Equation 15). The study was designed and 
powered for the primary outcome of major adverse event. 
 
N = 10 x 10 / 0.30 = 333 Equation 15: Required sample size for this study for 
outcome of major adverse event. 
Where N = minimum number of cases required 
 
Consideration was then given to ensure adequate power for the secondary endpoint of death 
where the incidence of death in the population with intermittent claudication is expected to be 
in the range of 4-6% per year, higher in those with more severe disease.24,25,29,49,72,222 From 
previous experience with the study population (p) was estimated to be ~0.25 (25%). 371 
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N = 10 x 10 / 0.25 = 400 Equation 16: Calculation of required sample size for 
secondary outcome of death alone. 
Where N = minimum number of cases required 
 
It was acknowledged from the outset that the endpoints of heart attack, stroke and major 
amputation were unlikely to contain sufficient events to provide sufficient power for 
independent testing. 
 
In multi-model analysis it has been accepted as convention that a sample size ‘rule of thumb’ 
of 10:1 subjects to predictors be applied.132,372,373 This study was adequately powered to 
examine the 15 predictors included in the multi-model analysis consisting of the 10 variables 
listed above combined with Neutrophil Category, Lymphocyte Category, Monocyte Category, 
Haemoglobin Category and calculated Neutrophil/Lymphocyte Ratio (NLR) Category. 
 
Sufficient participants were recruited based on sample size estimates for the outcomes of major 
adverse event and death and allowed for rigorous application of inclusion and exclusion criteria 
to the 632 potential participants (described in detail in Chapter 5).  
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5. Results - section 1 
Cohort characteristics 
 
The characteristics of patients with peripheral arterial occlusive disease vary with the 
population assessed. Prior to investigating the outcomes for this patient cohort with 
symptomatic peripheral arterial occlusive disease it is important to examine the characteristics 
of the cohort and compare to other populations of patients with peripheral arterial occlusive 
disease. Chapter 5 will set the scene for the following results chapters by describing and 
examining the characteristics of this cohort of patients with peripheral arterial occlusive disease 
at recruitment. This cohort will then be compared to previously investigated cohorts with 
symptomatic peripheral arterial occlusive disease.  
 
The detailed methodology for this results section is described in Chapter 4. The selection of 
the cohort is presented with exclusion and inclusion criteria results. The characteristics of the 
cohort are presented in tabular form and compared to previously described populations with 
this disease.  
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5.1. Inclusion and exclusion results 
A total of 632 patients were considered for inclusion into the study with 398 patients eligible 
for inclusion in the final analysis. The most common reason for exclusion was the absence of 
symptomatic peripheral arterial occlusive disease (n=158), followed by no pre-operative or 
study baseline bloods (n=27) and less than one month follow up (n=18) with the complete list 
of exclusions included in Figure 5.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Flow diagram of patients included in this study 
 
 
Patients considered for inclusion by chart review (n=632)  
Inclusion in the study (n=398) 
Inclusion/exclusion criteria applied  
Not Symptomatic peripheral arterial occlusive 
disease (PAOD) (n= 158)  
No pre-operative or baseline bloods (n = 27)  
<1 Month follow up (n= 18)  
Aneurysm requiring surgery (n= 16)  
Malignancy (n= 7)  
Renal Failure (n= 4)  
Vasculitis (n= 2)  
Immune modifying medication (n= 1)  
Total white cell count > 15x109 cells/L (n= 1)  
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5.2. Characteristics of the cohort 
The mean age of the cohort was 66.34 (±9.81) years ranging from 38 to 95.9 years at 
recruitment (Table 5.1). The indication for inclusion to the study at presentation was 
intermittent claudication in 291 patients (73.1%), tissue loss in 59 patients (14.8%), rest pain 
in 39 patients (9.8%) and acute lower limb ischaemia was less represented with only 13 patients 
(3.3%). The risk factors and medication use of the total cohort and each disease severity at 
presentation group are presented in Table 5.1. The Tissue Loss group had the highest 
proportion of never smokers (37.3%) compared to the Rest Pain group (11.4%), the intermittent 
claudication group (10.7%) and the Acute Lower Limb Ischaemia group (7.7%). Current 
smokers were more common in the Rest Pain (54.3%) and Acute Lower Limb Ischaemia 
(53.8%) groups than the Intermittent Claudication group (47.1%) and the Tissue Loss group 
(42.4%). The largest proportion of Ex-smokers was in the Intermittent Claudication group 
(38.2%) with the smallest proportion of ex-smokers in the Tissue Loss group (20.3%). 
 
While the presence of diabetes mellitus in the total cohort was 37.4%, there was a larger 
representation of diabetics in the Rest Pain group with 79.7% of the Rest Pain group diagnosed 
with diabetes or taking medication for glycaemic control. The Acute Lower Limb Ischaemia 
group had the lowest proportion of diabetes with 23.1% of this population diagnosed or under 
treatment for this condition. The Intermediate Claudication, Rest Pain and Tissue Loss groups 
had a similar percentage of participants diagnosed with ischaemic heart disease or previous 
heart attack to that of the overall cohort ~45%. The Acute Lower Limb Ischaemia group was 
lower with only 30% of this group known to have ischaemic heart disease or previous heart 
attack.  
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Table 5.1: Characteristics of the cohort 
Characteristic 
 
Total Cohort 
 
(n=398) 
Disease Severity at Presentation 
Intermittent 
Claudication  
 
(n=291) 
Tissue Loss 
 
 
(n=59) 
Rest Pain 
 
 
(n=35) 
Acute Lower 
Limb 
Ischaemia  
(n=13) 
Age (years) 66.3 (±9.8) 66.1 (±9.5) 69.1 (±10.3) 64.2 (±10.8) 65.8 (±11.7) 
Male gender 278 (69.8%)  214 (73.5%)  34 (57.6%) 19 (54.3%) 11 (84.6%) 
Never Smoker 58 (14.6%) 31 (10.7%) 22 (37.3%) 4 (11.4%) 1 (7.7%) 
Current Smoking 188 (47.2%) 137 (47.1%) 25 (42.4%) 19 (54.3%) 7 (53.8%) 
Ex-smoking 152 (38.2%) 123 (42.3%) 12 (20.3%) 12 (34.3%) 5 (38.5%) 
Hypertension 298 (74.9%) 219 (75.3%) 47 (79.7%) 25 (71.4%) 7 (53.8%) 
Diabetes 149 (37.4%) 91 (31.3%) 43 (79.7%) 12 (34.3%) 3 (23.1%) 
Previous MI/IHD 177 (44.5%) 131 (45%) 26 (44.1%) 16 (45.7%) 4 (30.8%) 
Stroke 36 (9.0%) 28 (9.6%) 5 (8.5%) 2 (5.7%) 1 (7.7%) 
TIA 35 (8.8%) 31 (10.7%) 1 (1.7%) 3 (8.6%) 0 (0%) 
Prev Endovascular  55 (13.8%) 40 (13.7%) 8 (13.6%) 5 (14.3%) 2 (15.4%) 
Prev Open  49 (12.3%) 30 (10.3%) 11 (18.6%) 4 (11.4%) 4 (30.8%) 
Aspirin 276 (69.3%) 207 (71.1%) 37 (62.7%) 23 (65.7%) 9 (69.2%) 
Other Antiplatelet 53 (13.3%) 45 (15.5%) 5 (8.5%) 3 (8.6%) 13 (100%) 
Warfarin 31 (7.8%) 21 (7.2%) 6 (10.2%) 3 (8.6%) 1 (7.7%) 
CCB 111 (27.9%) 81 (27.8%) 17 (28.8%) 11 (31.4%) 2 (15.4%) 
Beta-blockers 114 (28.6%) 89 (30.6%) 14 (23.7%) 7 (20.0%) 4 (30.8%) 
ACE-inhibitors 167 (42.0%) 122 (41.9%) 29 (49.2%) 13 (37.4%) 3 (23.1%) 
Ang II blockers 90 (22.6%) 64 (22.0%) 19 (32.2%) 5 (14.3%) 2 (15.4%) 
Frusemide 50 (12.6%) 28 (9.6%) 17 (28.8%) 5 (14.3%) 0 (0%) 
Other Diuretic 52 (13.1%) 39 (13.4%) 10 (16.9%) 2 (5.7%) 1 (7.7%) 
Statins 259 (65.1%) 189 (64.9%) 37 (62.7%) 25 (71.4%) 8 (61.5%) 
Fibrate 14 (3.5%) 10 (3.4%) 1 (1.7%) 3 (8.6%) 0 (0%) 
NSAIDs 63 (15.8%) 47 (16.2%) 10 (16.9%) 5 (14.3%) 1 (7.7%) 
Cox2 38 (9.5%) 29 (10.0%) 6 (10.2%) 2 (5.7%) 1 (7.7%) 
Metformin 103 (25.9%) 65 (22.3%) 29 (49.2%) 9 (25.7%) 1 (7.7%) 
 
ACE inhibitors = angiotensin converting enzyme inhibitor (antihypertensive medication) 
Ang II blockers = angiotensin II receptor antagonist (antihypertensive medication) 
CCB = calcium channel blocker (antihypertensive medication) 
Cox2 = Cox 2 receptor selective non-steroidal anti-inflammatory drug 
MI/IHD = myocardial infarction (heart attack) or ischaemic heart disease     
NSAIDs = non-steroidal anti-inflammatory drugs  
Prev Endovascular = previous endovascular intervention   
Prev Open = previous open revascularisation 
TIA = transient ischaemic attack 
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The previous occurrence of stroke was between five and ten percent in all groups, with nine 
percent of the overall cohort having a previous stroke. The Rest Pain group had the lowest 
proportion of previous strokes with only 5.7%. The prevalence of previous transient ischaemic 
attack in the cohort was 8.8%, with a higher percentage in the Intermittent Claudication group 
(10.7%) and the Rest Pain group (8.6%) than the Tissue Loss group (1.7%) with no previous 
transient ischaemic attacks in the Acute Lower Limb Ischaemia group. 
 
Previous endovascular intervention was relatively consistent across all disease severity at 
presentation groups with rates from 13.6 – 15.4%. Previous open revascularisation was more 
common in the Acute Lower Limb Ischaemia group (30.8%) compared to 10.3% of the 
Intermittent Claudication group and 11.4% of the Rest Pain group. 
 
Aspirin was used in 69.3% of the cohort at recruitment, and was similar across disease severity 
at presentation groups. Aspirin was most commonly used in the Intermittent Claudication 
group (71.1%) and Acute Lower Limb Ischaemia group (69.2%) with the lowest frequency of 
aspirin use in the Tissue Loss group (62.7%) and in the Rest Pain group (65.7%). Other 
antiplatelet drugs were used in all of the Acute Lower Limb Ischaemia patients, meaning that 
69.2% of this population were on dual antiplatelet therapy. In the Intermittent Claudication 
group other antiplatelet use was 13.3% with similar rates in the Tissue Loss (8.5%) and Rest 
Pain (8.6%) groups. 
 
5.3. Discussion 
The mean age of this cohort is within ten years of the mean age of all of the cohorts that reported 
age in Chapter 3.223 This population is however younger than six49,74,122,222,320,322 of those 
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nine24,49,72-74,122,222,320,322 populations. The Tissue Loss group in this study had a mean age three 
years older than the Intermittent Claudication group and almost five years older than the Rest 
Pain group (Table 5.1). 
 
Variation is seen in the gender mix of disease severity at presentation groups with 69.8% of 
the total cohort male but 51% of the Rest pain group and 43% of the tissue loss group female 
(Table 5.1) consistent with previous description of higher representation of females in the 
critical limb ischaemia population.9 There is a range of variability in the gender of previously 
examined cohorts varying between 50-93% male gender with six studies72,74,122,320-322 reporting 
between 60-80% male gender with this study population in the middle of that range.  
 
A larger percentage of the studied cohort are current smokers (47.2%) than five49,72,73,122 of the 
comparative studies. The current and ex-smoking groups combined make up 85.4% of the total 
cohort (“smokers”) which is greater than all the reported incidence of smoking in Chapter 3223 
in the studies that included both current and ex-smokers in this group.12,74,322  
 
The risk factor of hypertension was present in 74.9% of the cohort which is comparable to 
five72,74,122,320,322of the eight studies that reported this information. Arain et al.222 reported a 
lower incidence of hypertension (66%) while Dormandy and Murray24 reported a lower 
incidence again (57%) and Violi et al.73 a much lower incidence with only 35% of the patients 
in that cohort having hypertension. It is possible that the definition of hypertension plays a part 
in the observed variation between populations with the patients in this study recorded as having 
the risk factor of hypertension if they were on anti-hypertensive medication even if their blood 
pressure was normal. 
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Diabetes was present in 37.4% of the examined cohort which is a similar result to that of two 
studies,72,322 but less than that of one study122 with 51-57% of their population diabetic. This 
cohort had more diabetics than two studies with ~25%222,320 and two studies with less (14%24, 
19%73). 
 
Previous heart attack or ischaemic heart disease was present in 44.5% of the total cohort which 
is comparable to two studies74,222 and consistent with the consensus of population studies of 
~40%28. This cohort had significantly more heart disease than two other studies with 1.9-
2.5%320 and 10%24 having ischaemic heart disease. It is unclear from the published 
methodology why the population of Amaranto et al.320 would have a rate of ischaemic heart 
disease so much lower than that generally expected of a population with peripheral arterial 
occlusive disease although diagnosis can greatly depend on the sensitivity of methods used.28 
 
Tissue Loss was present on admission to the study in 14.8% of the total cohort, almost double 
the 7.8% concentration in the cohort of Barani et al.122. Rest pain was present in 9.8%. Three 
studies24,73,74 only included patients with intermittent claudication while the other populations 
did not report the severity of peripheral arterial occlusive disease of included cases. In this 
study there were 94 patients in the combined groups of Rest Pain and Tissue Loss, which would 
give 24.6% of this cohort having critical limb ischaemia at presentation. This is similar to the 
22.3% of the Haumer et al.72 cohort of exactly the same size. Of the critical limb ischaemia 
patients in this study 62.8% had tissue loss, less than the 75% in the Pedrinelli et al.322 cohort 
which only included patients with critical limb ischaemia.  
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Previous interventions and medication use were not reported consistently enough in 
comparable populations to enable valuable comparison. Thorough inclusion of cohort 
characteristics in future research will allow for more accurate comparison and compilation of 
results. It is recommended that this include not only incidence of traditional risk factors but 
disease severity and medication use. 
 
5.4. Conclusion 
Definitions of risk factors for the included populations with peripheral arterial occlusive are 
not standardised and only sometimes published223 making comparison between populations 
and compilation of like populations for meta-analysis problematic. This study population of 
peripheral arterial occlusive disease patients does have a greater number of smokers compared 
with the compared previous populations and does have a comparatively high record of 
comorbidities overall.  
 
This cohort of patients with peripheral arterial occlusive disease is suitable for comparison to 
the other populations with peripheral arterial occlusive disease although caution needs to be 
taken in applying the outcome analysis from this population directly to other populations with 
peripheral arterial occlusive disease as there are inconsistencies in risk factors between 
populations. How much of this variation is due to methodological differences is difficult to 
ascertain as there are not currently standardised methods for assessing and recording risk 
factors in populations with peripheral arterial occlusive disease.  
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Comparison between populations of patients with peripheral arterial occlusive disease and 
collation of population data for meta-analysis would be significantly facilitated if standardised 
definitions of comorbidities were developed and employed for future research. 
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6. Results - section 2 
Cardiovascular event incident in cohort of patients 
with peripheral arterial occlusive disease 
 
Cardiovascular outcomes of patients with peripheral arterial occlusive disease vary depending 
on the population assessed. With variation in the comparison of reported cardiovascular risk 
factors shown in Chapter 5 it is important to establish the comparability of the cardiovascular 
event rate of the studied cohort to other populations with peripheral arterial occlusive disease. 
The principle aim of this chapter was to define and describe the incidence of major adverse 
event and the individual cardiovascular outcomes of death, heart attack, stroke, major 
amputation and peripheral revascularisation over the course of the study and then compare to 
previously published populations with peripheral arterial occlusive disease described in the 
systematic review in Chapter 3.223 
 
The detailed methodology for the results presented in this section is available in Chapter 4. The 
time-point of 3500 days is shown consistently throughout the results chapters as no patients 
remained in the study alive at 4000 days (10.96 years). As outlined in Chapter 4 when the 
Kaplan-Meir survival function does not get below 0.5 the median is presented as n/a and when 
the confidence interval for the median or mean is unable to be calculated it is presented as n/a.  
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6.1. Cohort major adverse event (death, heart attack or stroke) Kaplan-
Meier analysis 
Kaplan-Meier survival plot of the freedom from major adverse event in the cohort is shown in 
Figure 6.2 with the dotted lines representing the 95% confidence intervals. The horizontal axis 
is displayed in days with 1000 days (2.74 years), 2000 days (5.48 years), 3000 days (8.22 years) 
and 3500 days (9.59 years). The shape of the Kaplan-Meier freedom from major adverse event 
plot graphically displays the steady rate of major adverse event observed over the duration of 
the study.  
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Figure 6.2: Kaplan-Meier non-parametric survival plot - freedom from major adverse event (death, heart 
attack or stroke) of cohort with 95% confidence intervals 
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The average yearly rate of major adverse events was calculated to allow comparison with other 
populations over variable follow up times and is 4.9% major adverse event per year, although 
the true rate is more uneven (Figure 6.2).  
 
A total of 124 out of the 398 patients in the cohort either died or sustained a heart attack or 
stroke, giving an incidence of major adverse event of 35.16% over the course of the study. 
There were 269 patients discharged from follow up without major adverse event and a total of 
503 237 patient follow up days (Table 6.1).  
 
Median time to major adverse event was 2625 days (7.2 years) and is the preferred measure of 
central tendency for Kaplan-Meier analysis. The mean time to major adverse event of 2405 
days (6.6 years) was calculated using the area under the curve function. 
 
The progress of patients over time (Table 6.1) is shown with number of patients remaining in 
the study, the number of events and survivor function with 95% confidence intervals at each 
time point of 1000, 2000, 3000 and 3500 days.  
 
 
Table 6.1: Kaplan-Meier freedom from major adverse event (death, heart attack or stroke) rate of cohort 
with 95% confidence intervals displayed by days follow up. 
Major Adverse Event 0 days 1000 days 2000 days 3000 days 3500 days 
Total 
Cohort 
At Risk 398 205 98 20 5 
Events in previous 
interval 
0 59 34 27 4 
Freedom from major 
adverse event  
(95% CI) 
1 0.81 
(0.77-0.86) 
0.65 
(0.59-0.72) 
0.37 
(0.29-0.48) 
0.28 
(0.19-0.41) 
CI = Confidence Interval 
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In the first 1000 days 59 patients sustained a major adverse event with 134 patients discharged 
from follow up in this period leaving 205 patients at risk on day 1000 (Table 6.1). Of all the 
major adverse events that occurred during this study 47.6% of them occurred within the first 
1000 days. At 2000 days, 98 patients remained at risk with a further 34 having sustained a 
major adverse event and a further 73 patients discharged from the study. By 3000 days only 20 
patients remain at risk with 27 patients having sustained either death, heart attack or stroke in 
the previous 1000 days, and a total of 258 patients discharged from the study by this time. 
Between 3000 and 3500 days a further four major adverse events were sustained with only five 
patients remaining in the study at risk by day 3500, all of whom were discharged without 
sustaining a major adverse event prior to 4000 days.  
 
The endpoint of major adverse event for each patient is the time from study entry to the first 
event of heart attack, stroke or death. The patients in the study may have had multiple 
cardiovascular events prior to their death and the endpoints of death, heart attack and stroke 
are presented individually in addition to the endpoints of major amputation and peripheral 
revascularisation to clarify these relationships and describe events sustained by the study 
population. 
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6.2. Cohort death Kaplan-Meier analysis 
Kaplan-Meier survival plot of the freedom from death in the cohort is shown in Figure 6.3 with 
the 95% confidence intervals. During the 530 246 patient follow up days 100 patients of the 
total 398 patients in the cohort died with the remainder discharged from follow up over the 
course of the study. The terminal drop off in Figure 6.3 is due to the last remaining patient in 
the study dying at that time. 
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Figure 6.3: Kaplan-Meier non-parametric survival plot - freedom from death of cohort with 95% 
confidence intervals 
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The freedom from major adverse event curve (Figure 6.2) has a different end shape to the 
freedom from death curve (Figure 6.3). Although the same patient is included in both data sets 
and death was recorded at the same time point, only the first major adverse event is counted 
therefore that patient exits with a major adverse event (heart attack or stroke) prior to the 
recorded death. There is a noticeable change in the freedom from death function at around 3000 
days with a flattening out of the curve (Figure 6.3) indicating a stabilising of the freedom from 
death function that had been increasing in gradient prior to 3000 days although with only 24 
patients left at risk at 3000 days. 
 
The overall incidence of death was 25.1% (total deaths 100) with median freedom from death 
2899 days (7.9 years) and mean freedom from death more than 180 days less at 2715 days (7.4 
years). The observed difference in median and mean freedom from death is due to the skewed 
nature of the freedom from death function. While it takes 2899 days for the median freedom 
from death to occur, the half of the population that survive to this time do not live as long after 
this point as they did prior (in this study) reducing the mean which is calculated using an area 
under the curve method. 
 
The total mortality rate over the duration of the study is 25.1% with an average yearly mortality 
rate of 3.3% although this varies over the duration of the study (Table 6.2). The progress of 
patients over time is shown in Table 6.2 with the number of patients remaining in the study (at 
risk), the number of deaths and the Kaplan-Meier survivor function with 95% confidence 
intervals at each time point of 1000, 2000, 3000 and 3500 days.  
  
 146 
Chapter 6: Results section 2 – Cohort survival and cardiovascular events in patients with peripheral arterial occlusive disease 
Table 6.2: Kaplan-Meier freedom from death rate of cohort with 95% confidence intervals displayed by 
days follow up. 
Death 0 days 1000 days 2000 days 3000 days 3500 days 
Total 
Cohort 
At Risk 398 215  108 24 7 
Events in previous 
interval 
0 44 27 25 3 
Freedom from death 
(95% CI) 
1 0.85 
(0.82-0.90) 
0.72 
(0.66-0.78) 
0.46 
(0.37-0.56) 
0.39 
(0.29-0.51) 
No. = number    n/a = not applicable  CI= Confidence Interval 
 
398 patients began the study at day 0, by 1000 days only 215 patients were remaining in the 
study, with 44 patients dying prior to this and 139 patients being discharged from the study 
(Table 6.2). By 2000 days 108 patients remained in the study (at risk), with a further 27 patients 
deceased, and a further 80 patients discharged from follow up. At 3000 days only 24 patients 
remained in the study because between 2000 and 3000 days 25 patients died and 59 patients 
were discharged from follow up. At 3500 days there were seven patients remaining at risk 
(freedom from death 0.388) while three patients died in the prior 500 days. The last patient 
being followed up dies at 3952 days, therefore the freedom from death curve drops to 0 at this 
point (Figure 6.3). 3500 days is shown consistently throughout the results chapters as no 
patients remained in the study alive at 4000 days.   
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6.3. Cohort heart attack Kaplan-Meier analysis 
Kaplan-Meier plot of the freedom from heart attack for the entire cohort is shown in Figure 6.4 
with the dotted lines displaying the 95% confidence intervals. Of the 398 patients in the cohort 
only 34 patients sustained a heart attack over a total of 511 846 patient follow up days, making 
the freedom from heart attack survival curve (Figure 6.4) less steep than the freedom from 
major adverse event (Figure 6.2) and freedom from death (Figure 6.3) Kaplan-Meier plots 
presented previously. 
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Figure 6.4: Kaplan-Meier non-parametric survival plot - freedom from heart attack of cohort with 95% 
confidence intervals. 
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The larger drops in the freedom from heart attack curve toward the end of the study (Figure 
6.4) are because each heart attack is sustained in a smaller at risk population and has a greater 
effect on the freedom from heart attack function than heart attacks that were sustained early in 
the course of the study when there was a comparatively larger at risk population. 
 
Heart attack was sustained by 34 patients with five patients remaining in the study at conclusion 
(therefore no terminal drop off in Figure 6.4). Discharge from follow up without heart attack 
occurred in 359 patients over the course of the study (Table 6.3). 
 
 
Overall incidence of heart attack was 8.5%, occurring in 34 of the 398 patients, and the 
calculated mean freedom from heart attack by the area under curve method was 3299 days (± 
78days) or 9.0 years. Median freedom from heart attack and 95% confidence intervals for the 
median were not applicable due to the relatively small number of heart attacks resulting in the 
freedom from heart attack curve not reaching 0.5.  
 
The tabular presentation of progress of patients over time (Table 6.3) may be used to view the 
patients remaining at risk in the study, and when heart attacks occurred in relation to time posts 
1000, 2000, 3000 and 3500 days.  
  
 149 
Chapter 6: Results section 2 – Cohort survival and cardiovascular events in patients with peripheral arterial occlusive disease 
 
Table 6.3: Kaplan-Meier freedom from heart attack rate of cohort with 95% confidence intervals displayed 
by days follow up. 
Heart Attack  0 days 1000 days 2000 days 3000 days 3500 days 
Total 
Cohort 
At Risk 398 208 102 20 5 
Events in previous 
interval 
0 15 10 7 2 
Freedom from heart 
attack (95% CI) 
1 0.95 
(0.93-0.98) 
0.89 
(0.85-0.94) 
0.78 
(0.70-0.88) 
0.66 
(0.50-0.86) 
CI = Confidence Interval 
 
 
Of the 34 heart attacks sustained by patients enrolled in the study, the majority of these events 
occurred in the first 2000 days with only 9 further events occurring after this time (Table 6.3). 
The two heart attacks that occur between 3000 and 3500 days result in much larger drops in 
the survival cure (Figure 6.4) as discussed above because there are markedly fewer (≤20) 
patients still at risk. This shows the importance of discharge or censorship of other patients that 
can also be ascertained from Table 6.3, prior to 1000 days 175 patients were discharged from 
follow up, with a further 96 discharged between 1000 and 2000 days, 75 between 2000 and 
3000 days and 13 between 3000 and 3500 days. 
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6.4. Cohort stroke Kaplan-Meier analysis 
Kaplan-Meier survival plot of the freedom from stroke curve for the entire cohort is shown in 
Figure 6.5 with the 95% confidence intervals displayed with the dotted lines. The flatter shape 
of the freedom from stoke plot is due to only 18 strokes being sustained over 519 695 patient 
follow up days. 
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Figure 6.5: Kaplan-Meier non-parametric survival plot - freedom from stroke of cohort with 95% 
confidence intervals. 
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Mean time to stroke was calculated to be well over 3000 days or >9 years (with median not 
applicable), and should be interpreted with caution due to the small number of strokes (Table 
6.4). Overall incidence of stroke was 4.5% of the recruited population. 
 
The progress of patients over time (Table 6.4) is shown with number of patients remaining in 
the study, the number of strokes and survivor function with 95% confidence intervals at each 
time point of 1000, 2000, 3000 and 3500 days.  
 
Table 6.4: Kaplan-Meier freedom from stroke rate of cohort with 95% confidence intervals displayed by 
days follow up. 
Stroke 0 days 1000 days 2000 days 3000 days 3500 days 
Total 
Cohort 
At Risk 398 211  104 23 6 
Events in previous 
interval 
0 10 6 2 0 
Freedom from stroke  
(95% CI) 
1 0.97 
(0.95-0.99) 
0.93 
(0.90-0.99) 
0.90 
(0.84-0.96) 
0.90 
(0.84-0.96) 
CI = Confidence Interval 
 
 
Ten of the 18 strokes (55.5%) occurred in the first 1000 days of the study (Table 6.4). There 
were six strokes that occurred between 1000 and 2000 days and two strokes between 2000 and 
3000 days. The freedom from stroke rate does not change from 3000 to 3500 days as there 
were no recorded strokes during this time. Discharge from follow up without stroke occurred 
in 177 patients in the first 1000 days, 101 patients between 1000 and 2000 days, 79 patients 
between 2000 and 3000 days and 17 patients between 3000 and 3500 days.  
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6.5. Cohort major amputation Kaplan-Meier analysis 
Kaplan-Meier survival plot of the incidence of major amputation in the cohort is shown in 
Figure 6.6 with the dotted lines displaying the 95% confidence intervals. The freedom from 
major amputation function shows gradual decline over the course of the study with one step 
down before flattening out prior to 3000 days (Figure 6.6). 
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Figure 6.6: Kaplan-Meier non-parametric survival plot - freedom from major amputation of cohort with 
95% confidence intervals 
 
Of the 398 patients in the cohort 27 patients required major lower limb amputation and 365 
were discharged from follow up with a total of 509 787 patient follow up days (Table 6.5).  
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The mean freedom from major amputation is calculated from the area under the curve method 
and is well over 3000 days or >9 years and again should be interpreted with caution due to the 
small number of major amputations and the median not being applicable. Overall incidence of 
major amputation was 6.8% of the study population. 
 
The progress of patients over time (Table 6.5) is shown with number of patients remaining in 
the study, the number of major amputations and survivor function with 95% confidence 
intervals at each time point of 1000, 2000, 3000 and 3500 days.  
 
Table 6.5: Kaplan-Meier freedom from major amputation rate of cohort with 95% confidence intervals 
displayed by days follow up. 
Major amputation 0 days 1000 days 2000 days 3000 days 3500 days 
Total 
Cohort 
At Risk 398 207 101 21 6 
Events in previous 
interval 
0 20 5 2 0 
Freedom from major 
amputation (95% CI) 
1 0.94 
(0.91-0.97) 
0.91 
(0.87-0.95) 
0.87 
(0.80-0.94) 
0.87 
(0.80-0.94) 
CI = Confidence Interval 
 
 
Table 6.5 demonstrates that 74% of the 27 major amputations took place in the first 1000 days 
of the study. The number of patients remaining in the study and the number of events may be 
used to interpret the number of patients being discharged from the study at each time point of 
1000, 2000, 3000 and 3500 days: giving 171, 101, 78 and 15 patients respectively. The survivor 
function and 95% confidence intervals do not change from 3000 to 3500 days as there were no 
major amputations in this period.  
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6.6. Cohort peripheral revascularisation Kaplan-Meier analysis 
Kaplan-Meier survival plot of the freedom from peripheral revascularisation in the cohort is 
shown in Figure 6.7 and demonstrates that the cohort experienced this endpoint in a very 
different timeframe to the other outcomes. The sharp initial drop and concave shape of the 
freedom from peripheral revascularisation plot reveal that many of the patients underwent 
peripheral revascularisation early after recruitment to the study.  
 
Figure 6.7: Kaplan-Meier non-parametric survival plot - freedom from peripheral revascularisation of 
cohort with 95% confidence intervals. 
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With 220 patients undergoing peripheral revascularisation during the course of the study the 
incidence of peripheral revascularisation was 55.3% with 178 patients discharged from follow 
up without having undergone a peripheral revascularisation procedure.  
 
The calculated mean time to peripheral revascularisation was 1501 ± 90.7 days (4.1 years) but 
50% of the population at risk had undergone peripheral revascularisation by day 782 (382 – 
1364). The initial steepness of the curve (Figure 6.7) was caused by 174 patients undergoing 
peripheral revascularisation within the first year, while only 32 patients were discharged in that 
year with the freedom from peripheral revascularisation function almost at 50% by this time 
(55.4%). A large difference between median and mean can be seen in skewed data, with both 
median and mean together giving a better understanding of the data distribution. It takes 
another year for five percent of the population to require peripheral revascularisation showing 
the rapid change of freedom from peripheral revascularisation rate over this early course of the 
study.  
 
The total of 295 633 patient follow up days is much less than previous endpoints and is largely 
made up of the population who did not undergo early revascularisation but remain in the study 
at risk thus elevating the calculated mean. 
 
The progress of patients over time (Table 6.6) is shown with number of patients remaining in 
the study, the number of peripheral revascularisations and freedom from peripheral 
revascularisation function with 95% confidence intervals at each time point of 1000, 2000, 
3000 and 3500 days.  
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Table 6.6: Kaplan-Meier freedom from peripheral revascularisation rate of cohort with 95% confidence 
intervals displayed by days follow up. 
Peripheral Revascularisation 0 days 1000 days 2000 days 3000 days 3500 days 
Total 
Cohort 
At Risk 398 123 49 6 1 
Events in previous 
interval 
0 197 19 3 1 
Freedom from 
peripheral 
revascularisation  
(95% CI) 
1 0.48 
(0.43-0.53) 
0.38 
(0.32-0.44) 
0.35 
(0.30-0.42) 
0.29 
(0.20-0.43) 
CI = Confidence Interval 
 
 
The progress of patients over time (Table 6.6) confirms that the freedom from peripheral 
revascularisation rate is <0.5 prior to 1000 days with 197 patients undergoing 
revascularisations prior to this point and 78 patients discharged from follow up in the same 
period. The further decline of the freedom from peripheral revascularisation rate can be seen 
with ongoing events to 3500 days. The step down in freedom from peripheral revascularisation 
rate at 3000 days (Figure 6.7) is the last peripheral revascularisation in the cohort during the 
study, with four other patients being discharged from follow up after 3000 days without 
requiring revascularisation. The last patient being followed was discharged at 3555 days 
without requiring revascularisation. 
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6.7. Discussion 
The overall incidence of major adverse event during this study is similar to other populations 
of patients with peripheral arterial occlusive disease discussed in Chapter 3.223 A total of 
35.16% of the initially recruited population sustained a major adverse event with median 
freedom from major adverse event of 7.2 years. The observed average yearly rate of 4.9% 
major adverse event per year is consistent with Giugliano et al.74 who reported an average 4.3% 
per year incidence of major adverse event over 30 month follow up of patients with peripheral 
arterial occlusive disease. Amaranto et al.320 reported a lower average 3.7% yearly incidence 
of major adverse event in patients undergoing major open or endovascular procedures. Major 
adverse event in the ADEP (Atherosclerotic Disease Evolution by Picotamide) study73 was less 
with 2.7% average incidence per annum despite their endpoint including major amputation. 
The incidence of major adverse events was greater in the PACK (Prevention of Atherosclerotic 
Complication with Ketanserin) study 20 years earlier, with Dormandy and Murray24 reporting 
a 6.8% incidence of major adverse event, possibly reflecting the improved outcomes from 
medical and surgical management of atherosclerotic disease in the interval between these 
studies. This data confirms that the estimated rate of major adverse event rate used in power 
calculations (30%) was slightly conservative and the power calculations confirm adequate 
power for the study of this endpoint in this population. 
 
 
Mortality rate of the studied population is similar to previously examined populations with 
peripheral arterial occlusive disease. The 100 deaths over the duration of the study occurred 
with mean freedom from death of 7.7 years. The total mortality rate over the duration of the 
study was 25.1% with an average yearly mortality rate of 3.3% which is comparable to the 
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average 3.8% yearly mortality reported by Arain et al.222 although greater than the 1.1% 
average yearly mortality in the ADEP study73 and the 1.7% average yearly mortality following 
major open and endovascular procedures reported by Amaranto et al.320. The average yearly 
mortality rate of this study was less than the 4.3% yearly claudicant mortality of Dormandy 
and Murray24 and 4.8% first year mortality in the study of a similar population by Bloor23.  The 
population of Bhutta et al.49 was observed to have a higher average annual mortality of 6.1% 
per year in 1021 patients undergoing vascular surgery which may have been due to inclusion 
of a higher risk population or operative mortality being significantly different to the mortality 
of patients managed conservatively. This data confirms that the estimated mortality rate used 
in power calculations (25%) was very close to the observed rate (25.1%) and that power 
calculations confirm adequate power for the study of the endpoint of mortality in this 
population. 
 
The incidence of heart attack in this study is similar to previously published studies. Heart 
attacks were sustained by 34 of the participants in this study with a mean freedom from heart 
attack of 9.0 years giving an average rate of 0.9% per year, identical to the average yearly 
occurrence of heart attack in the ADEP study73. Other populations with peripheral arterial 
occlusive disease exhibit higher rates of heart attack with the average rate of 2.2% heart attacks 
per year in the Giugliano et al.74 population, average 2.1% per year in Haumer et al.72 
population and 1.8% in Dormandy and Murry24 claudicant population. One possible cause for 
this lower rate in this study is methodological as a heart attack resulting in death was recorded 
as death and not heart attack. 
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Stroke occurred in this study with similar frequency to previously published studies. Mean 
freedom from stroke was 9.8 years and equated to an average rate of 0.46% stroke per year 
which is similar to the 0.6% average from the ADEP study73. Two previous studies have 
reported more than double this rate with an average of average of 1.1% per year in the 
Giugliano et al.74 population and 1.4% in the Dormandy and Murray24 claudicants. Haumer et 
al.72 recorded a much higher average incidence of stroke of 3.1% per year although it is unclear 
how much of this difference could be accounted for by the inclusion of fatal strokes in this 
group.  
 
The rate of major amputation in this study was between previously published rates of major 
amputation. Mean freedom from major amputation was 9.9 years with an average annual 
incidence of major amputation of 0.7% per year which was more than triple the 0.2% average 
major amputation rate per year in the ADEP study73 although this study excluded Rest Pain 
and Tissue Loss patients who have an inherently higher rate of major amputation.26,97 
Interestingly the annual rate of major amputation was less than half of the 1.6% major 
amputation rate of Dormandy and Murray24 study which only included patients with 
intermittent claudication.  
 
The skewed nature of the freedom from peripheral revascularisation results of the cohort 
(Figure 6.7) was confirmed by the large difference in the median and mean freedom from 
peripheral revascularisation. This skewed data is largely a function of the described methods 
of this study which outlined the timing of patient recruitment into the study. Only patients with 
symptomatic peripheral arterial occlusive disease were included in this study and were 
recruited from the outpatient department or when they presented to hospital to undergo a 
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peripheral revascularisation procedure. Because this patient group was recruited at a time when 
they required peripheral revascularisation or were being considered for peripheral 
revascularisation, the time to peripheral revascularisation is understandably short in a large 
portion of the population thus providing the left skew to this endpoint. The peripheral 
revascularisation endpoint is not analysed in the following results chapters due to the skewed 
nature of the data distribution and the inherent bias due to the method of patient recruitment 
and inclusion criteria of this study. 
 
6.8. Conclusion 
The incidence of adverse cardiovascular outcomes in the studied patient group with 
symptomatic peripheral arterial occlusive disease is similar to previously studied populations 
with this disease. Some of the reported differences in the incidence of cardiovascular outcomes 
are due to the methodological differences between studies. The main methodological difference 
between this study and some previous studies is that heart attack that resulted in the patient 
death in this study was recorded as death, thus the outcome of heart attack in this study only 
includes non-fatal heart attacks. Similarly if the patient sustained a stroke that resulted in death 
then that was recorded as death making the outcome of stroke only the non-fatal strokes. 
Including the fatal events in the stroke and heart attack endpoints would have increased the 
event numbers of these outcomes and may have improved the power for statistical analysis to 
examine these endpoints individually. Future reporting of the number of the individual events 
within composite outcomes is important as it will allow detailed future comparisons and 
compilations for outcomes with comparatively small incidence in patients with peripheral 
arterial occlusive disease. 
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7. Results - section 3 
Disease severity associated with major adverse 
events in patients with peripheral arterial occlusive 
disease 
 
7.1. Introduction 
Disease severity of patients with peripheral arterial occlusive disease has been associated with 
cardiovascular events8,24,26,28 however it has been inconsistently adjusted for in analysis of 
cardiovascular events in this population.223 Patients with symptomatic peripheral arterial 
occlusive disease have a 15-year accrued survival rate of approximately 22%, compared with 
a survival rate of 78% in patients without peripheral arterial occlusive disease symptoms.374 
The San Diego Artery study29 that followed patients with peripheral arterial occlusive disease 
over 10 years found that survival rates decreased with increasing severity of peripheral arterial 
occlusive disease symptoms.29  
 
Patients with intermittent claudication are expected to have an annual major adverse event rate 
of 5%-7% which has been reported as being 2.5 times higher than age matched controls 
independent of risk factors.28  Patients with critical limb ischaemia (rest pain or tissue loss) 
have a higher risk of sustaining cardiovascular ischaemic events than those with intermittent 
claudication25, with a ~20% mortality in the first year after presentation26,28,375 and mortality 
approaching 50% at 5 years and 70% at 10 years27,28,376,377. Conte et al.378 developed objective 
performance goals to define appropriate outcome measures for critical limb ischaemia trials 
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and advocated the composite outcome of death, heart attack and stroke (among others) for 
investigating the outcomes of critical limb ischaemia with new and evolving treatments.  
 
Major amputation has been previously observed in 12% of a large prospective multicentre 
cohort of patients with critical limb ischaemia at six months.375 Following revascularisation 
with vein bypass, patients with critical limb ischaemia still have a 12% major amputation rate 
at one year.379 If treated conservatively then as many as 38% of patients with critical limb 
ischaemia will require major amputation at one year with only 25% of ulcers healed at 12 
months and 50% healed at one year.108 Very different rates of major amputation are 
experienced by patients with intermittent claudication with between one and three percent24,28 
requiring major amputation per year. 
 
Despite these apparent differences in outcomes based on disease severity, disease severity is 
not always reported or adjusted for in statistical analysis of outcome in patients with peripheral 
arterial occlusive disease.223 
 
 
The hypothesis being tested in this chapter is that disease severity is associated with the 
outcomes of major adverse events (composite outcome of death, heart attack or stroke) in a 
population of patients with peripheral arterial occlusive disease. 
 
7.2. Methods 
The hypothesis of this study was tested through a prospective cohort study, the methodology 
is detailed in Chapter 4 with definitions of disease severity presented in Appendix I. The 
division of critical limb ischaemia into Rest Pain and Tissue Loss groups has been suggested 
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previously as these two groups have appreciably different natural histories.26 To enable 
comparison with other literature the survival rates are also presented for 365 days. 3500 days 
is shown consistently throughout the results chapter as no patients remained in the study alive 
at 4000 days (10.96 years).  
 
7.3. Results 
The results of the entire cohort grouped by disease severity at presentation is examined with 
the endpoint of major adverse event. Kaplan-Meir survival analysis is presented through both 
graphical and tabular form to demonstrate timeline of events over the duration of the study and 
Log rank testing to assess statistical difference between the groups for each endpoint. 
 
Kaplan-Meir plot of the freedom from composite endpoint of major adverse event (either death, 
heart attack or stroke) is shown in Figure 7.2 grouped by disease severity at presentation for 
inclusion into the study with the dotted lines representing the 95% confidence intervals. The 
horizontal axis is again displayed in days with the time points described in Chapter 4. The 
disease severity groups do not have equal numbers of patients and the survival rate plots need 
to be interpreted with consideration of the number of patients in that group. The Intermittent 
Claudication group (green, Figure 7.2) has the smoothest freedom from major adverse event 
curve because the largest number of patients (291) are in that group. The Acute Lower Limb 
Ischaemia group (orange, Figure 7.2) has the smallest number of patients (13) resulting in 
comparatively large drops in the freedom from major adverse event curve with each major 
adverse event.  
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Figure 7.2: Kaplan-Meir non-parametric survival plot - freedom from major adverse event (death, heart 
attack or stroke) by disease severity at presentation with 95% confidence intervals. 
 
The Rest Pain group (red, Figure 7.2) and Tissue Loss group (blue, Figure 7.2) follow a visibly 
different course to the Intermittent Claudication group (green, Figure 7.2) with a lower freedom 
from major adverse event for the majority of the study. The Tissue Loss plot initially takes a 
lower freedom from major adverse event course than the Rest Pain group until they meet at 
~750 days and experience similar freedom from major adverse event rates until prior to 2000 
days when the Rest Pain group falls lower and remains lower for the remainder of the study. 
The Acute Lower Limb Ischaemia group follows a course lower than that of the Intermittent 
Claudication group for most of the study but crosses plots at ~2750 days. 
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The Intermittent Claudication group sustained the largest number of major adverse events with 
75 although this group had the largest number of patients (291) meaning 25.8% of the 
Intermittent Claudication group sustained a major adverse event over the course of the study. 
The Intermittent Claudication group had the longest calculated mean freedom from major 
adverse event of 2628 ± 95.3 days (7.20 years) and the longest median freedom from major 
adverse event 2864 (2572 – 3375) days. The shortest mean freedom from major adverse event 
was 1626 ± 219.5 days (4.45 years) in the Rest Pain group in which 35 patients (51.4% of that 
population) sustained a major adverse event. The Rest Pain group also had the shortest median 
freedom from major adverse event with 1308 (911 – 2789) days. Of the Tissue Loss group, 
45.8% (27 of 59) sustained a major adverse event over the duration of the study with a mean 
freedom from major adverse event of 1775 ± 200.4 days. The median freedom from major 
adverse event of both the Tissue Loss group (1348 days = 3.69 years) and the Rest Pain group 
(1308 days = 3.58 years) are less than half of that for the Intermittent Claudication group (2864 
days = 7.85 years). Within the Acute Lower Limb Ischaemia group, 30.8% (4 of 13) sustained 
a major adverse event over the duration of the study with mean freedom from major adverse 
event 2020 days (5.5 years) with the median not applicable for this group. 
 
The average annual incidence of major adverse event over the entire duration of the study was 
3.6% for the Intermittent Claudication group, 11.6% for the Rest Pain group, 9.4% for the 
Tissue Loss group and 5.6% for the Acute Lower Limb Ischaemia group. The observed rate of 
major adverse event was not consistent over time as can be seen in Figure 7.2 and Table 7.1. 
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The progress of patients over time is shown in Table 7.1 with the number of patients remaining 
in the study, the number of events and survivor function with 95% confidence intervals at each 
time point of 1000, 2000, 3000 and 3500 days. 
 
  
Table 7.1: Kaplan-Meir freedom from major adverse event (death, heart attack or stroke) rate by disease 
severity at presentation with 95% confidence intervals displayed by days follow up. 
Major adverse event 0 days 1000 days 2000 days 3000 days 3500 days 
Intermittent 
Claudication 
At Risk 291 159 80 16 5 
Events in 
previous interval 
0 30 20 23 2 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.87 
(0.82-0.94) 
0.73 
(0.67-0.80) 
0.40 
(0.30-0.53) 
0.32 
(0.22-0.49) 
Acute Lower 
Limb 
Ischaemia 
At Risk 13 7 3 - - 
Events in 
previous interval 
0 2 2 - - 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.82  
(0.61-1.00) 
0.54 
(0.23-1.00) 
- - 
Rest Pain At Risk 35 13 6 2 - 
Events in 
previous interval 
0 10 4 3 - 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.59 
(0.42-0.83) 
0.37 
(0.21-0.66) 
0.19 
(0.07 0.50) 
- 
Tissue Loss At Risk 59 26 10 2 - 
Events in 
previous interval 
0 17 8 1 - 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.66 
(0.54-0.81) 
0.43 
(0.29-0.62) 
0.37 
(0.23-0.59) 
- 
CI = Confidence Interval 
 
In the group of 291 patients that presented with Intermittent Claudication, 30 patients sustained 
a major adverse event in the first 1000 days, with 102 being discharged from follow up in this 
time (Table 7.1). From 1000 to 2000 days a further 20 patients had a major adverse event and 
59 patients were discharged. Between 2000 and 3000 days 23 patients from the Intermittent 
Claudication group had a major adverse event and 41 patients were discharged from follow up. 
In the period from 3000 to 3500 days two further patients had major adverse events while nine 
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patients were discharged. Between 3500 follow up days and the conclusion of the study there 
were no further major adverse events in the remainder of the group and those five patients were 
discharged from follow up without event (Table 7.1). 
 
The Acute Lower Limb Ischaemia group of 13 patients sustained four major adverse events 
over the course of the study, two of these events were prior to 1000 days and two events 
occurred between 1000 and 2000 days (Table 7.1). The discharge from follow up was four 
patients prior to 1000 days, two patients between 1000 and 2000 days and the remaining three 
between 2000 and 3000 days (Table 7.1). 
 
Ten of the 35 patients with Rest Pain had a major adverse event prior to 1000 days with 12 
patients discharged from follow up in this time (Table 7.1). Between 1000 and 2000 days there 
were four major adverse events in the Rest Pain group with three patients discharged from 
follow up. From 2000 to 3000 days there were a further three major adverse events with one 
patient discharged from follow up. The last two remaining patients in the Rest Pain group were 
discharged prior to 3500 days (Table 7.1). 
 
Of the 59 patients in the Tissue Loss group, 17 sustained a major adverse event prior to 1000 
days with 16 patients from this group discharged in that time (Table 7.1). Between 1000 and 
2000 days there were a further eight major adverse events and eight patients discharged from 
follow up. The last event occurred in the 2000 to 3000 day window, with seven patients 
discharged from follow up. No patients who presented with Tissue Loss remained in the study 
at 3500 days (Table 7.1). 
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At one year the Tissue Loss group freedom from major adverse event function is 0.81 (95% CI 
0.72 – 1.00) having sustained 10 major adverse events in the first 365 days of the study. The 
freedom from major adverse event function of the Rest Pain group at 365 days is 0.90 (95% CI 
0.79 -1.00) having sustained three major adverse events in the first year of the study. The Acute 
Lower Limb Ischaemia group had one major adverse event in the first year with resultant 
freedom from major adverse event rate 0.92 (95% CI 0.77 – 1.00). There were eight major 
adverse events in the Intermittent Claudication group within the first year giving this group a 
freedom from major adverse event function of 0.97 (95% CI 0.95 – 0.99). 
 
Kaplan-Meier freedom from death function presented in both graphical (Figure 7.2) and tabular 
(Table 7.1) form indicate that the Intermittent Claudication group is distinct from both Rest 
Pain and Tissue Loss groups for the endpoint of major adverse event. A log rank test was 
performed to test the hypothesis that there is no difference between these survival curves for 
major adverse event. The purpose of the log rank analysis was to test if disease severity at 
presentation was a potential confounding variable for major adverse event that should be 
adjusted for when testing the association between circulating cell counts and cardiovascular 
outcomes in Chapter 8 Section 4 and 5. The log rank test resulted in a Chi-square value of 26.1 
and a p-value <0.01 (probability of obtaining a test statistic as extreme as this if there is no 
difference in survival curves). This high degree of significance on the log rank test indicates 
that there may be a true difference in the survival curves between the disease severity groups 
however it does not attribute this risk to the disease severity alone as there has not been 
adjustment for confounding factors.  
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7.4. Discussion 
Disease severity at presentation in patients with peripheral arterial occlusive disease has 
significant association with the cardiovascular endpoint of major adverse event. The 
contribution of disease severity to outcome should be considered and statistically adjusted for 
when assessing other factors that may be associated with cardiovascular outcomes in patients 
with peripheral arterial occlusive disease. 
 
Disease severity at presentation groups were significantly different on log rank testing (p<0.01) 
for the outcome of major adverse event. The Intermittent Claudication group has the lowest 
incidence of major adverse event with 25.8%, the average annual rate of major adverse event 
in the Intermittent Claudication population was 3.6% over the duration of the study although 
in the first year of the study it was only 3%. This population is below the expected range 
reported by TASC II who reported the annual overall rate of major adverse event to be 
approximately 5-7% per year.28 Intermittent claudicants in the PACK (Prevention of 
Atherosclerotic Complication with Ketanserin) study were at the other end of this range with 
an annual rate of 6.8% major adverse events reported by Dormandy and Murray.24 The Tissue 
Loss group initially has the lowest freedom from major adverse event function (0.81 at one 
year) with 19% of that group sustaining a major adverse event in the first year. However, the 
Rest Pain freedom from major adverse event function drops below the Tissue Loss group prior 
to 1000 days. When the groups of Rest Pain and Tissue Loss are combined into a single group 
of Critical Limb Ischaemia, the total incidence of major adverse event in this population is 
47.9% over the entire duration of the study. The composite endpoint of major adverse event 
needs further research in the subgroup of patients with Critical Limb Ischaemia as 
recommended by Conte et al.378 
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Patients with critical limb ischaemia often have their risk factors for atherosclerotic disease 
inadequately treated compared with patients with ischaemic heart disease or cerebrovascular 
disease.127,380,381 This is a potential contributing factor to the worse outcomes of this sub 
population in this study with less aspirin use in Rest Pain (65.7%) and Tissue Loss (62.7%) 
group patients than in the population of Intermittent claudication (71.1%, Table 5.1) and only 
8.5/8.6% of the Rest Pain and Tissue loss groups taking another antiplatelet agent compared to 
15.5% of the Intermittent Claudication group. Statin use however was proportionately higher 
in the Rest Pain group (71.4%) compared to the Tissue Loss group (62.7%) and Intermittent 
Claudication group (64.9%, Table 5.1). 
 
The higher incidence of major adverse events in the disease severity groups of Rest Pain and 
Tissue loss are possibly an indicator of the burden of systemic atherosclerotic disease, with 
greater burden in both the coronary, cerebral as well as peripheral circulation. The ischaemia 
of tissue (in this case in the lower limb) and has previously been shown to affect white blood 
cell adhesion and deformability resulting in adverse effects in remote organs.230,231,341  
 
7.5. Conclusion 
Disease severity is associated with the outcome of major adverse event. These results were 
comparable to other populations of peripheral arterial occlusive disease and demonstrate that 
disease severity should be reported and adjusted for in the analysis of outcomes for this 
population. 
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8. Results - section 4 and 5 
Total and differential circulating cell counts 
associated with major adverse events and death in 
patients with peripheral arterial occlusive disease 
 
8.1. Introduction 
Circulating cell counts of patients with peripheral arterial occlusive disease have been 
associated with major adverse events24,49,69,72,99,222,260,266,320 and 
death.24,49,72,74,99,122,152,222,238,260,316,321,322 Relative leucocytosis at admission for cardiovascular 
or cerebrovascular events correlates with severity of ischaemic damage and subsequent 
course,99 and is associated with all-cause mortality in patients with peripheral arterial occlusive 
disease24,222 and the subset with critical limb ischaemia.122,322 Elevated total white cell count 
(TWCC) has also been associated with mortality after cardiac surgery209 and percutaneous 
coronary intervention205. The relationship of total white cell count with the composite outcome 
of major adverse event may not always be linear, with previous report of a U shaped correlation 
after open operations for arterial disease.320 
  
When analysing the total white cell count as subtypes, a neutrophil count of greater than 5.8 
x109cells/L has previously been shown to be associated with an increased risk for major 
adverse events in patients with peripheral occlusive arterial disease diagnosed with >50% 
stenosis on angiogram.72 The neutrophil count was the parameter that contributed most strongly 
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arterial occlusive disease. 
to increased risk of death in Grau et al.69, and was a predictive index, particularly for vascular 
death (relative risk 1.86). Neutrophil count was also associated with death in Haumer et al.72 
study of 398 patients with symptomatic peripheral arterial occlusive disease. 
High neutrophil count has also been shown to add prognostic information to traditional 
atherothrombotic risk factors in a population of 368 patients, 27% of whom had critical limb 
ischaemia although the hazard or risk ratios were not reported.72  
 
Lymphocyte count demonstrated an inverse relationship with recurrent ischaemic events in the 
Clopidogrel versus aspirin in patients at risk of adverse ischaemic events trial (CAPRIE) of 
patients with heart attack, stroke and peripheral arterial occlusive disease.69 This relationship 
has been replicated in large studies of patients with coronary artery disease following coronary 
percutaneous intervention,205 and studies of left ventricular dysfunction.208 To the authors 
knowledge there is no published evidence of lymphocyte count and the association with 
mortality in patients with peripheral arterial occlusive disease. 
 
Monocyte count has previously been associated with the presence of peripheral arterial 
occlusive disease in population studies.264 Monocyte count in patients with coronary artery 
disease is associated with adverse cardiovascular event although to a lesser extent than 
neutrophil count.99 In patients with peripheral arterial occlusive disease circulating monocyte 
count has been associated with vein graft stenosis following lower limb bypass surgery but not 
mortality.266 Evidence of any association of monocyte count with the composite endpoint of 
major adverse event remains to be demonstrated. 
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Low haemoglobin concentration (anaemia) may be an independent risk factor of cardiovascular 
risk in the general population270 with the Framingham study demonstrating a U-shaped 
relationship between haematocrit and mortality.271,272 Even mild anaemia has been shown (via 
haematocrit) in a very large population (310311 participants) to increase 30 day post-operative 
mortality and cardiac events in older male patients undergoing non-cardiac surgery.287 In 
patients with coronary artery disease haemoglobin has been associated with early and late 
mortality382 death following heart attack,275 cardiac surgery,276-278,280 percutaneous 
intervention,215,272,281,282 and heart failure.270,284 In patients undergoing elective vascular 
surgery low haemoglobin concentration has been shown to be associated with composite 
endpoint of death or heart attack with 30 day hazard ratio of 4.7 (2.6-10.9) for the severe 
anaemia group (haemoglobin 98±8 x109g/L).288 In the same patient group the five year hazard 
ratio for heart attack or death was 6.1 (95% CI 4.1-9.1) adjusted for other comorbidities 
including renal function and heart failure.288 Pre-operative haemoglobin has been associated 
with two year mortality in patients undergoing major vascular surgery,49 and haematocrit was 
lower in patients who died during follow up for critical limb ischaemia.322 
Although haemoglobin concentration has been associated with adverse surgical outcome in 
patients with peripheral arterial occlusive disease through vascular surgical incisional 
complications,225 amputation site healing224 and early loss of bypass patency,289 the 
relationship between haemoglobin with mortality and major adverse events remains unclear in 
patients with peripheral arterial occlusive disease. 
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Pre-operative neutrophil-lymphocyte ratio (NLR) identified patients at increased risk of death 
following major vascular surgery49 and in patients with chronic critical limb ischaemia.260 In 
patients with coronary artery disease neutrophil-lymphocyte ratio has a strong relationship to 
adverse outcomes229,242-245 in patients undergoing percutaneous coronary interventions212,249 
and coronary artery bypass grafting.250,251 
 
The aim of this study was to combine the assessment of all the circulating cell types discussed 
above on the same population with peripheral arterial occlusive disease for the composite 
endpoint of major adverse event and death alone. A secondary aim is to generate a model that 
combines the cell count values (from an inexpensive, reliable data source that is already 
routinely obtained with known risk factors) as a predictive tool for major adverse event that 
may be applied by the clinician at the bedside. Developing the understanding of the true 
relationships and relative predictive value of the circulating cells combined with and compared 
to the known risk factors for major adverse event and death will not only better guide risk 
stratification models for patient treatment but guide further research into understanding of the 
pathogenesis of major adverse events and death in this population. 
 
The hypothesis being tested in this study is that baseline total and differential circulating cell 
counts are associated with major adverse events (composite outcome of death, heart attack or 
stroke) and death alone in patients with peripheral arterial occlusive disease. The circulating 
cell counts investigated in this study are total white cell count (TWCC), neutrophil count, 
lymphocyte count, monocyte count, calculated neutrophil-lymphocyte ratio plus haemoglobin 
concentration as a measure of red blood cell parameters. 
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8.2. Methods  
The two separate hypothesis to be tested in this chapter will be separately addressed in Section 
4 for the outcome of major adverse event and Section 5 for the outcome of death. Both 
hypothesis were tested through a prospective cohort study, with the detailed methodology 
available in Chapter 4. Both hypothesis were tested by Kaplan-Meier non-parametric survival 
analysis, Cox proportional hazards analysis and multi-model averaging. Each section will be 
followed by a discussion and conclusion for that endpoint. 
 
Kaplan-Meier analysis of freedom from major adverse event for the entire cohort grouped by 
cell count (or haemoglobin concentration) tertile is presented in both graphical and tabular form 
with the x axis time points described in Chapter 4 to show progress of patients over time 
throughout the study. Patients that were discharged from follow up without event are discussed.  
 
Cox proportional hazards analysis for the outcome of major adverse event and death is 
presented for each circulating cell type a priori, adjusted for traditional risk factors (defined in 
Chapter 4) and adjusted for comprehensive risk factors (defined in Chapter 4) with the model 
stratified when required. Conformity of all Cox models with the assumptions of proportionality 
is tested using the Cox.zph score for each variable and each global model, any significant 
Cox.zph scores indicating a potential breach in the assumption of proportionality are discussed. 
 
The multi-model averaging process is used to assess which models and subsequently which 
variables are best associated with the outcome of major adverse event and death separately. 
 178 
Chapter 8: Results section 4 and 5 - Total and differential circulating cell counts associated with major adverse events and death in peripheral 
arterial occlusive disease. 
Multi-model averaging included the comprehensive risk factors noted above and neutrophil 
category, lymphocyte category, monocyte category, haemoglobin category and calculated 
neutrophil/lymphocyte ratio category. Total white cell count category was unable to be used as 
it is an additive expression of the other cell types. The best models are presented with AICc 
and Akaike weight and described with relative variable importance for the outcome of major 
adverse event. The full model for each outcome that combines the most important variables 
with averaged coefficients is presented and the implications discussed. 
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8.3. Results section 4 
Total and differential circulating cell counts associated with major 
adverse events in patients with peripheral arterial occlusive disease  
 
Each circulating cell type is examined and presented in turn for association with the end point 
of major adverse event with Kaplan-Meier survival analysis and Cox proportional hazards 
analysis with and without adjustment for traditional and comprehensive confounding factors. 
The multi-model averaging process is presented at the end of this chapter to assess all cell types 
and comprehensive confounding factors together in modelling the outcome of major adverse 
event and will report which models and subsequently which variables are best associated with 
the outcome of major adverse event.  
 
8.3.1. Total white cell count associated with major adverse event (death, heart attack 
or stroke) 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from major adverse event plot of the cohort is presented in Figure 8.2 
by total white cell count (TWCC) category. The horizontal axis is displayed in days with time 
points described in Chapter 4. The cohort was divided into tertiles based on the “baseline 
bloods” TWCC using the quantile formula in S+. This resulted in the low tertile “Low TWCC 
Category” including baseline total white cell counts from 3.6 to <6.9 (x109 cells/L), the mid 
tertile “Mid TWCC Category” including baseline total white cell counts from 6.9 to <8.7 (x109 
cells/L), and the upper tertile “High TWCC Category” including baseline total white cell counts 
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from 8.7 to 14.5 (x109 cells/L). There were no missing values for the continuous TWCC 
variable. The TWCC categories created remain consistent throughout all the results chapters. 
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Figure 8.2: Kaplan-Meier non-parametric survival plot - freedom from major adverse event (death, heart 
attack or stroke) by total white cell count category with 95% confidence intervals 
 
The freedom from major adverse event plot of the low TWCC group (green, Figure 8.2) appears 
visually distinct from the other two plots in Figure 8.2. There are multiple intersections between 
the Mid TWCC Category (orange, Figure 8.2) and High TWCC Category (red, Figure 8.2) 
freedom from major adverse event plots for the first 500 days then again at 1000 days, ~2500 
days and prior to 3000 days. 
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The Low TWCC Category has the least number of major adverse events (28, 21.4% of the 
patients in this category) and has the greatest median (2789 days = 7.6 years) and mean (2631 
± 145 days = 7.2 years) freedom from major adverse events. The number of major adverse 
events that occurred in the High TWCC Category (48, 36.6% of the patients in this category) 
was the same as the Mid TWCC Category (48, 35.3% of the patients in this category) but the 
High TWCC Category experienced the shortest mean (2244 ± 146 days = 6.1 years) and median 
(2462 days = 6.7 years) freedom from major adverse events times. The Mid TWCC Category 
had a mean freedom from major adverse event of 2280 ± 133 days and median 2589 (2053 – 
2985) days. 
 
The progress of patients over time is shown in Table 8.1 with the number of patients remaining 
in the study at 1000, 2000, 3000 and 3500 days.  
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Table 8.1: Kaplan-Meier freedom from major adverse event (death, heart attack or stroke) rate by total 
white cell count category with 95% confidence intervals displayed by days follow up. 
Major adverse event  0 days 1000 days 2000 days 3000 days 3500 days 
Low  
TWCC 
Category 
At Risk 131 66 32 6 2 
Events in previous 
interval 
0 14 5 8 1 
Freedom from 
major adverse 
event  
(95% CI) 
1.00 0.87 
(0.79-0.93) 
0.78 
(0.69-0.88) 
0.49 
(0.34-0.70) 
0.37 
(0.19-0.72) 
Mid  
TWCC 
Category 
At Risk 136 70 34 7 2 
Events in previous 
interval 
0 22 13 12 1 
Freedom from 
major adverse 
event  
(95% CI) 
1.00 0.80 
(0.73-0.88) 
0.62 
(0.52-0.73) 
0.29 
(0.17-0.48) 
0.23 
(0.18-0.45) 
High  
TWCC 
Category 
At Risk 131 69 32 7 1 
Events in previous 
interval 
0 23 16 7 2 
Freedom from 
major adverse 
event  
(95% CI) 
1.00 0.78 
(0.70-0.86) 
0.56 
(0.46-0.68) 
0.38 
(0.27-0.55) 
0.24 
(0.11-0.51) 
CI = Confidence Interval TWCC = Total White cell count 
 
The Low TWCC Category has the greatest freedom from major adverse event rate at each of 
the reported time points (Table 8.1). The High TWCC Category has the lowest freedom from 
major adverse event rate for the 1000 day and 2000 day time points but the Mid TWCC 
Category has the lowest freedom from major adverse event rate at the 3000 and 3500 day time 
points (Table 8.1). 
 
Apparent differences in the TWCC categories for the outcome of major adverse event with 
Kaplan-Meir analysis were then analysed with Cox proportional hazards model testing to allow 
adjustment for traditional and comprehensive risk factors and can be seen in Table 8.2. 
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 Cox proportional hazards 
Table 8.2: Cox proportional hazards analysis - major adverse event and total white cell count category. 
Outcome - Major adverse event 
Cell Type  p 
Value 
HR (95% CI ) Other Significant 
Variables 
Cox 
zph 
Global 
zph 
TWCC a priori mid 0.05 1.60 (1.00-2.54) n/a 0.89 0.83 
high 0.03 1.68 (1.06-2.69) 0.59 
TWCC adjusted 
TRF1 
mid 0.11 1.48 (0.92-2.37) Age (p<0.01),  
IHD (p=0.02) 
0.73 0.21 
high 0.03 1.71 (1.06-2.77) 0.81 
TWCC adjusted 
TRF1 strata IHD 
mid 0.11 1.48 (0.92-2.37) Age (p<0.01) 0.73 0.23 
high 0.02 1.75 (1.08-2.83) 0.94 
TWCC adjusted 
CRF2 
mid 0.01 1.89 (1.15-3.09) Age (p<0.01),  
IHD (p<0.01),  
HTN (p=0.02),  
Ex-smoker (p=0.03), 
Smoker (p=0.07), 
Gender (p=0.08) 
0.72 0.29 
high 0.02 1.83 (1.12-2.99) 0.76 
TWCC adjusted 
CRF2 strata (Gender, 
smoking, HTN, 
IHD) 
mid 0.02 1.87 (1.10-3.18) Age (p<0.01) 0.79 0.98 
high <0.01 2.07 (1.21-3.54) 0.63 
CI = Confidence Interval   TWCC = Total white cell count  n/a = not applicable 
IHD = Ischaemic heart disease  HTN = Hypertension   HR = Hazard Ratio 
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
strata = statistical stratification for (variable/s in brackets following) 
Significant p values at the 0.05 level and corresponding hazard ratio are presented in bold 
 
The High TWCC Category is significantly associated with the endpoint of major adverse event 
in all models at the p<0.05 level when tested with the Cox proportional hazards analysis (Table 
8.2). When the model was adjusted for traditional risk factors alone (adjusted TRF1) High 
TWCC Category remained significantly associated with major adverse events (p<0.05, Table 
8.2) and when this analysis was stratified for the other significant categorical variable 
ischaemic heart disease High TWCC Category remained significantly associated with major 
adverse event (p=0.02, Table 8.2). When the model was adjusted for traditional risk factors, 
disease severity and medication use (adjusted CRF2) the High TWCC category was 
significantly associated with major adverse event (p=0.02, Table 8.2). This association was 
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persistently significant when the adjusted CRF2 model was stratified for other significant 
categorical variables of ischaemic heart disease, hypertension, smoking and gender (p<0.01, 
Table 8.2). The Hazard ratio of 2.07 in the stratified model adjusted for comprehensive risk 
factors (adjusted CRF2 stratified for Gender, smoking, HTN, IHD), Table 8.2) indicates that 
the High TWCC category is twice as likely as the Low TWCC Category to sustain a major 
adverse event when all other risk factors are taken into consideration. 
 
The Mid TWCC Category is significantly associated with the endpoint of major adverse event 
at the p=0.05 level when tested with the Cox proportional hazards analysis a priori (Table 8.2). 
When the model was adjusted for traditional risk factors alone (adjusted TRF1) Mid TWCC 
Category was not significantly associated with major adverse events or when this analysis was 
stratified for the other significant categorical variable ischaemic heart disease. When the model 
was adjusted for comprehensive risk factors: traditional risk factors, disease severity and 
aspirin and statin use (adjusted CRF2), the Mid TWCC category was significantly associated 
with major adverse event (p=0.01, Table 8.2). This association was persistently significant 
when the adjusted CRF2 model was stratified for other significant categorical variables of 
ischaemic heart disease, hypertension, smoking and gender (p=0.02, Table 8.2). The Hazard 
ratio of 1.87 in the stratified model adjusted for comprehensive risk factors (adjusted CRF2 
stratified for Gender, smoking, HTN, IHD), Table 8.2) indicates that the Mid TWCC category 
is almost twice as likely as the Low TWCC Category to sustain a major adverse event when 
all other risk factors are taken into consideration. 
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The probability of a violation of the assumptions of the Cox proportional hazards model was 
checked with the Cox.zph function for each model. The Cox.zph function tests the 
proportionality of each predictor in the model by creating interactions with time and comparing 
the residuals, in this case giving values 0.21 - 0.98, (Table 8.2) or a low probability of 
assumption violation for each of the TWCC and major adverse event models. With a low 
probability of assumption breach the Cox proportional hazards models are appropriate to use 
for this data set and generate valid results. 
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8.3.2. Neutrophil count associated with major adverse event (death, heart attack or 
stroke). 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from major adverse event plot of the cohort is presented in Figure 8.3 
by neutrophil count category. The cohort was divided into categories of neutrophil count with 
the quantile formula in S+. This resulted in the Low Neutrophil Category including baseline 
neutrophil counts from 1.4 to <4.0 (x109 cells/L), the Mid Neutrophil Category from 4.0 to 
<5.5 (x109 cells/L), and the High Neutrophil Category from 5.5 to 12.75 (x109 cells/L). 
Categorisation of the neutrophil data was done to minimise non-linear effects of the variable 
on the outcome. There were no missing values for the continuous neutrophil variable. These 
categories remain consistent throughout all the results chapters. 
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Figure 8.3: Kaplan-Meier non-parametric survival plot - freedom from major adverse event (death, heart 
attack or stroke) by neutrophil count category with 95% confidence intervals. 
 
In Figure 8.3 the three neutrophil categories appear to have mostly distinct rates of freedom 
from major adverse event over the course of the study. The High Neutrophil Category (red, 
Figure 8.3) appears visually to be separate from the other two plots for Low and Mid Neutrophil 
Category for the outcome of major adverse event despite a similar trajectory to the Mid 
Neutrophil Category <500 days. Whilst there is a trend to separation of the Low Neutrophil 
Category (green, Figure 8.3) from the Mid Neutrophil Category (orange, Figure 8.3) there is 
an intersection of the freedom of major adverse event plots prior to 3000 days.  
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The High Neutrophil Category experienced the greatest number of major adverse events (53, 
40.8% of the patients in this category) over the course of the study with the lowest mean (2051 
± 143 days = 5.6 years) and median of 2148 days  (1484 – 2985) or 5.9 years freedom from 
major adverse event. The Low Neutrophil Category has the lowest number of major adverse 
events (28, 20.6% of the patients in this category) over the course of the study and has the 
greatest mean (2655 ± 143 days = 7.3 years) and median (2789 days = 7.6 years) freedom from 
major adverse event. The Mid Neutrophil Category experienced 43 major adverse events in 
132 patients, with mean freedom from major adverse event 2447 ± 132 days (6.7 years) and 
median 2654 days or 7.3 years. 
 
Table 8.3: Kaplan-Meier freedom from major adverse event (death, heart attack or stroke) rate by 
neutrophil count category with 95% confidence intervals displayed by days follow up. 
Major adverse event  0 days 1000 days 2000 days 3000 days 3500 days 
Low 
Neutrophil 
Category 
At Risk 136 68 31 6 2 
Events in 
previous interval 
0 13 7 8 0 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.87 
(0.81-0.94) 
0.75 
(0.65-0.86) 
0.44 
(0.29-0.67) 
0.44 
(0.29-0.67) 
Mid 
Neutrophil 
Category 
At Risk 132 75 39 8 2 
Events in 
previous interval 
0 17 12 12 2 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.85 
(0.78-0.92) 
0.68 
(0.59-0.79) 
0.40 
(0.28-0.57) 
0.29 
(0.16-0.51) 
High 
Neutrophil 
Category 
At Risk 130 62 28 6 1 
Events in 
previous interval 
0 29 15 7 2 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.72 
(0.64-0.81) 
0.52 
(0.42-0.63) 
0.30 
(0.18-0.49) 
0.16 
(0.06-0.45) 
CI = Confidence Interval 
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The High Neutrophil Category has the greatest number of major adverse events (29) prior to 
1000 days and has the lowest freedom from major adverse events at all reported time points 
(Table 8.3). The Low Neutrophil Category has the greatest freedom from major adverse events 
at all reported time points (Table 8.3).  
 
Apparent differences in the neutrophil categories for the outcome of major adverse event with 
Kaplan-Meir analysis were then analysed with Cox proportional hazards model testing to allow 
adjustment for traditional and comprehensive risk factors and can be seen in Table 8.4. 
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 Cox proportional hazards 
Table 8.4: Cox proportional hazards analysis - major adverse event and neutrophil category 
Outcome - major adverse event 
Cell Type  p 
Value 
HR (95% CI)  Other Significant 
Variables 
Cox 
zph 
Global 
zph 
Neutrophil a priori mid 0.23 1.34 (0.83-2.16) n/a 0.81 0.64 
high <0.01 2.06 (1.30-3.26) 0.39 
Neutrophil adjusted 
TRF1 
mid 0.28 1.31 (0.81-2.13) Age (p<0.01),  
IHD (p=0.04) 
0.56 0.22 
high <0.01 1.94 (1.21-3.10) 0.57 
Neutrophil adjusted 
TRF1 strata IHD 
mid 0.25 1.33 (0.82-2.17) Age (p<0.01) 0.62 0.23 
high <0.01 1.95 (1.22-3.13) 0.60 
Neutrophil adjusted 
CRF2 
mid 0.15 1.44 (0.88-2.35) Age (p<0.01),  
Ex-smoker (p=0.02),  
HTN (p=0.02),  
IHD (p=0.02),  
Smoker (p=0.04) 
0.97 0.25 
high <0.01 2.02 (1.24-3.27) 0.92 
Neutrophil adjusted 
CRF2 strata 
(smoking, IHD & 
HTN) 
mid 0.11 1.35 (0.91-2.54) Age (p<0.01) 0.72 0.88 
high 0.02 1.98 (1.12-3.10) 0.75 
CI = Confidence Interval   n/a = not applicable   
IHD = Ischaemic heart disease  HTN = Hypertension   
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
Significant p values at the 0.05 level and corresponding hazard ratio are presented in bold 
 
The High Neutrophil Category is significantly associated with the endpoint of major adverse 
event in all models at the p<0.05 level when tested with the Cox proportional hazards analysis 
(Table 8.4). In the a priori model High Neutrophil category was associated with major adverse 
events at the p<0.01 level (Table 8.4) with a hazard ratio of >2 indicating that without adjusting 
for other risk factors the High Neutrophil Category was twice as likely to sustain a major 
adverse event than the Low Neutrophil Category. When the model was adjusted for traditional 
risk factors alone (adjusted TRF1), High Neutrophil Category remained significantly associated 
with major adverse events (p<0.01, Table 8.4) and when this analysis was stratified for the 
other significant categorical variable ischaemic heart disease, High Neutrophil Category 
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remained significantly associated with major adverse event (p<0.01, Table 8.4) although the 
hazard ratio dropped slightly below 2 in both these models. When the model was adjusted for 
traditional risk factors, disease severity and medication use (adjusted CRF2) the High 
Neutrophil category was significantly associated with major adverse event (p<0.01, Table 8.4). 
This association was persistently significant when the adjusted CRF2 model was stratified for 
other significant categorical variables of ischaemic heart disease, hypertension, smoking and 
gender (p=0.02, Table 8.4) with the hazard ratio approaching 2 meaning that the High 
Neutrophil Category was almost twice as likely to sustain a major adverse event as the Low 
Neutrophil Category. 
 
The Mid Neutrophil Category was not significantly associated in any of the Cox proportional 
Hazards analysis (Table 8.4) and the confidence intervals for the hazard ratio of the Mid 
Neutrophil Category always included 1 meaning that the Mid Neutrophil Category was not 
confidently at greater risk of sustaining a major adverse event than the Low Neutrophil 
Category. 
 
There was a low probability of breach of the assumptions of the Cox model with Neutrophil 
count and major adverse event models judged with Cox.zph testing results (0.23 – 0.97, Table 
8.4). With a low probability of assumption breach the Cox proportional hazards models are 
appropriate to use for this data set and generate valid results.  
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8.3.3. Lymphocyte count associated with major adverse event (death, heart attack or 
stroke). 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from major adverse event plot of the cohort is presented in Figure 8.4 
by lymphocyte count category. The cohort was divided into categories of lymphocyte count 
with the quantile formula in S+. This resulted in the Low Lymphocyte Category including 
baseline lymphocyte cell counts from 0.5 to <1.7 (x109 cells/L), the Mid Lymphocyte Category 
including baseline lymphocyte cell counts from 1.7 to <2.33 (x109 cells/L), and the High 
Lymphocyte Category including baseline lymphocyte cell counts from 2.33 to 5.6 (x109 
cells/L). Categorisation of the lymphocyte data was done to minimise non-linear effects of the 
variable on the outcome. There were no missing values for the continuous lymphocyte variable. 
These categories remain consistent throughout all results chapters.  
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Figure 8.4: Kaplan-Meier non-parametric survival plot - freedom from major adverse event (death, heart 
attack or stroke) by lymphocyte count category with 95% confidence intervals. 
 
The terminal drop off in the Low Lymphocyte Category in Figure 8.4 is due to the last 
remaining patient in the category dying at this time. In the other categories the last remaining 
patients were discharged from follow up without major adverse event.  
 
The Low Lymphocyte Category (green, Figure 8.4) has a distinctly lower freedom from major 
adverse event plot than the High Lymphocyte Category (red, Figure 8.4). The Low 
Lymphocyte Category is also mostly lower than the Mid Lymphocyte Category (orange, Figure 
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8.4) with the exception of an intersection at ~3000 days. The difference between the low and 
high lymphocyte categories appears visually constant, while the difference between the low 
and mid lymphocyte categories is greatest between 500 to 2000 days before becoming more 
closely approximated ~2500 days prior to the intersection discussed above. 
 
The Low Lymphocyte Category has the greatest number of major adverse events over the 
course of the study (48, 40.7% of the patients in this category) with the lowest mean (1879 ± 
128 days = 5.1 years) and median (2471 days = 6.8 years) freedom from major adverse event. 
The Mid Lymphocyte Category has the lowest number of major adverse events over the course 
of the study (36, 24.5% of the patients in this category) with mean 2492 ± 132 days (6.8 years) 
and median 2572 days (7.0 years). The High Lymphocyte Category has the greatest mean (2606 
± 137 days = 7.1 years) and median (2879 days = 7.9 years) freedom from major adverse event 
experiencing 40 events in a group of 133 patients. 
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Table 8.5: Kaplan-Meier freedom from major adverse event (death, heart attack or stroke) rate by 
lymphocyte count category with 95% confidence intervals displayed by days follow up. 
Major adverse event  0 days 1000 days 2000 days 3000 days 3500 days 
Low 
Lymphocyte 
Category 
At Risk 118 33 8 5 - 
Events in 
previous interval 
0 33 8 5 - 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.65 
(0.56-0.76) 
0.52 
(0.41-0.65) 
0.34 
(0.22-0.53) 
- 
Mid 
Lymphocyte 
Category 
At Risk 147 80 32 5 3 
Events in 
previous interval 
0 9 14 13 0 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.92 
(0.87 -0.97) 
0.72 
(0.62 -0.83) 
0.28 
(0.15-0.51) 
0.28 
(0.15-0.51) 
High 
Lymphocyte 
Category 
At Risk 133 77 44 11 2 
Events in 
previous interval 
0 17 12 9 2 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.84 
(0.77-0.91) 
0.69 
(0.60-0.79) 
0.48 
(0.36-0.64) 
0.36 
(0.23-0.59) 
CI = Confidence Interval 
 
The Low Lymphocyte Category has the greatest number of major adverse events prior to 1000 
days (33) and has the lowest freedom from major adverse events at 1000 and 2000 days (Table 
8.5). The Mid Lymphocyte Category has the greatest freedom from major adverse events at 
1000 and 2000 days but then the lowest freedom from major adverse events at 3000 days (Table 
8.5). This relationship can also be appreciated in Figure 8.4. 
 
Apparent differences in the lymphocyte categories for the outcome of major adverse event with 
Kaplan-Meir analysis were then analysed with Cox proportional hazards model testing to allow 
adjustment for traditional and comprehensive risk factors and is seen in Table 8.6.  
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 Cox proportional hazards 
Table 8.6: Cox proportional hazards analysis - major adverse event and lymphocyte category. 
Outcome - major adverse event 
Cell Type  p 
Value 
HR (95% CI)  Other Significant 
Variables 
Cox 
zph 
Global 
zph 
Lymphocyte  
a priori 
mid <0.01 0.52 (0.34-0.80) n/a <0.01 0.03  
 high <0.01 0.51 (0.33-0.77) 0.36 
Lymphocyte 
adjusted TRF1 
mid 0.01 0.56 (0.36-0.87) Age (p=<0.01),  
IHD (p=0.03) 
0.03 0.06 
high 0.01 0.58 (0.37-0.90) 0.40 
Lymphocyte 
adjusted TRF1 
strata IHD 
mid 0.02 0.58 (0.37-0.91) Age (p<0.01),  
Ex-smoker (p=0.05) 
<0.01 0.03  
 high 0.02 0.60 (0.38-0.93) 0.28 
Lymphocyte 
adjusted TRF1 
strata (IHD & 
smoking) 
mid 0.03 0.61 (0.39-0.96) Age (p<0.01) <0.01 0.05 
high 0.04 0.62 (0.40-0.97) 0.11 
Lymphocyte 
adjusted CRF2 
mid 0.04 0.62 (0.40-0.98) Age (p<0.01),  
Ex-smoker (p<0.01) 
IHD (p=0.02),  
HTN (p=0.03) 
0.02 0.06 
high 0.05 0.64 (0.41-1.00) 0.25 
Lymphocyte 
adjusted CRF2 
strata (HTN, IHD 
& smoking) 
mid 0.11 0.63 (0.42-1.09) Age (p<0.01) 0.02 0.26 
high 0.29 0.75 (0.47-1.25) 0.14 
 
CI = Confidence Interval   n/a = not applicable   
IHD = Ischaemic heart disease  HTN = Hypertension  
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
strata = statistical stratification for (variable/s in brackets following) 
Significant p values at the 0.05 level and corresponding hazard ratio are presented in bold 
 
The Mid Lymphocyte Category is significantly inversely associated with the endpoint of major 
adverse event at the p<0.05 level when tested with the Cox proportional hazards analysis a 
priori (p<0.01, Table 8.6). The hazard ratio of less than one indicates that Mid Lymphocyte 
category has a protective effect on the outcome of major adverse event with patients in the Mid 
Lymphocyte Category less likely to sustain a major adverse event than the patients in the Low 
Lymphocyte Category. When the model was adjusted for traditional risk factors alone (adjusted 
TRF1) Mid Lymphocyte Category was also significantly associated with major adverse events 
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(p=0.01, Table 8.6) and when this analysis was stratified for the other significant categorical 
variable ischaemic heart disease, Mid Lymphocyte Category remained significantly inversely 
associated with major adverse event (p=0.02, Table 8.6). This stratified model revealed another 
significantly associated categorical variable smoking (p=0.05) so a further stratified model was 
created. The second stratified model which stratified for ischaemic heart disease and smoking 
also showed Mid Lymphocyte Category to be significantly inversely associated with major 
adverse event (p=0.03, Table 8.6). When the model was adjusted for traditional risk factors, 
disease severity and medication use (adjusted CRF2) the Mid Lymphocyte category was 
significantly inversely associated with major adverse event (p=0.04, Table 8.6) however when 
this adjusted CRF2 model was stratified for the other significantly associated categorical 
variables smoking, ischaemic heart disease and hypertension Mid Lymphocyte Category was 
no longer significantly associated with major adverse event (p=0.11, Table 8.6).  
 
The High Lymphocyte Category is significantly inversely associated with the endpoint of 
major adverse event at the p=0.05 level when tested with the Cox proportional hazards analysis 
a priori (p<0.01, Table 8.6). The hazard ratio of less than one indicates that High Lymphocyte 
category has a protective effect on the outcome of major adverse event. When the model was 
adjusted for traditional risk factors alone (adjusted TRF1) High Lymphocyte Category was also 
significantly inversely associated with major adverse events (p=0.02, Table 8.6) and when this 
analysis was stratified for the other significant categorical variable ischaemic heart disease 
High Lymphocyte Category remained significantly inversely associated with major adverse 
event (p=0.02, Table 8.6). This stratified model revealed another significantly associated 
categorical variable smoking (p=0.05) so a further stratified model was created. The second 
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stratified model which stratified for ischaemic heart disease and smoking also showed High 
Lymphocyte Category to be significantly inversely associated with major adverse event 
(p=0.04, Table 8.6). When the model was adjusted for traditional risk factors, disease severity 
and medication use (adjusted CRF2) the High Lymphocyte category was not significantly 
associated with major adverse event at the 0.05 level and the confidence interval includes 1 
(p=0.05, Table 8.6). The association of High Lymphocyte Category with major adverse event 
was not demonstrated as significant when the adjusted CRF2 model was stratified for the other 
significantly associated categorical variables smoking, ischaemic heart disease and 
hypertension (p=0.29, Table 8.6). 
 
Cox.zph values for the Mid Lymphocyte Category are significant in all models for major 
adverse event (<0.01 in a priori and adjusted TRF1 models and 0.02 in the adjusted CRF2 
models, Table 8.6) raising the possibility of an assumption violation of these Cox proportional 
hazards models. This is not unexpected given the Kaplan-Meier results previously that showed 
the Mid Lymphocyte group experiencing a different path of major adverse events during the 
course of the study. This is an important finding in that the Mid Lymphocyte group freedom 
from major adverse event varies over time in a different way to the other groups. This is seen 
graphically in Figure 8.4 with the Mid Lymphocyte Category initially experiencing a greater 
freedom from major adverse event rate than the other two lymphocyte categories before 
descending at a steeper rate than the other two groups, crossing the High Lymphocyte Category 
at approx. 2000 days and the Low Lymphocyte Category prior to 3000 days so that at the time 
point of 3000 days the Mid Lymphocyte Category has the lowest freedom from major adverse 
event. The Cox.zph score alerts us that this is a distinct difference between the groups and is 
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unlikely due to chance alone, thus the initial protective function of the Mid Lymphocyte 
Category is greatest compared to the other two groups at 1000 days undergoes a real shift such 
that the Mid Lymphocyte Category then has the lowest freedom from major adverse event 
function at 3000 days. The global zph score is also significant in the a priori and adjusted TRF1 
models confirming that the overall assumptions of the model are breached by the non-
proportionality of the Mid Lymphocyte Category. While the Cox proportional hazards model 
p values and hazard ratios should be interpreted with this in mind, the most important outcome 
of this analysis is the dynamic risk of the Mid Lymphocyte Category over time.  
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8.3.4. Monocyte count associated with major adverse event (death, heart attack or 
stroke). 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from major adverse event plot of the cohort is presented in Figure 8.5 
by monocyte count category. The categories of monocyte count were derived with the quantile 
formula in S+. This resulted in the Low Monocyte Category including baseline monocyte cell 
counts from 0.06 to <0.51 (x109 cells/L), the Mid Monocyte Category including baseline 
monocyte cell counts from 0.51 to <0.7 (x109 cells/L), and the High Monocyte Category 
including baseline monocyte cell counts from 0.7 to 1.87 (x109 cells/L). Categorisation of the 
monocyte data was done to minimise non-linear effects of the variable on the outcome. There 
were no missing values for the continuous monocyte variable. These categories remain 
consistent throughout all results chapters. 
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Figure 8.5: Kaplan-Meier non-parametric survival plot - freedom from major adverse event (death, heart 
attack or stroke) by monocyte count category with 95% confidence intervals. 
 
The High Monocyte Category (red, Figure 8.5) has a visually lower freedom from major 
adverse event plot which is distinct from the Low Monocyte Category (green, Figure 8.5). The 
Mid Monocyte Category (orange, Figure 8.5) is mostly between the High and Low Monocyte 
Categories with the exception of when it crossed and then remains below the High Monocyte 
Category prior to 3000 days. 
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The Low Monocyte Category experienced the lowest number of major adverse events over the 
course of the study (31, 23.1% of the patients in this category) with the greatest mean (2622 ± 
139 days = 7.2 years) and median (2544 days = 7.0 years) freedom from major adverse event. 
The Mid Monocyte Category has the greatest number of major adverse events over the course 
of the study (48, 33.1% of the patients in this category) with mean of 2341 ± 127 days (6.4 
years) and median 2148 (2148 – 3105) days or 5.9 years. The High Monocyte Category had 
the highest total incidence of major adverse event (37.8% of the patients in this category) and 
the lowest mean (2182 ± 160 days = 6.0 years) and median (1693 days = 4.6 years) freedom 
from major adverse event. 
 
Table 8.7: Kaplan-Meier freedom from major adverse event (death, heart attack or stroke) rate by 
monocyte count category with 95% confidence intervals displayed by days follow up. 
Major adverse event  0 days 1000 days 2000 days 3000 days 3500 days 
Low 
Monocyte 
Category 
At Risk 134 75 33 4 2 
Events in 
previous interval 
0 13 10 8 0 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.88 
(0.82-0.94) 
0.74 
(0.64-0.84) 
0.40 
(0.24-0.66) 
0.40 
(0.24-0.66) 
Mid 
Monocyte  
Category 
At Risk 145 76 35 11 1 
Events in 
previous interval 
0 19 15 11 3 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.83  
(0.76-0.90) 
0.63 
(0.53-0.74) 
0.37 
(0.25-0.53) 
0.22 
(0.11-0.44) 
High 
Monocyte 
Category 
At Risk 119 54 30 5 1 
Events in 
previous interval 
0 27 9 8 1 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.72 
(0.60-0.81) 
0.58 
(0.47-0.70) 
0.34 
(0.22-0.54) 
0.27 
(0.15-0.51) 
CI = Confidence Interval 
 
The High Monocyte Category has the greatest number of major adverse events prior to 1000 
days and has the lowest freedom from major adverse event rate at 1000, 2000 and 3000 days 
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(Table 8.7). Mid Monocyte Category has the lowest freedom from major adverse event rate at 
3500 days. The Low Monocyte Category has the fewest major adverse events prior to 1000 
days (13) and has the greatest freedom from major adverse events at all reported time points 
(Table 8.7). This relationship can also be seen in Figure 8.5. 
 
Apparent differences in the monocyte categories for the outcome of major adverse event with 
Kaplan-Meir analysis were then analysed with Cox proportional hazards model testing to allow 
adjustment for traditional and comprehensive risk factors and can be seen in Table 8.8. 
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 Cox proportional hazards 
Table 8.8: Cox proportional hazards analysis - major adverse event and monocyte category. 
Outcome - major adverse event 
Cell Type  p 
Value 
HR (95% CI) Other Significant 
Variables 
Cox 
zph 
Global 
zph 
Monocyte a priori mid 0.11 1.44 (0.92-2.27) n/a 0.99 0.09 
high <0.01 1.85 (1.17-2.92) 0.08 
Monocyte adjusted 
TRF1 
mid 0.21 1.34 (0.85-2.12) Age (p<0.01),  
IHD (p=0.02) 
0.91 0.04 
high 0.01 1.82 (1.13-2.91) 0.05 
Monocyte adjusted 
TRF1 strata IHD 
mid 0.24 1.32 (0.83-2.09) Age (p<0.01) 0.97 0.06 
high <0.01 1.88 (1.18-3.02) 0.10 
Monocyte adjusted 
CRF2 
mid 0.22 1.33 (0.84-2.12) Age (p<0.01), 
 IHD (p<0.01),  
Ex-smoker(p=0.02), 
HTN (p=0.03) 
0.74 0.11 
high 0.02 1.81 (1.12-2.92) 0.19 
Monocyte adjusted 
CRF2 strata (IHD, 
HTN & smoking) 
mid 0.16 1.42 (0.87-2.32) Age (p<0.01) 0.65 0.69 
high 0.03 1.75 (1.07-2.87) 0.80 
CI = Confidence Interval   n/a = not applicable   
IHD = Ischaemic heart disease  HTN = Hypertension     
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
strata = statistical stratification for (variable/s in brackets following) 
Significant p values at the 0.05 level and corresponding hazard ratio are presented in bold 
 
The High Monocyte Category is significantly associated with the endpoint of major adverse 
event at the p<0.05 level when tested with the Cox proportional hazards analysis in all models 
although the level of significance varies (Table 8.8). In the a priori model the High Monocyte 
Category is significant at the p<0.01 level with a hazard ratio of 1.85 indicating that the High 
Monocyte Category is 1.85 times more likely than the Low Monocyte Category to sustain a 
major adverse event (Table 8.8). When the model was adjusted for traditional risk factors alone 
(adjusted TRF1), High Monocyte Category was also significantly associated with major 
adverse events (p=0.01, Table 8.8) and when this analysis was stratified for the other significant 
categorical variable ischaemic heart disease, High Monocyte Category remained significantly 
associated with major adverse event (p<0.01, Table 8.8). 
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When the Cox model was adjusted for traditional risk factors, disease severity and medication 
use (adjusted CRF2) the High Monocyte category was significantly associated with major 
adverse event (p=0.02, Table 8.8) and when this adjusted CRF2 model was stratified for the 
other significantly associated categorical variables smoking, ischaemic heart disease and 
hypertension High Monocyte Category remained significantly associated with major adverse 
event (p=0.03, Table 8.8). 
 
The Mid Lymphocyte Category was not significantly different to the Low Lymphocyte 
Category for the outcome of major adverse event in either the a priori or adjusted cox models 
(Table 8.8). 
 
There was a low probability of breach (0.08–0.99, Table 8.8) of the assumptions of the Cox 
model with Monocyte count for major adverse event models except the model adjusted for 
traditional risk factors alone (adjusted TRF1 - Table 8.8). In the adjusted TRF1 model the High 
Monocyte Category had a Cox.zph of 0.05 and the global zph for that model was 0.04 (Table 
8.8) raising suspicion that the Cox assumptions of the proportional hazards model are breached 
when the Low Monocyte Category is compared to the High Monocyte Category and adjusted 
for traditional risk factors. This is an important finding and tells us that the relationship between 
these two monocyte categories and the outcome of major adverse event changes over time. 
While the results of the Cox model should be interpreted with caution in light of the zph breach, 
this is also a finding that the High Monocyte Category trajectory through the study is not 
proportional to the Low Monocyte Category for the duration of the study. This is best 
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understood referring to Figure 8.5 where it can be visibly seen that the High Monocyte 
Category (red, Figure 8.5) diverges from the Low Monocyte Category (green, Figure 8.5) until 
approximately 2000 days when the two categories trend closer together. The significant zph 
score is a measure that this unlikely due to chance alone and likely represents a real change in 
the relative risk between the groups. One possible explanation is that the pathophysiological 
benefit of a low monocyte count reduces over time although clarification of this will require 
further research. 
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8.3.5. Haemoglobin associated with major adverse event (death, heart attack or 
stroke). 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from major adverse event plot of the cohort is presented in Figure 8.6 
by haemoglobin category. The cohort was divided into categories of haemoglobin 
concentration with the quantile formula in S+. This resulted in the Low Haemoglobin Category 
including baseline haemoglobin concentration from 85 to <131 (g/L), the Mid Haemoglobin 
Category including baseline haemoglobin concentration from 131 to <146 (g/L), and the High 
Haemoglobin Category including baseline haemoglobin concentration from 146 to 197 (g/L). 
Categorisation of the haemoglobin data was done to minimise non-linear effects of the variable 
on the outcome. There were no missing values for the continuous haemoglobin variable. These 
categories remain consistent throughout all results chapters.  
 
 208 
Chapter 8: Results section 4 - Total and differential circulating cell counts associated with major adverse events in peripheral arterial occlusive 
disease. 
0 1000 2000 3000
Time (days)
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Fr
ee
do
m
 fr
om
 m
aj
or
 a
dv
er
se
 e
ve
nt
   
  (
de
at
h,
 h
ea
rt 
at
ta
ck
 o
r s
tro
ke
)
 
Figure 8.6: Kaplan-Meier non-parametric survival plot - freedom from major adverse event (death, heart 
attack or stroke) by haemoglobin category with 95% confidence intervals. 
 
Prior to 3000 days the Low Haemoglobin Category (green, Figure 8.6) has a visually lower 
freedom from major adverse event plot than Mid and High Haemoglobin Categories. The Mid 
Haemoglobin Category (orange, Figure 8.6) and High Haemoglobin Category (red, Figure 8.6) 
have visually intertwined freedom from major adverse event plots prior to 1000 days that then 
separate with the Mid Haemoglobin Category having a higher freedom from major adverse 
event plot until ~2750 days when they again intersect. 
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The Low Haemoglobin Category has the greatest number of major adverse events over the 
course of the study (49, 36.3% of the patients in this category) with the shortest mean (2174 ± 
145 days = 6.0 years) and median (2462 days (1685 – 2789) = 6.7 years) freedom from major 
adverse event. The High Haemoglobin Category has the least number of major adverse events 
over the course of the study (37, 29.1% of the patients in this category) and the greatest median 
freedom from major adverse event (2931= 8.0 years) and a mean of 2412 ± 129 days (6.6 
years). The Mid Haemoglobin Category has the greatest mean freedom from major adverse 
event (2563 days = 7.0 years) with a total of 38 major adverse events in a group of 136 patients 
and a median freedom from major adverse event of 2864 days (7.8 years) 
 
Table 8.9: Kaplan-Meier freedom from major adverse event (death, heart attack or stroke) rate by 
haemoglobin category with 95% confidence intervals displayed by days follow up. 
Major adverse event   0 days 1000 days 2000 days 3000 days 3500 days 
Low 
Haemoglobin 
Category 
At Risk 135 67 29 2 2 
Events in 
previous interval 
0 27 14 8 0 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.75 
(0.67-0.84) 
0.57 
(0.47-0.68) 
0.31 
(0.19-0.50) 
0.31 
(0.19-0.50) 
Mid  
Haemoglobin 
Category 
At Risk 136 69 37 12 3 
Events in 
previous interval 
0 16 8 12 2 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.84 
(0.77-0.92) 
0.72 
(0.62-0.83) 
0.38 
(0.26-0.57) 
0.29 
(0.17-0.51) 
High 
Haemoglobin 
Category 
At Risk 127 69 32 6 - 
Events in 
previous interval 
0 16 12 7 - 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.84 
(0.78-0.92) 
0.67 
(0.57-0.78) 
0.49 
(0.36-0.66) 
- 
CI = Confidence Interval   Hb= Haemoglobin 
 
The Low Haemoglobin Category has the greatest number of major adverse events prior to 1000 
days (27) and has the lowest freedom from major adverse event rate at all 1000, 2000, 3000 
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but not 3500 day time points (Table 8.9). The Mid Haemoglobin Category has the greatest 
freedom from major adverse event rate at 1000 and 2000 days but at 3000 days it is the High 
Haemoglobin Category that has the highest freedom from major adverse event (Table 8.9). The 
Mid Haemoglobin Category then achieves the lowest freedom from major adverse event rate 
by 3500 days (Table 8.9). This relationship can also be seen in Figure 8.6. 
 
Apparent differences in the haemoglobin categories for the outcome of major adverse event 
with Kaplan-Meir analysis were then analysed with Cox proportional hazards model testing to 
allow adjustment for traditional and comprehensive risk factors and can be seen in Table 8.10.  
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 Cox proportional hazards 
Table 8.10: Cox proportional hazards analysis - major adverse event and haemoglobin category. 
Outcome - major adverse event 
Haemoglobin Level  p 
Value 
HR (95% CI) Other Significant 
Variables 
Cox 
zph 
Global 
zph 
Haemoglobin a priori mid 0.04 0.63 (0.41-0.97) n/a 0.33 0.63 
high 0.06 0.66 (0.43-1.02) 0.64 
Haemoglobin adjusted 
TRF1 
mid 0.37 0.81 (0.52-1.28) Age (p<0.01), IHD 
(p=0.03) 
0.37 0.13 
high 0.82 0.94 (0.58-1.54) 0.54 
Haemoglobin adjusted 
TRF1 strata IHD 
mid 0.38 0.82 (0.52-1.29) Age (<0.01) 0.34 0.11 
 high 0.83 0.95 (0.58-1.55) 0.59 
Haemoglobin adjusted 
CRF2 
mid 0.86 0.92 (0.59-1.57) Age (p<0.01),  
IHD (p=0.01),  
Ex-smoker (p=0.02), 
HTN (p=0.02),  
0.97 0.14 
 high 0.89 1.01 (0.62-1.74) 0.46 
Haemoglobin adjusted 
CRF2 strata (Smoking, 
IHD &HTN) 
mid 0.91 0.93 (0.61-1.74) Age (p<0.01) 0.33 0.44 
high 0.76 1.03 (0.66-1.88) 0.90 
CI = Confidence Interval   n/a = not applicable   
IHD = Ischaemic heart disease  HTN = Hypertension   
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
strata = statistical stratification for (variable/s in brackets following) 
Significant p values at the 0.05 level and corresponding hazard ratio are presented in bold 
 
The Mid Haemoglobin Category is significantly associated with the endpoint of major adverse 
event at the p<0.05 level when tested with the Cox proportional hazards analysis a priori 
(p=0.04, Table 8.10). The hazard ratio of less than one (p=0.63, Table 8.10) indicates that Mid 
Haemoglobin Category has a protective effect on the outcome of major adverse event 
compared to the Low Haemoglobin Category. When the model was adjusted for traditional risk 
factors alone (adjusted TRF1) and adjusted for comprehensive risk factors: traditional risk 
factors, disease severity and medication use (adjusted CRF2), neither Mid or High 
Haemoglobin category was significantly associated with major adverse event (Table 8.10). 
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There was a low probability of breach of the assumptions of the Cox model with Haemoglobin 
count and major adverse event models assessed with Cox.zph testing results (0.11 – 0.90, Table 
8.10). With a low probability of assumption breach the Cox proportional hazards models are 
appropriate to use for this data set and generate valid results.  
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8.3.6. Neutrophil-Lymphocyte Ratio associated with major adverse event (death, heart 
attack or stroke). 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from major adverse event plot of the cohort is presented in Figure 8.7 
by neutrophil-lymphocyte ratio (NLR) category. The cohort was divided into categories of 
NLR with the quantile formula in S+. This resulted in the Low NLR Category including 
baseline NLR from 0.73 to <1.89, the Mid NLR Category including baseline NLR from 1.89 
to <2.64, and the High NLR Category including baseline NLR from 2.64 to 20.87. 
Categorisation of the NLR data was done to minimise non-linear effects of the variable on the 
outcome. It is worth noting that there were no missing values for the continuous NLR variable. 
These categories remain consistent throughout all results chapters.  
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Figure 8.7: Kaplan-Meier non-parametric survival plot - freedom from major adverse event (death, heart 
attack or stroke) by neutrophil-lymphocyte ratio category with 95% confidence intervals. 
 
All three NLR categories have visually distinct freedom from major adverse event plots (Figure 
8.7) with the exception of an intersection of the High NLR Category (red, Figure 8.7) and the 
Mid NLR Category (orange, Figure 8.7) just prior to 3000 days. The terminal drop off in the 
High NLR Category (red, Figure 8.7) is due to the last remaining patient in the High NLR 
Category sustaining a major adverse event at this time. In the Mid and Low NLR Categories 
the last remaining patients were discharged from follow up without sustaining a major adverse 
event. 
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The High NLR Category has the greatest number of major adverse events over the course of 
the study (54, 40.6% of the patients in this category) with the shortest mean (1859 ± 119 days 
= 5.1 years) and median (2148 days (1484 – 2789) = 5.9 years) freedom from major adverse 
event. The Low NLR Category has the least number of major adverse events over the course 
of the study (30, 22.6% of the patients in this category) and the greatest median freedom from 
major adverse event (2572 days = 7.0 years) and the greatest mean freedom from major adverse 
event (2811 ± 139 days = 7.7 years). The Mid NLR Category sustained 40 events from a 
population of 132 patients with a mean of 2411 ± 132 days (6.6 years) and a median of 2352 
(2352 – 2985) days (6.4 years). 
 
Table 8.11: Kaplan-Meier freedom from major adverse event (death, heart attack or stroke) rate by 
neutrophil-lymphocyte ratio category with 95% confidence intervals displayed by days follow up. 
Major adverse event   0 days 1000 days 2000 days 3000 days 3500 days 
Low 
NLR 
Category 
At Risk 133 77 39 12 3 
Events in 
previous interval 
0 10 13 5 2 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.89 
(0.84-0.96) 
0.72 
(0.63-0.83) 
0.58 
(0.46-0.74) 
0.44 
(0.27-0.70) 
Mid  
NLR 
Category 
At Risk 132 70 34 5 2 
Events in 
previous interval 
0 16 10 14 0 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.84 
(0.77-0.92) 
0.69 
(0.59-0.80) 
0.25 
(0.14-0.47) 
0.25 
(0.14-0.47) 
High 
NLR 
Category 
At Risk 133 58 25 3 - 
Events in 
previous interval 
0 33 11 8 - 
Freedom from 
major adverse 
event (95% CI) 
1.00 0.69 
(0.61-0.79) 
0.52 
(0.43-0.65) 
0.30 
(0.19-0.48) 
- 
CI = Confidence Interval   NLR = Neutrophil-lymphocyte ratio 
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The High NLR Category has the greatest number of major events in the first 1000 days (33) 
and continues with the lowest freedom from major adverse event at 1000 and 2000 days (Table 
8.11). The lowest freedom from major adverse event at 3000 is the Mid NLR Category (Table 
8.11). The Low NLR Category has the greatest freedom from major adverse event at each 
reported time point (Figure 8.7 and Table 8.11). 
 
Apparent differences in the NLR categories for the outcome of major adverse event with 
Kaplan-Meir analysis were then analysed with Cox proportional hazards model testing to allow 
adjustment for traditional and comprehensive risk factors and can be seen in Table 8.12. 
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 Cox proportional hazards 
Table 8.12: Cox proportional hazards analysis - major adverse event and neutrophil/lymphocyte ratio 
category. 
Outcome - major adverse event  
Cell Ratio  p Value HR( 95% CI) Other Significant 
Variables 
Cox 
zph 
Global 
zph 
NLR a priori mid 0.07 1.54 (0.96-2.48) n/a 0.58 0.34 
high <0.01 2.70 (1.72-4.25) 0.45 
NLR adjusted TRF1 mid 0.28 1.31 (0.17-1.49) Age (p<0.01) 0.88 0.11 
high <0.01 2.10 (0.73-4.32) 0.34 
NLR adjusted CRF2 mid 0.32 1.29 (0.78-2.14) Age (p<0.01),  
Ex-smoker (p<0.01), 
IHD (p=0.01),  
HTN (p=0.02), 
Smoker (p=0.03) 
0.92 0.12 
 high 0.02 1.80 (1.11-2.91) 0.27 
NLR adjusted CRF2 
strata (smoking, 
HTN, IHD) 
mid 0.48 1.21 (0.72-2.04) Age (p<0.01) 0.28 0.25 
 high 0.09 1.56 (0.93-2.61) 0.36 
CI = Confidence Interval   NLR = Neutrophil-lymphocyte ratio n/a = not applicable 
IHD = Ischaemic heart disease  HTN = Hypertension    
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
strata = statistical stratification for (variable/s in brackets following) 
Significant p values at the 0.05 level and corresponding hazard ratio are presented in bold 
 
The High NLR Category is significantly associated with the endpoint of major adverse event 
at the p<0.05 level when tested with the Cox proportional hazards analysis a priori (p<0.01, 
Table 8.12). The hazard ratio of 2.70 indicates that without taking into account other risk 
factors patients in the High NLR Category are 2.7 times more likely to sustain a major adverse 
event than patients in the Low NLR Category. When the model was adjusted for traditional 
risk factors alone (adjusted TRF1) High NLR Category was also significantly associated with 
major adverse events (p<0.01, Table 8.12) although the hazard ratio reduced to 2.10 (Table 
8.12). When the model was adjusted for comprehensive risk factors: traditional risk factors, 
disease severity and medication use (adjusted CRF2), the High NLR category was again 
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significantly associated with major adverse event (p=0.02, Table 8.12) and the hazard ratio 
remained high (HR=1.80, Table 8.12). 
 
The association of High NLR Category with major adverse event was trended toward 
association but was not significantly associated at the p<0.05 level with major adverse event 
when the adjusted CRF2 model was stratified for the other significantly associated categorical 
variables smoking, ischaemic heart disease and hypertension (p=0.09, Table 8.12). 
 
The Mid NLR Category was not significantly associated with major adverse event in any of 
the Cox models either a priori or when adjusted for risk factors. 
 
There was a low probability of breach of the assumptions of the Cox model with 
Neutrophil/Lymphocyte Ratio Category and major adverse event models as assessed by the 
Cox.zph testing results (0.11 – 0.92, Table 8.12). With a low probability of assumption breach 
the Cox proportional hazards models are appropriate to use for this data set and generate valid 
results.  
 219 
Chapter 8: Results section 4 - Total and differential circulating cell counts associated with major adverse events in peripheral arterial occlusive 
disease. 
8.3.7. Summary of circulating cell types Cox proportional hazards analysis for major 
adverse event 
All previously displayed single circulating cell type Cox proportional hazard models for the 
outcome of major adverse event are summarised in Table 8.13.  
 
Table 8.13: Single cell type Cox proportional hazards analysis summary - major adverse event. 
Major Adverse Event 
Cell Type a priori Adjusted 
TRF 
Adjusted 
TRF strata 
Adjusted 
CRF 
Adjusted 
CRF strata 
TWCC Category mid * NS NS ** * high * * * * ** 
Neutrophil Category mid NS NS NS NS NS high ** ** ** ** * 
Lymphocyte 
Category 
mid ** ** * * NS 
high ** ** * * NS 
Monocyte Category mid NS NS NS NS NS high ** ** ** * * 
Haemoglobin 
Category 
mid * NS NS NS NS 
high # NS NS NS NS 
NLR Category mid # NS n/a NS NS high ** ** n/a * # 
NS = Not significant 
# = p value approaching significance = 0.1 to 0.05 
* = p value = 0.01 to 0.05 
** = p value <0.01 
n/a = not applicable 
TWCC = Total white cell count 
NLR = Neutrophil-lymphocyte ratio 
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus 
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
strata = statistical stratification for other significant categorical variables 
 
The level of significance for the circulating cell type in the various Cox proportional hazards 
models (Table 8.13) depends in all cases on the variables adjusted for and the statistical method 
of dealing with statistically significant co-variables. The cell types most consistently 
significantly associated across all models are the High TWCC category, the High Neutrophil 
Category and the High Monocyte Category, which are significantly associated with the 
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outcome of major adverse event in all models. The High Neutrophil-Lymphocyte Ratio (NLR) 
category is significantly associated with major adverse event in the a priori model and when 
adjusting for traditional risk factors but only trending to significance when the models are 
adjusted for comprehensive risk factors (Table 8.13). The Mid Neutrophil Category and the 
Mid Monocyte Category were not significantly associated with major adverse event in any 
model. 
 
Table 8.14: Combined cell types Cox proportional hazards analysis – major adverse event and all cell types 
by category. 
Major adverse event 
Cell Type  p Value HR (95% CI ) Cox.zph Global zph 
Neutrophil Category mid 0.24 1.37 (0.81-2.30) 0.83 0.08 
high 0.03 * 1.77 (1.05-2.98) 0.83 
Lymphocyte Category mid <0.01 ** 0.50 (0.32-0.79) <0.01 
high <0.01 ** 0.40 (0.25-0.64) 0.10 
Monocyte Category mid 0.18 1.40 (0.86-2.30) 0.69 
high <0.01 ** 2.04 (1.19-3.48) 0.04 
Haemoglobin Category mid 0.06 # 0.66 (0.42-1.00) 0.51 
high 0.05 * 0.64 (0.41-0.99) 0.95 
# = p value = 0.1 to 0.05    HR = Hazard Ratio 
* = p value = 0.01 to 0.05 (bold type)  NS = Not significant 
** = p value <0.01(bold type) 
 
A combined circulating cell types Cox proportional hazards model was used to assess all cell 
subtypes and the outcome of major adverse event tested a priori and the results are displayed 
in Table 8.14. Multiple cell categories were significantly associated with the outcome of major 
adverse event and are represented in Table 8.14 in bold type. The High Neutrophil Category 
was significantly associated with major adverse event with (p=0.03, Table 8.14) with the 
hazard ratio of 1.77 indicating that patients in the High Neutrophil Category are 1.77 times 
more likely to sustain a major adverse event than patients in the Low Neutrophil Category.  
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Both Mid and High Lymphocyte Categories were significantly negatively associated with 
major adverse event (p<0.01, Table 8.14). Both Mid and High Lymphocyte Categories have a 
hazard ratio range less than one that indicating that these categories of lymphocyte count have 
reduced risk of sustaining a major adverse event when compared to the Low Lymphocyte 
Category (Table 8.14).  
 
High Monocyte Category was also significantly associated with major adverse event in this 
model (p<0.01, Table 8.14). In the case of High Monocyte Category the hazards ratio of 2.04 
indicates that patients in the High Monocyte Category were more than twice as likely to have 
a major adverse event as those patients in the Low Monocyte Category. 
 
High Haemoglobin Category was also significantly associated with major adverse event in this 
model (p=0.05, Table 8.14). High Haemoglobin Category has a hazards ratio range less than 
one indicating a protective association with major adverse event. It is also worth noting that 
the Mid Haemoglobin Category was only just outside the chosen range of significance and the 
95% confidence interval for the hazard ratio only just includes one (Table 8.14). 
 
This model was not adjusted for confounding variables as with previous models of only one 
cell type due to the eight degrees of freedom already required for this model. Population and 
event incidence do not allow for meaningful adjustment with either traditional risk factors 
(TRF) or comprehensive risk factors (CRF) due to the number of degrees of freedom these 
models would require being beyond the power of this study.  
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The probability of breach of the assumptions of the Cox model for all circulating cell types and 
major adverse event models was raised with both Mid Lymphocyte Category (p<0.01, Table 
8.14) and High Monocyte Category (p=0.04, Table 8.14) significant at the p<0.05 level. As 
discussed previously this is most likely due to a change in the relationship of the Mid  
Lymphocyte Category and High Monocyte Category with the endpoint of major adverse event 
over time. This raises suspicion that the Cox proportional hazards models may not generate 
valid results for this data set and caution should be used when interpreting the results. It was 
determined that further analysis of cell counts, risk factors and the outcome of major adverse 
event was warranted by the likelihood of a priori relationships of circulating cell types and the 
outcome of major adverse event. Transformation of the data and analysis with other 
semiparametric testing was considered, however after reviewing the nature of complex 
interactions of the cell types and risk factors it was determined that analysis that not only allows 
for term interaction, but is able to statistically account for that interaction was more appropriate. 
This was done using multi-model averaging and is presented below. 
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8.3.8. Multi-model analysis for the outcome of major adverse event 
For the outcome of major adverse event the traditional risk factors of entry age, gender, diabetes 
mellitus, hypertension, ischaemic heart disease, transient ischaemic attack and stoke as well as 
disease severity at presentation and the medications of aspirin and statin were included in multi-
model analysis with cell counts Neutrophil Category, Lymphocyte Category, Monocyte 
Category, Haemoglobin Category and calculated Neutrophil/Lymphocyte Ratio Category. 
These variables were selected for the multi-model analysis due to their significant a priori 
associations with the outcome of major adverse event demonstrated with Cox proportional 
hazards analysis presented earlier in this chapter (Table 8.13) establishing the relationship of 
these variables with the outcome of major adverse event. 
 
The statistical package R354 was used to run all possible models using the explanatory variables 
above for the outcome of major adverse event with the package MuMIn355 (with K=15 
parameters described above). For the outcome of major adverse event the variable of gender 
had a very low frequency in one category and required stratification to exclude unintended 
influence on the analysis. The variable of smoking was also found to be better represented for 
the purpose of multi-model analysis when the three categories of never smoking, ex-smoking 
and current smoking were reduced to only two categories of never smoker and smoker 
(previous or current).The models were then reduced to just the models that were not 
significantly different to the “best” single model using the delta Δi <2 function (Table 8.15). 
The results of this analysis are presented in Table 8.15 with all the information required to 
interpret the analysis.368 Background information and equations are found in Chapter 4 
summarised in Table 4.3.   
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Table 8.15: Multi-model analysis: top model set for major adverse event (Δi <2) 
Component models: df   log(𝓛𝓛) AICc  Δi wi 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category/strata(gender) 
10 -507.18  1034.93 0.00    0.10 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / Neutrophil Category / strata(gender) 
12 -505.17  1035.15 0.22 0.09 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Neutrophil Category / strata(gender)  
10 -507.51  1035.59 0.66 0.07 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / strata(gender) / TIA 
11 -506.47  1035.63 0.70 0.07 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / Neutrophil Category / Smoking / 
strata(gender) 
13 -504.50  1035.94 1.01 0.06 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Neutrophil Category / Smoking / strata(gender) 
11 -506.65  1035.98 1.05 0.06 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / Smoking/ strata(gender) 
11 -506.74  1036.16 1.23 0.06 
Age / HTN / IHD / Disease Severity / Neutrophil Category / 
strata(gender) 
8 -509.93  1036.24 1.31 0.05 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / Statin / strata(gender) / DM 
11 -506.86  1036.40 1.47 0.05 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / strata(gender) 
11 -506.90  1036.48 1.55 0.05 
Age / HTN / IHD / Disease Severity / Neutrophil Category / 
Smoking / strata(gender) 
9 -509.06  1036.58 1.65 0.05 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / Neutrophil Category / strata(gender) / TIA 
13 -504.86  1036.66 1.73 0.04 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / Smoking / strata(gender) / TIA 
12 -505.94  1036.68 1.75 0.04 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / Neutrophil Category / Statin / strata(gender) 
13 -504.91  1036.76 1.83 0.04 
Age / HTN / Disease Severity / Lymphocyte Category / Neutrophil 
Category / strata(gender) 
9 -509.17  1036.80 1.87 0.04 
Age / HTN / Disease Severity / Lymphocyte Category / Monocyte 
Category / Neutrophil Category / strata(gender) 
11 -507.06  1036.81 1.88 0.04 
Age / HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / Neutrophil Category / strata(gender) / DM   
13 -504.94  1036.84 1.91 0.04 
Age / IHD / Disease Severity / Lymphocyte Category / Monocyte 
Category / strata(gender) 
9  -509.22  1036.91 1.98 0.04 
AICc = Akaike information criterion corrected for sample size (Equation 10) df = Degrees of Freedom 
Δi = AICi-AICmin (Equation 11)      DM = Diabetes Mellitus 
log(𝓛𝓛) = Log likelihood of individual model (𝓛𝓛 from Equation 12) HTN = Hypertension  
wi = Akaike weight (Equation 13)      
IHD = Ischaemic Heart Disease 
Disease Severity = Disease Severity at presentation    
Smoking = Smoking Category (Never smoker, Ex-smoker, Current smoker)  
The two top models are highlighted. 
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The models not significantly worse than the “best” model (Δi <2) were selected from the whole 
set of models for the data set with the outcome major adverse event, these 18 top models (Δi 
<2) are presented in Table 8.15. The simplest model had only 8 degrees of freedom while four 
models had 13 degrees of freedom. The log(𝓛𝓛) values range from -504.50 to -509.93 
demonstrating comparable fit of the selected models. The individual AICc are not interpretable 
as they contain arbitrary constrains and are greatly affected by sample size367 but once 
transformed to Δi with the best model given a Δ value of 0 and three other models having a Δi 
<1 the information loss in using those models over the “best” model is quantified. 
 
The “best” model contained the variables age, hypertension, ischaemic heart disease, disease 
severity, lymphocyte category and monocyte category with gender stratified (highlighted in 
Table 8.15). The “best” model has been estimated to be the best but the wi results show that no 
one model is supported as being clearly superior over the other considered models with the 
“best” model having a probability of only 10% and the second model 9% and all other models 
from the top model set (with Δi <2) ≥ 4%. The wi/ wj evidence support ratio demonstrates the 
empirical support for the “best” model is 2.5 times that of the 7 models with wi = 0.04 and 
twice that of the 4 models with wi = 0.05. 
 
The second best model for the outcome of major adverse event contained the  
Neutrophil Category in addition to the same variables contained within the best model and 
results in a Δi of 0.22 which may be interpreted as having minimal information loss despite the 
requirement of two additional degrees of freedom. The wi/ wj evidence support ratio confirms 
the empirical support for the “best” model is only 1.1 times that of the second best model.  
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Multi-model averaging is recommended to account for model selection uncertainty when the 
wi of the best model is <0.90.132,372 Multi-model averaging was undertaken which has the 
benefit of being able to include important information not included in the “best” model and 
account for model selection uncertainty in calculating robust parameter estimates or 
predictions.372 Multi-model averaging was then applied to make inference from all of the 
models with Δi <2 with adjustment for their supportive value and model probability. The 
variables from all the models in Table 8.15 were thus ranked according to the number of models 
(from the top model set with Δi <2) that each variable appeared in and factored for the 
complexity of each of those models using the Akaike weight for the model (wi) to calculate the 
importance for each variable for the outcome of major adverse event. The results of ranking 
variables using this process are presented in Table 8.16 and is particularly important in this 
analysis due to the similar levels of support for the top models (Table 8.15). The subsequent 
averaged model is then analysed to assess the coefficients and significance of contributing 
variables to the averaged model (Table 8.17).  
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Table 8.16: Relative variable importance from multi-model analysis for major adverse event 
Variable Importance  No. of models  
Age 1.00 18 
Disease Severity 1.00 18 
Strata (Gender) 1.00 18 
Hypertension 0.96 17 
Ischaemic Heart Disease 0.92 16 
Lymphocyte Category 0.90 16 
Monocyte Category 0.73 13 
Neutrophil Category 0.59 11 
Smoking 0.27 5 
Transient Ischaemic Attack 0.16 3 
Statin 0.09 2 
Diabetes Mellitus 0.09 2 
 
Table 8.16 shows that eight variables (Entry Age, Disease severity at presentation, Stratified 
Gender, Hypertension, Ischaemic Heart Disease, Lymphocyte Category, Monocyte Category 
and Neutrophil Category) were present in more than half of the models in the top model set 
with Δi <2. These variables are the best predictors for the outcome of major adverse event in 
the population. The “best” model contained seven of these eight variables.  
 
The lower relative importance of smoking and that it only appeared in five models in the top 
model set implies that it is less likely to be a good predictor of major adverse event than the 
best predictors referred to earlier but may still have significant influence in the models in which 
it was included. Of the models that included smoking two of the five did not include Neutrophil 
Category. Transient ischaemic attack, statin use and diabetes mellitus were present in the 
fewest models and are less likely to be strong predictors of major adverse event compared to 
the best predictors. Two of the three models that contained Transient Ischaemic Attack did not 
contain Neutrophil Category. One model that did not contain Neutrophil category contained 
both statin use and diabetes. 
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Neutrophil-Lymphocyte Ratio has the advantage of less degrees of freedom than including 
both the Neutrophil Category and Lymphocyte Category however this variable was not in any 
of the models from the top model set with Δi <2, although both Neutrophil Category and 
Lymphocyte Category appear together in 10 of the 18 models.  
 
The model averaged coefficients were generated using the natural average method132,372 and 
are displayed in Table 8.17.  The coefficients indicate the direction of effect for each variable 
with size of standard error, i.e. a negative coefficient indicates a negative effect on the outcome 
of major adverse event, that the event is less likely to occur. 
Table 8.17: Multi-model inference averaged coefficients for major adverse event 
Variable                         Standardised 
Coefficient 
SE of 
coefficient 
z value  Pr(>|z|) 
Rest pain                     0.71 0.59 1.19 0.24 
High Monocyte Category                     0.56 0.43 1.29 0.20 
High Lymphocyte Category               -0.53 0.30 1.78 0.08 
Hypertension                                   -0.53 0.28 1.90 0.06 
Mid Lymphocyte Category                  -0.49 0.28 1.76 0.07 
Tissue Loss                  0.41 0.58 0.70 0.49 
High Neutrophil Category                 0.39 0.39 0.98 0.32 
Intermittent claudication  -0.39 0.54 0.74 0.46 
Ischaemic Heart Disease                                    0.38 0.23 1.66 0.09 
Mid Monocyte Category                     0.23 0.27 0.87 0.39 
Mid Neutrophil Category                   0.18 0.26 0.70 0.49 
Age                                   0.06 0.01 5.32 <0.001 
Transient Ischaemic Attack                                   -0.05 0.17 0.30 0.76 
Smoking                         0.04 0.09 0.42 0.67 
Statin                                -0.01 0.07 0.19 0.85 
Diabetes Mellitus                                    -0.01 0.07 0.17 0.86 
SE = Standard error 
 
Table 8.17 presents the multi-model inference results for the averaged model which combined 
the top model set of Δi <2 candidate models weighted by their support. The standardised 
coefficient and standard error were used to generate a z value and the probability of each z 
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value (Pr(>|z|)) are included in Table 8.17. Caution needs to be taken in interpreting these 
results from a null hypothesis testing paradigm that traditionally uses the probabilities of z 
statistics to accept or reject the null hypothesis.132,368 These results are included here to 
demonstrate the relative effect of coefficient and standard error on the individual variables in 
the averaged model and not in the binary significant/not significant way.368 The z value is one 
way of quantifying the effect of a variable in the averaged model that accounts for the 
magnitude of the adjusted coefficient and allows comparison of coefficients with different 
standard errors. Importantly, variables with a non-significant Pr value are not discarded, 
because the overall averaged model is better with them than without them but in the averaged 
model they have weaker effects on the outcome of major adverse event than variables with 
smaller Pr values. The variable with the smallest Pr value was Age which was in all of the top 
model set, and the effect of age in the “best model” and subsequent averaged model is not 
substitutable by any of the other variables. The Pr values are very useful in the interpretation 
of the averaged model for variables that are likely to be correlated and hence partly 
substitutable in the averaged model. The low Pr values of High Lymphocyte Category, Mid 
Lymphocyte Category, Hypertension and Ischaemic Heart Disease along with the presence of 
these variables in most or all of the top model set may be interpreted as these variables being 
key or non-substitutable in the averaged model for major adverse event. High Neutrophil 
Category demonstrated a comparatively larger Pr value of 0.49 (Table 8.17) and was only in 
11 of the 18 models in the top model set (Table 8.16). Of the seven models that did not contain 
Neutrophil Category in Table 8.15: two contain Smoking, two contain TIA and one contains 
Diabetes Mellitus, none of which were represented in the “best model”. Smoking and 
Neutrophil Category are expected from previously published literature to be correlated,383 
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therefore when they included in the same model it is expected to see that both will have their 
level of significance reduced or eliminated compared to if only one of these variables was 
included. 
 
The averaged coefficients presented in Table 8.17 will always be weaker than the coefficients 
in the “best” model but the process is designed to be generous with inclusion over exclusion 
and will tend to underestimate the relative strength of variable effect compared with the “best” 
model. 
 
From the categorical variables, Rest Pain has the largest coefficient (0.71, Table 8.17), which 
is best described as the magnitude of effect. Rest Pain therefore exhibits the largest effect on 
the model for the outcome of major adverse event. Rest pain does have a standard error of 0.59 
which is why the z value is 1.19 (Pr=0.24, Table 8.17). This z value and corresponding p value 
do not mean that this is not an important (or non-significant) result. It is instead a method of 
quantifying the largest variable effect in the averaged model also having a large standard error. 
 
High Monocyte Category demonstrated the largest effect of the circulating cell types in the 
averaged model which was greater than all traditional risk factors included. Again the standard 
error of High Monocyte Category approaches the coefficient resulting in a z value of 1.29 
(Table 8.17). High Lymphocyte Category was shown to have the same effect size as the 
traditional risk factor of hypertension with both coefficients negative indicating a protective 
effect for the outcome of major adverse event. With both High Lymphocyte Category and 
Hypertension having the same coefficient the effect of a smaller standard error for the variable 
 231 
Chapter 8: Results section 4 - Total and differential circulating cell counts associated with major adverse events in peripheral arterial occlusive 
disease. 
of hypertension can be seen to result in a larger z value of 1.90 (Pr=0.06, Table 8.17). Mid 
Lymphocyte Category also displayed a negative coefficient larger than the rest of the 
traditional risk factors (i.e. other than hypertension). 
 
High and Mid Neutrophil category and Mid Monocyte category all demonstrated larger 
coefficients than the other traditional risk factors of transient ischaemic attack, smoking, statin 
and diabetes mellitus. Hypertension, High and Mid Lymphocyte Category and Intermittent 
claudication all have a negative coefficient or are protective for the outcome of major adverse 
event. 
 
In the averaged model Tissue Loss has a coefficient of 0.41 but the standard error of this value 
is greater resulting in a z value <1. High Neutrophil category carried the same variable 
weighting as the disease severity category of intermittent claudication, although High 
Neutrophil Category was positively associated with the outcome of major adverse event and 
Intermittent claudication was protective for this outcome. 
 
Ischaemic Heart Disease is the ninth strongest variable for the outcome of major adverse event 
(coefficient 0.38) but with relatively small standard error of 0.23 (Table 8.17). 
 
Age is the only continuous variable in this multi-model analysis and although the coefficient 
is seeming more modest than other variables (0.06, Table 8.17) it has the smallest standard 
error and as such generated the largest z value. The coefficient for age applies to the value for 
that continuous variable and it has a strong effect on the outcome in this case major adverse 
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event. For example in an 80 year old patient the age term would be a function of the coefficient 
(0.06, Table 8.17) and the value 80. 
 
The four weakest standardised coefficients also belong to the variables that feature in the least 
number of best fit models (Table 8.16) and interestingly these are all traditional risk factors 
that currently constitute models for major adverse event in patients with peripheral arterial 
occlusive disease. It is possible that transient ischaemic attack, smoking, diabetes mellitus and 
statin use interact with one or more of the other variables in the model (e.g. smoking and/or 
neutrophil count383) and the better predictor may suffice but in the interests of caution these 
variables have been included in the average model because it is not possible to tell from this 
data set alone which of these variables can be safely excluded. Care should be exercised in 
interpreting the direction of association of these weakly correlated variables as assigning the 
incorrect sign to a weak parameter is a possibility in any inference analysis.384,385 
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8.4. Discussion for MAE 
The aim of this study was to combine the assessment of all the circulating cell types for the 
composite endpoint of major adverse event, and to generate a predictive model for the outcome 
of major adverse event that combines the circulating cell count values with established risk 
factors and clinical disease severity. This is the first study to apply the Information-Theoretical 
paradigm and in particular multi-model inference to a population of patients with peripheral 
arterial occlusive disease. The resultant model deepens understanding of the true relationships 
and relative predictive value of the circulating cells for major adverse event in ways not 
possible with traditional null hypothesis testing statistics. The resultant robust averaged model 
can be used to risk stratify patients for treatment selection and increase patient compliance with 
lifestyle modifications and medication use. The developed model should be used to guide 
further research into understanding of the pathogenesis of major adverse events in this 
population. 
 
Circulating cell counts of monocytes, lymphocytes and neutrophils together with disease 
severity at presentation, hypertension and age were more important predictors for the outcome 
of major adverse event than other traditional risk factors using multi-model inference to 
develop the best fit model for this data set (Table 8.17). Only variables with strong biological 
reasoning and established a priori relationship were included in the multi-modelling analysis132 
and this evidence was established in the null-hypothesis testing sections of this chapter prior to 
commencing multi-model analysis. Multi-model analysis was selected as the most appropriate 
method because it is able to identify the best predictors of an outcome in complex systems 
where controlling for the large number of factors affecting outcome is impractical.132,386 The 
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multi-model averaging results provide evidence that the morbidity and mortality of major 
adverse events among patients with peripheral arterial occlusive disease may be more related 
to the circulating cells as markers of inflammation than the traditional risk factors of smoking, 
diabetes mellitus, ischaemic heart disease, stroke and transient ischaemic attack associated with 
the establishment of the disease.  
 
Disease Severity was established as a strong predictor of major adverse event in this 
population, being present in all 18 of the top models (Δi <2) of the multi-model analysis (Table 
8.16). The strongest variable effect in the resultant averaged model was demonstrated from the 
variable Rest Pain despite the small numbers in this group. Tissue Loss also demonstrated an 
important effect with a larger standardised coefficient in the averaged model for major adverse 
event than the traditional risk factors of ischaemic heart disease and smoking. Future analysis 
could consider combining the Rest Pain and Tissue Loss groups into the clinical entity of 
critical limb ischaemia to increase the power of this group, potentially establishing the disease 
severity of critical limb ischaemia as the most important categorical variable for the outcome 
of major adverse event. These findings are consistent with the published literature that 
demonstrates the high major adverse event rate in this clinically important subsection of the 
population with peripheral arterial occlusive disease.28,108 The strength of Disease Severity as 
a predictor of major adverse event is also important to consider when reviewing peripheral 
arterial occlusive disease literature as not all studies report or account for the clinical severity 
of disease when investigating these patients.49,222,320 One question not addressed by this 
research is the mechanism by which Disease Severity influences major adverse event; is it 
solely as a marker of total atherosclerotic disease burden including in the coronary and cerebral 
 235 
Chapter 8: Results section 4 - Total and differential circulating cell counts associated with major adverse events in peripheral arterial occlusive 
disease. 
circulations, or does the ischaemia of peripheral tissue cause inflammation and a change in the 
circulating cells that is able to effect ischaemic change in distant organs and subsequent major 
adverse event. 
 
Age and gender (stratified) were also strong predictors of major adverse event in the multi-
model analysis, present in all 18 of the best fit models (Δi <2). Age is the only continuous 
variable in the analysis and although has a small relatively small standardised coefficient in the 
averaged model (0.06 ±0.01, Table 8.17) generated the largest z value due to the continuous 
nature of this variable. Gender required stratification due to skewed distribution to ensure 
reliable inference from the final averaged model and therefore does not have a standardised 
coefficient presented in Table 8.17. Age and gender are important to include in the resultant 
averaged model and should be included in any further investigations of this population. 
 
The circulating cells of neutrophils, lymphocytes and monocytes were present in more than 
half of the best fit models for major adverse event and should be considered consistent 
predictors for the outcome of major adverse event (Table 8.16). The High Monocyte Category 
and High Neutrophil Category demonstrated a positive association with the endpoint of major 
adverse event while both High Lymphocyte Category and Mid Lymphocyte Category had a 
negative or protective association with this outcome. The circulating cells relationship with the 
outcome of major adverse event will be addressed individually, with comparison to the null 
hypothesis testing precedent for inclusion in multi model analysis in previously published 
literature. 
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High Monocyte Category was the strongest cell type predictor of major adverse event with the 
largest standardised coefficient of the circulating cells in the averaged model (0.56 ±0.43) 
although with a larger standard error than the other circulating cell count categories. The High 
Monocyte Category was significantly associated with the outcome of major adverse event in 
all Cox models and clearly established evidence to support Monocyte Category inclusion in 
the multi-model analysis. High monocyte count has previously been associated with the 
presence of peripheral arterial occlusive disease in population studies264 and major adverse 
event in patients with ischaemic heart disease99 and has been previously reported to be 
associated with major adverse event in patients with peripheral arterial occlusive disease.69 
High Monocyte Count has been associated with the early development of atherosclerotic 
disease387-390and although Monocytes are believed to play a critical role in the initiation of 
atherosclerotic plaque development, they have also been implicated in promoting plaque 
instability and remodelling after heart attack.391 When the Cox proportional hazards 
comprehensive risk factor adjusted model was stratified for other significant categorical 
variables (smoking, ischaemic heart disease and hypertension) the hazard ratio indicated a 1.75 
greater risk of major adverse event with a high monocyte count. This was greater than the upper 
quartile monocyte category relative risk of major adverse event 1.24 (1.08–1.41, 0.01) found 
by Grau et al.69 although they comment that their study may have underestimated risk by 30-
35% due to regression dilution. In the current study, the non-stratified Cox model adjusted for 
traditional risk factors alone, the Cox.zph value reached the 0.05 level indicating a possible 
breach in the proportional hazards assumption of the model. This was not the case with the 
comprehensive risk factor adjusted models and the strong positive association of High 
Monocyte count with major adverse event is a sound and important basis for inclusion in the 
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multi-model analysis. The increase in circulating monocyte count associated with major 
adverse event is potentially a result of increased mobilisation of these cells from the marginal 
pool caused by tissue ischaemia.392 This study was not designed to investigate monocyte 
subtypes although the CD14+/CD16+ monocyte subset have previously been shown to 
contribute to inflammation through their production of tumour necrosis factor – alpha 
(TNFα).393 Replication of this study in a larger population using multi-model analysis could be 
powered to analyse subtypes and may reduce the resultant standard error of this variable and 
establish monocytes as an important direction for further research in the peripheral arterial 
occlusive disease population. 
 
The strong protective effect of both High Lymphocyte Category and Mid Lymphocyte 
Category is demonstrated in this study through negative coefficients in the averaged model  
(-0.53 ±0.30, -0.49 ±0.28 respectively, Table 8.17). This finding confirms the direction and 
strength of association demonstrated on Cox proportional hazards testing but also quantifies 
the relative strength of each Lymphocyte Category with relation to the contribution of other 
variables to the averaged model. High Lymphocyte Category and Hypertension have the same 
negative standardised co-efficient or similar protective effect for the outcome of major adverse 
event, an effect thirteen times that of traditional risk factor smoking (Table 8.17). Lymphocytes 
have been rarely demonstrated to be significant contributors to the outcome of major adverse 
event in published literature with significant univariate analysis results of the large population 
with atherosclerosis in the CAPRIE study, although in that study the association was not 
significant in that multivariate analysis.69 In null hypothesis testing Cox proportional hazards 
analysis both Mid and High Lymphocyte categories were significantly associated with the 
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endpoint of major adverse event in all Cox models except the stratified comprehensive risk 
factor adjusted model (Table 8.6). This effect was not found in the  
CAPRIE study by Grau et al.69 who reported the upper quartile lymphocyte category non-
significant relative risk of major adverse event as 1.04 (0.91–1.19) on multivariate analysis. 
Caution needs to be employed in reviewing the Cox proportional hazards results from the 
current study because the Mid Lymphocyte Category had significant Cox.zph scores indicating 
a breach of the assumption of proportionality. The Low Lymphocyte Category in the Haumer 
et al.72 study of 398 similar patients, showed a trend to significance with the lower tertile 
lymphocyte count that was not significant (0.07) although the Cox.zph scores were not 
reported. Tests of proportionality are not commonly published in studies assessing outcome in 
patients with peripheral arterial occlusive disease, and as the aim is to investigate and describe 
a complex biological system the most appropriate analysis needs to be again considered. While 
it may be argued that alternative null hypothesis testing statistics may be performed, the 
significance of these findings and the potential breach of the assumption of proportionality was 
sufficient to include Lymphocyte Category in the more appropriate multi-model analysis. 
Information-Theoretical approaches and model averaging have been proposed to be 
methodologically superior to traditional null hypothesis testing when variables are 
correlated.132 It is possible that the use of the multi-model analysis has unmasked the protective 
effect of the Lymphocyte category that in null hypothesis testing multivariate analysis and 
stepwise regression was being clouded by a weaker correlated traditional risk factor. The 
protective relationship of lymphocytes for the outcome of major adverse event requires 
replication in other populations with peripheral arterial occlusive disease prior to application 
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of this information in directing pathophysiological research or potential therapeutic 
exploitation.  
 
High Neutrophil Category demonstrated a stronger positive effect on the endpoint of major 
adverse event in the averaged model than all of the traditional risk factors which quantifies and 
adds support to the previously reported effect of neutrophil count adding to the information of 
traditional risk factors in predicting major adverse event.72 High Neutrophil Category was 
significantly associated with the endpoint of major adverse event in all Cox models including 
the comprehensive risk factor adjusted model that stratified for other significant categorical 
variables (smoking, hypertension, ischaemic heart disease) with a hazards ratio 1.98 (1.12-
3.10). This is consistent with the hazard ratio found by Haumer et al.72 (hazard ratio 2.20) for 
upper tertile neutrophil count and major adverse event in patients with peripheral arterial 
occlusive disease. A lesser hazard ratio was found for Neutrophil count by Giugliano et al.74 
investigating 259 patients with peripheral arterial occlusive disease (hazard ratio 1.29, 1.06–
1.56) after adjusting for cardiovascular drugs although this result was still highly significant 
(0.02). The Mid Neutrophil Category was not significantly associated with the endpoint of 
major adverse event in either the a priori or adjusted Cox models, but note that in the Kaplan-
Meir freedom from major adverse event analysis, Mid Neutrophil Category did trend below 
that of the Low Neutrophil Category although the plots intersected several times throughout 
the study possibly as a result of sample size (Figure 8.3). The Mid Neutrophil Category 
demonstrated the weakest effect of the important circulating cell subtypes in the averaged 
model (0.18 ±0.26, Table 8.17) and the standard error is larger than the standardised coefficient, 
although this effect remains 4.5 times the effect of the traditional risk factor smoking. High 
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Neutrophil Category was a better predictor of major adverse event in multi-model analysis and 
Mid Neutrophil Category may have its predictive value in the model strengthened by 
replication of this study in a larger population. The mechanism by which high neutrophil count 
contributes to major adverse event may be through free radical release,321 aggregation,394,395 
adhesion,396 obstruction of microvasculature190,234 or plaque disruption397 or a combination of 
all these factors. 
 
The calculated neutrophil-lymphocyte ratio did not feature in any of the 18 top models (with 
Δi <2) for the outcome of major adverse event. The neutrophil-lymphocyte ratio has recently 
in other studies been associated with the outcome of major adverse event in patients with 
peripheral arterial occlusive disease.49,260,263 The current study objectively demonstrates that 
the information gained in using both the Neutrophil Category and Lymphocyte Category in 
multi-model analysis is greater than that of the simplified neutrophil-lymphocyte ratio despite 
the penalty of additional degrees of freedom. This is an important finding as traditional 
stepwise regression does not allow direct comparison of these variables in their precision306 of 
predicting major adverse event in this population. In null hypothesis testing analysis High NLR 
Category was significantly associated with the outcome of major adverse event in a priori and 
non-stratified adjusted models. In the Cox proportional hazards model which adjusted for 
comprehensive risk factors there were five other variables that were also significantly 
associated with the outcome of major adverse event (age, smoker, ex-smoker, ischaemic heart 
disease and hypertension). When this model was stratified for the significant categorical 
variables (smoking, hypertension, ischaemic heart disease) the High NLR Category was no 
longer significantly associated with the outcome of major adverse event at the 0.05 level (0.09) 
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and the hazard ratio of 1.56 with 95% confidence interval including the value of 1 (0.93-2.61) 
while age remained significantly associated. Whilst there remains a trend to significance in null 
hypothesis testing analysis these results raise the possibility of one or more of the confounding 
factors actually providing the statistical significance for the High NLR Category in other 
models. This is another illustration of how the variables that are selected for adjustment in Cox 
proportional hazards analysis can greatly influence outcome. The potential that a confounder 
is actually providing some of the effect attributed to the High NLR Category in the a priori 
and non-stratified null hypothesis testing approach is another possible reason that NLR 
Category did not feature in any of the top model set (Δi <2) of the multi-modelling approach 
with other variables more accurately able to describe the association seen in null hypothesis 
testing. This finding directly demonstrates one flaw of the null hypothesis testing approach 
where truly less important variables may appear significant. In a biological system such as the 
one being investigated here with complex interactions between confounding variables many of 
which have small but important effects, a more accurate and reliable method of statistical 
analysis needs to be considered and applied. One fundamental difference in these statistical 
processes is that instead of disproving the null hypothesis, multi-model analysis allows 
simultaneous comparison of multiple variables involved in creating the model set and is able 
to quantify the contribution of these variables. The result of this multi-model analysis is clear 
that inclusion of Neutrophil Category and Lymphocyte Category better predicts the outcome 
of major adverse event than the calculated Neutrophil-Lymphocyte Ratio. 
 
The strongest effect from a traditional risk factor in the averaged model was the negative 
association of hypertension with major adverse event (-0.53 ±0.30, Table 8.17). The reason for 
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this negative association is not clear from the analysed data with hypertension traditionally 
having a positive association with mortality.100,103,398 Treatment of hypertension in peripheral 
arterial occlusive disease has been demonstrated to lower the incidence of major adverse event 
in large population studies such as the HOPE (Heart Outcomes Prevention Evaluation) 
study104,399,400 with similar results in other study subpopulations with peripheral arterial 
occlusive disease.125 At recruitment 74.9% of this study population was noted to have a 
diagnosis of hypertension or be on treatment for hypertension with 42.0% of the total study 
population taking ACE-inhibitors, 28.6% beta-blockers, 27.9% calcium channel blockers, 
22.6% angiotensin II antagonists, 12.6% taking frusemide and 13.1% were taking another 
diuretic (Table 5.1). The influence of these antihypertensive medications at recruitment and 
any changes in anti-hypertensive medication that were recorded at each follow up visit, or 
correlation with non-invasive blood pressure measurements were outside the scope of the 
current study and are suggested directions for further investigation of the negative predictive 
value of the risk factor Hypertension. 
 
Intermittent claudication was also negatively associated with the outcome of major adverse 
event in the averaged model indicating a protective effect of this disease severity at presentation 
(-0.39 ±0.54, Table 8.17). The small magnitude of the negative averaged coefficient and 
relatively large standard error demonstrate that the direction of this result should be interpreted 
with caution as the large standard error includes 0. Intermittent claudicants have previously 
been demonstrated to have a lower risk of cardiovascular event than patients with critical limb 
ischaemia28 so whether Intermittent Claudication is truly protective or only relatively 
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protective compared to more advanced disease severity at presentation would need to be 
examined in a larger population. 
 
Null hypothesis testing of the TWCC categories demonstrated comparable results to previously 
published studies although TWCC Category was not included in the multi-model analysis as 
TWCC is a direct result of the summation of cell subtypes. High TWCC was associated with 
the endpoint of major adverse event in all Cox proportional hazards models at a p <0.01 and a 
hazard ratio of 2.07 (1.21-3.54, Table 8.2) in the stratified model that adjusted for 
comprehensive risk factors. This hazard is greater than that reported by Grau et al.69 who 
reported a relative risk of 1.42 (1.25–1.63) in a large study of 18,000 patients with 
atherosclerotic vascular disease, and Giugliano et al.74 who found a hazard ratio 1.29 (1.06-
1.57) in a smaller study of 259 peripheral arterial occlusive disease patients after adjusting for 
cardiovascular drugs. A study with exactly the same number of patients with peripheral arterial 
occlusive disease as this study, did not demonstrate a significant association of TWCC with 
major adverse event over a median follow up of 20 months (p=0.22).72 The ADEP73 study of 
2111 patients did not use tertiles for TWCC but found an odds ratio of 1.15 for a difference of 
2.0 x109 cells/L which was significant for a larger composite outcome of cerebrovascular event 
(which included death, heart attack and stroke +TIA, +angina, + severe renal failure, + 
pulmonary embolism, + DVT, + peripheral obstructive arterial disease deterioration). 
Amaranto et al.320 showed a significant association with increasing TWCC prior to major 
endovascular surgery and major adverse event with an odds ratio of 1.67. Future comparison 
of TWCC with cell subtypes using multi-model analysis would objectively quantify whether 
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TWCC or the cell subtypes are better predictors of major adverse event and should be 
considered in future study and analysis design. 
 
The relationship of Mid TWCC Category with major adverse event on null hypothesis testing 
analysis was less clear than that of High TWCC Category. Mid TWCC Category was 
significantly associated with the endpoint of major adverse event in a priori and comprehensive 
risk factor adjusted Cox models but was not associated with the endpoint of major adverse 
event when adjusted for traditional risk factors alone. This raises suspicion that one of the 
comprehensive risk factors (disease severity, aspirin or statin use) that were not adjusted for in 
the traditional risk factor analysis, plays an important role and may mask association with the 
endpoint of major adverse event. In the comprehensive risk factor adjusted Cox model: age, 
ischaemic heart disease, hypertension, smoking and gender were all significantly associated 
with major adverse event as well as Mid TWCC (0.01, Table 8.2). When the comprehensive 
risk factor adjusted Cox model was stratified for the significant categorical variables Mid 
TWCC remained significantly associated with the outcome of major adverse event (0.02, 
hazard ratio 1.87, Table 8.2). These results clearly display the underlying complex interaction 
of Mid TWCC Category and the interplay of risk factors for the outcome of major adverse 
event. This is one example demonstrating the importance of the publication of all statistical 
analysis that were implemented and not merely the reporting of significant results. In this case 
one of the traditional risk factors of age, gender, hypertension, ischaemic heart disease, stroke, 
transient ischaemic attack, smoking or diabetes mellitus is interacting in a way that affects the 
null hypothesis testing of the association of Mid TWCC Category and the outcome of major 
adverse event. This is unlikely to be caused by ischaemic heart disease alone as stratifying for 
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this variable did not change the hazard ratio or p value (Table 8.2). Adjusting for the 
comprehensive risk factors in Cox analysis not only produced a significant result for Mid 
TWCC Category but also revealed six of the risk factors to have a significant association with 
the outcome of major adverse event. Although all of these variables were present in the 
previously described analysis, interaction with Disease Severity, Aspirin or Statin use revealed 
a different profile of significant factors. When the Cox proportional analysis was then stratified 
for these significant factors Mid TWCC Category remained significantly associated with the 
outcome of major adverse event. The interpretation of one of these results in isolation would 
omit important information on the interactions of the risk factors and TWCC for the outcome 
of MAE and unfortunately in simplifying the presentation of results for publication the 
complexity of these relationships are often understated. 
 
Mid Haemoglobin Category was significantly associated with the outcome of major adverse 
event in the a priori Cox proportional hazards model only, while the High Haemoglobin 
Category trended to significance (0.06, Table 8.10) and justified the inclusion of this variable 
in the multi-model analysis. Neither Haemoglobin Category remained significant when the 
model was adjusted for traditional or comprehensive risk factors suggesting that one or more 
of the confounding factors were truly responsible for the apparent difference seen on a priori 
modelling. This data set demonstrates the importance of considering and adjusting for potential 
confounding factors that may mask or exaggerate the true relationship of a variable with the 
tested outcome. Whilst Haemoglobin has been associated with the outcome of death in 
populations of patients with peripheral arterial occlusive disease49,288 there is a paucity of 
evidence for Haemoglobin association with the outcome of major adverse event. This finding 
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was confirmed by the total exclusion of Haemoglobin Category from the top model set (Δi <2) 
in the multi-model analysis for the outcome of major adverse event in this study. Multi-model 
analysis in this study demonstrates that Haemoglobin category is not a good predictor of major 
adverse event and need not be included in future analysis for this outcome. 
 
The comparative nature of multi-model analysis does not directly compare pathophysiological 
causality of investigated variables with the outcome of major adverse event. However, it 
quantifies the relative ability of these variables to discriminate the patients with established 
peripheral arterial occlusive disease that will sustain a major adverse event which may be very 
different to the risk factors that cause the establishment of the disease. All categories of disease 
severity, High and Mid Monocyte Category, High and Mid Lymphocyte Category, High and 
Mid Neutrophil Category, Hypertension and Ischaemic heart disease, all demonstrated stronger 
effects in the averaged model for major adverse event than other traditional risk factors of 
transient ischaemic attack, smoking, statin use and diabetes mellitus. These results are 
consistent with the early findings of Dormandy and Murray24 who reported the absence of 
predictive value for the traditional risk factors of hypertension, diabetes, smoking and high 
plasma cholesterol levels and suggested that these risk factors for the development and early 
progression of atherosclerosis are not necessarily prognostic factors in the final stages of the 
disease.24 
 
While the averaged model may seem complicated for the clinician to use at the bedside, a 
simple computational application for smartphone is proposed to make the model more clinician 
friendly. With smart phones now commonplace among medical professionals,401,402 an 
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application with simple interface that requires selecting the patient risk factors in a yes/no 
toggle and category of circulating cell count via a high / medium / low slide (with values 
provided for each category) the clinician would be able to apply this model with nothing more 
than clinical history and full blood count results. Validation of these results among other 
populations of patients with peripheral arterial occlusive disease is considered essential prior 
to this application development. Multi-model inference analysis results show that patient age, 
gender, clinical disease severity, history of hypertension or ischaemic heart disease should be 
combined with Lymphocyte Category, Neutrophil Category, and Monocyte Category in the 
model to predict major adverse events in patients with peripheral arterial occlusive disease. 
Smoking status, history of Transient Ischaemic Attack, Diabetes Mellitus and Statin use would 
best have their role in the model clarified by replication with another population, however from 
this study alone they add meaningfully to the model and should be included. This proposed 
handheld application may assist the clinician to predict and communicate risk of major adverse 
event to the patient in a way that may enhance adherence to lifestyle changes and medication 
use133 that have been shown to improve outcomes in patients with peripheral arterial occlusive 
disease,83,85,135,136 and may help select the most appropriate treatment for individual patients.137 
 
Future investigations should replicate this study design with multi-model analysis of larger 
data sets in similar populations of patients with symptomatic peripheral arterial occlusive 
disease to refine the predictive ability of the model. Multi-model comparison to compare 
TWCC with subtypes for the outcome of major adverse event should be considered. Further 
investigation to define the protective effect of hypertension or the treatment applied for 
hypertension within this population may give further insight and add strength to the known 
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benefits of management of this risk factor in peripheral arterial occlusive disease patients.400 
Future multi-model analysis could also be designed to quantitatively compare Ankle Brachial 
Index and clinical disease severity categories in their ability to predict major adverse event. 
Expansion of the study population to the wider population of peripheral arterial occlusive 
disease patients including asymptomatic patients and subsequent model development could aid 
in identifying asymptomatic patients at the highest risk of major adverse event who would 
benefit most from the lifestyle changes and medical management discussed above. Using 
multi-model averaging to create these models for outcome of major adverse event will address 
the multiple complex interactions of variables demonstrated to complicate null hypothesis 
testing analysis and will allow comparison of the variables and their association with the 
endpoint of major adverse event, these results may also be used to infer the key underlying 
biological processes at work.132,386  
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8.5. Conclusion for MAE 
Multi-model averaging is a relatively new statistical paradigm. It is the preferred statistical 
method for analysing data from complex biological systems needing to account for multiple 
co-variables of modest effect that interact132 to produce clinically relevant outcomes including 
major adverse events for patients with peripheral arterial occlusive disease. Multi-model 
averaging in this study has demonstrated that circulating cell counts of monocytes, 
lymphocytes and neutrophils together with disease severity at presentation, hypertension and 
age are more important in models to predict the outcome of major adverse event than other 
traditional risk factors.  
 
Rest Pain was the strongest predictor of major adverse event in the best averaged model and as 
previously established in Chapter 7, disease severity should continue to be reported and 
accounted for when examining outcomes in patients with peripheral arterial occlusive disease. 
 
High Monocyte Category exerted the strongest effect of the circulating cell types almost 1.5 
times the effect of ischaemic heart disease in the averaged model for the major adverse event 
outcome. However strong corroborating evidence for the association of monocytes with the 
composite outcome of major adverse event in peripheral arterial occlusive disease patients is 
lacking. 
 
Both High and Mid Lymphocyte Categories were shown to have a strong protective effect on 
the outcome of major adverse event when analysed with multi-model inference. Despite this 
effect being reported in large studies69 it has not been demonstrated to be significant on 
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multivariate analysis possibly because of interactions with one or more of the traditional risk 
factors as suggested by the significant Cox.zph scores in the null hypothesis testing sections of 
this chapter. The Information-Theoretical approach has been suggested as superior when 
variables are correlated403 and has objectively revealed High Monocyte Category to be as 
important as the traditional risk factor of Hypertension and superior to all other traditional risk 
factors in the prediction of major adverse event. This result previously unavailable with null 
hypothesis testing statistics of an important protective effect of Lymphocytes for major adverse 
event in peripheral arterial occlusive disease patients deserves further research. 
 
Analysis using Information-Theoretical framework has shown that the inclusion of 
Lymphocyte Category and Neutrophil Category together provide better modelling of the 
outcome major adverse event than the combined Neutrophil-Lymphocyte ratio. This study is 
the first to use the Information-Theoretical approach to directly compare the strength of 
variables contribution to models of outcome through quantifying the approach of best model 
selection. Caution should be employed in further investigation of the comparatively less 
informative Neutrophil-Lymphocyte ratio in patients with peripheral arterial occlusive disease. 
 
The strong protective effect of Hypertension or the treatment of hypertension in this study is 
demonstrated to have the largest and most consistent effect of the traditional risk factors. 
Although this study has not investigated the relative benefits of antihypertensive treatment this 
has been identified as an interesting area of further research and is suggested to be assessed 
using the relatively more informative statistical approach of multi-model inference. 
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Multi-model inferencing should be applied to larger data sets of patients with peripheral arterial 
occlusive disease to validate the results of this study and provide valuable information about 
the association of cell counts with outcomes in this population. Once the nature of these 
associations is refined, more accurate models will be generated to predict the likelihood of 
major adverse events for individual patients and thus aid patient compliance with lifestyle 
change and medical therapy and guide treatment selection. It will also enable the generation of 
future pathophysiological research and treatment options. 
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8.6. Results section 5 
Total and differential circulating cell counts associated with death in 
patients with peripheral arterial occlusive disease 
 
Each circulating cell type is examined and presented in turn for association with death using 
Kaplan-Meier survival analysis and Cox proportional hazards analysis with and without 
adjustment for traditional and comprehensive risk factors. The multi-model averaging process 
is presented at the end of this section to assess all circulating cell types and comprehensive risk 
factors together in modelling the outcome of death and will report which models and 
subsequently which variables are best associated with the outcome of death. 
 
8.6.1. Total white cell count associated with death 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from death plot of the cohort is presented in Figure 8.9 by Total White 
Cell Count (TWCC) Category. Tertile calculation has been previously explained in Chapter 4 
with values available in Chapter 8 Section 4. The horizontal axis is displayed with time points 
described in Chapter 4. 
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Figure 8.9: Kaplan-Meier nonparametric survival plot - freedom from death by total white cell count 
category with 95% confidence intervals.  
 
After the first 500 days the Low TWCC Category (green, Figure 8.9) separates and remains 
above the other two categories for the remainder of the study. The Mid TWCC Category 
(orange, Figure 8.9) and High TWCC Category (red, Figure 8.9) have multiple visual points of 
intersection between 2000 and 3000 days (Figure 8.9). The terminal drop off in Figure 8.9 of 
the Low TWCC Category is due to the last remaining patient dying at that time with all the 
other groups having the final patients discharged from follow up. 
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The Mid TWCC Category mean (2511 ±131 days = 6.9 years) and median (2864 days = 7.8 
years) survival and the High TWCC mean (2550 ±153 days = 7.0 years) and median (2879 
days = 7.8 years) survival are very similar with a similar number of deaths (39, 38 respectively, 
~29% of the patients in each category) in both these groups. The Low TWCC category has the 
greatest mean (2984 ± 171 days = 8.2 years) and median (3105 days = 8.5 years) freedom from 
death and the least deaths (23, 17.6% of the patients in this category). 
 
Table 8.18: Kaplan-Meier freedom from death rate by total white cell count category with 95% confidence 
intervals displayed by days follow up. 
Death 0 days 1000 days 2000 days 3000 days 3500 days 
Low 
TWCC  
Category 
At Risk 131 70 35 7 3 
Events in previous 
interval 
0 9 4 8 1 
Freedom from 
death (95% CI) 
1.00 0.91 
(0.73-0.82) 
0.85 
(0.78-0.99) 
0.59 
(0.44-0.78) 
0.47 
(0.29-0.79) 
Mid 
TWCC 
Category 
At Risk 131 70 35 7 3 
Events in previous 
interval 
0 15 13 10 1 
Freedom from 
death (95% CI) 
1.00 0.86 
(0.79-0.93) 
0.66 
(0.56-0.78) 
0.36 
(0.23-0.56) 
0.31 
(0.19-0.52) 
High 
TWCC 
Category 
At Risk 136 75 36 9 2 
Events in previous 
interval 
0 20 10 7 1 
Freedom from 
death (95% CI) 
1.00 0.80 
(0.72-0.88) 
0.66 
(0.59-0.77) 
0.47 
(0.34-0.64) 
0.40 
(0.26-0.62) 
CI = Confidence Interval  TWCC = Total white cell count 
 
The freedom from death rate is highest in the Low TWCC Category at each of the time points 
reported (Table 8.18). The number of deaths in the Mid TWCC and High TWCC Categories is 
higher at both 1000 and 2000 days resulting in lower freedom from death rates in these groups 
at these time points. The High TWCC Category has a greater drop in freedom from death rate 
prior to 2000 days but is overtaken by the Mid TWCC Category during the latter half of the 
study indicating crossing of the survival curves after 2000 days. As these groups appear to be 
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behaving differently they are analysed with Cox proportional hazards model to quantify 
differences and allow adjustment for confounding factors with results presented in Table 8.19. 
 
 Cox proportional hazards 
Table 8.19: Cox proportional hazards analysis - death and total white cell count category. 
Outcome - Death 
Cell Type  p 
Value 
HR (95% CI) Other Significant 
Variables 
Cox 
zph 
Global 
zph 
TWCC a priori mid 0.07 1.61 (0.96-2.72) NA 0.79 0.33 
high 0.05 1.68 (0.99-2.84) 0.34 
TWCC adjusted 
TRF1 
mid 0.13 1.50 (0.89-2.55) Age (p<0.01) 0.88 0.18 
 high 0.04 1.75 (1.02-3.02) 0.48 
TWCC adjusted 
CRF2 
mid <0.01 2.38 (1.35-4.21) Age (p<0.01),  
IHD (p=0.02),  
Tissue Loss (p=0.02) 
0.66 0.23 
high <0.01 2.09 (1.19-3.67) 0.80 
WCC adjusted CRF2 
strata (IHD & 
Disease severity) 
mid 0.02 2.00 (1.12-3.55) Age (p<0.01) 0.85 0.68 
high 0.02 1.95 (1.11-3.41) 0.75 
CI = Confidence Interval  TWCC = Total white cell count  IHD = Ischaemic heart disease 
1 = adjusted for entry age, gender, hypertension, ischaemic heart disease, stroke, transient ischaemic attack, 
smoking and diabetes mellitus  
2 = adjusted for entry age, gender hypertension, ischaemic heart disease, stroke, transient ischaemic attack, 
smoking, diabetes mellitus, disease severity, aspirin and statin 
strata = statistical stratification for (variable/s in brackets following) 
Significant p values at the 0.05 level and corresponding hazard ratio are presented in bold 
 
The High TWCC Category was significantly different to the Low TWCC Category freedom 
from death rates in all models. Without adjustment for confounding variables (a priori) the 
High TWCC Category was significant at the p<0.05 level (Table 8.19). This significant 
association remains when the model is adjusted for the confounding variables of the traditional 
risk factors (adjusted TRF1, Table 8.19): hypertension, ischaemic heart disease, stroke, 
transient ischaemic attack, smoking and diabetes mellitus (p=0.04, Table 8.19). The 
relationship remains consistently significant with adjustment for the comprehensive risk 
factors (adjusted CRF2: previous traditional risk factors and disease severity and aspirin and 
statin use) with a significant difference demonstrated in the freedom from death for both the 
Mid TWCC and High TWCC Category (p<0.01, Table 8.19). In this comprehensive risk factor 
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(CRF2) adjusted model for High TWCC Category, the risk factors of ischaemic heart disease 
and disease severity of tissue loss were also significantly associated with freedom from death. 
The risk factors of ischaemic heart disease and disease severity were then stratified in the Cox 
model to determine the individual contribution of High TWCC Category which was again 
significantly associated with freedom from death (p=0.02, Table 8.19) with the hazard ratio 
1.95 (95% CI 1.11-3.41) meaning that the patients in the High TWCC Category were almost 
twice as likely to die during the follow up period than the patients in the Low TWCC Category. 
 
When the Low TWCC Category and Mid TWCC Category are compared a priori (without any 
adjustment for confounding variables) a non-significant trend was found with p = 0.07, hazard 
ratio 1.61 (95% CI 0.96-2.72, Table 8.19) with the hazard ratio confidence interval including 
the value of 1 (no significant difference). When the traditional risk factor confounding variables 
(adjusted TRF1, Table 8.19) of hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus are adjusted for, again the difference between 
these groups was not statistically significant (p=0.13, Table 8.19). However, when Mid TWCC 
Category was adjusted for comprehensive risk factors (adjusted CRF2, Table 8.19) of 
traditional risk factors plus disease severity and aspirin and statin use, a significant difference 
is demonstrated in the freedom from death of the two groups (p=0.01, Table 8.19) with the 
hazard ratio of Mid TWCC Category 2.38 (95%CI 1.35-4.21, Table 8.19). In this second 
comprehensive risk factor (CRF2) adjusted model for Mid TWCC Category the risk factors of 
ischaemic heart disease and disease severity of tissue loss were also significantly associated 
with freedom from death. The risk factors of ischaemic heart disease and disease severity were 
then stratified in the Cox model to determine the individual contribution of Mid TWCC 
Category which was again significantly associated with freedom from death (p=0.02) with a 
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hazard ratio of 2.00 (95% CI 1.12-3.55, Table 8.19) indicating that the patients in the Mid 
TWCC Category were twice as likely to die during the follow up period of this study than their 
counterparts in the Low TWCC Category.  
 
The probability of a violation of the assumptions of the Cox proportional hazards model was 
checked with the Cox.zph function for each model. The Cox.zph function tests the 
proportionality of each predictor in the model by creating interactions with time and comparing 
the residuals. There was a low probability of breach of the assumptions of the Cox model for 
TWCC category and death models with Cox.zph testing results p = 0.23 – 0.88 (Table 8.19). 
With a low probability of assumption breach the Cox proportional hazards models are 
appropriate to use for this data set and generate valid results.  
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8.6.2. Neutrophil count associated with death. 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from death plot of the cohort is presented in Figure 8.20 by Neutrophil 
Category.  
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Figure 8.20: Kaplan-Meier nonparametric survival plot - freedom from death by neutrophil count category 
with 95% confidence intervals. 
 
The High Neutrophil Category (red, Figure 8.20) diverges from the other two neutrophil 
categories with a consistently lower freedom from death rate. The Mid Neutrophil Category 
(orange, Figure 8.20) is mostly between the other two groups but has at least four points of 
intersection with the Low Neutrophil Category (green, Figure 8.20). The terminal drop in 
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freedom from death in the Low Neutrophil category in Figure 8.20 is due to the last patient in 
this category dying at this time. The last remaining patients in both other neutrophil categories 
were discharged from follow up without dying. 
 
The Low Neutrophil Category has the longest duration mean (3041 ±162 days = 8.3 years) and 
median (3592 days = 9.8 years) freedom from death with the least events (22, 16.2% of the 
patients in the Low Neutrophil Category). High Neutrophil Category has the shortest mean 
(2295 ±150 days = 6.3 years) and median (2511 days = 6.9 years) freedom from death and the 
greatest number of deaths per group (46, 35.4% of the patients in the High Neutrophil 
category). The Mid Neutrophil Category has a mean freedom from death (2717 ±128days = 
7.4 years), median freedom from death (2931 days = 8.0 years) and total number of deaths (32, 
24.2% of the patients in the Mid Neutrophil Category) approximately in the middle of the other 
two groups. 
Table 8.20: Kaplan-Meier freedom from death rate by neutrophil count category with 95% confidence 
intervals displayed by days follow up. 
Death  0 days 1000 days 2000 days 3000 days 3500 days 
Low 
Neutrophil 
Category 
At Risk 136 72 34 7 3 
Events in 
previous 
interval 
0 7 6 8 0 
Freedom from 
death (95% CI) 
1.00 0.93 
(0.88-0.98) 
0.83 
(0.74-0.93) 
0.54 
(0.38-0.76) 
0.54 
(0.38-0.76) 
Mid 
Neutrophil 
Category 
At Risk 132 79 41 8 2 
Events in 
previous 
interval 
0 11 9 11 1 
Freedom from 
death (95% CI) 
1.00 0.89 
(0.83-0.96) 
0.76 
(0.67-0.86) 
0.47 
(0.34-0.65) 
0.41 
(0.27-0.62) 
High 
Neutrophil 
Category 
At Risk 130 64 33 9 2 
Events in 
previous 
interval 
0 26 12 6 2 
Freedom from 
death (95% CI) 
1.00 0.74 
(0.66-0.83) 
0.57 
(0.47-0.69) 
0.39 
(0.26-0.57) 
0.28 
(0.15-0.50) 
CI = Confidence Interval 
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The striking outcome of Table 8.20 is the lower freedom from death rate in the High Neutrophil 
Category and Mid Neutrophil Category at all reported time points. The freedom from death 
plot in Figure 8.20 gives additional information with the Mid and Low Neutrophil category 
sharing similar rates of death prior to 1000 days and between 2000 and 3000 days despite a 
greater total number of deaths in each period in the Mid Neutrophil Group. The difference in 
survival curves was then analysed with Cox proportional hazards model to compare Neutrophil 
Categories for the outcome of freedom from death and allow adjustment for confounding 
factors (Table 8.21). 
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 Cox proportional hazards 
Table 8.21: Cox proportional hazards analysis - death and neutrophil category 
Outcome - Death 
Cell Type  p 
Value 
HR (95% CI) Other Significant 
Variables 
Cox 
zph 
Global zph 
Neutrophil a priori mid 0.31 1.33 (0.76-2.30) n/a 0.95 0.20 
high <0.01 2.28 (1.36-3.83) 0.18 
Neutrophil adjusted 
TRF1 
mid 0.38 1.29 (0.73-2.26) Age (p<0.01) 0.91 0.14 
high <0.01 2.15 (1.26-3.66) 0.19 
Neutrophil adjusted 
CRF2 
mid 0.14 1.55 (0.87-2.76) Age (p<0.01) 0.87 0.15 
 high <0.01 2.49 (1.43-4.32) 0.41 
CI = Confidence Interval  n/a = not applicable 
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
Significant p values at the 0.05 level and corresponding hazard ratio are presented in bold 
 
The High Neutrophil Category group had significantly different freedom from death function 
to the Low Neutrophil category in a priori and both adjusted models (adjusted for traditional 
risk factors TRF1 and adjusted for comprehensive risk factors CRF2, Table 8.21). The only 
other variable significantly associated with freedom from death was age which was 
significantly associated in adjustment for traditional risk factors with, and comprehensive risk 
factors (p<0.01, Table 8.21). The hazard ratio of 2.49 (1.43-4.32, Table 8.21) for the 
comprehensive risk factor adjusted Cox model means that the High TWCC Category patients 
were two and a half times more likely to die over the course of this study than the patients in 
the Low TWCC Category. 
 
The Mid Neutrophil Category was not significantly different to the Low Neutrophil category 
for the freedom from death outcome in any of the Cox models (Table 8.21) despite apparent 
differences at the reported time points in Table 8.20. The hazard ratios for the Mid Neutrophil 
Category all include 1 confirming the lack of significance compared to the Low Neutrophil 
Category. The crossing of the Mid and Low Neutrophil Category freedom from death curves 
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at four points in Figure 8.20 (less than 1000 days and between 2000 and 3000 days) is one 
explanation for this finding. 
 
There was a low probability of breach of the assumptions of the Cox model for Neutrophil 
Category and death models with Cox.zph testing results p = 0.14 – 0.95 (Table 8.21). With a 
low probability of assumption breach the Cox proportional hazards models are appropriate to 
use for this data set and generate valid results.  
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8.6.3. Lymphocyte count associated with death. 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from death plot of the cohort is presented in Figure 8.21 by Lymphocyte 
Category. The terminal drop off in Low Lymphocyte Category (green, Figure 8.21) is due to 
the last remaining patient dying at that time with all the other groups having the final patients 
discharged. 
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Figure 8.21: Kaplan-Meier nonparametric survival plot - freedom from death by lymphocyte count 
category with 95% confidence intervals. 
 
The Low Lymphocyte Category plot (green, Figure 8.21) displays an overall lower freedom 
from death rate than the other two Lymphocyte Categories but does cross over with the Mid 
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Lymphocyte Category (orange, Figure 8.21) prior to 3000 days. The High Lymphocyte 
Category (red, Figure 8.21) has the greatest freedom from death rate after 2000 days but prior 
to 1500 days is below the Mid Lymphocyte Category. The Mid Lymphocyte Category plot 
(orange, Figure 8.21) displays complex interaction with the other two groups, commencing the 
study with the greatest freedom from death rate prior to 1500 days, before trending down at a 
faster rate than the other two categories to fall below the Low Lymphocyte Category plot at 
3000 days. 
 
The Low Lymphocyte Category has the most deaths (40, 33.9% of the Low Lymphocyte 
Category patients) and the shortest mean (2240 ±181 days = 6.1 years) and median (2589 days 
= 7.1 years) time to death followed by the Mid Lymphocyte Category and the High 
Lymphocyte Category respectively in all measures of central tendency. The High Lymphocyte 
Category has the least deaths (27, 20.3% of the High Lymphocyte Category patients) and the 
longest mean freedom from death (2980 ±136 days = 8.2 years) and a median was not 
applicable. The Mid Lymphocyte Category was in-between the 2 other groups with 33 events 
in 147 patients and a mean freedom from death of 2594 ±125 days (7.1 years and a median 
freedom from death of 2564 days (7.0 years). 
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Table 8.22: Kaplan-Meier freedom from death rate by lymphocyte count category with 95% confidence 
intervals displayed by days follow up. 
Death  0 days 1000 days 2000 days 3000 days 3500 days 
Low 
Lymphocyte 
Category 
At Risk 118 53 27 5 1 
Events in 
previous interval 
0 25 7 5 2 
Freedom from 
death (95% CI) 
1.00 0.73 
(0.64-0.83) 
0.61 
(0.51-0.73) 
0.44 
(0.31-0.63) 
0.17 
(0.04-0.77) 
Mid 
Lymphocyte 
Category 
At Risk 147 83 34 6 3 
Events in 
previous interval 
0 6 14 12 1 
Freedom from 
death (95% CI) 
1.00 0.94 
(0.90-0.99) 
0.73 
(0.63-0.84) 
0.33 
(0.19-0.56) 
0.27 
(0.14-0.52) 
High 
Lymphocyte 
Category 
At Risk 133 79 47 13 3 
Events in 
previous interval 
0 13 6 8 0 
Freedom from 
death (95% CI) 
1.00 0.87 
(0.81-0.94) 
0.79 
(0.70-0.88) 
0.59 
(0.46-0.75) 
0.59 
(0.46-0.75) 
CI = Confidence Interval 
 
The Low Lymphocyte Category has the greatest number of deaths in the first 1000 days (25, 
Table 8.22) and has a lower freedom from death rate at each reported time point than the High 
Lymphocyte Category. The Mid Lymphocyte Category has the largest number of deaths in the 
1000 to 2000 day period and has a freedom from death rate lower than the High Lymphocyte 
Category from this point until the end of the study. The Low and Middle Lymphocyte 
Categories do cross over with their respective freedom from death functions at approximately 
3000 days which can be seen in both Figure 8.21 and Table 8.22. The groups were compared 
with Cox proportional hazard model to allow adjustment for confounding factors with results 
and are presented in Table 8.23.  
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 Cox proportional hazards 
Table 8.23: Cox proportional hazards analysis - death and lymphocyte category. 
Outcome - Death 
Cell Type  p Value 95% CI) Other Significant 
Variables 
Cox 
zph 
Global 
zph 
Lymphocyte  
a priori 
mid 0.04 0.61 (0.38-0.99) n/a <0.01 <0.01 
high <0.01 0.43 (0.26-0.70) 0.57 
Lymphocyte 
adjusted TRF1 
mid 0.06 0.64 (0.40-1.03) Age (p<0.01) 0.01 <0.01 
high <0.01 0.49 (0.29-0.81) 0.69 
Lymphocyte 
adjusted CRF2 
mid 0.22 0.73 (0.44-1.20) Age (p<0.01),  
Ex-smoker (p=0.04), 
IHD (p=0.04),  
Tissue loss (p=0.07), 
Smoker (p=0.08), 
HTN, (p=0.09),  
0.01 0.02 
high 0.02 0.54 (0.31-0.91) 0.60 
Lymphocyte fully 
adjusted CRF2 
Strata (smoking, 
HTN, IHD, Disease 
severity) 
mid 0.21 0.68 (0.37-1.24) Age (p<0.01) 0.08 0.49 
high 0.10 0.59 (0.32-1.11) 0.44 
CI = Confidence Interval   HTN = Hypertension  IHD = Ischaemic heart disease 
n/a = not applicable   Smoker = Current smoker 
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
strata = statistical stratification for (variable/s in brackets following) 
Significant p values at the 0.05 level and corresponding hazard ratio are presented in bold 
 
Low Lymphocyte Category was significantly different to both Mid Lymphocyte Category and 
High Lymphocyte category when analysed with the Cox proportional hazards model a priori 
(Table 8.23). The Mid Lymphocyte Category was significantly inversely associated in the a 
priori Cox model with p=0.04 and hazard ratio of 0.61 (0.38-0.99, Table 8.23). With the hazard 
ratio being less than one, the Mid Lymphocyte Category is at lower risk of death than the Low 
Lymphocyte Category. The High Lymphocyte Category was also significantly different to the 
Low Lymphocyte Category a priori at the p<0.01 level and hazard ratio 0.43 (0.26-0.70, Table 
8.23). The hazard ratio for High Lymphocyte Category is also less than one indicating a lower 
risk of death or protective function in this category when compared to the Low Lymphocyte 
Category. 
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When adjusted for the traditional risk factors of hypertension, ischaemic heart disease, stroke, 
transient ischaemic attack, smoking and diabetes mellitus (adjusted TRF1, Table 8.23) only the 
High Lymphocyte Category is significantly different to Low Lymphocyte Category (p<0.01, 
Table 8.23). 
 
The Cox model that adjusts for comprehensive risk factors: disease severity and aspirin and 
statin use as well as traditional risk factors (adjusted CRF2), revealed multiple factors to be 
significant including High Lymphocyte Category. The other significant risk factors in the 
adjusted CRF2 model were age, previous smoking, disease severity – tissue loss, current 
smoking and hypertension. The Cox model adjusted CRF2 was then stratified for these other 
significant categorical variables and neither Mid or High Lymphocyte Category was 
significantly associated with death more than the Low Lymphocyte Category at the p<0.05 
level, however the High Lymphocyte Category did trend toward an association (p=0.10, Table 
8.23). 
 
Cox.zph values for the Mid Lymphocyte Category are significant in all non-stratified models 
for death (p≤0.01, Table 8.23) raising the possibility of an assumption violation of these Cox 
proportional hazards models. The global zph score is also significant in these models 
confirming that the overall assumptions of the model are breached by the non-proportionality 
of the Mid Lymphocyte Category. A visual representation for this non-proportionality was seen 
in the Kaplan-Meir freedom from death plot (Figure 8.21) with the Mid Lymphocyte Category 
commencing the study above the other lymphocyte categories and finishing below. This raises 
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suspicion that the Cox proportional hazards model is not appropriate to use for this data set and 
may generate invalid results.   
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8.6.4. Monocyte count associated with death. 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from death plot of the cohort is presented in Figure 8.22 by Monocyte 
Category. 
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Figure 8.22: Kaplan-Meier nonparametric survival plot - freedom from death by monocyte count category 
with 95% confidence intervals. 
 
The High Monocyte Category (red, Figure 8.22) displays a lower freedom from death plot than 
the other two categories with the exception of an intersection with the Mid Monocyte Category 
(orange, Figure 8.22) prior to 3000 days. The terminal drop in the Low Monocyte Category 
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(Figure 8.22) is due to the last remaining patient in that category dying at that time, in the other 
groups the last remaining patients are discharged from follow up.  
 
The High Monocyte Category has the lowest mean (2497 ± 164 days = 6.8 years) and median 
(2526 days = 6.9 years) freedom from death. The Low Monocyte Category has the highest 
mean (2922 ±160 days = 8.0 years) and median (2985 days = 8.2 years) freedom from death 
and the smallest number of deaths (28, 20.9% of the Low Monocyte Category patients). The 
Mid Monocyte Category sustained the highest number of deaths (38, 26.2% of the Mid 
Monocyte Category patients) although this category had the largest number of patients (145) 
giving a mean 2653 ±133 days (7.3 years) and a median of 2879 days (7.9 years) 
 
Table 8.24: Kaplan-Meier freedom from death rate monocyte count category with 95% confidence 
intervals displayed by days follow up. 
Death  0 days 1000 days 2000 days 3000 days 3500 days 
Low 
Monocyte 
Category 
At Risk 134 78 37 5 3 
Events in 
previous interval 
0 10 9 8 0 
Freedom from 
death (95% CI) 
1.00 0.91 
(0.86-0.96) 
0.78 
(0.69-0.88) 
0.48 
(0.32-0.73) 
0.48 
(0.32-0.73) 
Mid 
Monocyte  
Category 
At Risk 145 80 39 13 2 
Events in 
previous interval 
0 14 11 10 3 
Freedom from 
death (95% CI) 
1.00 0.87 
(0.80-0.94) 
0.72 
(0.62-0.82) 
0.46 
(0.33-0.62) 
0.33 
(0.20-0.54) 
High 
Monocyte 
Category 
At Risk 119 57 32 6 2 
Events in 
previous interval 
0 20 7 7 0 
Freedom from 
death (95% CI) 
1.00 0.78 
(0.70-0.87) 
0.65 
(0.55-0.78) 
0.43 
(0.29-0.63) 
0.43 
(0.29-0.63) 
CI = Confidence Interval 
 
The High Monocyte Category has the lowest freedom from death at each time point reported 
(Table 8.24) although there is some interaction of the freedom from death curves prior to the 
3000 day time point which is best seen in Figure 8.22. The differences between the monocyte 
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category associations with death were analysed with Cox proportional hazards model to allow 
for adjustment of confounding factors and are presented in Table 8.25. 
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 Cox proportional hazards 
Table 8.25: Cox proportional hazards analysis - death and monocyte category. 
Outcome - Death 
Cell Type  p 
Value 
HR (95% CI) Other Significant 
Variables 
Cox 
zph 
Global 
zph 
Monocyte a priori mid 0.35 1.27 (0.77-2.08) n/a 0.79 0.10 
high 0.06 1.64 (0.99-2.71) 0.12 
Monocyte adjusted 
TRF1 
mid 0.54 1.17 (0.71-1.94) Age (p<0.01) 0.76 0.07 
 high 0.06 1.66 (0.98-2.79) 0.13 
Monocyte adjusted 
CRF2 
mid 0.44 1.22 (0.73-2.03) Age (p<0.01) 0.60 0.07 
high 0.06 1.69 (0.98-2.84) 0.29 
CI = Confidence Interval    n/a = not applicable   
IHD = Ischaemic heart disease   HTN = Hypertension     
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
strata = statistical stratification for (variable/s in brackets following) 
Significant p values at the 0.05 level and corresponding hazard ratio are presented in bold 
 
High Monocyte Category was not significantly associated with death in either a priori or 
adjusted Cox models as the p values remained slightly above the chosen level of significance 
of p<0.05 (p=0.06, Table 8.25). The only variable significantly associated with death on 
adjusting for traditional risk factors (adjusted TRF1) and adjusting for comprehensive risk 
factors (adjusted CRF2) was age with a p value <0.01 (Table 8.25). Mid Monocyte Category 
was not significantly associated with the outcome of death in any of the Cox proportional 
hazards models (Table 8.25). 
 
There was a low probability of breach of the assumptions of the Cox model for Monocyte 
category and death models with Cox.zph testing results p = 0.07 – 0.79 (Table 8.25). With a 
low probability of assumption breach the Cox proportional hazards models are appropriate to 
use for this data set and generate valid results.  
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8.6.5. Haemoglobin associated with death. 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from death plot of the cohort is presented in Figure 8.23 by 
Haemoglobin Category.  
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Figure 8.23: Kaplan-Meier nonparametric survival plot - freedom from death by haemoglobin category 
with 95% confidence intervals. 
 
The Low Haemoglobin Category (green, Figure 8.23) displays a lower freedom from death rate 
to the other two categories prior to 3000 days. The Low Haemoglobin Category (green, Figure 
8.23) has a terminal drop to 0 when the last remaining patient in that category dies, with the 
other groups having the final patients discharged from follow up without dying. There are 
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multiple intersections between the Mid Haemoglobin Category plot (orange, Figure 8.23) and 
the High Haemoglobin Category plot (red, Figure 8.23). 
 
The Low Haemoglobin Category has the greatest number of deaths over the course of the study 
(39, 28.9% of the Low Haemoglobin Category patients) and has the lowest mean (2594 ± 164 
days = 7.1 years) and median (2589 days = 7.1 years) freedom from death. The least deaths 
occurred in the High Haemoglobin group (30, 23.6% of the High Haemoglobin Category 
patients) which also had the greatest median freedom from death, taking 3079 days (8.4 years) 
to have a freedom from death rate less than 0.5. The Mid Haemoglobin Category has the 
greatest calculated mean freedom from death using the area under the curve calculation (2758 
± 136 days = 7.6 years) although with a median less than the High Haemoglobin Category 
(2985 days, 8.2years). 
 
Table 8.26 Kaplan-Meier freedom from death rate by haemoglobin category with 95% confidence intervals 
displayed by days follow up. 
Death  0 days 1000 days 2000 days 3000 days 3500 days 
Low 
Haemoglobi
n 
Category 
At Risk 135 70 32 5 4 
Events in 
previous 
interval 
0 20 12 6 0 
Freedom from 
death (95% CI) 
1.00 0.81 
(0.74-0.89) 
0.63  
(0.53-0.75) 
0.43 
(0.31-0.62) 
0.43 
(0.31-0.62) 
Mid  
Haemoglobin 
Category 
At Risk 136 72 39 13 3 
Events in 
previous 
interval 
0 13 6 10 2 
Freedom from 
death (95% CI) 
1.00 0.87 
(0.80-0.94) 
0.77 
(0.69-0.87) 
0.47 
(0.33-0.66) 
0.38 
(0.25-0.60) 
High 
Haemoglobi
n 
Category 
At Risk 127 73 37 6 - 
Events in 
previous 
interval 
0 11 9 9 - 
Freedom from 
death (95% CI) 
1.00 0.89 
(0.83-0.95) 
0.75 
(0.66-0.86) 
0.52 
(0.37-0.69) 
- 
CI = Confidence Interval   Hb= Haemoglobin 
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The greatest number of deaths was seen in the Low Haemoglobin Category prior to 2000 days 
with this group having the lowest freedom from death until the 3000 day time point (Table 
8.26). Both the Mid Haemoglobin Category and High Haemoglobin Category intersect the Low 
Haemoglobin category freedom from death rate between 3000 and 3500 days (Table 8.26 and 
Figure 8.23). There are multiple points of crossing in the freedom from death function for Mid 
Haemoglobin Category and High Haemoglobin Category and these are best seen in Figure 
8.23. The differences between the haemoglobin category associations with death were analysed 
with Cox proportional hazards model to allow for adjustment of confounding factors and are 
presented in Table 8.27. 
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 Cox proportional hazards 
Table 8.27: Cox proportional hazards analysis - death and haemoglobin category. 
Outcome - Death 
Haemoglobin Level  p 
Value 
HR (95% CI) Other Significant 
Variables 
Cox 
zph 
Global 
zph 
Haemoglobin  
a priori 
mid 0.13 0.69 (0.43-1.11) n/a 0.22 0.36 
high 0.15 0.71 (0.44-1.14) 0.23 
Haemoglobin 
adjusted TRF1 
mid 0.44 0.82 (0.49-1.36) Age (p<0.01) 0.56 0.19 
high 0.93 0.98 (0.56-1.69) 0.89 
Haemoglobin 
adjusted CRF2 
mid 0.85 1.08 (0.61-1.84)  0.95 0.13 
high 0.50 1.22 (0.69-2.19) 0.82 
CI = Confidence Interval  n/a = not applicable 
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
 
Cox proportional hazard analysis for the endpoint of freedom from death are seen in Table 8.27 
comparing both Mid Haemoglobin Category and High Haemoglobin Category to Low 
Haemoglobin Category. No significant difference was seen between the Haemoglobin 
categories in either a priori or adjusted models using traditional risk factors of hypertension, 
ischaemic heart disease, stroke, transient ischaemic attack, smoking and diabetes mellitus 
(adjusted TRF1, Table 8.27) or comprehensive risk factors consisting of traditional risk factors, 
disease severity and aspirin and statin use (adjusted CRF2, Table 8.27). 
 
There was a low probability of breach of the assumptions of the Cox model for Haemoglobin 
category and death models with Cox.zph testing results p = 0.13 – 0.95 (Table 8.27). With a 
low probability of assumption breach the Cox proportional hazards models are appropriate to 
use for this data set and generate valid results. 
  
 278 
Chapter 8: Results section 5 – Total and differential circulating cell counts associated with death in peripheral arterial occlusive disease 
8.6.6. Neutrophil-Lymphocyte Ratio associated with death. 
 Kaplan-Meier survival analysis 
Kaplan-Meier freedom from death plot of the cohort is presented in Figure 8.24 by Neutrophil-
Lymphocyte Ratio (NLR) Category.  
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Figure 8.24: Kaplan-Meier nonparametric survival plot - freedom from death by neutrophil-lymphocyte 
ratio category with 95% confidence intervals. 
 
The High NLR Category plot (red, Figure 8.24) displays a lower freedom from death rate than 
the other two categories with the exception of an intersection with the Mid NLR Category plot 
(orange, Figure 8.24) prior to 3000 days. The terminal drop to 0 of the High NLR Category 
plot is due to the last remaining patient in the High NLR Category dying at that time, with the 
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other groups having the final patients discharged from follow up. The Low NLR Category plot 
(green, Figure 8.24) and Mid NLR Category plot (orange, Figure 8.24) are closely related until 
they diverge after 2000 days with the Mid NLR Category plot dropping to a lower freedom 
from death. 
 
The greatest number of deaths (47, 35.3% of the High NLR Category patients) was seen in the 
High NLR Category also having the lowest calculated mean freedom from death using the area 
under the curve method (2141 ±149 days = 5.9 years). The least number of deaths (22, 16.5% 
of the Low NLR Category patients) was seen in the Low NLR Category which also had the 
greatest mean freedom from death (3072 ±136 days = 8.4 years). The Mid NLR Category 
sustained 31 deaths from a population of 132 patients with mean freedom from death 2679 
±128 days (7.3 years) and a median of 2711 days (7.2 years)  
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Table 8.28: Kaplan-Meier freedom from death rate by neutrophil-lymphocyte ratio category with 95% 
confidence intervals displayed by days follow up. 
Death  0 days 1000 days 2000 days 3000 days 3500 days 
Low 
NLR 
Category 
At Risk 133 78 40 13 4 
Events in 
previous interval 
0 8 9 5 0 
Freedom from 
death (95% CI) 
1.00 0.92 
(0.86-0.97) 
0.78 
(0.69-0.88) 
0.63 
(0.51-0.80) 
0.63 
(0.51-0.80) 
Mid  
NLR 
Category 
At Risk 132 74 40 6 2 
Events in 
previous interval 
0 10 7 14 0 
Freedom from 
death (95% CI) 
1.00 0.90 
(0.84-0.96) 
0.79 
(0.70-0.89) 
0.34 
(0.20-0.58) 
0.34 
(0.20-0.58) 
High 
NLR 
Category 
At Risk 127 63 28 5 1 
Events in 
previous interval 
0 26 11 6 3 
Freedom from 
death (95% CI) 
1.00 0.75 
(0.67-0.84) 
0.57 
(0.47-0.70) 
0.40 
(0.28-0.57) 
0.10 
(0.02-0.57) 
CI = Confidence Interval   NLR = Neutrophil-lymphocyte ratio 
 
The Low NLR Category commences the study with 133 patients, of whom eight are deceased 
prior to 1000 days with 47 patients discharged from follow up during the same period (Table 
8.28). From 1000 to 2000 days nine further patients die and 29 are discharged from follow up. 
Between 2000 and 3000 days five patients from the Low NLR Category die and 22 are 
discharged from follow up. There are no further deaths in this group between 3000 and 3500 
days with 9 patients discharged from follow up in the same period. Of the four patients 
remaining at 3500 days three are discharged from follow up without event but the last patient 
remaining in the study in the Low NLR Category dies at 3952 days which is why the freedom 
from death curve (Figure 8.24) drops to 0 at this point. The Low NLR Category is not distinct 
from the Mid NLR Category freedom from death function with crossing of their curves at 
approximately the 2000 day time point. Whether these freedom from death functions were 
significantly different was tested using the Cox proportional hazards model to allow adjustment 
for confounding factors and is presented in Table 8.29. 
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 Cox proportional hazards 
Table 8.29: Cox proportional hazards analysis - death and neutrophil/lymphocyte ratio category 
Outcome - Death 
Cell Type  p Value 95% CI) Other Significant 
Variables 
Cox 
zph 
Global 
zph 
NLR a priori mid 0.12 1.55 (0.90-2.68) n/a 0.15 0.17 
high <0.01 2.93 (1.76-4.89) 0.96 
NLR adjusted TRF1 mid 0.33 1.33 (0.75-2.34) Age (p<0.01),  
IHD (p=0.42) 
0.40 0.13 
 high <0.01 2.24 (1.31-3.81) 0.80 
NLR adjusted TRF1 
strata (IHD) 
mid 0.26 1.39 (0.78-2.46) Age (p<0.01) 0.28 0.12  
high <0.01 2.25 (1.32-3.84) 0.78 
NLR adjusted CRF2 mid 0.18 1.49 (0.83-2.69) Age (p<0.01),  
IHD (p=0.02), 
Tissue loss (p=0.04),  
Ex-smoker (p=0.05),  
Smoker (p=0.05),  
0.36 0.07 
high <0.01 2.13 (1.23-3.68) 0.89 
NLR adjusted CRF2 
strata (Smoking, 
IHD & Disease 
severity) 
mid 0.36 1.34 (0.72-2.48) Age (p<0.01) 0.35 0.51 
high 0.04 1.84 (1.02-3.31) 0.94 
CI = Confidence Interval  NLR = Neutrophil-lymphocyte ratio n/a = not applicable 
IHD = Ischaemic heart disease Smoker = Current smoker 
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
strata = statistical stratification for (variable/s in brackets following) 
Significant p values at the 0.05 level and corresponding hazard ratio are presented in bold 
 
The High NLR Category was significantly different to Low NLR Category in all Cox 
proportional hazards models. In the a priori model the High NLR Category had the greatest 
hazard ratio of 2.93 (95% CI 1.76-4.89, Table 8.29). The High NLR Category was significantly 
different in all adjusted models with adjustment for traditional risk factors (adjusted TRF1: 
hypertension, ischaemic heart disease, stroke, transient ischaemic attack, smoking and diabetes 
mellitus) and comprehensive risk factors (adjusted CRF2: traditional risk factors, disease 
severity and aspirin and statin use, Table 8.29). When the initial adjusted model revealed other 
variables to be significantly associated with death, they were stratified in the model to account 
for their contribution to the outcome of death. With this stratification in the comprehensive risk 
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factor adjusted model the High NLR category was still significantly associated with death 
(p=0.04, Hazard ratio 1.84, Table 8.29). 
 
There was a low probability of breach of the assumptions of the Cox model for 
Neutrophil/Lymphocyte Ratio category and death models with Cox.zph testing results p = 0.07 
– 0.94 (Table 8.29). With a low probability of assumption breach the Cox proportional hazards 
models are appropriate to use for this data set and generate valid results. 
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8.6.7. Summary of circulating cell types Cox proportional hazards analysis for death 
All previously displayed single circulating cell type Cox proportional hazard models for the 
outcome of death are summarised in Table 8.30. 
 
Table 8.30: Single cell type Cox proportional hazards analysis summary - death. 
Death 
Cell Type a priori Adjusted 
TRF 
Adjusted 
TRF strata 
Adjusted 
CRF 
Adjusted 
CRF strata 
TWCC Category mid # NS n/a ** * high * * n/a ** * 
Neutrophil Category mid NS NS n/a NS n/a high ** ** n/a ** n/a 
Lymphocyte 
Category 
mid * # n/a NS NS 
high ** ** n/a * # 
Monocyte Category mid NS NS n/a NS n/a high # # n/a # n/a 
Haemoglobin 
Category 
mid NS NS n/a NS n/a 
high NS NS n/a NS n/a 
NLR Category mid NS NS NS NS NS high ** ** ** ** * 
NS = Not significant    n/a = not applicable 
* = p value = 0.01 to 0.05    # = p value approaching significance = 0.1 to 0.05  
** = p value <0.01    TWCC = Total white cell count 
NLR = Neutrophil-lymphocyte ratio 
strata = statistical stratification for other significant categorical variables   
TRF1 = traditional risk factors: entry age, gender, hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking and diabetes mellitus  
CRF2 = comprehensive risk factors: entry age, gender hypertension, ischaemic heart disease, stroke, transient 
ischaemic attack, smoking, diabetes mellitus, disease severity, aspirin and statin 
 
The level of significance for the circulating cell type in the various Cox proportional hazards 
models (Table 8.30) depends in all cases on the variables adjusted for and the statistical method 
of dealing with statistically significant co-variables. The most consistently significantly 
associated across all models are the High TWCC Category, the High Neutrophil Category and 
the High NLR Category which are significantly associated with the outcome of death in all 
models. The High Lymphocyte Category is significantly associated with death in all but the 
stratified comprehensive risk factor model in which there was still a trend to significance. The 
Mid TWCC Category was strongly significant (p=0.01, Table 8.30) in the model adjusting for 
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comprehensive risk factors (CRF) but not significant with traditional risk factor (TRF) 
adjustment alone. Adjusting for risk factors had the opposite effect with the Mid Lymphocyte 
Category which was significant in the a priori model but only trended to significance when 
adjusting for traditional risk factors and was not significant when the model was adjusted for 
comprehensive risk factors. The Mid Neutrophil Category, the Mid Monocyte Category and 
the Mid and High Haemoglobin Categories were not significantly associated with death in any 
model. 
 
Table 8.31: Combined cell types Cox proportional hazards analysis - death and all cell types by category. 
Outcome - Death 
Cell Type  p Value HR (95% CI) Cox.zph Global zph 
Neutrophil Category mid 0.20 1.49 (0.81-2.72) 0.85 0.03 
high <0.01 ** 2.36 (0.13-4.24) 0.71 
Lymphocyte Category mid 0.04 * 0.60 (0.37-0.98) <0.01 
high <0.01 ** 0.33 (0.20-0.57) 0.38 
Monocyte Category mid 0.58 1.16 (0.68-1.99) 0.85 
high 0.08 # 1.68 (0.94-3.02) 0.16 
Haemoglobin Category mid 0.24 0.75 (0.46-1.22) 0.48 
high 0.14 0.69 (0.42-1.13) 0.48 
# = p value = 0.1 to 0.05     HR = Hazard Ratio 
* = p value = 0.01 to 0.05 (bold type)   NS = Not significant 
** = p value <0.01(bold type) 
 
A combined cell types Cox proportional hazards model was used to assess all cell subtypes and 
the outcome of death tested a priori and the results are displayed in Table 8.31. The 
significantly associated cell types were High Lymphocyte Category (<0.01, hazard ratio 0.33), 
High Neutrophil Category (<0.01, hazard ratio = 2.36), Mid Lymphocyte Category (<0.01, 
hazard ratio 0.60). The High Monocyte Category trended to significance but did not reach the 
0.05 level (0.08, Hazard ratio 1.68, Table 8.31).  
 
The probability of breach of the assumptions of the Cox model for all circulating cell types and 
major adverse event models was raised with Mid Lymphocyte Category significant at the 0.05 
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level (<0.01, Table 8.31) and the global zph for the combined model significant with  0.03. 
This raises suspicion that the Cox proportional hazards model is not appropriate to use for this 
data set and may generate invalid results. 
 
This model was not adjusted for confounding variables as with previous models of only one 
cell type due to the eight degrees of freedom already required for this model. Population size 
and event incidence do not allow for meaningful adjustment with either traditional risk factors 
(TRF) or comprehensive risk factors (CRF) due to the number of degrees of freedom these 
models would require being beyond the power of this study. It was determined that further 
analysis of cell counts and risk factors was warranted and this is presented below using multi-
model averaging. 
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8.6.8. Multi-model analysis for the outcome of death 
For the outcome of death the traditional risk factors of entry age, gender, diabetes mellitus, 
hypertension, ischaemic heart disease, transient ischaemic attack and stoke as well as disease 
severity at presentation and the medication use of aspirin and statin were included in multi-
model analysis with circulating cell counts Neutrophil Category, Lymphocyte Category, 
Monocyte Category, Haemoglobin Category and calculated Neutrophil/Lymphocyte Ratio 
(NLR) Category. Careful consideration of the evidence to support the variables was undertaken 
with Haemoglobin Category not significantly associated with mortality in any of the a priori 
Cox proportional hazards analysis and High Monocyte Category only trending to significance 
(Table 8.30). Previously published evidence for these associations was assessed49,270-272,322 and 
both of these variables were included in the multi-model analysis because of the precedent 
associations in the scientific literature.132 TWCC Category was not included in the multi-model 
analysis as it is an additive product of the neutrophil, lymphocyte and monocyte subtypes. 
 
The statistical package R354 was used to run all possible models using the explanatory variables 
above for the outcome of Death with the package MuMIn355 (with K=15 parameters which are 
listed above). The models were then reduced to just the models that were not significantly 
different to the “best” single model using the Δi <2 function and are presented as the top model 
set (Table 8.32) with all the information required to interpret the analysis including degrees of 
freedom and log-likelihood (log(𝓛𝓛)) for each model.368 Background information and equations 
are found in Chapter 4: Akaike Information criterion adjusted for sample size AICc (Equation 
10); the Δi for each model (Equation 11); and Akaike weight wi (Equation 13) summarised in 
Table 4.3.  
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Table 8.32: Multi-model analysis: top model set for death (Δi <2) 
Component models:                  df log(𝓛𝓛) AICc  Δi  wi 
Age/ HTN / IHD / Disease Severity / Lymphocyte Category / 
Neutrophil Category / Smoking 
11 -458.53  939.74 0.00 0.10 
Age/ HTN / IHD / Disease Severity / Lymphocyte Category / 
Neutrophil Category 
10 -459.76  940.09 0.35 0.08 
Age/ HTN / Disease Severity / Lymphocyte Category / 
Neutrophil Category / Smoking 
10 -459.87  940.31 0.57 0.07 
Age/ HTN / IHD / Disease Severity / Lymphocyte Category / 
Neutrophil Category / Smoking / Statin    
12 -457.76  940.33 0.59 0.07 
DM/Age/ HTN / IHD / Disease Severity / Lymphocyte Category / 
Neutrophil Category / Smoking    
12 -457.87  940.56 0.82 0.06 
Age/ Gender / HTN / IHD / Disease Severity / Lymphocyte 
Category / Neutrophil Category 
11 -459.14  940.97 1.23 0.05 
Age/ Gender / HTN / IHD / Disease Severity / Lymphocyte 
Category / Neutrophil Category / Smoking   
12 -458.12  941.04 1.30 0.05 
Age/ HTN / Disease Severity / Lymphocyte Category / 
Neutrophil Category 
9 -461.30  941.06 1.32 0.05 
Age/ HTN / IHD / Disease Severity / Lymphocyte Category / 
Neutrophil Category / Statin   
11 -459.21  941.11 1.37 0.05 
Age/ HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / Neutrophil Category 
12 -458.20  941.21 1.47 0.05 
DM/ Age / HTN / IHD / Disease Severity / Lymphocyte Category 
/ Neutrophil Category 
11 -459.32  941.33 1.59 0.04 
Age/ Gender / HTN / Disease Severity / Lymphocyte Category / 
Neutrophil Category / Smoking    
11 -459.33  941.35 1.61 0.04 
Age/Gender/HTN/IHD/Disease Severity / Lymphocyte Category / 
Neutrophil Category / Smoking / Statin  
13 -457.23  941.41 1.67 0.04 
Age/ Gender /HTN / Disease Severity/Lymphocyte Category / 
Neutrophil Category 
10 -460.44  941.44 1.70 0.04 
Age/ HTN / IHD / Disease Severity / Lymphocyte Category / 
Monocyte Category / Neutrophil Category / Smoking     
13 -457.26  941.47 1.73 0.04 
Age/ HTN / IHD / Disease Severity / Lymphocyte Category / 
Neutrophil Category / Smoking / TIA    
12 -458.33  941.47 1.73 0.04 
Age/ HTN / Disease Severity / Lymphocyte Category / 
Neutrophil Category / Smoking / Statin      
11 -459.46  941.60 1.86 0.04 
Age/ HTN / IHD / Disease Severity / Lymphocyte Category / 
Neutrophil Category / Smoking / Stroke    
12 -458.42  941.66 1.91 0.04 
Aspirin/Age/ HTN / IHD / Disease Severity / Lymphocyte 
Category / Neutrophil Category / Smoking   
12 -458.46  941.74 2.00 0.04 
AICc = Akaike information criterion corrected for sample size (Equation 10) df = Degrees of Freedom 
Δi = AICi-AICmin (Equation 11)      DM = Diabetes Mellitus 
log(𝓛𝓛) = Log likelihood of individual model (𝓛𝓛 from Equation 12) HTN = Hypertension  
wi = Akaike weight (Equation 13)      
IHD = Ischaemic Heart Disease 
Disease Severity = Disease Severity at presentation    
Smoking = Smoking Category (Never smoker, smoker – ex or current)  
 
Of the top model set Δi < 2, the simplest model had only nine degrees of freedom while two 
models had 13 degrees of freedom. The log(𝓛𝓛) values range from -457.23 to -461.30 
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demonstrating comparable fit of the selected models. The individual AICc are not 
interpretable as they contain arbitrary constrains and are greatly affected by sample size367 
but once transformed to Δi with the best model given a Δ value of 0 and four other models 
having a Δi <1 the information loss in using those models over the “best” model is quantified. 
 
The “best” model contained the variables Age, Hypertension, Ischemic Heart Disease, Disease 
Severity, Lymphocyte Category and Neutrophil Category and Smoking status (the first model 
presented in Table 8.32 with a Δ value of 0). The “best” model has been estimated to be the 
best but the wi results show that no one model is supported as a being clearly superior over the 
other considered models with the “best” model having a probability of only 10% and the second 
model 8% and all other models from the top model set (with Δi <2) ≥ 4%. The wi/ wj evidence 
support ratio demonstrates the empirical support for the “best” model is 2.5 times that of the 
nine models with wi = 0.04 and twice that of the five models with wi = 0.05. 
 
The second best model for the outcome of death contained the same variables as the “best” 
model without smoking and results in a Δi of 0.36 which may be interpreted as having minimal 
information loss despite the removal of one degree of freedom. The wi/ wj evidence support 
ratio confirms the empirical support for the “best” model is only 1.25 times that of the second 
best model.  
 
This model selection uncertainty was incorporated by multi-model averaging which has the 
benefit of being able to include important information not included in the best model. This was 
done due to the wi of the “best” model being <0.9 and to objectively account for uncertainty in 
the selection of the best model.132,372  Multi-model averaging was then applied to make 
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inference from all of the models from the top model set with Δi <2 with adjustment for their 
supportive value and model probability. The variables from all the models in Table 8.32 were 
thus ranked according to the number of models (from the top model set with Δi <2) that each 
variable appeared in and factored for the complexity of each of those models using the Akaike 
weight for the model (wi) to calculate the importance for each variable for the outcome of death. 
The results of ranking variables using this process are presented in Table 8.33. The subsequent 
averaged model is analysed to assess the coefficients and significance of contributing variables 
to the averaged model (Table 8.34).  
 
Table 8.33: Relative variable importance from multi-model analysis for death 
Variable Importance   No. of models   
Disease Severity at presentation 1.00 19 
Neutrophil Category  1.00 19 
Lymphocyte Category  1.00 19 
Hypertension 1.00  19 
Age 1.00 19  
Ischaemic Heart Disease 0.75 14 
Smoking 0.64 12 
Gender 0.23 5 
Statin 0.20 4 
Diabetes Mellitus 0.11 2 
Monocyte Category 0.09 2 
Transient Ischaemic Attack 0.04 1 
Stroke 0.04 1 
Aspirin 0.04 1 
 
Table 8.33 shows that five variables (Lymphocyte Category, Neutrophil Category, Entry Age, 
Hypertension and Disease severity at presentation) were present in all 19 of the models in the 
top model set Δi <2. The variables of Ischaemic Heart Disease and smoking were present in 
more than half the models in the top model set (14 and 12 respectively, Table 8.33). These 
variables collectively are the best predictors for the outcome of Death. The “best” model 
contained all of the best predicting variables. Gender, statin use, diabetes mellitus, Monocyte 
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Category, Transient Ischaemic attack, stroke and aspirin are inconsistent contributors to the Δi 
<2 top model set (Table 8.33). 
 
Closer examination of the top model set (Δi <2, Table 8.32) in light of the results presented in 
Table 8.33 shows that five of the seven models from the top model set that do not containing 
smoking do contain IHD, and two of the four models that do not contain IHD contain smoking 
whilst the two variables appear together in nine of the total 19 models in the top model set. 
 
The lower relative importance of gender is due to the fact it appeared in five models and also 
was not in any models with wi >0.05. Gender is less likely to be a good predictor of death than 
the best predictors referred to earlier but may still have significant influence in the models in 
which it was included. Transient ischaemic attack, stroke and statin use were present in only 
one model each and are less likely to be strong predictors of death compared to the best 
predictors.  
 
Neutrophil-Lymphocyte Ratio has the advantage of less degrees of freedom than including 
both the Neutrophil Category and Lymphocyte Category however was not in any of the top 
model set with Δi <2, although both Neutrophil Category and Lymphocyte Category appear 
together in all 19 models.  
 
The model averaged coefficients were generated using the natural average method132,372(Table 
8.34) indicate the direction of effect for each variable with the standard error for each variable, 
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i.e. a negative coefficient indicates a negative effect on the outcome of death, meaning that 
death is less likely to occur. 
 
Table 8.34: Full model averaged coefficients for Death 
Variable                         Standardised 
Coefficient 
SE of 
coefficient 
z value  Pr(>|z|)     
Tissue Loss               1.58 0.76    2.08  0.04 
Rest pain                 1.15 0.78    1.48  0.14 
High Neutrophil Category 1.03 0.29    3.60  <0.01 
High Lymphocyte  Category -0.78 0.27    2.92  <0.01  
Hypertension                    -0.60 0.28   2.11  0.04 
Mid Neutrophil  Category 0.50 0.30    1.67  0.09 
Intermittent claudication  0.39 0.73    0.53  0.59 
Ischaemic Heart Disease                     0.30 0.26    1.13  0.26 
Mid Lymphocyte Category -0.24 0.25    0.94  0.34 
Smoking                   0.14 0.15    0.91  0.36 
Age                0.06 0.01    4.37  <0.01 
Gender                   -0.06 0.16    0.37  0.71 
Statin                   -0.05 0.14    0.36  0.72 
High Monocyte  Category      0.04 0.16    0.25  0.80 
Diabetes Mellitus                     -0.03 0.11    0.25  0.81 
Transient Ischaemic Attack                    -<0.01 0.08    0.11 0.92 
Stroke                   <0.01 0.07    0.08 0.93 
Mid Monocyte  Category       <0.01 0.09    0.06  0.96 
Aspirin                 <0.01 0.05    0.06 0.95 
SE = Standard Error 
 
Table 8.34 presents the multi-model inference results which combined the entire set of 
candidate models weighted by their support. The standardised coefficient and standard error 
were used to generate a z value and the probability of each z value is included in Table 8.34. 
Caution needs to be taken in interpreting these results from a null hypothesis testing paradigm 
that traditionally uses the probabilities of z statistics to accept or reject the null hypothesis.132,368 
These results are presented here to demonstrate the relative effect of coefficient and standard 
error on the individual variables in the averaged model and not in the binary significant, not 
significant way.368 Importantly, variables with a non-significant p value are not discarded, 
because the overall model is better with them than without them. The Pr values are very useful 
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in the interpretation of the averaged model for variables that are likely to be correlated and 
hence partly substitutable in the averaged model. The low Pr values of High Lymphocyte 
Category, High Neutrophil Category and Age along with the presence of these variables in 
most or all of the top model set (Table 8.33) may be interpreted as these variables being key or 
non-substitutable in the averaged model for death. The comparatively larger Pr value of 
Smoking (0.36, Table 8.34), despite its presence in the “best model” and presence in more than 
half of the models in the top model set (Table 8.33) is an interesting finding. The larger Pr 
value of Smoking is indicative that when included in the same model as a correlated or 
substitutable variable it is expected that that both variables will have their level of significance 
reduced or eliminated compared to if only one of these variables was included. The averaged 
coefficients seen in Table 8.34 will always be weaker than the coefficients in the “best” model 
but the process is designed to be generous with inclusion over exclusion and will tend to 
underestimate the relative strength of variable effect compared with the “best” model. 
 
The disease severity categories of Tissue Loss and Rest pain had the largest coefficients in the 
averaged model (1.58, 1.15 respectively, Table 8.34) although they also had the largest 
standard errors for these coefficients (0.76, 0.78 respectively, Table 8.34). The z value of 2.08 
for variable Tissue Loss and the subsequent Pr(>|z|) 0.04 are included to quantify the strength 
of this effect which is greater than that of Rest Pain which demonstrated a smaller coefficient 
with a similar size standard error which resulted in a z value of 1.48 and larger Pr(>|z|) of 0.14 
meaning we can be less confident of the magnitude of this effect. The disease severity category 
of Intermittent Claudication was also positively associated with death with a larger effect than 
all traditional risk factors except hypertension. The variable has a standard error greater than 
 293 
Chapter 8: Results section 5 – Total and differential circulating cell counts associated with death in peripheral arterial occlusive disease 
the coefficient of the variable which is why the z value is so much less (0.53, Table 8.34) than 
the disease severity categories of Tissue Loss and Rest Pain. 
 
Both High Neutrophil Category and Mid Neutrophil Category exhibit strong influence in the 
averaged model for the outcome of death with both exhibiting larger positive coefficients than 
any of the traditional risk factors. The High Neutrophil category has a positive coefficient that 
is twice that of the Mid Neutrophil category with similar standard error for both groups, 
generating the largest z value of the categorical variables of 3.6 (Pr<0.01, Table 8.34).  
 
High Lymphocyte Category displayed the strongest negative association with Death (-0.78, 
Table 8.34) indicating that a High Lymphocyte Category was protective for the outcome of 
Death. The High Lymphocyte Category demonstrated a strong effect with comparatively small 
standard error (0.27, Table 8.34) generating a large z value of 2.92(Pr<0.01, Table 8.34). The 
Mid Lymphocyte Category a more modest negative coefficient (-0.24, Table 8.34) with a larger 
standard error than coefficient the strength of this association is less certain. 
 
Hypertension had the largest effect of all the traditional risk factors and also had a negative 
coefficient (-0.60, Table 8.34) suggesting a significant negative association with Death over 
the course of this study. Ischaemic heart disease despite appearing in 14 of the 19 models with 
Δi <2, had a more modest effect with coefficient of 0.30 and standard error of 0.26 (Table 8.34). 
Smoking was the other traditional risk factor to appear in more than half of the models with Δi 
<2 with a smaller effect in the averaged model. 
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Age is the only continuous variable in this multi-model analysis and although the coefficient 
is seeming more modest than other variables (0.06, Table 8.34) it has the smallest standard 
error (0.01) and as such generated the largest z value (4.37, <0.01 Table 8.34). The coefficient 
for age applies to the value for that continuous variable and it has a strong effect on the 
outcome, in this case death. For example in an 80 year old patient the age term would be a 
function of the coefficient (0.06, Table 8.34) and the value 80. 
 
The remaining traditional risk factors of Aspirin and Statin use, Diabetes Mellitus, Transient 
Ischaemic Attack and Stroke along with both Mid and High Monocyte Category exhibited 
modest effects that should be interpreted with caution. It is possible that these variables interact 
with one or more of the other variables in the model and the better predictor may suffice but in 
the interests of caution these variables have been included in the average model because it is 
not possible to tell from this data set alone which of these variables can be safely excluded. 
Care should be exercised in interpreting the direction of association of these weakly correlated 
variables as assigning the incorrect sign to a weak parameter is a possibility in any inference 
analysis.384,385 
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8.7. Discussion for death 
The aim of this study was to combine the assessment of all the circulating cell types for the 
endpoint of death and subsequently generate a model that combines the circulating cell counts 
with established risk factors and clinical severity of disease. This is the first study to use multi-
model averaging from the Information-Theoretical paradigm for model creation for the 
outcome of death in patients with peripheral arterial occlusive disease. The resultant model 
from this study may be used as a risk prediction tool for death in peripheral arterial occlusive 
disease patients that may be applied by the clinician at the bedside. The development of a model 
for death in this population not only explores the true relationships and relative predictive value 
of the circulating cells for mortality but has the potential to be applied to increase patient 
compliance with lifestyle modifications and medical treatment,133 better guide risk 
stratification models for patient treatment137 and also guide further research into understanding 
of the pathogenesis of death in this population. 
 
Disease severity and the circulating neutrophil and lymphocyte cells were stronger predictors 
of death using multi-model inference than the traditional atherosclerotic risk factors of gender, 
hypertension, ischaemic heart disease, stroke, transient ischaemic attack, smoking and diabetes 
mellitus. Disease Severity, Lymphocyte Category and Neutrophil Category along with age, and 
hypertension were present in all 19 of the top model set for death Δi <2 (Table 8.33). The 
traditional risk factors of ischaemic heart disease and smoking were present in more than half 
of the top model set; while gender, statin, diabetes mellitus and Monocyte Category were 
inconsistent contributors. Multi-model analysis was used for the analysis of this complex 
system because controlling for the enormous number of factors affecting outcome is 
impractical,132,386 and many of the variables may exhibit small but clinically important 
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effects.302 Only variables with strong biological reasoning and established a priori relationship 
were included in the multi-modelling analysis132 and this evidence was established in the null-
hypothesis testing section of this chapter prior to commencing multi-model analysis. The 
TWCC was not included in the multi-model analysis because it is a function of the addition of 
other cell types. 
 
Disease severity at presentation was present in all 19 of the top model set with Δi <2 (Table 
8.32) and the two strongest variable effects in the averaged model for death were Tissue loss 
(1.58 ±0.76) and Rest Pain (1.15 ±0.78, Table 8.34). The effect of Tissue Loss for the outcome 
of death was 2.6 times that of hypertension and 5.2 times that of ischaemic heart disease. Tissue 
Loss exerted 4 times the effect of the other Disease Severity category Intermittent Claudication 
on the outcome of death. The effect size of Tissue Loss was large enough to generate a z value 
of 2.08 despite the large standard error of 0.76 (Pr=0.04, Table 8.34). The objective and 
quantified finding that Disease severity is the most important predictor of mortality in patients 
with peripheral arterial occlusive disease has important implications for future research in this 
field as previous literature has inconsistently reported and adjusted for clinical severity of 
disease when investigating this patient group.49,122,222,320 The strength of the variables Tissue 
Loss and Rest Pain should be interpreted in light of their generation not only by the quantified 
process of model selection with model likelihoods and estimates of model precision, but this 
accuracy of parameter estimates for the components of the averaged model is not achievable 
through null hypothesis testing statistical methods. 
 
This research methodology demonstrates Disease Severity and the High Neutrophil Category 
to be strong predictors for the outcome of death. A causative relationship between these 
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variables has not been established and is not necessary to be established for the model to 
function as it is. However, to progress understanding of the underlying disease process it is 
important to consider whether the tissue ischaemia of more severe peripheral arterial disease 
causes activation of the neutrophils, increasing their adhesion and reducing their deformability 
and thus causing adverse effects in distant organs,230,231,341 or the high count of circulating 
neutrophils are causative of the lower limb tissue ischaemia through plaque disruption397 as a 
marker of atherosclerotic disease burden. A longitudinal study design incorporating cell 
functional assessment would be one method of better defining this relationship.  
 
Neutrophil Category and Lymphocyte Category were the only cell types present in all 19 of 
the top model set Δi <2 (Table 8.32) along with Disease severity, Hypertension and Age. The 
calculated Neutrophil-Lymphocyte Ratio did not feature in any of the 19 models within the top 
model set for the outcome of death although neutrophil-lymphocyte ratio has the advantage of 
less degrees of freedom than including both the Neutrophil Category and Lymphocyte 
Category. This is consistent with the findings of multi-model analysis for the outcome of major 
adverse event in this population. The quantitative comparison of variable contribution to 
models for outcome has been previously unavailable with null hypothesis testing based 
statistics and this new paradigm of Information-Theoretical statistical analysis should be 
employed to more accurately direct future research. 
 
High Neutrophil Category had the largest effect size in the averaged model an effect twice that 
of the Mid Neutrophil Category with a similar size standard error (Table 8.34). Both the High 
Neutrophil Category and High Lymphocyte Category exhibited a larger effect than that of the 
best traditional risk factor Hypertension. The High Lymphocyte Category had the largest 
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negative effect in the averaged model with coefficient -0.78 (<0.01, Table 8.34), 3.25 times 
that of the Mid Lymphocyte Category with a coefficient of -0.24 (z score 0.94, Table 8.34), 
both of which had a larger effect than the traditional risk factors of smoking, diabetes, Transient 
Ischaemic Attack, Stroke, Aspirin and Statin use. This re-enforces the early findings of 
Dormandy and Murray24 who reported the absence of predictive value for the traditional risk 
factors of hypertension, diabetes, smoking and high plasma cholesterol levels and suggested 
that these risk factors for the development and early progression of atherosclerosis are not 
necessarily prognostic factors in the final stages of the disease.24 
 
Both High and Mid Monocyte Categories feature in the averaged model although Monocyte 
Category was present in only two of the 19 best fit models (Δi <2 ) both of which had Δi ≥1.47 
with wi of 0.05 and 0.04. Because of this low Akaike weight weaker effects in the averaged 
model for the outcome of death are expected. Further research with a larger sample may clarify 
this relationship, but currently the High and Mid Monocyte Categories contribute weakly to 
the averaged model for death. 
 
The strongest effect from a traditional risk factor in the averaged model for death was the 
negative coefficient of hypertension of -0.60±0.28 (<0.04, Table 8.34) which was consistent 
with the negative coefficient for hypertension in the averaged model for major adverse event. 
The reason for this negative association is not clear from the analysed data with hypertension 
traditionally having a positive association with mortality.100,398 As discussed with regard to the 
averaged model for major adverse event; treatment of hypertension in peripheral arterial 
occlusive disease has been demonstrated to lower the incidence of mortality in population 
studies.104,399,400 The influence of antihypertensive medications at recruitment, any changes in 
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anti-hypertensive medication, or correlation with non-invasive blood pressure measurements 
were outside the scope of the current study and warrant further investigation in this population 
preferably with consideration of the Information-Theoretical approach. 
 
Smoking, despite being present in 12 of the 19 top model set with Δi <2 and generating an 
importance of 0.64, displayed a relatively small effect (0.14±.015) having approximately 9% 
of the predictive power of the disease severity group Tissue Loss and 13.6% the predictive 
power of High Neutrophil Category. One explanation for this is the established relationship 
between circulating cell counts especially neutrophils and number of cigarettes smoked,383 and 
the effect of cigarette smoking is better accounted for in the outcome model by the circulating 
cell counts that the patient report of cigarette smoking. Smoking should still be included in the 
averaged model for the outcome of death despite the lower predictive power as the effect of 
this variable is not replaced by the circulating cell counts alone. 
 
This study convincingly demonstrates the importance of adjusting for confounding factors 
when undertaking null hypothesis testing (Cox proportional hazards used in this study) of 
circulating cell types with the outcomes of death in a population of patients with peripheral 
arterial occlusive disease. Variable incorporation into multi-model analysis of outcomes may 
be appropriate on the basis of a priori investigations and established literature alone132 but the 
adjustment for traditional risk factors and comprehensive risk factors was performed to enable 
comparison of the investigated population with previously published populations of patients 
with peripheral arterial occlusive disease. Inconsistency of adjustment for confounding factors 
in the published literature examining this population has been described223 and in this study is 
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demonstrated to have a significant effect on the observed significance of associations with 
death. 
 
High TWCC was associated with the endpoint of death in all Cox proportional hazards models 
although variations in the variables adjusted for in published studies makes direct comparison 
problematic. In the stratified model that adjusted for comprehensive risk factors High TWCC 
had a hazard ratio of close to 2 (Table 8.19), which was less than the hazard ratio found by 
Arain et al.222 who found a hazard ratio of 4.09 (1.57-10.64) when they adjusted the Cox 
proportional hazards model for age, sex, smoking, hypertension, ischaemic heart 
disease/stroke, serum creatinine and ankle brachial index. The hazard ratio for death found in 
this study is greater than the relative risk of vascular death (1.51, 1.20–1.89) of the patients in 
the upper TWCC quartile described by Grau et al.69 in the CAPRIE study which included 
patients with stroke and ischaemic heart disease as well as peripheral vascular disease. Haim 
et al.404 described a similar relative risk to Grau et al.69 in patients with coronary heart disease 
(1.47)404 although the relative risk does not take into account the timing of deaths.405 In the 
study of 108 patients with critical limb ischaemia by Pedrinelli322 elevated TWCC had a risk 
ratio for death of 3 (2.76-3.28) on univariate analysis which was not persistently significant on 
multivariate analysis. The findings of TWCC association with mortality were not replicated in 
the study of 1021 patients undergoing major vascular surgery by Bhutta et al.49 who did not 
demonstrate a significant association of TWCC with two year mortality (univariate odds ratio 
1.02 (0.95-1.09.) and Haumer et al.72 who also did not demonstrate a significant association of 
TWCC with death over a median follow up of 20 months. This may be due to methodological 
differences between the studies with 51.8% of the population studied Bhutta et al.49 undergoing 
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aneurysm repair, a population that was excluded from the current study and this study having 
a median follow up four times longer than the study by Haumer et al.72 
 
The importance of adjusting for disease severity was seen in the Cox proportional hazard 
results of Mid TWCC Category testing with death where the 0.05 level of significance was 
only reached in the comprehensive risk factor adjusted Cox models (Table 8.19 and Table 8.30) 
raising the possibility that one of the confounding factors not adjusted for in the traditional risk 
factor adjustment may have masked the effect of TWCC on death. It is likely that this was 
disease severity, previously established as an important confounding variable to consider with 
Tissue Loss significant (p = 0.02) when included in the comprehensive risk factor adjusted 
model. Once the Cox model for TWCC and death was adjusted for the comprehensive risk 
factors and stratified for the other significant categorical variables (ischaemic heart disease and 
Tissue Loss) Mid TWCC was demonstrated to be significant (p = 0.02) with a hazard ratio of 
2.00 (1.12-3.55) greater than that of the High TWCC Category. TWCC was not included in the 
multi-model analysis because it is a direct function of the addition of cell subtypes but future 
research should compare TWCC with cell subtypes as predictors of death through multi-model 
analysis with different design. 
 
The High Neutrophil Category was significantly associated with death in all Cox models at the 
<0.01 level establishing precedent for its inclusion into multi-model analysis. Hazard ratio for 
the High Neutrophil Category in the comprehensive risk factor adjusted model was 2.49 (1.43-
4.32) with age the only other significant variable (<0.01, Table 8.21). The High Neutrophil 
Category was also highly significant in the combined cell types Cox model for death (<0.01, 
Table 8.31) with a similar hazard ratio of 2.36 (0.13-4.24). This is lower than the hazard ratio 
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of 3.4 (1.34-8.53)72 found by Haumer et al.72 after adjusting for comprehensive risk factors 
who followed 398 patients with symptomatic peripheral arterial occlusive disease for a median 
of 20 months. The hazard ratio in this study of High Neutrophil Category for death was greater 
than reported by Grau et al.69 in the CAPRIE study 1.86 (1.47–2.36) although specific comment 
was made that they may have underestimated risk by 30-35% for neutrophil count due to 
regression dilution.  
 
High Lymphocyte Category was significantly negatively associated with the endpoint of death 
in all Cox proportional hazards models except the comprehensive risk factor adjusted model 
stratified for other significant variables. In the comprehensive risk factor adjusted Cox 
proportional hazards model for death the High Lymphocyte Category was statistically 
significant (0.02, hazard ratio 0.54, Table 8.23) with the other statistically significant variables 
smoking, ischaemic heart disease, Tissue Loss and Hypertension. Once this model was 
stratified for other significantly associated categorical variables the High Lymphocyte 
Category only trended toward significance (0.10, Table 8.23) It is not clear if this effect is 
related the potential breach of the proportionality assumptions of the Cox model by the Mid 
Lymphocyte Category or the relationship of one of the other statistically significant variables. 
The Mid Lymphocyte Category was significantly associated with the outcome of death in the 
a priori model only (0.04, Table 8.23) with hazard ratio of 0.61 (0.38-0.99, Table 8.23) 
indicating that the Mid Lymphocyte Category was negatively associated or protective for the 
outcome of death. The Mid Lymphocyte Category had a significant Cox.zph score in all models 
except the stratified model for comprehensive risk factors indicating a breach of the 
assumptions of proportionality of the Cox models. The Mid Lymphocyte Category was also 
statistically significant in association with death in the combined cell types Cox model with 
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hazard ratio 0.60 (0.37-0.98) although the assumptions of proportionality were breached in this 
model. Tests of proportionality have not been published commonly in studies assessing 
outcome in patients with peripheral arterial occlusive disease, and as the aim is to investigate 
and describe a complex biological system the most appropriate analysis needs to be again 
considered with multi-model analysis considered superior for analysis of complex models with 
proven interactions between variables with small effects of some or all of the variables.302  
While the protective effect of relative lymphocytosis has been observed in other large 
studies69,205,208 the underlying pathophysiological mechanisms of benefit from these lymphoid 
derived cells, possibly from a more competent immune response, requires further research. 
 
High NLR Category was significantly associated with death in all Cox models. The High NLR 
Category was associated with death at the <0.01 level in all models except the stratified 
comprehensive risk factor model (0.04, Table 8.29) which stratified for the other significantly 
associated comprehensive risk factors (age, ischaemic heart disease, disease severity – Tissue 
Loss and smoking). In this stratified model adjusting for comprehensive risk factors the hazard 
ratio of 1.84 (1.02-3.31, Table 8.29) was lower than that of the other models suggesting that 
some of the hazard for association with death that was attributed to the High NLR Category in 
the model adjusted for traditional risk factors with stratified ischaemic heart disease (hazard 
ratio 2.25, Table 8.29) may have been due to one or more of the confounding variables in the 
comprehensive risk factor group. This is a similar to the results reported by Spark et al.260 who 
reported a hazard ratio of 2.3 (1.2-4.2) using a Cox stepwise regression model adjusted for age, 
stroke, previous heart attack, statin use, renal failure, smoking history and elevated troponin in 
a cohort of 151 patients with critical limb ischaemia, and Bhutta et al.49 who reported a 
multivariate odds ratio 2.21 (1.22-4.01) with NLR >5 in 1021 patients undergoing vascular 
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surgery. Importantly, the calculated neutrophil-lymphocyte ratio did not feature in any of the 
19 top models from multi-model analysis with Δi <2 (Table 8.32) for the outcome of death, 
similar to the findings of multi-model analysis for the endpoint of major adverse event. This 
study demonstrates objectively in two separate multi-model analyses that despite NLR being 
significant in null-hypothesis testing when combined with Neutrophil Category and 
Lymphocyte Category in multi-model analysis the information lost using the NLR for the 
outcome of death is greater than the statistical advantage that should be seen from less degrees 
of freedom. To clarify, this finding is not disproving that NLR is associated with death or major 
adverse event, NLR is just inferior to the inclusion of both Neutrophil Category and 
Lymphocyte Category when creating models for the outcome of death and major adverse event 
in this population. This has important implications in the interpretation of previous research 
and demonstrates an inherent problem with the null-hypothesis testing paradigm as stepwise 
regression is unable to compare models without model likelihoods or estimates of precision,306 
making this relationship difficult to elucidate with previously applied methods. As a result of 
the findings of this study inclusion of both Neutrophil Category and Lymphocyte Category 
should be considered superior to the inclusion of Neutrophil-Lymphocyte Ratio in future 
models for the outcome of death in patients with peripheral arterial occlusive disease. 
 
High Monocyte Category was not significantly associated with death in any of the Cox models 
although did trend to significance (0.06, Table 8.25). The hazard ratio of the High Monocyte 
Category of 1.69 (0.98-2.84) in the comprehensive risk factor adjusted model was greater than 
that in the CAPRIE study69 where the upper quartile monocyte count vascular death Risk Ratio 
1.29 (1.06–1.55) although by self-report they may have underestimated risk by up to 50% for 
monocyte counts due to regression dilution. High Monocyte Category displayed a similar trend 
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to significance in the combined cell types Cox model (0.08, Table 8.31) with hazard ratio 1.68 
(0.94-3.02), the Mid Monocyte Category was not significantly associated with the outcome of 
death in any Cox Models. While monocyte derived macrophages have been described as 
mediating all the stages of atherosclerotic plaque formation and rupture,47 and patients with 
peripheral arterial occlusive disease having monocytes that are more active than control 
groups,265 the pathophysiological mechanisms by which monocytes lead to increased risk of 
death in this population require further investigation. 
 
Neither Mid nor High Haemoglobin Category demonstrated a significant association with 
death in any of the Cox proportional hazards model. A finding that is consistent with the 
Dormandy and Murray24 who also did not demonstrate significant association of haemoglobin 
with mortality in patients with Intermittent Claudication. Haemoglobin has previously been 
associated with two year mortality in patients undergoing major vascular surgery with 
univariate analysis of Haemoglobin (g/dL) demonstrating an odds ratio of 0.81 (0.72-0.91) but 
this association was not significant when adjusted for other risk factors.49 
 
With these complex interactions established through null hypothesis testing analysis between 
circulating cells as markers of systemic inflammation, risk factors for vascular disease and 
clinical disease severity; multi-model analysis and averaging was undertaken. Multi-model 
analysis allowed comparison of all the variables and their association with the endpoint of 
death and may be used to infer the key underlying biological processes at work.132,386 The 
multi-model analysis confirmed most of the highly significant findings from the Cox 
proportional hazards analysis with Neutrophil Category and Lymphocyte Category featuring 
in all 19 of the top model set with Δi <2. High Neutrophil-Lymphocyte Ratio was significant 
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in all Cox Proportional Hazards analysis but did not feature at all in the top model set for the 
outcome of death despite having the significant mathematical advantage of less degrees of 
freedom to include Neutrophil-Lymphocyte Ratio instead of Neutrophil Category and 
Lymphocyte Category. This is clinically important as quantitatively comparing which of these 
measures are best to include in a model for the outcome of death is problematic using null 
hypothesis testing statistical analysis. Monocyte Category which trended to significance in the 
Cox Proportional Hazards analysis was only in two of the top model set and produced a 
relatively weak positive coefficient in the averaged model although was still included as an 
important variable. This effect of Monocyte Category on the model for death in patients with 
peripheral arterial occlusive disease may be clearer from replication in a larger study 
population. 
 
As described in Section 8.4 the developed averaged model may be applied by the clinician at 
the bedside using a simple computational application for smartphone. From the results of this 
multi-model inference analysis, Lymphocyte category and Neutrophil Category should be 
combined with clinical disease severity, patient age, history of hypertension and ischaemic 
heart disease in the model to predict death in patients with peripheral arterial occlusive disease. 
Monocyte Category, Smoking status, history of Transient Ischaemic Attack or Stroke, Diabetes 
Mellitus and Statin use would best have their role in the model clarified by replication with 
another population, however from this study alone they add meaningfully to the model and 
should be included. This proposed handheld application to assist the clinician to predict and 
communicate risk of death may help select the most appropriate treatment for individual 
patients137 and may communicate risk to the patient in a way that enhances adherence to 
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lifestyle changes and medication use133 that have been shown to improve outcomes in patients 
with peripheral arterial occlusive disease.83,85,135,136 
 
As suggested for the outcome of major adverse event, the predictive value of the developed 
model for death in patients with symptomatic peripheral arterial occlusive disease would be 
confirmed and refined by replication of this study method in a larger population. Multi-model 
analysis to allow direct comparison of TWCC with subtypes of lymphocyte, neutrophil and 
monocyte for the outcome of death should be considered. As suggested for the outcome of 
major adverse event, the protective effect of hypertension or the treatment applied for 
hypertension plus the Ankle Brachial Index as an objective measure of the severity of 
peripheral arterial occlusive disease deserves further investigation. Expansion of the study 
population to include people with asymptomatic peripheral arterial occlusive disease would aid 
in identifying asymptomatic people at the highest risk of death who would benefit most from 
lifestyle changes and medical management. Models for mortality developed using multi-model 
analysis will be better able to identify underlying biological processes and should be used to 
guide future pathophysiological and therapeutic research into peripheral arterial occlusive 
disease. 
 
8.8. Conclusions for death 
Multi-model averaging is a relatively new statistical paradigm and is the preferred statistical 
method for analysing data from complex biological systems needing to account for multiple 
co-variables of modest effect that interact to produce clinically relevant outcomes and is here 
used to analyse death for patients with peripheral arterial occlusive disease. Multi-model 
averaging in this study has demonstrated that circulating cell counts of lymphocytes and 
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neutrophils together with disease severity at presentation, hypertension and age are more 
important in models to predict the outcome of major adverse event than other traditional risk 
factors.  
 
Tissue Loss and Rest Pain were the two strongest predictors of death in the best averaged model 
in which the effect of the disease severity category Tissue Loss was 2.6 times that of 
hypertension and 5.2 times that of ischaemic heart disease. Intermittent Claudication also had 
a larger effect than the traditional risk factors of ischaemic heart disease, smoking, Diabetes 
mellitus, Transient Ischemic Attack, Stroke, Aspirin and Statin use. Disease severity should 
continue to be reported and accounted for when examining outcomes in patients with peripheral 
arterial occlusive disease. 
 
Analysis using Information-Theoretical framework has shown that the inclusion of 
Lymphocyte Category and Neutrophil Category together provide better modelling for the 
outcome of death than the combined Neutrophil-Lymphocyte ratio. Lymphocyte Category and 
Neutrophil Category were in all of the models in the best model set. 
 
The protective role of lymphocytes and hypertension (or the subsequent management) in the 
averaged outcome model for death in patients with symptomatic peripheral arterial occlusive 
disease deserves further research. Initially in the form of replication of these results in other 
populations of patients with peripheral arterial occlusive disease preferably with the power to 
investigate hypertensive management. Future expansion into pathophysiological research 
would then be able to determine if these protective effects may be exploited clinically. 
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Multi-model inferencing should be applied to larger data sets of patients with peripheral arterial 
occlusive disease to provide valuable information about the association of cell counts with 
outcomes in this population. Once the nature of these associations is refined not only will more 
accurate models be generated to predict the likelihood of death for individual patients and guide 
treatment selection, aid patient compliance with lifestyle change and medical therapy but future 
pathophysiological research and new treatment options will be able to be generated. 
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9. Discussion 
This is the first study to use multi-model averaging to assess the contribution of circulating 
cells, severity of disease and traditional risk factors with cardiovascular endpoints in patients 
with peripheral arterial occlusive disease. This new paradigm of hypothesis testing using the 
Information-Theoretic approach of multi-model averaging is more appropriate and meaningful 
than traditional null hypothesis testing approaches for patients with peripheral arterial 
occlusive disease. Outcome model development has important implications for the substantial 
population of patients with peripheral arterial occlusive disease estimated to 202 million adults 
worldwide.13 Multi-model averaging has demonstrated that disease severity and the circulating 
cells of inflammation (neutrophils, lymphocytes and monocytes) are better predictors of major 
adverse event and death than the risk factors associated with the development of peripheral 
arterial occlusive disease. Through the process of multi-model averaging these results have 
been combined to produce outcome models for major adverse event and death in patients with 
peripheral arterial occlusive disease.  
 
Limitations of the traditional null hypothesis testing approach have been demonstrated by the 
complex interplay of risk factors, circulating cells of inflammation and clinical disease severity. 
Adjustments in null hypothesis testing methods have significant effects on the relationships of 
variables such as circulating cells and outcomes. The variables adjusted for in published 
literature involving patients with peripheral arterial occlusive disease are inconsistent, with one 
potential reason that publication bias leads to selection of statistically significant results for 
publication.406,407 This consequence is based on the inherent misunderstanding that null 
hypothesis testing is fundamental to the scientific method and can lead to a false sense of 
objectivity and rigor in statistical analysis and interpretation of research data.408 
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Null hypothesis testing methods traditionally utilise some form of step-wise regression to 
generate models with multiple predictors. Irrespective of the method used305 this process 
completely ignores model selection uncertainty358 and results in significant bias in parameter 
estimation.132,358 Subsequently inappropriate focus is placed on the  single “best” model, the 
consequences of which are not only erroneous conclusions,358 but potentially misdirection of 
future research. These problems may be more pronounced when the predictors are correlated409 
or contain equivocal variables close to statistical significance132 as they have been 
demonstrated to be in this population of patients with peripheral arterial occlusive disease. 
While these limitations of the null hypothesis testing method are being increasing recognised 
in other scientific disciplines358,360,362,368,410 they remain rarely commented on in medical 
research. Traditional null-hypothesis testing still has a place in scientific research, it is just 
comparatively less informative compared with modern methods of analysis.362 The 
Information-Theoretic approach arises strongly from the science of likelihood theory132 and 
objectively compares models created to approximate an unknown reality367 through measured 
observations. The Information-Theoretic approach is good with multiple predictors410 and is 
able to account for model selection uncertainty and provide scientific results based on 
quantified support from collected data.411 In other scientific fields initial uptake of this new 
paradigm was slow, potentially due to unawareness of this statistical technique, and also that 
this newer philosophy is a significant departure from traditional statistical training.412 
 
The best fit averaged model calculated in this study for both the outcome of major adverse 
event (Table 8.17) and death (Table 8.34) in patients with peripheral arterial occlusive disease 
may be used to weight the predictive value of disease severity, circulating cells and clinical 
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risk factors to generate outcome predictions for individual patients with peripheral arterial 
occlusive disease. The consistency of variables in the top model set for both major adverse 
event and death is presented in Table 9.1 with the standardised coefficients for both averaged 
models presented in Table 9.2. The consistency of clinical disease severity and age which were 
present in all of the top model set in both averaged models for death and major adverse event 
can be seen in Table 9.1 with strong coefficients of Rest Pain and Tissue Loss in both averaged 
models (Table 9.2) is an important message for future research which should include and adjust 
for these variables in future investigations. Correlation of clinical disease severity with the 
objective measure of Ankle Brachial Index is advised and comparison using multi-model 
analysis would assess which of these measures of disease severity is best to include in models 
for these outcomes. 
 
Table 9.1: Relative variable importance in multi-model analysis for major adverse event and death 
Variable Major Adverse Event Death 
 Importance  No. of models 
(out of 18) 
Importance  No. of models 
(out of 19) 
Age 1.00 18 1.00 19  
Disease Severity 1.00 18 1.00 19 
Gender 
(Stratified in MAE analysis) 
1.00 18 0.23 5 
Hypertension 0.96 17 1.00  19 
Ischaemic Heart Disease 0.92 16 0.75 14 
Lymphocyte Category 0.90 16 1.00 19 
Monocyte Category 0.73 13 0.09 2 
Neutrophil Category 0.59 11 1.00 19 
Smoking 0.27 5 0.64 12 
Transient Ischaemic Attack 0.16 3 0.04 1 
Statin 0.09 2 0.20 4 
Diabetes Mellitus 0.09 2 0.11 2 
Stroke Not significant 0.04 1 
Aspirin Not significant 0.04 1 
MAE = Major Adverse Event 
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Table 9.2: Full averaged model coefficients for major adverse event and death 
Variable       Major adverse event Death 
Standardised 
Coefficient 
SE of 
coefficient 
Standardised 
Coefficient 
SE of 
coefficient 
Rest pain                     0.71 0.59 1.15 0.78    
High Monocyte Category                     0.56 0.43 0.04 0.16    
High Lymphocyte Category               -0.53 0.30 -0.78 0.27    
Hypertension                                   -0.53 0.28 -0.60 0.28   
Mid Lymphocyte Category                  -0.49 0.28 -0.24 0.25    
Tissue Loss                  0.41 0.58 1.58 0.76    
High Neutrophil Category                 0.39 0.39 1.03 0.29    
Intermittent claudication  -0.39 0.54 0.39 0.73    
Ischaemic Heart Disease                                    0.38 0.23 0.30 0.26    
Mid Monocyte Category                     0.23 0.27 <0.01 0.09    
Mid Neutrophil Category                   0.18 0.26 0.50 0.30    
Age                                   0.06 0.01 0.06 0.01    
Transient Ischaemic Attack                                   -0.05 0.17 -<0.01 0.08    
Smoking                         0.04 0.09 0.14 0.15    
Statin                                -0.01 0.07 -0.05 0.14    
Diabetes Mellitus                                    -0.01 0.07 -0.03 0.11    
Gender Stratified in model -0.06 0.16    
Stroke Not significant <0.01 0.07    
Aspirin Not significant <0.01 0.05    
SE = Standard Error 
 
Monocyte Category was the most important circulating cell in the averaged model for major 
adverse event (Table 9.2) while it was less important in the model for death raising the 
possibility that Monocyte Category may be a better predictor of the outcomes of heart attack 
or stroke than the outcome of death alone in the population of patients with peripheral arterial 
occlusive disease. Monocytes play a key role in the formation of atherosclerotic plaque46 and 
their accumulation in atherosclerotic plaque has been described preceding plaque rupture413 but 
why the circulating monocyte count may be a better predictor of heart attack or stroke rather 
than death remains unclear and warrants further investigation. Circulating monocyte count has 
also been reported to decrease following revascularisation for critical limb ischaemia267 and 
the effects of this in a large population would be worthwhile to assess if the observed reduction 
in circulating monocytes after revascularisation results in reduced risk of major adverse event. 
This study was not significantly powered to investigate the effects of revascularisation or the 
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endpoints of heart attack or stroke individually, but replication of this study in a larger 
population would enable that analysis and may give important insight into the role of 
circulating monocytes and their role in predicting individual cardiovascular adverse events. 
 
Neutrophil Category was the strongest circulating cell count predictive of death appearing in 
all of the top model set for death (Table 9.1) with the largest coefficient of the circulating cells 
(Table 9.2), but was less well represented in the top model set for major adverse event 
appearing in only 11 of the 18 top models whilst still having a stronger positive coefficient for 
major adverse event than any of the traditional risk factors. This observed difference that 
Neutrophil Category is potentially less predictive of heart attack and stroke than death alone is 
not explained by this study. One potential reason may be methodological, with a heart attack 
that resulted in death recorded as death alone and Neutrophils having strong positive 
association with mortality following heart attack.205,234,235 Neutrophilia has been associated 
with the development of coronary artery disease,176 and experimentally neutrophils have been 
demonstrated to have a proinflammatory role in atherosclerosis.414 It is not clear from the 
design of this study the mechanism by which the high circulating neutrophil count contributes 
to the risk of death. Neutrophils have previously been demonstrated to be involved in the 
development of ischaemic events through adherence to the endothelium, and plaque disruption 
through the release of superoxide radicals, proteolytic enzymes and arachidonic acid 
metabolites,190,227,228 reduced deformability232 or the aggregation with platelets that contributes 
to microvascular and macrovascular plugging promoting infarction,72,228,229 leading to organ 
compromise and subsequent death. That this study demonstrates  
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Lymphocytes were consistent negative predictors in the averaged model for both major adverse 
event and death (Table 9.1, Table 9.2). T lymphocytes have long been established to have a 
role in plaque establishment, secreting cytokines and growth factors that control migration and 
proliferation of smooth muscles cells into plaque, and play a role in the production of 
procoagulant tissue factor that triggers thrombus formation following plaque rupture.46 
However despite the protective effect of relative circulating lymphocytosis being observed in 
large studies,69,205,208 and the known atheroprotective effects of regulatory T lymphocytes and 
B lymphocytes415 the link between circulating lymphocytosis and the pathophysiology of this 
atheroprotection remains unclear. One possibility is that a more competent immune response 
indicated by the high lymphocyte count restricts the progression of atherosclerotic disease but 
would require further research. Given the strength and consistency of the protective association 
of circulating lymphocytes with the outcomes of major adverse event and death in this study 
this is an area that warrants further investigation. Lymphocyte subset analysis may inform 
relative contributions of lymphocyte types to this observation. 
 
Neutrophil-Lymphocyte Ratio did not feature in either of the top model sets using the multi-
modal approach (Table 9.1). Although a strong relationship with both death and major adverse 
event was established through null-hypothesis testing analysis this was not as important in the 
modelling for either outcome as the inclusion of both Neutrophil Category and Lymphocyte 
Category. This is the first study to be able to objectively compare the relative contributions of 
variables to outcome in this population through the use of multi-model analysis; a result not 
achievable using traditional null hypothesis statistical approaches. This finding demonstrates 
that while Neutrophil-Lymphocyte Ratio is associated with death and major adverse event it is 
a less powerful predictor in outcome models than inclusion of both cell subtype categories. 
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Hypertension was also shown to have a strong and consistent effect as a negative predictor of 
both major adverse event and death in this population and was an unexpected finding, as 
hypertension traditionally has a positive effect on mortality.100,398 Hypertension was present in 
17/18 of the top model set for major adverse event and all of the top model set for death (Table 
9.1). Hypertension demonstrated a consistent negative standard co-efficient for both major 
adverse event and death greater than -0.50 (Table 9.2). Treating hypertension has shown 
mortality benefit in peripheral arterial occlusive disease patients400 and other patient groups,416-
418 although treatment of hypertension is less intensive in the peripheral arterial occlusive 
disease population than in patients with coronary artery disease.5 This study was not designed 
to examine the relative contribution of different antihypertensive agents to the reduction in risk 
of major adverse event or death but is however an important finding. Multi-model inference 
would be an ideal tool to use for this analysis in a population of patients with peripheral arterial 
occlusive disease where controlling for all other factors affecting outcome including their 
interactions would be impossible. 
 
Other traditional risk factors of smoking, transient ischaemic attack, stroke, diabetes mellitus, 
aspirin and statin use contributed inconsistently to the models in the top model set for both 
major adverse event and death (Table 9.1). Small coefficients with relatively large standard 
error were observed for these variables in the averaged model (Table 9.2), and the direction of 
prediction is not clear with most values close to 0. From this study alone these variables 
contribute significantly to the averaged model and should be included but this role would be 
clarified by replication of this study in a larger population. As previously discussed these risk 
factors may not be as important predictors of outcome in symptomatic peripheral arterial 
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occlusive disease as they are in the establishment of the disease.24 Another explanation is that 
the circulating cell counts better represent the contribution of the risk factor/s to the outcome 
in the averaged model and are therefore represented with larger coefficients in the averaged 
model, a process not achievable with null hypothesis testing methods.  
 
TWCC categories were demonstrated to be associated with both outcomes of death and major 
adverse event using null hypothesis testing methods. Direct comparison of the predictive value 
of TWCC compared to cell subtypes was not possible in the multi-model analysis conducted 
as the TWCC is a direct function of the addition of other cell types. The relative contribution 
of TWCC category compared to cell subtypes would be possible with a specifically designed 
multi-model approach although that was outside the scope of the present study. Although 
providing less pathophysiological insight, the development of the simplest and most accurate 
model for outcome in these patients would benefit from the quantified comparison of this 
relationship. 
 
The null hypothesis testing sections of this thesis demonstrate complex interactions between 
the circulating cells, disease severity, traditional risk factors and medication use in the 
population with peripheral arterial occlusive disease. The nature of these interactions is 
demonstrated to have strong effects on the significance and strength of reported effect when 
tested using null hypothesis testing methods. The inconsistency of variable adjustment in 
published literature223 makes direct comparison and meta-analysis of published literature 
problematic and standards for minimal variable adjustment that include disease severity should 
be considered in addition to standardised definitions and methods for assessing and recording 
risk factors previously discussed.223  
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Proportionality of variables is inconsistently reported in the population with peripheral arterial 
occlusive disease although the circulating lymphocyte count exhibited a significant cox.zph in 
most of the Cox proportional hazards analysis with the outcomes of death and major adverse 
event. Although null hypothesis methods exist to examine association in systems with 
proportional variables, particularly the use of time dependent variables, these were not 
considered necessary to establish precedent for inclusion in the multi-model analysis of this 
study. Such techniques may be considered in future studies where uncertainty exists about 
which variables to include in future multi-model analysis. The Information-Theoretical 
statistical approach offers an alternative for examining correlated variables that should be 
considered more informative in future analysis of this population.  
 
The method of application of the averaged models for outcome in patients with peripheral 
arterial occlusive disease by the clinician at the bedside or in the outpatient clinic have been 
described using a simple computational application for smartphone. Such an application 
consisting of an interface that enables the clinician to select the patient risk factors, clinical 
severity of disease and category of circulating cell counts will enable individual clinicians to 
be able to apply this model to individual patients with nothing more than clinical history, full 
blood count results and a smartphone. It has been proposed that this application should not be 
released for widespread use until the model has been validated among other populations of 
patients with peripheral arterial occlusive disease.419  From the multi-model inference results 
presented in this thesis, Lymphocyte category, Neutrophil Category, Monocyte Category, 
clinical disease severity, patient age, gender, history of hypertension and ischaemic heart 
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disease should be combined in the model (Figure 9.2) they strong predictors of major adverse 
events and death in patients with peripheral arterial occlusive disease.  
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Figure 9.2: Schematic representation of multi-model outcomes showing the essential variables in each category 
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Multi-model analysis has revealed essential variables from each of the categories of disease 
severity, circulating cells and traditional risk factors for the outcomes of major adverse event 
and death (Figure 9.2). The relative importance of these essential variables was different in the 
averaged model for each outcome as discussed above but are considered essential variables to 
the model. Smoking status, history of Transient Ischaemic Attack, Diabetes Mellitus along with 
aspirin and statin use require further clarification (Figure 9.2) and would best have their role in 
the final model clarified by replication with another population.  
 
From this study alone, the variables that require further clarification (shown in Figure 9.2) add 
meaningfully to the model and should be included. When variables are present in multiple 
models in the top model set with a small coefficient assigned or with the standard error 
including 0, it is worth considering if that variable has an interaction with another variable 
included in the model. For example, smoking is present in 12 of the 19 best fit models for 
death, with an averaged co-efficient of 0.14 and a standard error of 0.15. This may seem to be 
a small co-efficient for a risk factor that has been well associated with death in this population, 
however in the averaged model the contribution of smoking status is mostly accounted for by 
one or more of the other variables. Smoking status has a clear association with increased total 
white cell count,22,420,421 predominantly neutrophil count,422 therefore in the averaged model 
for death the contribution of smoking to the model is mostly accounted for by the circulating 
cell counts. Smoking is not completely replaced by these surrogate markers in the developed 
average model, therefore requires inclusion but it also is not able to predict the outcome of 
death as well as the circulating counts which is why their respective weights are larger. To the 
authors knowledge this is the first time these variables have been quantitatively compared in 
this way.  
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The variables of aspirin, statin use and transient ischaemic attack were only present in 1 of the 
19 top models for death and their inclusion in the averaged model is to ensure that an important 
weak variable is not discarded. With the averaged model co-efficient for these three variables 
approaching 0 it is unlikely these variables offer any substantial contribution to this model for 
the outcome of death that is not already accounted for by another variable/s, although which 
variable/s remains unclear and will require further investigation. Aspirin use has been 
associated with lower total white cell count values in four non-randomised studies of 
cardiovascular risk86,88,87,118 although neither those trials nor this study were designed to 
investigate that relationship. Until these relationships are clarified or these variables are 
excluded from the best model set by replication in a larger population they add meaningful 
information to the model and should remain. 
 
The proposed handheld application of these models may be used to improve individual patient 
compliance with lifestyle and risk factor modification133 including targeted smoking cessation, 
weight loss and dietary modifications,135 exercise therapy to increase tolerated walking 
distance,423-425 and improve individual patient compliance with drug therapy including 
antiplatelet, antihypertensive, statin426 and ACE135 that have been shown to improve outcomes 
in patients with peripheral arterial occlusive disease.83,85,135,136 Optimising medical 
management of patients identified as high risk or with clinically advanced disease has 
important implications in the prevention of subsequent major adverse events and death for 
these patients.427 Once prospectively validated this model may be used to risk stratify patients 
and allow selection of the most appropriate vascular intervention for the individual patient.137 
Risk stratification is important in this population as early successful intervention is crucially 
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important to reduce the risk of major adverse event, minimise long term disability and improve 
quality of life, but exposing patients who have high mortality risk to ineffectual operations or 
interventions has serious ethical and resource implications.152 The accuracy of the instrument 
that is used to aid in such decision making is therefore of crucial importance.152 
 
Future application of this modelling technique to include the larger population including people 
asymptomatic of vascular disease has the potential to identify patients at high risk of major 
adverse cardiovascular event in the future who would benefit from early aggressive risk factor 
management.428 The low detection rates for peripheral arterial occlusive disease result in 
problems identifying the large burden of asymptomatic disease in the primary care setting5. 
This is problematic from a public health perspective as asymptomatic patients have similar 
cardiovascular risk to claudicants. Expanding this study structure and subsequent outcome 
model development to include asymptomatic patients would possibly require the inclusion of 
the Ankle Brachial Index to quantify disease severity of asymptomatic patients.429,430 Further 
research would potentially offer a handheld application to identify patients at high risk in the 
primary care setting who would benefit from early risk factor modification and result in the 
proven reduction in morbidity and mortality for this population.12 
 
The outcome models developed in this study should be used to guide further research direction 
into the pathophysiological basis of peripheral arterial occlusive disease as multi-model 
analysis results may be used to infer the key biological processes determining an outcome.132 
Multi-model analysis is also suggested as an ideal tool to objectively compare other potential 
predictors of outcome including Ankle Brachial Index and other circulating biomarkers with 
outcome in the population of patients with peripheral arterial occlusive disease. Following 
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validation the developed models may also be used to identify interventions that may offer 
immediate survival advantage for this patient group.   
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9.1. Limitations 
Direct causation was not established with this study and whether the circulating cell counts are 
causative or reactive to the underlying inflammatory disease of atherosclerosis requires further 
investigation. While the underlying processes and causal relationships are being investigated 
there is clinical potential to exploit the association of circulating cells with major adverse event 
and death. Patients with peripheral arterial occlusive disease identified as being at high risk of 
sustaining major adverse event or death should be offered targeted interventions while the 
pathophysiological causal relationship is elucidated. 
 
This study design was observational in nature and therefore inherently subject to selection bias. 
The population recruited did not represent all peripheral arterial occlusive disease patients in 
the community as it was a hospital acquired sample. Caution should therefore be used in 
extrapolating these results to different populations, particularly including asymptomatic 
patients. The study sample was representative of patients with symptomatic peripheral arterial 
occlusive disease who were referred for intervention, as represented by the skewed nature of 
the freedom from peripheral revascularisation data (Figure 6.7, Table 6.6). The study did not 
intend to assess or infer applicability to patients with asymptomatic peripheral arterial 
occlusive disease although these patients have been described to have a similar cardiovascular 
risk to claudicants21,74 and expansion of the investigated population to include patients with 
asymptomatic peripheral arterial occlusive disease is suggested as a further direction of study. 
 
The sample size of this study did not allow adequate power to investigate the cardiovascular 
endpoints of heat attack, stroke or major amputation individually and would require replication 
in a larger study population to investigate these outcomes. 
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This study used patient report of smoking status which although has previously been shown to 
be a valid measure,342 a more recent systematic review has shown self-reporting underestimates 
the true prevalence of smoking although the degree is dependent on the population studied.431 
In order to better define this relationship the author would recommend an objective measure of 
smoking habit (serum or saliva cotinine) be applied in future research to objectively define this 
variable. 
 
The efficacy of treatments, both medical and surgical and influence on cardiovascular events 
was outside the scope of this study, although the implications of both medical and surgical 
management have been raised as important directions for further research. The alteration of 
medical treatment after the sampling of “baseline study bloods” was recorded but not examined 
within this study design. 
 
9.2. Suggested objectives of future research 
Future investigations should replicate this study design with multi-model analysis of larger 
data sets in similar populations of patients with peripheral arterial occlusive disease to refine 
the predictive ability of the developed models. Multi-model comparison of TWCC with cell 
subtypes for the outcome of major adverse event and death should be considered. A broader 
population of peripheral arterial occlusive disease patients including asymptomatic patients 
may aid in identifying the patients at highest risk of major adverse event who would benefit 
most from the lifestyle changes and medical management discussed above. The individual 
endpoints of heart attack, stroke, major amputation and requirement for peripheral 
revascularisation would require larger study populations than in this study to power 
investigations of those endpoints. 
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The Information-Theoretical approach and in particular multi-model analysis should also be 
applied to other manifestations of atherosclerosis in particular coronary artery disease and 
aneurysmal disease to enable the creation of robust predictive outcome models for these 
distinct populations. This may aid in directly comparing the value of existing predictors of 
outcome, identifying further predictive markers, increase understanding of underlying 
pathophysiology to direct further research and identify potential targets for therapy whilst 
better investigating differences in these populations. 
 
Treatment efficacy, both medical and surgical, and their influence on the outcomes of major 
adverse event and death warrant further investigation. Investigation to define the protective 
effect of hypertension identified in this study, or defer this benefit to the treatment applied for 
hypertension within this population may give further insight and add strength to the known 
benefits of management of this risk factor in peripheral arterial occlusive disease patients. The 
effect of revascularisation on both circulating cell counts and morbidity and mortality would 
require a larger study population to provide the power to investigate these endpoints. White 
blood cell function and behaviour including deformability and adhesion properties and how 
this varies between the groups is another direction of future research to investigate potentially 
modifiable risk. The Information-Theoretical approach would be ideal to account for the 
complex variable interactions within these analysis. Comparison of different therapies, for 
example exercise therapy vs revascularisation could also be done using these statistical 
techniques. Developed models for outcome of major adverse event and death will be better 
able to identify underlying biological processes and should be used to guide future 
pathophysiological and therapeutic research into peripheral arterial occlusive disease. 
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10. Conclusion 
Multi-model averaging is a relatively new statistical paradigm based on the Information-
Theoretic approach132 and is the preferred statistical method for analysing data from complex 
biological systems needing to account for multiple co-variables of modest effect that interact 
to produce clinically relevant outcomes including major adverse events and death for patients 
with peripheral arterial occlusive disease. This is the first study to employ multi-model 
averaging to the population of patients with peripheral arterial occlusive disease. This study 
has demonstrated that circulating cell counts of monocytes, lymphocytes and neutrophils 
together with disease severity at presentation, hypertension and age are more important in 
models to predict the outcome of major adverse event and death than other traditional risk 
factors.  
 
Rest Pain was the strongest predictor of major adverse event and Tissue Loss was the strongest 
predictor of death in the respective best averaged models. Disease severity should continue to 
be reported and accounted for when examining outcomes in patients with peripheral arterial 
occlusive disease. 
 
High Monocyte Category exerted the strongest effect of the circulating cell types in the 
averaged model for major adverse event almost 1.5 times the effect of ischaemic heart disease 
although corroborating evidence for the association of monocytes with the composite outcome 
of major adverse event in peripheral arterial occlusive disease patients is lacking. High 
Monocyte Category was not as strong a predictor for the outcome of death, possibly indicating 
that is a stronger predictor of heart attack or stroke in this population than death alone. 
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High Neutrophil Category in the best averaged model for death had an effect size twice that of 
the Mid Neutrophil Category and the High Lymphocyte Category had the largest negative 
effect for the outcome of death, 3.25 times that of the Mid Lymphocyte Category, both of which 
had a larger effect than the traditional risk factors of smoking, diabetes, transient ischaemic 
attack, stroke and Aspirin and Statin use. Both the High Neutrophil Category and High 
Lymphocyte Category (negative/protective) exhibited a larger effect for the outcome of death 
than that of the best traditional risk factor predictor hypertension. Lymphocyte Category was 
the circulating cell in the largest number of models in the top model set for the outcome of 
major adverse event and was in all of the top model set for the outcome of death. The protective 
association of Lymphocytes for major adverse event and death in peripheral arterial occlusive 
disease patients deserves further research. The inclusion of both Lymphocyte Category and 
Neutrophil Category together provides better modelling of the outcome major adverse event 
and death than the combined Neutrophil-Lymphocyte ratio and this finding should be 
considered in future study design.  
 
Hypertension was the strongest and most consistent traditional risk factor in both models for 
death and major adverse event with a negative or protective predictive value for both endpoints. 
This effect was possibly due to the protective effects of hypertensive treatment with a large 
proportion of the study population on antihypertensive treatment. This study was not designed 
to investigate the relative protective effect of antihypertensive medications although this is a 
suggested direction of further research. 
 
Multi-model inferencing should be applied to larger data sets of patients with peripheral arterial 
occlusive disease to provide valuable information about the association of cell counts with 
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outcomes in this population. Once the outcome models for major adverse event and death are 
refined and prospectively validated, not only will they predict the likelihood of major adverse 
event and death for individual patients with peripheral arterial occlusive disease to tailor 
treatment selection, but drive future pathophysiological research and generate potential 
treatment options. 
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Appendix F: Participant Information Sheet – Townsville Hospital 
 
Townsville Health Service District 
Institutional Ethics Committee 
Version 3 Approved 5/9/11 
PROTOCOL NAME: The role of differences in circulating factors in the pathogenesis of vascular disease. 
INVESTIGATORS: 
 
You are being invited to take part in a research study. Please let us know if you are already taking part in any other 
medical studies. Before you decide it is important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it with relatives, friends and your GP 
if you wish. Ask us if there is anything that is not clear or if you would like more information.  
The study is to further our understanding of the process of blood vessel disease, i.e. why blood vessels weaken or block. 
We are looking at the relationship between common differences in genes which control the level of circulating factors 
in the human body and the weakening and blockage process. The study will involve examining the presence of common 
alterations in these genes and relating it to disease in your artery. At present these genetic differences are not known to 
have any long term effects on yourself or your offspring. The work will not provide you with any useful information 
about your personal genetic background, but rather will further our understanding of the role of specific proteins in 
blood vessel disease and will be published in scientific journal. The blood vessel disease level will be assessed by 
analysis of scans you undergo as part of your clinical care including ultrasounds and CT scans. 
It is up to you to decide whether or not to take part. If you do decide you will be asked to sign a consent form and given 
this information sheet to keep. Participation in the study is entirely voluntary and you have the right to withdraw from 
the study at any time. If you decide not to participate in this study you may do this freely without prejudice to any future 
treatment.  
If you consent to participation in the study we will collect a blood sample from you and in addition if your treatment 
involves an operation to remove part of your diseased blood vessel we also request your permission to collect and 
analyse this rather than it being discarded. This will allow us to relate our studies of the circulating proteins (from your 
blood test) to the disease within the blood vessel (from the excised specimen). The information and samples we collect 
will be de-identified to maintain your privacy and stored in secure facilities. Following the operation you are normally 
followed up in the outpatients clinic at around six weeks and then as necessary after this. The study will not require you 
to make any extra visits to the clinic.  
Any further information you require can be obtained from , telephone . The Ethics 
Committee has approved this study at the Townsville Hospital. Should you wish to discuss the study with someone not 
directly involved, in particular in relation to matters concerning policies, information about the conduct of the study, or 
your rights as a participant, you may contact the Chairperson, Townsville Health Service District Human Research 
Ethics Committee, PO Box 670, Townsville QLD 4810; Phone: (07) 47961140. 
INVESTIGATOR CONTACT NAME:   
INVESTIGATOR CONTACT TELEPHONE NO.  
DATED:  
SIGNATURE OF CONTACT INVESTIGATOR:  
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MATER MISERICORDIAE HOSPITAL TOWNSVILLE LIMITED  
 
 
PROTOCOL NAME: The role of differences in circulating factors in the pathogenesis of vascular disease. 
INVESTIGATORS:  
 
You are being invited to take part in a research study. Please let us know if you are already taking part in any 
other medical studies. Before you decide it is important for you to understand why the research is being done 
and what it will involve. Please take time to read the following information carefully and discuss it with 
relatives, friends and your GP if you wish. Ask us if there is anything that is not clear or if you would like 
more information. The study is to further our understanding of the process of blood vessel disease, i.e. why 
blood vessels weaken or block. We are looking at the relationship between common differences in genes 
which control the level of circulating factors in the human body and the weakening and blockage process. The 
study will involve examining the presence of common alterations in these genes and relating it to disease in 
your artery. At present these genetic differences are not known to have any long term effects on yourself or 
your offspring. The work will not provide you with any useful information about your personal genetic 
background, but rather will further our understanding of the role of specific proteins in blood vessel disease 
and will be published in scientific journal.  
It is up to you to decide whether or not to take part. If you do decide you will be asked to sign a consent form 
and given this information sheet to keep. Participation in the study is entirely voluntary and you have the right 
to withdraw from the study at any time. If you decide not to participate in this study you may do this freely 
without prejudice to any future treatment.  
If you consent to participation in the study we will collect a blood sample from you and in addition if your 
treatment involves an operation to remove part of your diseased blood vessel we also request your permission 
to collect and analyse this rather than it being discarded. This will allow us to relate our studies of the 
circulating proteins (from your blood test) to the disease within the blood vessel (from the excised specimen). 
The information and samples we collect will be de-identified to maintain your privacy and stored in secure 
facilities. Following the operation you are normally followed up in the outpatients clinic at around six weeks 
and then as necessary after this. The study will not require you to make any extra visits to the clinic. Any 
further information you require can be obtained from  telephone . 
The Ethics Committee has approved this study at the Mater Hospital. Should you wish to discuss the study 
with someone not directly involved, in particular in relation to matters concerning policies, information about 
the conduct of the study, or your rights as a participant, you may contact the Executive Officer of the Ethics 
Committee at the Mater Hospital (47274444). 
INVESTIGATOR CONTACT NAME:   
INVESTIGATOR CONTACT TELEPHONE NO.  DATED: 16/7/05 
SIGNATURE OF CONTACT INVESTIGATOR:
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Appendix I: Classification of peripheral arterial occlusive disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Fontaine 
classification, initially published in 1954345 classifies the severity of vascular insufficiency into 4 stages is 
presented beside the Rutherford classification344 which further categorised the  moderate and severe 
claudication as well as minor tissue loss from major tissue loss. The classification scheme of this study is 
demonstrated as directly arising from the Fontaine classification system with depiction of how the  Rutherford 
categories were applied to this study population. 
Fontaine Rutherford This Study 
Stage Clinical Grade Category Clinical  
I Asymptomatic 0 0 Asymptomatic Excluded from this 
study 
IIa Mild Claudication 
>200m 
I 1 Mild 
Claudication 
 
Intermittent 
Claudication 
IIb Moderate to 
Severe 
Claudication 
<200m 
I 2 Moderate 
Claudication  
I 3 Severe 
Claudication 
III Ischaemic Rest 
pain 
II 4 Ischaemic Rest 
pain 
Rest Pain 
IV Ulceration or 
Gangrene 
III 5 Minor tissue loss Tissue Loss 
III 6 Major tissue loss 
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